3.4.22.B28 Acantholysis https://pubmed.ncbi.nlm.nih.gov/16314468/ Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus. causal interaction 1 3.4.22.B28 Acantholysis https://pubmed.ncbi.nlm.nih.gov/16314468/ Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus. therapeutic application 3 3.4.22.B28 Acantholysis https://pubmed.ncbi.nlm.nih.gov/16314468/ Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus. unassigned - 3.4.22.B28 Acidosis https://pubmed.ncbi.nlm.nih.gov/18829701/ Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium. causal interaction 1 3.4.22.B28 Acidosis https://pubmed.ncbi.nlm.nih.gov/20211186/ Calpain translocation and activation as pharmacological targets during myocardial ischemia/reperfusion. causal interaction 1 3.4.22.B28 Acidosis https://pubmed.ncbi.nlm.nih.gov/32678496/ Acid-sensing ion channel 1a mediates acid-induced pyroptosis through calpain-2/calcineurin pathway in rat articular chondrocytes. causal interaction 2 3.4.22.B28 Acidosis https://pubmed.ncbi.nlm.nih.gov/18829701/ Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium. therapeutic application 2 3.4.22.B28 Acidosis https://pubmed.ncbi.nlm.nih.gov/20211186/ Calpain translocation and activation as pharmacological targets during myocardial ischemia/reperfusion. therapeutic application 3 3.4.22.B28 Acidosis https://pubmed.ncbi.nlm.nih.gov/18829701/ Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium. ongoing research 1 3.4.22.B28 Acidosis https://pubmed.ncbi.nlm.nih.gov/18829701/ Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium. unassigned - 3.4.22.B28 Acidosis https://pubmed.ncbi.nlm.nih.gov/20211186/ Calpain translocation and activation as pharmacological targets during myocardial ischemia/reperfusion. unassigned - 3.4.22.B28 Acidosis https://pubmed.ncbi.nlm.nih.gov/32678496/ Acid-sensing ion channel 1a mediates acid-induced pyroptosis through calpain-2/calcineurin pathway in rat articular chondrocytes. unassigned - 3.4.22.B28 Acidosis, Lactic https://pubmed.ncbi.nlm.nih.gov/9208136/ Effect of calpain inhibitor I, an inhibitor of the proteolysis of I kappa B, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. causal interaction 3 3.4.22.B28 Acidosis, Lactic https://pubmed.ncbi.nlm.nih.gov/9208136/ Effect of calpain inhibitor I, an inhibitor of the proteolysis of I kappa B, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. ongoing research 1 3.4.22.B28 Acidosis, Lactic https://pubmed.ncbi.nlm.nih.gov/9208136/ Effect of calpain inhibitor I, an inhibitor of the proteolysis of I kappa B, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. unassigned - 3.4.22.B28 Acquired Immunodeficiency Syndrome https://pubmed.ncbi.nlm.nih.gov/16528469/ HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. causal interaction 4 3.4.22.B28 Acquired Immunodeficiency Syndrome https://pubmed.ncbi.nlm.nih.gov/14555228/ Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. causal interaction 4 3.4.22.B28 Acquired Immunodeficiency Syndrome https://pubmed.ncbi.nlm.nih.gov/16528469/ HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. diagnostic usage 1 3.4.22.B28 Acquired Immunodeficiency Syndrome https://pubmed.ncbi.nlm.nih.gov/16528469/ HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. therapeutic application 4 3.4.22.B28 Acquired Immunodeficiency Syndrome https://pubmed.ncbi.nlm.nih.gov/14555228/ Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. therapeutic application 4 3.4.22.B28 Acquired Immunodeficiency Syndrome https://pubmed.ncbi.nlm.nih.gov/14555228/ Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. unassigned - 3.4.22.B28 Acquired Immunodeficiency Syndrome https://pubmed.ncbi.nlm.nih.gov/16528469/ HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. unassigned - 3.4.22.B28 Acute Kidney Injury https://pubmed.ncbi.nlm.nih.gov/10611418/ Proteasome participates in the pathogenesis of ischemic acute renal failure in rats. causal interaction 4 3.4.22.B28 Acute Kidney Injury https://pubmed.ncbi.nlm.nih.gov/16822870/ Extracellular calpains increase tubular epithelial cell mobility. Implications for kidney repair after ischemia. causal interaction 1 3.4.22.B28 Acute Kidney Injury https://pubmed.ncbi.nlm.nih.gov/32346126/ Protective role of endothelial calpain knockout in lipopolysaccharide-induced acute kidney injury via attenuation of the p38-iNOS pathway and NO/ROS production. therapeutic application 1 3.4.22.B28 Acute Kidney Injury https://pubmed.ncbi.nlm.nih.gov/10611418/ Proteasome participates in the pathogenesis of ischemic acute renal failure in rats. therapeutic application 3 3.4.22.B28 Acute Kidney Injury https://pubmed.ncbi.nlm.nih.gov/16822870/ Extracellular calpains increase tubular epithelial cell mobility. Implications for kidney repair after ischemia. therapeutic application 1 3.4.22.B28 Acute Kidney Injury https://pubmed.ncbi.nlm.nih.gov/32346126/ Protective role of endothelial calpain knockout in lipopolysaccharide-induced acute kidney injury via attenuation of the p38-iNOS pathway and NO/ROS production. ongoing research 2 3.4.22.B28 Acute Kidney Injury https://pubmed.ncbi.nlm.nih.gov/10611418/ Proteasome participates in the pathogenesis of ischemic acute renal failure in rats. ongoing research 1 3.4.22.B28 Acute Kidney Injury https://pubmed.ncbi.nlm.nih.gov/16822870/ Extracellular calpains increase tubular epithelial cell mobility. Implications for kidney repair after ischemia. ongoing research 2 3.4.22.B28 Acute Kidney Injury https://pubmed.ncbi.nlm.nih.gov/32346126/ Protective role of endothelial calpain knockout in lipopolysaccharide-induced acute kidney injury via attenuation of the p38-iNOS pathway and NO/ROS production. unassigned - 3.4.22.B28 Acute Kidney Injury https://pubmed.ncbi.nlm.nih.gov/10611418/ Proteasome participates in the pathogenesis of ischemic acute renal failure in rats. unassigned - 3.4.22.B28 Acute Kidney Injury https://pubmed.ncbi.nlm.nih.gov/16822870/ Extracellular calpains increase tubular epithelial cell mobility. Implications for kidney repair after ischemia. unassigned - 3.4.22.B28 Acute Lung Injury https://pubmed.ncbi.nlm.nih.gov/30338266/ Calpain inhibition ameliorates scald burn-induced acute lung injury in rats. causal interaction 4 3.4.22.B28 Acute Lung Injury https://pubmed.ncbi.nlm.nih.gov/30338266/ Calpain inhibition ameliorates scald burn-induced acute lung injury in rats. therapeutic application 2 3.4.22.B28 Acute Lung Injury https://pubmed.ncbi.nlm.nih.gov/30338266/ Calpain inhibition ameliorates scald burn-induced acute lung injury in rats. ongoing research 3 3.4.22.B28 Acute Lung Injury https://pubmed.ncbi.nlm.nih.gov/30338266/ Calpain inhibition ameliorates scald burn-induced acute lung injury in rats. unassigned - 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/7575520/ Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. causal interaction 2 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/23329366/ Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. causal interaction 3 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/28112357/ Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. causal interaction 3 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. causal interaction 4 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. causal interaction 4 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. causal interaction 3 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/7575520/ Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. diagnostic usage 3 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/23329366/ Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. diagnostic usage 3 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/28112357/ Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. diagnostic usage 3 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. diagnostic usage 4 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. diagnostic usage 4 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. diagnostic usage 4 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/7575520/ Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. therapeutic application 3 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/23329366/ Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. therapeutic application 1 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/28112357/ Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. therapeutic application 4 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. therapeutic application 1 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. therapeutic application 1 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. therapeutic application 3 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/7575520/ Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. ongoing research 4 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/23329366/ Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. ongoing research 4 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. ongoing research 1 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. ongoing research 4 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. ongoing research 3 3.4.22.B28 Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/28112357/ Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. unassigned - 3.4.22.B28 Adenocarcinoma of Lung https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. causal interaction 1 3.4.22.B28 Adenocarcinoma of Lung https://pubmed.ncbi.nlm.nih.gov/18214855/ Calpain-mediated pathway dominates cisplatin-induced apoptosis in human lung adenocarcinoma cells as determined by real-time single cell analysis. causal interaction 1 3.4.22.B28 Adenocarcinoma of Lung https://pubmed.ncbi.nlm.nih.gov/32928150/ From tobacco smoking to cancer mutational signature: a mediation analysis strategy to explore the role of epigenetic changes. causal interaction 2 3.4.22.B28 Adenocarcinoma of Lung https://pubmed.ncbi.nlm.nih.gov/18214855/ Calpain-mediated pathway dominates cisplatin-induced apoptosis in human lung adenocarcinoma cells as determined by real-time single cell analysis. diagnostic usage 3 3.4.22.B28 Adenocarcinoma of Lung https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. therapeutic application 1 3.4.22.B28 Adenocarcinoma of Lung https://pubmed.ncbi.nlm.nih.gov/18214855/ Calpain-mediated pathway dominates cisplatin-induced apoptosis in human lung adenocarcinoma cells as determined by real-time single cell analysis. therapeutic application 1 3.4.22.B28 Adenocarcinoma of Lung https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. ongoing research 3 3.4.22.B28 Adenocarcinoma of Lung https://pubmed.ncbi.nlm.nih.gov/18214855/ Calpain-mediated pathway dominates cisplatin-induced apoptosis in human lung adenocarcinoma cells as determined by real-time single cell analysis. ongoing research 4 3.4.22.B28 Adenocarcinoma of Lung https://pubmed.ncbi.nlm.nih.gov/32928150/ From tobacco smoking to cancer mutational signature: a mediation analysis strategy to explore the role of epigenetic changes. ongoing research 2 3.4.22.B28 Adenocarcinoma of Lung https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. unassigned - 3.4.22.B28 Adenocarcinoma of Lung https://pubmed.ncbi.nlm.nih.gov/32928150/ From tobacco smoking to cancer mutational signature: a mediation analysis strategy to explore the role of epigenetic changes. unassigned - 3.4.22.B28 Adenoviridae Infections https://pubmed.ncbi.nlm.nih.gov/12499268/ Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. diagnostic usage 3 3.4.22.B28 Adenoviridae Infections https://pubmed.ncbi.nlm.nih.gov/12499268/ Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. unassigned - 3.4.22.B28 Albuminuria https://pubmed.ncbi.nlm.nih.gov/24531545/ Podocyte-associated talin1 is critical for glomerular filtration barrier maintenance. therapeutic application 1 3.4.22.B28 Albuminuria https://pubmed.ncbi.nlm.nih.gov/24531545/ Podocyte-associated talin1 is critical for glomerular filtration barrier maintenance. unassigned - 3.4.22.B28 Altitude Sickness https://pubmed.ncbi.nlm.nih.gov/32916280/ Redox modification of ryanodine receptor contributes to impaired Ca2+ homeostasis and exacerbates muscle atrophy under high altitude. causal interaction 1 3.4.22.B28 Altitude Sickness https://pubmed.ncbi.nlm.nih.gov/32916280/ Redox modification of ryanodine receptor contributes to impaired Ca2+ homeostasis and exacerbates muscle atrophy under high altitude. therapeutic application 2 3.4.22.B28 Altitude Sickness https://pubmed.ncbi.nlm.nih.gov/32916280/ Redox modification of ryanodine receptor contributes to impaired Ca2+ homeostasis and exacerbates muscle atrophy under high altitude. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/1797346/ Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease. causal interaction 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12212771/ Calpain inhibitors: a treatment for Alzheimer's disease. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/14501020/ Calpain inhibitors, a treatment for Alzheimer's disease: position paper. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/16884489/ Implication of calpain in neuronal apoptosis. A possible regulation of Alzheimer's disease. causal interaction 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17513017/ Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17908236/ Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/20595388/ Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/22733009/ Calpain inhibition as a potential treatment of Alzheimer's disease. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/23948930/ Elevated [Ca2+]i Levels Occur with Decreased Calpain Activity in Aged Fibroblasts and Reversal by Energy-Rich Compounds: Implications for Alzheimer's Disease Prevention. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/24122005/ Elevated [Ca2+]i levels occur with decreased calpain activity in aged fibroblasts and their reversal by energy-rich compounds: new paradigm for Alzheimer's disease prevention. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/25200336/ Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/25969760/ Calpain dysregulation in Alzheimer's disease. causal interaction 2 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/27036949/ Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/28759231/ Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/29805718/ Potential Alzheimer's Disease Therapeutics Among Weak Cysteine Protease Inhibitors Exhibit Mechanistic Differences Regarding Extent of Cathepsin B Up-Regulation and Ability to Block Calpain. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/30584150/ Role of Post-Transcriptional Control of Calpain by miR-124-3p in the Development of Alzheimer's Disease. causal interaction 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/2358536/ Distribution of calcium-activated protease calpain in the rat brain. causal interaction 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/7588778/ Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/7615058/ Differential sensitivity to proteolysis by brain calpain of adult human tau, fetal human tau and PHF-tau. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/7847693/ Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/9654354/ m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. causal interaction 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10830966/ Neurotoxicity induces cleavage of p35 to p25 by calpain. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10847556/ Inhibitory effect of a brain derived peptide preparation on the Ca++-dependent protease, calpain. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10903889/ Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12173413/ The calpain system in human placenta. causal interaction 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12500971/ Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/14673209/ The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/14992597/ The beta- and gamma-CH2 of B27-WT's Leu11 and Ile18 side chains play a direct role in calpain inhibition. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/15491615/ Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/16641670/ Calpain activation in okadaic-acid-induced neurodegeneration. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17506859/ p25/cyclin-dependent kinase 5 promotes the progression of cell death in nucleus of endoplasmic reticulum-stressed neurons. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17569662/ N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17593948/ Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/18396356/ Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. causal interaction 2 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/18590784/ The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/19041242/ Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. causal interaction 2 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/20969723/ Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric Abeta. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/21504847/ Synthesis of cinnamoyl ketoamides as hybrid structures of antioxidants and calpain inhibitors. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/22613839/ The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/22688056/ Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/23266720/ Expression profiles of hippocampal regenerative sprouting-related genes and their regulation by E-64d in a developmental rat model of penicillin-induced recurrent epilepticus. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/23508964/ Negative regulation of 26S proteasome stability via calpain-mediated cleavage of Rpn10 upon mitochondrial dysfunction in neurons. causal interaction 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/25851230/ Towards Understanding the Role of the Na²?-Ca²? Exchanger Isoform 3. causal interaction 2 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/26484927/ Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/26872373/ DARPP-32: from neurotransmission to cancer. causal interaction 2 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/30177812/ Isoform-specific hyperactivation of calpain-2 occurs presymptomatically at the synapse in Alzheimer's disease mice and correlates with memory deficits in human subjects. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/30497524/ In vivo induction of membrane damage by ?-amyloid peptide oligomers. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/31133534/ Discovery of ABT-957: 1-Benzyl-5-oxopyrrolidine-2-carboxamides as selective calpain inhibitors with enhanced metabolic stability. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/31804596/ Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces A? and P25 accumulation in 5XFAD mice. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/32840034/ Synthesis of ?-Ketoamide-Based Stereoselective Calpain-1 Inhibitors as Neuroprotective Agents. causal interaction 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/33556560/ Phenanthroline impairs ?APP processing and expression, increases p53 protein levels and induces cell cycle arrest in human neuroblastoma cells. causal interaction 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/1797346/ Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease. diagnostic usage 2 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/24122005/ Elevated [Ca2+]i levels occur with decreased calpain activity in aged fibroblasts and their reversal by energy-rich compounds: new paradigm for Alzheimer's disease prevention. diagnostic usage 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/2072120/ Comparison of Ca(2+)-activated proteinase enzyme and endogenous inhibitor activity in brain tissue from normal and Alzheimer's disease cases. diagnostic usage 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/7847693/ Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. diagnostic usage 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/9326284/ Tau released from paired helical filaments with formic acid or guanidine is susceptible to calpain-mediated proteolysis. diagnostic usage 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. diagnostic usage 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. diagnostic usage 2 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/31640160/ Novel Peptidomic Approach for Identification of Low and High Molecular Weight Tauopathy Peptides Following Calpain Digestion, and Primary Culture Neurotoxic Challenges. diagnostic usage 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12212771/ Calpain inhibitors: a treatment for Alzheimer's disease. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/14501020/ Calpain inhibitors, a treatment for Alzheimer's disease: position paper. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/22733009/ Calpain inhibition as a potential treatment of Alzheimer's disease. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/27036949/ Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/28759231/ Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/29805718/ Potential Alzheimer's Disease Therapeutics Among Weak Cysteine Protease Inhibitors Exhibit Mechanistic Differences Regarding Extent of Cathepsin B Up-Regulation and Ability to Block Calpain. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/7588778/ Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments. therapeutic application 2 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/9654354/ m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. therapeutic application 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12500971/ Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. therapeutic application 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] therapeutic application 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/14992597/ The beta- and gamma-CH2 of B27-WT's Leu11 and Ile18 side chains play a direct role in calpain inhibition. therapeutic application 2 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/15491615/ Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. therapeutic application 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. therapeutic application 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17569662/ N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/18396356/ Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/18590784/ The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/19041242/ Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/20969723/ Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric Abeta. therapeutic application 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/21504847/ Synthesis of cinnamoyl ketoamides as hybrid structures of antioxidants and calpain inhibitors. therapeutic application 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/22613839/ The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. therapeutic application 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/23266720/ Expression profiles of hippocampal regenerative sprouting-related genes and their regulation by E-64d in a developmental rat model of penicillin-induced recurrent epilepticus. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/26484927/ Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/31133534/ Discovery of ABT-957: 1-Benzyl-5-oxopyrrolidine-2-carboxamides as selective calpain inhibitors with enhanced metabolic stability. therapeutic application 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/31804596/ Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces A? and P25 accumulation in 5XFAD mice. therapeutic application 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/32840034/ Synthesis of ?-Ketoamide-Based Stereoselective Calpain-1 Inhibitors as Neuroprotective Agents. therapeutic application 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/33556560/ Phenanthroline impairs ?APP processing and expression, increases p53 protein levels and induces cell cycle arrest in human neuroblastoma cells. therapeutic application 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/1797346/ Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease. ongoing research 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17513017/ Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease. ongoing research 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/20595388/ Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. ongoing research 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/30584150/ Role of Post-Transcriptional Control of Calpain by miR-124-3p in the Development of Alzheimer's Disease. ongoing research 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/2072120/ Comparison of Ca(2+)-activated proteinase enzyme and endogenous inhibitor activity in brain tissue from normal and Alzheimer's disease cases. ongoing research 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/7847693/ Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. ongoing research 1 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/9654354/ m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. ongoing research 3 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. ongoing research 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/18812568/ Identification of small molecule inhibitors of beta-amyloid cytotoxicity through a cell-based high-throughput screening platform. ongoing research 2 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/30177812/ Isoform-specific hyperactivation of calpain-2 occurs presymptomatically at the synapse in Alzheimer's disease mice and correlates with memory deficits in human subjects. ongoing research 2 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/33556560/ Phenanthroline impairs ?APP processing and expression, increases p53 protein levels and induces cell cycle arrest in human neuroblastoma cells. ongoing research 4 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/15331404/ Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/20961659/ Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/23810804/ Hyperphosphorylation of tau protein by calpain regulation in retina of Alzheimer's disease transgenic mouse. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/23919677/ Calpain cleavage and inactivation of the sodium calcium exchanger-3 occur downstream of A? in Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/30260518/ Involvement of calpain in the neuropathogenesis of Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/30767411/ Dynamin-like protein 1 cleavage by calpain in Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/2072120/ Comparison of Ca(2+)-activated proteinase enzyme and endogenous inhibitor activity in brain tissue from normal and Alzheimer's disease cases. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/9326284/ Tau released from paired helical filaments with formic acid or guanidine is susceptible to calpain-mediated proteolysis. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/11231011/ Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12684463/ Partial rescue of the p35-/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/18812568/ Identification of small molecule inhibitors of beta-amyloid cytotoxicity through a cell-based high-throughput screening platform. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/31640160/ Novel Peptidomic Approach for Identification of Low and High Molecular Weight Tauopathy Peptides Following Calpain Digestion, and Primary Culture Neurotoxic Challenges. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12212771/ Calpain inhibitors: a treatment for Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/14501020/ Calpain inhibitors, a treatment for Alzheimer's disease: position paper. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/16884489/ Implication of calpain in neuronal apoptosis. A possible regulation of Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17513017/ Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17908236/ Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/20595388/ Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/22733009/ Calpain inhibition as a potential treatment of Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/23948930/ Elevated [Ca2+]i Levels Occur with Decreased Calpain Activity in Aged Fibroblasts and Reversal by Energy-Rich Compounds: Implications for Alzheimer's Disease Prevention. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/25200336/ Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/25969760/ Calpain dysregulation in Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/27036949/ Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/28759231/ Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/29805718/ Potential Alzheimer's Disease Therapeutics Among Weak Cysteine Protease Inhibitors Exhibit Mechanistic Differences Regarding Extent of Cathepsin B Up-Regulation and Ability to Block Calpain. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/30584150/ Role of Post-Transcriptional Control of Calpain by miR-124-3p in the Development of Alzheimer's Disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/2358536/ Distribution of calcium-activated protease calpain in the rat brain. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/7588778/ Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/7615058/ Differential sensitivity to proteolysis by brain calpain of adult human tau, fetal human tau and PHF-tau. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/9654354/ m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10830966/ Neurotoxicity induces cleavage of p35 to p25 by calpain. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10847556/ Inhibitory effect of a brain derived peptide preparation on the Ca++-dependent protease, calpain. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10903889/ Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12173413/ The calpain system in human placenta. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12500971/ Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/14673209/ The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/14992597/ The beta- and gamma-CH2 of B27-WT's Leu11 and Ile18 side chains play a direct role in calpain inhibition. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/15491615/ Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/16641670/ Calpain activation in okadaic-acid-induced neurodegeneration. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17506859/ p25/cyclin-dependent kinase 5 promotes the progression of cell death in nucleus of endoplasmic reticulum-stressed neurons. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17569662/ N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/17593948/ Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/18396356/ Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/18590784/ The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/19041242/ Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/20969723/ Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric Abeta. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/21504847/ Synthesis of cinnamoyl ketoamides as hybrid structures of antioxidants and calpain inhibitors. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/22613839/ The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/22688056/ Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/23266720/ Expression profiles of hippocampal regenerative sprouting-related genes and their regulation by E-64d in a developmental rat model of penicillin-induced recurrent epilepticus. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/23508964/ Negative regulation of 26S proteasome stability via calpain-mediated cleavage of Rpn10 upon mitochondrial dysfunction in neurons. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/25851230/ Towards Understanding the Role of the Na²?-Ca²? Exchanger Isoform 3. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/26484927/ Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/26872373/ DARPP-32: from neurotransmission to cancer. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/30177812/ Isoform-specific hyperactivation of calpain-2 occurs presymptomatically at the synapse in Alzheimer's disease mice and correlates with memory deficits in human subjects. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/30497524/ In vivo induction of membrane damage by ?-amyloid peptide oligomers. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/31133534/ Discovery of ABT-957: 1-Benzyl-5-oxopyrrolidine-2-carboxamides as selective calpain inhibitors with enhanced metabolic stability. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/31804596/ Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces A? and P25 accumulation in 5XFAD mice. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/32840034/ Synthesis of ?-Ketoamide-Based Stereoselective Calpain-1 Inhibitors as Neuroprotective Agents. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/33556560/ Phenanthroline impairs ?APP processing and expression, increases p53 protein levels and induces cell cycle arrest in human neuroblastoma cells. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/1797346/ Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/24122005/ Elevated [Ca2+]i levels occur with decreased calpain activity in aged fibroblasts and their reversal by energy-rich compounds: new paradigm for Alzheimer's disease prevention. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/7847693/ Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. unassigned - 3.4.22.B28 Alzheimer Disease https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. unassigned - 3.4.22.B28 Amyotrophic Lateral Sclerosis https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. causal interaction 1 3.4.22.B28 Amyotrophic Lateral Sclerosis https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. causal interaction 4 3.4.22.B28 Amyotrophic Lateral Sclerosis https://pubmed.ncbi.nlm.nih.gov/23250437/ A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. causal interaction 2 3.4.22.B28 Amyotrophic Lateral Sclerosis https://pubmed.ncbi.nlm.nih.gov/27005822/ CAST your vote: is calpain inhibition the answer to ALS? causal interaction 2 3.4.22.B28 Amyotrophic Lateral Sclerosis https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. diagnostic usage 4 3.4.22.B28 Amyotrophic Lateral Sclerosis https://pubmed.ncbi.nlm.nih.gov/23250437/ A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. therapeutic application 1 3.4.22.B28 Amyotrophic Lateral Sclerosis https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. ongoing research 3 3.4.22.B28 Amyotrophic Lateral Sclerosis https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. unassigned - 3.4.22.B28 Amyotrophic Lateral Sclerosis https://pubmed.ncbi.nlm.nih.gov/23250437/ A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. unassigned - 3.4.22.B28 Amyotrophic Lateral Sclerosis https://pubmed.ncbi.nlm.nih.gov/27005822/ CAST your vote: is calpain inhibition the answer to ALS? unassigned - 3.4.22.B28 Amyotrophic Lateral Sclerosis https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. unassigned - 3.4.22.B28 Anemia https://pubmed.ncbi.nlm.nih.gov/12625933/ The role of calpain and calpastatin in the catabolism of erythrocyte-membrane proteins during anaemia in hamsters (Mesocricetus auretus) infected with Leishmania donovani. causal interaction 4 3.4.22.B28 Anemia https://pubmed.ncbi.nlm.nih.gov/12625933/ The role of calpain and calpastatin in the catabolism of erythrocyte-membrane proteins during anaemia in hamsters (Mesocricetus auretus) infected with Leishmania donovani. diagnostic usage 3 3.4.22.B28 Anemia https://pubmed.ncbi.nlm.nih.gov/12625933/ The role of calpain and calpastatin in the catabolism of erythrocyte-membrane proteins during anaemia in hamsters (Mesocricetus auretus) infected with Leishmania donovani. therapeutic application 2 3.4.22.B28 Anemia https://pubmed.ncbi.nlm.nih.gov/2145987/ Comparative action of calpain on erythrocyte Ca2(+)-pumping ATPase in sickle cell anaemia, essential hypertension and kwashiorkor. ongoing research 3 3.4.22.B28 Anemia https://pubmed.ncbi.nlm.nih.gov/12625933/ The role of calpain and calpastatin in the catabolism of erythrocyte-membrane proteins during anaemia in hamsters (Mesocricetus auretus) infected with Leishmania donovani. ongoing research 2 3.4.22.B28 Anemia https://pubmed.ncbi.nlm.nih.gov/2145987/ Comparative action of calpain on erythrocyte Ca2(+)-pumping ATPase in sickle cell anaemia, essential hypertension and kwashiorkor. unassigned - 3.4.22.B28 Anemia, Sickle Cell https://pubmed.ncbi.nlm.nih.gov/2145987/ Comparative action of calpain on erythrocyte Ca2(+)-pumping ATPase in sickle cell anaemia, essential hypertension and kwashiorkor. ongoing research 3 3.4.22.B28 Anemia, Sickle Cell https://pubmed.ncbi.nlm.nih.gov/2145987/ Comparative action of calpain on erythrocyte Ca2(+)-pumping ATPase in sickle cell anaemia, essential hypertension and kwashiorkor. unassigned - 3.4.22.B28 Anthrax https://pubmed.ncbi.nlm.nih.gov/24085852/ Calpain-dependent cytoskeletal rearrangement exploited for anthrax toxin endocytosis. therapeutic application 1 3.4.22.B28 Anthrax https://pubmed.ncbi.nlm.nih.gov/24085852/ Calpain-dependent cytoskeletal rearrangement exploited for anthrax toxin endocytosis. unassigned - 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/21964156/ Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. causal interaction 4 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. causal interaction 4 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/23977256/ Calpain-2 Compensation Promotes Angiotensin II-Induced Ascending and Abdominal Aortic Aneurysms in Calpain-1 Deficient Mice. causal interaction 2 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/21964156/ Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. therapeutic application 3 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. therapeutic application 1 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/23977256/ Calpain-2 Compensation Promotes Angiotensin II-Induced Ascending and Abdominal Aortic Aneurysms in Calpain-1 Deficient Mice. therapeutic application 2 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/21964156/ Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. ongoing research 2 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. ongoing research 2 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/23977256/ Calpain-2 Compensation Promotes Angiotensin II-Induced Ascending and Abdominal Aortic Aneurysms in Calpain-1 Deficient Mice. ongoing research 2 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/21964156/ Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. unassigned - 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. unassigned - 3.4.22.B28 Aortic Aneurysm, Abdominal https://pubmed.ncbi.nlm.nih.gov/23977256/ Calpain-2 Compensation Promotes Angiotensin II-Induced Ascending and Abdominal Aortic Aneurysms in Calpain-1 Deficient Mice. unassigned - 3.4.22.B28 Aortic Valve Stenosis https://pubmed.ncbi.nlm.nih.gov/25336645/ Molecular basis of calpain cleavage and inactivation of the sodium-calcium exchanger 1 in heart failure. therapeutic application 1 3.4.22.B28 Aortic Valve Stenosis https://pubmed.ncbi.nlm.nih.gov/25336645/ Molecular basis of calpain cleavage and inactivation of the sodium-calcium exchanger 1 in heart failure. unassigned - 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/7632090/ Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice. causal interaction 2 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/8023588/ Immunohistochemical demonstration of calcium-dependent cysteine proteinase (calpain) in collagen-induced arthritis in mice. causal interaction 3 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. causal interaction 3 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. causal interaction 3 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/16176933/ Amelioration of experimental arthritis by a calpain-inhibitory compound: regulation of cytokine production by E-64-d in vivo and in vitro. causal interaction 3 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/32678496/ Acid-sensing ion channel 1a mediates acid-induced pyroptosis through calpain-2/calcineurin pathway in rat articular chondrocytes. causal interaction 2 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/7632090/ Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice. diagnostic usage 2 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. diagnostic usage 2 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/7632090/ Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice. therapeutic application 1 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/8023588/ Immunohistochemical demonstration of calcium-dependent cysteine proteinase (calpain) in collagen-induced arthritis in mice. therapeutic application 1 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/11106579/ Calpain inhibitor I reduces the development of acute and chronic inflammation. therapeutic application 2 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. therapeutic application 1 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. therapeutic application 1 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/16176933/ Amelioration of experimental arthritis by a calpain-inhibitory compound: regulation of cytokine production by E-64-d in vivo and in vitro. therapeutic application 4 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/7632090/ Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice. ongoing research 3 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/8023588/ Immunohistochemical demonstration of calcium-dependent cysteine proteinase (calpain) in collagen-induced arthritis in mice. ongoing research 2 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/11106579/ Calpain inhibitor I reduces the development of acute and chronic inflammation. ongoing research 4 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/16176933/ Amelioration of experimental arthritis by a calpain-inhibitory compound: regulation of cytokine production by E-64-d in vivo and in vitro. ongoing research 3 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/26608921/ Calpains Released by T Lymphocytes Cleave TLR2 To Control IL-17 Expression. ongoing research 2 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/11106579/ Calpain inhibitor I reduces the development of acute and chronic inflammation. unassigned - 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. unassigned - 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/26608921/ Calpains Released by T Lymphocytes Cleave TLR2 To Control IL-17 Expression. unassigned - 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/8023588/ Immunohistochemical demonstration of calcium-dependent cysteine proteinase (calpain) in collagen-induced arthritis in mice. unassigned - 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. unassigned - 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. unassigned - 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/16176933/ Amelioration of experimental arthritis by a calpain-inhibitory compound: regulation of cytokine production by E-64-d in vivo and in vitro. unassigned - 3.4.22.B28 Arthritis https://pubmed.ncbi.nlm.nih.gov/32678496/ Acid-sensing ion channel 1a mediates acid-induced pyroptosis through calpain-2/calcineurin pathway in rat articular chondrocytes. unassigned - 3.4.22.B28 Arthritis, Experimental https://pubmed.ncbi.nlm.nih.gov/8023588/ Immunohistochemical demonstration of calcium-dependent cysteine proteinase (calpain) in collagen-induced arthritis in mice. causal interaction 3 3.4.22.B28 Arthritis, Experimental https://pubmed.ncbi.nlm.nih.gov/8023588/ Immunohistochemical demonstration of calcium-dependent cysteine proteinase (calpain) in collagen-induced arthritis in mice. therapeutic application 1 3.4.22.B28 Arthritis, Experimental https://pubmed.ncbi.nlm.nih.gov/8023588/ Immunohistochemical demonstration of calcium-dependent cysteine proteinase (calpain) in collagen-induced arthritis in mice. ongoing research 2 3.4.22.B28 Arthritis, Experimental https://pubmed.ncbi.nlm.nih.gov/8023588/ Immunohistochemical demonstration of calcium-dependent cysteine proteinase (calpain) in collagen-induced arthritis in mice. unassigned - 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/9256029/ [Antigenic epitopes recognized by autoantibodies to calpastatin in patients with rheumatoid arthritis and their clinical significance] causal interaction 4 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/10600505/ Inflammatory cytokines induced down-regulation of m-calpain mRNA expression in fibroblastic synoviocytes from patients with osteoarthritis and rheumatoid arthritis. causal interaction 3 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. causal interaction 4 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/10600505/ Inflammatory cytokines induced down-regulation of m-calpain mRNA expression in fibroblastic synoviocytes from patients with osteoarthritis and rheumatoid arthritis. diagnostic usage 3 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/17963167/ Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. diagnostic usage 1 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/18165173/ Ex vivo measurement of calpain activation in human peripheral blood lymphocytes by detection of immunoreactive products of calpastatin degradation. diagnostic usage 3 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/18165173/ Ex vivo measurement of calpain activation in human peripheral blood lymphocytes by detection of immunoreactive products of calpastatin degradation. therapeutic application 1 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. therapeutic application 4 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/2547364/ Extracellular appearance of calpain and calpastatin in the synovial fluid of the knee joint. ongoing research 3 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/10600505/ Inflammatory cytokines induced down-regulation of m-calpain mRNA expression in fibroblastic synoviocytes from patients with osteoarthritis and rheumatoid arthritis. ongoing research 2 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/17963167/ Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. ongoing research 3 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/18165173/ Ex vivo measurement of calpain activation in human peripheral blood lymphocytes by detection of immunoreactive products of calpastatin degradation. ongoing research 3 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/2547364/ Extracellular appearance of calpain and calpastatin in the synovial fluid of the knee joint. unassigned - 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/17963167/ Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. unassigned - 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/18165173/ Ex vivo measurement of calpain activation in human peripheral blood lymphocytes by detection of immunoreactive products of calpastatin degradation. unassigned - 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/9256029/ [Antigenic epitopes recognized by autoantibodies to calpastatin in patients with rheumatoid arthritis and their clinical significance] unassigned - 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. unassigned - 3.4.22.B28 Arthritis, Rheumatoid https://pubmed.ncbi.nlm.nih.gov/10600505/ Inflammatory cytokines induced down-regulation of m-calpain mRNA expression in fibroblastic synoviocytes from patients with osteoarthritis and rheumatoid arthritis. unassigned - 3.4.22.B28 Asthma https://pubmed.ncbi.nlm.nih.gov/22673904/ Loss-of-function of inositol polyphosphate-4-phosphatase reversibly increases the severity of allergic airway inflammation. causal interaction 1 3.4.22.B28 Asthma https://pubmed.ncbi.nlm.nih.gov/27649066/ Calpain-activated mTORC2/Akt pathway mediates airway smooth muscle remodeling in asthma. causal interaction 3 3.4.22.B28 Asthma https://pubmed.ncbi.nlm.nih.gov/27649066/ Calpain-activated mTORC2/Akt pathway mediates airway smooth muscle remodeling in asthma. therapeutic application 3 3.4.22.B28 Asthma https://pubmed.ncbi.nlm.nih.gov/27649066/ Calpain-activated mTORC2/Akt pathway mediates airway smooth muscle remodeling in asthma. ongoing research 2 3.4.22.B28 Asthma https://pubmed.ncbi.nlm.nih.gov/22673904/ Loss-of-function of inositol polyphosphate-4-phosphatase reversibly increases the severity of allergic airway inflammation. unassigned - 3.4.22.B28 Asthma https://pubmed.ncbi.nlm.nih.gov/27649066/ Calpain-activated mTORC2/Akt pathway mediates airway smooth muscle remodeling in asthma. unassigned - 3.4.22.B28 Astrocytoma https://pubmed.ncbi.nlm.nih.gov/33026572/ Memantine and Ibuprofen pretreatment exerts anti-inflammatory effect against streptozotocin-induced astroglial inflammation via modulation of NMDA receptor-associated downstream calcium ion signaling. causal interaction 1 3.4.22.B28 Astrocytoma https://pubmed.ncbi.nlm.nih.gov/33026572/ Memantine and Ibuprofen pretreatment exerts anti-inflammatory effect against streptozotocin-induced astroglial inflammation via modulation of NMDA receptor-associated downstream calcium ion signaling. unassigned - 3.4.22.B28 Ataxia https://pubmed.ncbi.nlm.nih.gov/33790315/ Age-dependent ataxia and neurodegeneration caused by an ?II spectrin mutation with impaired regulation of its calpain sensitivity. causal interaction 4 3.4.22.B28 Ataxia https://pubmed.ncbi.nlm.nih.gov/33790315/ Age-dependent ataxia and neurodegeneration caused by an ?II spectrin mutation with impaired regulation of its calpain sensitivity. therapeutic application 2 3.4.22.B28 Ataxia https://pubmed.ncbi.nlm.nih.gov/34497286/ Publisher Correction: Age-dependent ataxia and neurodegeneration caused by an ?II spectrin mutation with impaired regulation of its calpain sensitivity. unassigned - 3.4.22.B28 Ataxia https://pubmed.ncbi.nlm.nih.gov/33790315/ Age-dependent ataxia and neurodegeneration caused by an ?II spectrin mutation with impaired regulation of its calpain sensitivity. unassigned - 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/21964156/ Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. causal interaction 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/23171729/ Calpain and atherosclerosis. causal interaction 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. causal interaction 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/28758430/ Calpain inhibitor attenuates atherosclerosis and inflammation in atherosclerotic rats through eNOS/NO/NF-?B pathway. causal interaction 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/12511593/ A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. causal interaction 3 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/22064597/ m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis. causal interaction 1 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. causal interaction 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/28366876/ Endothelial cell calpain as a critical modulator of angiogenesis. causal interaction 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/28432377/ Emerging roles of calpain proteolytic systems in macrophage cholesterol handling. causal interaction 1 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/29270409/ Defective Protein Catabolism in Atherosclerotic Vascular Inflammation. causal interaction 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/23171729/ Calpain and atherosclerosis. diagnostic usage 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/21964156/ Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. therapeutic application 3 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. therapeutic application 1 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/28758430/ Calpain inhibitor attenuates atherosclerosis and inflammation in atherosclerotic rats through eNOS/NO/NF-?B pathway. therapeutic application 1 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/12511593/ A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. therapeutic application 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/22064597/ m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis. therapeutic application 1 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. therapeutic application 1 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/28366876/ Endothelial cell calpain as a critical modulator of angiogenesis. therapeutic application 3 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/21964156/ Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. ongoing research 2 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/23171729/ Calpain and atherosclerosis. ongoing research 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. ongoing research 2 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/28758430/ Calpain inhibitor attenuates atherosclerosis and inflammation in atherosclerotic rats through eNOS/NO/NF-?B pathway. ongoing research 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/22064597/ m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis. ongoing research 4 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/21964156/ Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. unassigned - 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. unassigned - 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/28758430/ Calpain inhibitor attenuates atherosclerosis and inflammation in atherosclerotic rats through eNOS/NO/NF-?B pathway. unassigned - 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/12511593/ A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. unassigned - 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/22064597/ m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis. unassigned - 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. unassigned - 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/28366876/ Endothelial cell calpain as a critical modulator of angiogenesis. unassigned - 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/28432377/ Emerging roles of calpain proteolytic systems in macrophage cholesterol handling. unassigned - 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/29270409/ Defective Protein Catabolism in Atherosclerotic Vascular Inflammation. unassigned - 3.4.22.B28 Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/23171729/ Calpain and atherosclerosis. unassigned - 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/15158144/ Calpain inhibition prevents pacing-induced cellular remodeling in a HL-1 myocyte model for atrial fibrillation. causal interaction 2 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18577882/ Role of the Calpain System in Pulmonary Vein Connexin Remodeling in Dogs with Atrial Fibrillation. causal interaction 1 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18823990/ Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation. causal interaction 2 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/19882242/ Anti-apoptotic effects of a calpain inhibitor on cardiomyocytes in a canine rapid atrial fibrillation model. causal interaction 4 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/21108772/ Physiologic and Pathophysiologic Role of Calpain: Implications for the Occurrence of Atrial Fibrillation. causal interaction 4 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/15532451/ [Calpains and cardiac diseases] causal interaction 4 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18001554/ [Effect of calpain 1 on structural remodeling and contractile dysfunction in atrial fibrillation: experiment with dogs] causal interaction 1 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/21108772/ Physiologic and Pathophysiologic Role of Calpain: Implications for the Occurrence of Atrial Fibrillation. diagnostic usage 1 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18001554/ [Effect of calpain 1 on structural remodeling and contractile dysfunction in atrial fibrillation: experiment with dogs] diagnostic usage 3 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/15158144/ Calpain inhibition prevents pacing-induced cellular remodeling in a HL-1 myocyte model for atrial fibrillation. therapeutic application 3 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18577882/ Role of the Calpain System in Pulmonary Vein Connexin Remodeling in Dogs with Atrial Fibrillation. therapeutic application 1 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18823990/ Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation. therapeutic application 1 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/19813082/ Calpain in Atrial Fibrillation: Friend or Foe? : Editorial to: "Anti-apoptotic effects of a calpain inhibitor on cardiomyocytes in a canine rapid atrial fibrillation model" by Yue Li et al. therapeutic application 1 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/19882242/ Anti-apoptotic effects of a calpain inhibitor on cardiomyocytes in a canine rapid atrial fibrillation model. therapeutic application 4 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/21108772/ Physiologic and Pathophysiologic Role of Calpain: Implications for the Occurrence of Atrial Fibrillation. therapeutic application 1 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/15532451/ [Calpains and cardiac diseases] therapeutic application 3 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18001554/ [Effect of calpain 1 on structural remodeling and contractile dysfunction in atrial fibrillation: experiment with dogs] therapeutic application 1 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18208663/ Calpain I inhibition prevents atrial structural remodeling in a canine model with atrial fibrillation. therapeutic application 2 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18577882/ Role of the Calpain System in Pulmonary Vein Connexin Remodeling in Dogs with Atrial Fibrillation. ongoing research 2 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/19813082/ Calpain in Atrial Fibrillation: Friend or Foe? : Editorial to: "Anti-apoptotic effects of a calpain inhibitor on cardiomyocytes in a canine rapid atrial fibrillation model" by Yue Li et al. ongoing research 2 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/19882242/ Anti-apoptotic effects of a calpain inhibitor on cardiomyocytes in a canine rapid atrial fibrillation model. ongoing research 4 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18001554/ [Effect of calpain 1 on structural remodeling and contractile dysfunction in atrial fibrillation: experiment with dogs] ongoing research 3 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18208663/ Calpain I inhibition prevents atrial structural remodeling in a canine model with atrial fibrillation. ongoing research 1 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/19813082/ Calpain in Atrial Fibrillation: Friend or Foe? : Editorial to: "Anti-apoptotic effects of a calpain inhibitor on cardiomyocytes in a canine rapid atrial fibrillation model" by Yue Li et al. unassigned - 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18208663/ Calpain I inhibition prevents atrial structural remodeling in a canine model with atrial fibrillation. unassigned - 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/27123462/ Calpain-Calcineurin-Nuclear Factor Signaling and the Development of Atrial Fibrillation in Patients with Valvular Heart Disease and Diabetes. unassigned - 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/15158144/ Calpain inhibition prevents pacing-induced cellular remodeling in a HL-1 myocyte model for atrial fibrillation. unassigned - 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18577882/ Role of the Calpain System in Pulmonary Vein Connexin Remodeling in Dogs with Atrial Fibrillation. unassigned - 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/18823990/ Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation. unassigned - 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/19882242/ Anti-apoptotic effects of a calpain inhibitor on cardiomyocytes in a canine rapid atrial fibrillation model. unassigned - 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/15532451/ [Calpains and cardiac diseases] unassigned - 3.4.22.B28 Atrial Fibrillation https://pubmed.ncbi.nlm.nih.gov/21108772/ Physiologic and Pathophysiologic Role of Calpain: Implications for the Occurrence of Atrial Fibrillation. unassigned - 3.4.22.B28 Autoimmune Diseases https://pubmed.ncbi.nlm.nih.gov/25407941/ GWAS identifies four novel eosinophilic esophagitis loci. causal interaction 1 3.4.22.B28 Autoimmune Diseases https://pubmed.ncbi.nlm.nih.gov/25407941/ GWAS identifies four novel eosinophilic esophagitis loci. unassigned - 3.4.22.B28 Bacteremia https://pubmed.ncbi.nlm.nih.gov/24375267/ Calpains promote neutrophil recruitment and bacterial clearance in an acute bacterial peritonitis model. causal interaction 4 3.4.22.B28 Bacteremia https://pubmed.ncbi.nlm.nih.gov/24375267/ Calpains promote neutrophil recruitment and bacterial clearance in an acute bacterial peritonitis model. therapeutic application 4 3.4.22.B28 Bacteremia https://pubmed.ncbi.nlm.nih.gov/24375267/ Calpains promote neutrophil recruitment and bacterial clearance in an acute bacterial peritonitis model. ongoing research 4 3.4.22.B28 Bacteremia https://pubmed.ncbi.nlm.nih.gov/24375267/ Calpains promote neutrophil recruitment and bacterial clearance in an acute bacterial peritonitis model. unassigned - 3.4.22.B28 Bicuspid Aortic Valve Disease https://pubmed.ncbi.nlm.nih.gov/19720936/ Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms. causal interaction 1 3.4.22.B28 Bicuspid Aortic Valve Disease https://pubmed.ncbi.nlm.nih.gov/19720936/ Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms. unassigned - 3.4.22.B28 Blindness https://pubmed.ncbi.nlm.nih.gov/23428743/ Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract: In vivo and in vitro evaluation. causal interaction 2 3.4.22.B28 Blindness https://pubmed.ncbi.nlm.nih.gov/23428743/ Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract: In vivo and in vitro evaluation. unassigned - 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/9441801/ Prostacyclin analog-suppressed ischemia-reperfusion injury of the rat liver: evaluation by calpain mu activation. causal interaction 4 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/9749852/ Determination of a safe vascular clamping method for liver surgery: evaluation by measuring activation of calpain mu. causal interaction 1 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/11304481/ Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain. causal interaction 1 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/18666321/ Protective effect of prednisolone on ischemia-induced liver injury in rats. diagnostic usage 4 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/9441801/ Prostacyclin analog-suppressed ischemia-reperfusion injury of the rat liver: evaluation by calpain mu activation. therapeutic application 1 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/11304481/ Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain. therapeutic application 3 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/8964416/ Calpain activation in plasma membrane bleb formation during tert-butyl hydroperoxide-induced rat hepatocyte injury. ongoing research 4 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/9441801/ Prostacyclin analog-suppressed ischemia-reperfusion injury of the rat liver: evaluation by calpain mu activation. ongoing research 1 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/18076376/ Genetic disruption of calpain correlates with loss of membrane blebbing and differential expression of RhoGDI-1, cofilin and tropomyosin. ongoing research 4 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/18666321/ Protective effect of prednisolone on ischemia-induced liver injury in rats. ongoing research 4 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/8964416/ Calpain activation in plasma membrane bleb formation during tert-butyl hydroperoxide-induced rat hepatocyte injury. unassigned - 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/18076376/ Genetic disruption of calpain correlates with loss of membrane blebbing and differential expression of RhoGDI-1, cofilin and tropomyosin. unassigned - 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/18666321/ Protective effect of prednisolone on ischemia-induced liver injury in rats. unassigned - 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/19783801/ Role of purinergic receptor in alpha fodrin degradation in par c5 cells. unassigned - 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/9441801/ Prostacyclin analog-suppressed ischemia-reperfusion injury of the rat liver: evaluation by calpain mu activation. unassigned - 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/9749852/ Determination of a safe vascular clamping method for liver surgery: evaluation by measuring activation of calpain mu. unassigned - 3.4.22.B28 Blister https://pubmed.ncbi.nlm.nih.gov/11304481/ Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain. unassigned - 3.4.22.B28 Bone Resorption https://pubmed.ncbi.nlm.nih.gov/15809334/ Involvement of calpain in osteoclastic bone resorption. diagnostic usage 3 3.4.22.B28 Bone Resorption https://pubmed.ncbi.nlm.nih.gov/16461769/ Calpain is required for normal osteoclast function and is down-regulated by calcitonin. therapeutic application 3 3.4.22.B28 Bone Resorption https://pubmed.ncbi.nlm.nih.gov/15809334/ Involvement of calpain in osteoclastic bone resorption. ongoing research 4 3.4.22.B28 Bone Resorption https://pubmed.ncbi.nlm.nih.gov/15809334/ Involvement of calpain in osteoclastic bone resorption. unassigned - 3.4.22.B28 Bone Resorption https://pubmed.ncbi.nlm.nih.gov/16461769/ Calpain is required for normal osteoclast function and is down-regulated by calcitonin. unassigned - 3.4.22.B28 Brain Contusion https://pubmed.ncbi.nlm.nih.gov/16787640/ Relative effects of mannitol and hypertonic saline on calpain activity, apoptosis and polymorphonuclear infiltration in traumatic focal brain injury. ongoing research 4 3.4.22.B28 Brain Contusion https://pubmed.ncbi.nlm.nih.gov/16787640/ Relative effects of mannitol and hypertonic saline on calpain activity, apoptosis and polymorphonuclear infiltration in traumatic focal brain injury. unassigned - 3.4.22.B28 Brain Diseases https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. causal interaction 3 3.4.22.B28 Brain Diseases https://pubmed.ncbi.nlm.nih.gov/26551007/ Erythropoietin Modulates Cerebral and Serum Degradation Products from Excess Calpain Activation following Prenatal Hypoxia-Ischemia. causal interaction 1 3.4.22.B28 Brain Diseases https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. unassigned - 3.4.22.B28 Brain Diseases https://pubmed.ncbi.nlm.nih.gov/26551007/ Erythropoietin Modulates Cerebral and Serum Degradation Products from Excess Calpain Activation following Prenatal Hypoxia-Ischemia. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. causal interaction 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/16943669/ Regionally distinct patterns of calpain activation and traumatic axonal injury following contusive brain injury in immature rats. causal interaction 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/8965100/ Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. causal interaction 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/9089703/ Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity. causal interaction 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/10616794/ Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. causal interaction 3 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. causal interaction 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/12058036/ Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. causal interaction 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/12500971/ Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. causal interaction 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/14992597/ The beta- and gamma-CH2 of B27-WT's Leu11 and Ile18 side chains play a direct role in calpain inhibition. causal interaction 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/19141074/ Knockdown of m-calpain increases survival of primary hippocampal neurons following NMDA excitotoxicity. causal interaction 1 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. causal interaction 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/19422795/ A novel calpastatin-based inhibitor improves postischemic neurological recovery. causal interaction 3 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/20298691/ RNAi targeting micro-calpain increases neuron survival and preserves hippocampal function after global brain ischemia. causal interaction 1 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/22726623/ Introduction of calpain inhibitors in traumatic brain injury: A novel approach? causal interaction 3 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/32226486/ Calpastatin peptide attenuates early brain injury following experimental subarachnoid hemorrhage. causal interaction 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/11891778/ Hypothermia inhibits translocation of CaM kinase II and PKC-alpha, beta, gamma isoforms and fodrin proteolysis in rat brain synaptosome during ischemia-reperfusion. diagnostic usage 1 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. diagnostic usage 1 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. therapeutic application 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/15777753/ Calpain inhibitor MDL 28170 protects hypoxic-ischemic brain injury in neonatal rats by inhibition of both apoptosis and necrosis. therapeutic application 1 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/8965100/ Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. therapeutic application 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/9089703/ Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity. therapeutic application 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/10616794/ Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. therapeutic application 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. therapeutic application 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/12058036/ Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. therapeutic application 3 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/12500971/ Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. therapeutic application 1 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/14992597/ The beta- and gamma-CH2 of B27-WT's Leu11 and Ile18 side chains play a direct role in calpain inhibition. therapeutic application 2 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/18036155/ Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry. therapeutic application 1 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. therapeutic application 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/19422795/ A novel calpastatin-based inhibitor improves postischemic neurological recovery. therapeutic application 2 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/20298691/ RNAi targeting micro-calpain increases neuron survival and preserves hippocampal function after global brain ischemia. therapeutic application 2 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/22726623/ Introduction of calpain inhibitors in traumatic brain injury: A novel approach? therapeutic application 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. therapeutic application 1 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/32226486/ Calpastatin peptide attenuates early brain injury following experimental subarachnoid hemorrhage. therapeutic application 1 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. ongoing research 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/15777753/ Calpain inhibitor MDL 28170 protects hypoxic-ischemic brain injury in neonatal rats by inhibition of both apoptosis and necrosis. ongoing research 2 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/16787640/ Relative effects of mannitol and hypertonic saline on calpain activity, apoptosis and polymorphonuclear infiltration in traumatic focal brain injury. ongoing research 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/8965100/ Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. ongoing research 3 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/18036155/ Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry. ongoing research 1 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. ongoing research 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/19422795/ A novel calpastatin-based inhibitor improves postischemic neurological recovery. ongoing research 1 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/20298691/ RNAi targeting micro-calpain increases neuron survival and preserves hippocampal function after global brain ischemia. ongoing research 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. ongoing research 4 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/15777753/ Calpain inhibitor MDL 28170 protects hypoxic-ischemic brain injury in neonatal rats by inhibition of both apoptosis and necrosis. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/16787640/ Relative effects of mannitol and hypertonic saline on calpain activity, apoptosis and polymorphonuclear infiltration in traumatic focal brain injury. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/11891778/ Hypothermia inhibits translocation of CaM kinase II and PKC-alpha, beta, gamma isoforms and fodrin proteolysis in rat brain synaptosome during ischemia-reperfusion. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/17018026/ Identification and characterization of PEBP as a calpain substrate. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/17543553/ Memory impairments and hippocampal modifications in adult rats with neonatal isolation stress experience. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/18036155/ Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/20032879/ Calpain inhibition reduces axolemmal leakage in traumatic axonal injury. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/16943669/ Regionally distinct patterns of calpain activation and traumatic axonal injury following contusive brain injury in immature rats. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/8965100/ Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/9089703/ Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/10616794/ Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/12058036/ Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/12500971/ Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/14992597/ The beta- and gamma-CH2 of B27-WT's Leu11 and Ile18 side chains play a direct role in calpain inhibition. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/19141074/ Knockdown of m-calpain increases survival of primary hippocampal neurons following NMDA excitotoxicity. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/19422795/ A novel calpastatin-based inhibitor improves postischemic neurological recovery. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/20298691/ RNAi targeting micro-calpain increases neuron survival and preserves hippocampal function after global brain ischemia. unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/22726623/ Introduction of calpain inhibitors in traumatic brain injury: A novel approach? unassigned - 3.4.22.B28 Brain Injuries https://pubmed.ncbi.nlm.nih.gov/32226486/ Calpastatin peptide attenuates early brain injury following experimental subarachnoid hemorrhage. unassigned - 3.4.22.B28 Brain Injuries, Diffuse https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. causal interaction 4 3.4.22.B28 Brain Injuries, Diffuse https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. therapeutic application 4 3.4.22.B28 Brain Injuries, Diffuse https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. ongoing research 2 3.4.22.B28 Brain Injuries, Diffuse https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9070759/ A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. causal interaction 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9104930/ Mechanisms of calpain proteolysis following traumatic brain injury: implications for pathology and therapy: implications for pathology and therapy: a review and update. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15816594/ Moderate hypothermia, but not calpain inhibitor 2, attenuates the proteolysis of microtubule-associated protein 2 in the hippocampus following traumatic brain injury in rats. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/17263667/ Basic science; repetitive mild non-contusive brain trauma in immature rats exacerbates traumatic axonal injury and axonal calpain activation: a preliminary report. causal interaction 2 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/20129495/ Calpain as a therapeutic target in traumatic brain injury. causal interaction 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/22726623/ Introduction of calpain inhibitors in traumatic brain injury: A novel approach? causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/28091411/ Protective Effects of Calpain Inhibition on Neurovascular Unit Injury through Downregulating Nuclear Factor-?B-related Inflammation during Traumatic Brain Injury in Mice. causal interaction 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/30876457/ Calpain inhibitor MDL28170 improves the transplantation-mediated therapeutic effect of bone marrow-derived mesenchymal stem cells following traumatic brain injury. causal interaction 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. causal interaction 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/8858942/ mu-calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury. causal interaction 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9469158/ Subcellular localization and duration of mu-calpain and m-calpain activity after traumatic brain injury in the rat: a casein zymography study. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/10383627/ Calpain activation and inhibition in organotypic rat hippocampal slice cultures deprived of oxygen and glucose. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/10616794/ Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. causal interaction 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/12843408/ The calpain system. causal interaction 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/14734865/ Tacrolimus and cyclosporine A are of no benefit to young rats with kaolin-induced hydrocephalus. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15907950/ Neuroprotective effects of novel small peptides in vitro and after brain injury. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16312145/ Developments in the design and synthesis of calpain inhibitors. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16504408/ Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16943669/ Regionally distinct patterns of calpain activation and traumatic axonal injury following contusive brain injury in immature rats. causal interaction 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16956607/ Inhibition of calpain-mediated cell death by a novel peptide inhibitor. causal interaction 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/17600513/ Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/17715012/ [Time course of calpain activity changes in rat neurons following fluid percussion injury and the interventional effect of mild hypothermia] causal interaction 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/22077394/ Short-duration treatment with the calpain inhibitor MDL-28170 does not protect axonal transport in an in vivo model of traumatic axonal injury. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/22428606/ Mechanisms of calpain mediated proteolysis of voltage gated sodium channel ?-subunits following in vitro dynamic stretch injury. causal interaction 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23305291/ Brain injury-induced proteolysis is reduced in a novel calpastatin-overexpressing transgenic mouse. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23710421/ Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases. causal interaction 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/24691765/ Citicoline Protects Brain Against Closed Head Injury in Rats Through Suppressing Oxidative Stress and Calpain Over-Activation. causal interaction 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/27119554/ Protective effects of PARP inhibitor, PJ34, is related to down-regulation of calpain and NF-?B in a mouse model of TBI. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/28642177/ Protective functions of PJ34, a PARP inhibitor, is related to down-regulation of calpain and NF-?B in a mouse model of TBI. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/30145792/ Melatonin, a calpain inhibitor in the central nervous system: Current status and future perspectives. causal interaction 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/30149198/ Controlled cortical impact-induced neurodegeneration decreases after administration of the novel calpain-inhibitor Gabadur. causal interaction 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/32904488/ CPCGI Reduces Gray and White Matter Injury by Upregulating Nrf2 Signaling and Suppressing Calpain Overactivation in a Rat Model of Controlled Cortical Impact. causal interaction 2 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/33790315/ Age-dependent ataxia and neurodegeneration caused by an ?II spectrin mutation with impaired regulation of its calpain sensitivity. causal interaction 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23390828/ Calpain expression in the brain cortex after traumatic brain injury. diagnostic usage 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9469158/ Subcellular localization and duration of mu-calpain and m-calpain activity after traumatic brain injury in the rat: a casein zymography study. diagnostic usage 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9637408/ pH dependency of mu-calpain and m-calpain activity assayed by casein zymography following traumatic brain injury in the rat. diagnostic usage 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15193288/ Proteins released from degenerating neurons are surrogate markers for acute brain damage. diagnostic usage 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16504408/ Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate. diagnostic usage 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/20408766/ alphaII-Spectrin Breakdown Products (SBDPs): Diagnosis and Outcome in Severe Traumatic Brain Injury Patients. diagnostic usage 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. diagnostic usage 2 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/22428606/ Mechanisms of calpain mediated proteolysis of voltage gated sodium channel ?-subunits following in vitro dynamic stretch injury. diagnostic usage 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/31640160/ Novel Peptidomic Approach for Identification of Low and High Molecular Weight Tauopathy Peptides Following Calpain Digestion, and Primary Culture Neurotoxic Challenges. diagnostic usage 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9070759/ A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9104930/ Mechanisms of calpain proteolysis following traumatic brain injury: implications for pathology and therapy: implications for pathology and therapy: a review and update. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15529012/ Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15816594/ Moderate hypothermia, but not calpain inhibitor 2, attenuates the proteolysis of microtubule-associated protein 2 in the hippocampus following traumatic brain injury in rats. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/20129495/ Calpain as a therapeutic target in traumatic brain injury. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/22726623/ Introduction of calpain inhibitors in traumatic brain injury: A novel approach? therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23216523/ Pharmacological analysis of the cortical neuronal cytoskeletal protective efficacy of the calpain inhibitor SNJ-1945 in a mouse traumatic brain injury model. therapeutic application 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/24917042/ Dual vulnerability of TDP-43 to calpain and caspase-3 proteolysis after neurotoxic conditions and traumatic brain injury. therapeutic application 2 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/30876457/ Calpain inhibitor MDL28170 improves the transplantation-mediated therapeutic effect of bone marrow-derived mesenchymal stem cells following traumatic brain injury. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/8858942/ mu-calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9469158/ Subcellular localization and duration of mu-calpain and m-calpain activity after traumatic brain injury in the rat: a casein zymography study. therapeutic application 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9989462/ Altered calpastatin protein levels following traumatic brain injury in rat. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/10383627/ Calpain activation and inhibition in organotypic rat hippocampal slice cultures deprived of oxygen and glucose. therapeutic application 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/10616794/ Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/12843408/ The calpain system. therapeutic application 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/14734865/ Tacrolimus and cyclosporine A are of no benefit to young rats with kaolin-induced hydrocephalus. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. therapeutic application 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16312145/ Developments in the design and synthesis of calpain inhibitors. therapeutic application 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16504408/ Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate. therapeutic application 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16954597/ Calpain and synaptic function. therapeutic application 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16956607/ Inhibition of calpain-mediated cell death by a novel peptide inhibitor. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/22077394/ Short-duration treatment with the calpain inhibitor MDL-28170 does not protect axonal transport in an in vivo model of traumatic axonal injury. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23305291/ Brain injury-induced proteolysis is reduced in a novel calpastatin-overexpressing transgenic mouse. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23710421/ Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases. therapeutic application 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/24691765/ Citicoline Protects Brain Against Closed Head Injury in Rats Through Suppressing Oxidative Stress and Calpain Over-Activation. therapeutic application 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/25836613/ Propofol ameliorates calpain-induced collapsin response mediator protein-2 proteolysis in traumatic brain injury in rats. therapeutic application 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/27119554/ Protective effects of PARP inhibitor, PJ34, is related to down-regulation of calpain and NF-?B in a mouse model of TBI. therapeutic application 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/28642177/ Protective functions of PJ34, a PARP inhibitor, is related to down-regulation of calpain and NF-?B in a mouse model of TBI. therapeutic application 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/30149198/ Controlled cortical impact-induced neurodegeneration decreases after administration of the novel calpain-inhibitor Gabadur. therapeutic application 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/32904488/ CPCGI Reduces Gray and White Matter Injury by Upregulating Nrf2 Signaling and Suppressing Calpain Overactivation in a Rat Model of Controlled Cortical Impact. therapeutic application 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/33790315/ Age-dependent ataxia and neurodegeneration caused by an ?II spectrin mutation with impaired regulation of its calpain sensitivity. therapeutic application 2 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9070759/ A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. ongoing research 2 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15529012/ Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. ongoing research 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15816594/ Moderate hypothermia, but not calpain inhibitor 2, attenuates the proteolysis of microtubule-associated protein 2 in the hippocampus following traumatic brain injury in rats. ongoing research 2 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23216523/ Pharmacological analysis of the cortical neuronal cytoskeletal protective efficacy of the calpain inhibitor SNJ-1945 in a mouse traumatic brain injury model. ongoing research 1 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23390828/ Calpain expression in the brain cortex after traumatic brain injury. ongoing research 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/28091411/ Protective Effects of Calpain Inhibition on Neurovascular Unit Injury through Downregulating Nuclear Factor-?B-related Inflammation during Traumatic Brain Injury in Mice. ongoing research 3 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/30876457/ Calpain inhibitor MDL28170 improves the transplantation-mediated therapeutic effect of bone marrow-derived mesenchymal stem cells following traumatic brain injury. ongoing research 2 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. ongoing research 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9469158/ Subcellular localization and duration of mu-calpain and m-calpain activity after traumatic brain injury in the rat: a casein zymography study. ongoing research 4 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9637408/ pH dependency of mu-calpain and m-calpain activity assayed by casein zymography following traumatic brain injury in the rat. ongoing research 2 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. ongoing research 2 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15307896/ Effects of injury severity on regional and temporal mRNA expression levels of calpains and caspases after traumatic brain injury in rats. ongoing research 2 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9721910/ Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15529012/ Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16125733/ Concurrent calpain and caspase-3 mediated proteolysis of alpha II-spectrin and tau in rat brain after methamphetamine exposure: a similar profile to traumatic brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16893416/ Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/20874056/ A PHARMACOLOGICAL ANALYSIS OF THE NEUROPROTECTIVE EFFICACY OF THE BRAIN AND CELL PERMEABLE CALPAIN INHIBITOR MDL-28170 IN THE MOUSE CONTROLLED CORTICAL IMPACT TRAUMATIC BRAIN INJURY MODEL. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23216523/ Pharmacological analysis of the cortical neuronal cytoskeletal protective efficacy of the calpain inhibitor SNJ-1945 in a mouse traumatic brain injury model. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23390828/ Calpain expression in the brain cortex after traumatic brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/24917042/ Dual vulnerability of TDP-43 to calpain and caspase-3 proteolysis after neurotoxic conditions and traumatic brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9637408/ pH dependency of mu-calpain and m-calpain activity assayed by casein zymography following traumatic brain injury in the rat. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9989462/ Altered calpastatin protein levels following traumatic brain injury in rat. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15193288/ Proteins released from degenerating neurons are surrogate markers for acute brain damage. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15307896/ Effects of injury severity on regional and temporal mRNA expression levels of calpains and caspases after traumatic brain injury in rats. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16841024/ Detection of aII-spectrin and breakdown products in humans after severe traumatic brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16954597/ Calpain and synaptic function. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/17375999/ Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/20408766/ alphaII-Spectrin Breakdown Products (SBDPs): Diagnosis and Outcome in Severe Traumatic Brain Injury Patients. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/25836613/ Propofol ameliorates calpain-induced collapsin response mediator protein-2 proteolysis in traumatic brain injury in rats. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/31640160/ Novel Peptidomic Approach for Identification of Low and High Molecular Weight Tauopathy Peptides Following Calpain Digestion, and Primary Culture Neurotoxic Challenges. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9070759/ A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/9104930/ Mechanisms of calpain proteolysis following traumatic brain injury: implications for pathology and therapy: implications for pathology and therapy: a review and update. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15816594/ Moderate hypothermia, but not calpain inhibitor 2, attenuates the proteolysis of microtubule-associated protein 2 in the hippocampus following traumatic brain injury in rats. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/17263667/ Basic science; repetitive mild non-contusive brain trauma in immature rats exacerbates traumatic axonal injury and axonal calpain activation: a preliminary report. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/20129495/ Calpain as a therapeutic target in traumatic brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/22726623/ Introduction of calpain inhibitors in traumatic brain injury: A novel approach? unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/28091411/ Protective Effects of Calpain Inhibition on Neurovascular Unit Injury through Downregulating Nuclear Factor-?B-related Inflammation during Traumatic Brain Injury in Mice. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/30876457/ Calpain inhibitor MDL28170 improves the transplantation-mediated therapeutic effect of bone marrow-derived mesenchymal stem cells following traumatic brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/8858942/ mu-calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/10383627/ Calpain activation and inhibition in organotypic rat hippocampal slice cultures deprived of oxygen and glucose. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/10616794/ Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/12843408/ The calpain system. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/14734865/ Tacrolimus and cyclosporine A are of no benefit to young rats with kaolin-induced hydrocephalus. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/15907950/ Neuroprotective effects of novel small peptides in vitro and after brain injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16312145/ Developments in the design and synthesis of calpain inhibitors. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16943669/ Regionally distinct patterns of calpain activation and traumatic axonal injury following contusive brain injury in immature rats. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16956607/ Inhibition of calpain-mediated cell death by a novel peptide inhibitor. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/17600513/ Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/17715012/ [Time course of calpain activity changes in rat neurons following fluid percussion injury and the interventional effect of mild hypothermia] unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/22077394/ Short-duration treatment with the calpain inhibitor MDL-28170 does not protect axonal transport in an in vivo model of traumatic axonal injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23305291/ Brain injury-induced proteolysis is reduced in a novel calpastatin-overexpressing transgenic mouse. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/23710421/ Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/24691765/ Citicoline Protects Brain Against Closed Head Injury in Rats Through Suppressing Oxidative Stress and Calpain Over-Activation. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/27119554/ Protective effects of PARP inhibitor, PJ34, is related to down-regulation of calpain and NF-?B in a mouse model of TBI. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/28642177/ Protective functions of PJ34, a PARP inhibitor, is related to down-regulation of calpain and NF-?B in a mouse model of TBI. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/30145792/ Melatonin, a calpain inhibitor in the central nervous system: Current status and future perspectives. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/30149198/ Controlled cortical impact-induced neurodegeneration decreases after administration of the novel calpain-inhibitor Gabadur. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/32904488/ CPCGI Reduces Gray and White Matter Injury by Upregulating Nrf2 Signaling and Suppressing Calpain Overactivation in a Rat Model of Controlled Cortical Impact. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/33790315/ Age-dependent ataxia and neurodegeneration caused by an ?II spectrin mutation with impaired regulation of its calpain sensitivity. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/22428606/ Mechanisms of calpain mediated proteolysis of voltage gated sodium channel ?-subunits following in vitro dynamic stretch injury. unassigned - 3.4.22.B28 Brain Injuries, Traumatic https://pubmed.ncbi.nlm.nih.gov/16504408/ Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9445345/ Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9701348/ Calpain mediates eukaryotic initiation factor 4G degradation during global brain ischemia. causal interaction 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/11372450/ [Effects of 3-N-butylphthalide on cortical calcineurin and calpain activities in focal cerebral ischemia rats] causal interaction 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/15036603/ Delayed moderate hypothermia reduces calpain activity and breakdown of its substrate in experimental focal cerebral ischemia in rats. causal interaction 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/15978171/ Calpain inhibitor A-558693 in experimental focal cerebral ischemia in rats. causal interaction 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/16763180/ Cathepsin and calpain inhibitor E64d attenuates matrix metalloproteinase-9 activity after focal cerebral ischemia in rats. causal interaction 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17168715/ Currently evaluated calpain and caspase inhibitors for neuroprotection in experimental brain ischemia. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17712625/ Neuroprotective mechanism of taurine due to up-regulating calpastatin and down-regulating calpain and caspase-3 during focal cerebral ischemia. causal interaction 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18338260/ Activation of calpain, cathepsin-b and caspase-3 during transient focal cerebral ischemia in rat model. causal interaction 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/19947509/ [Study advancement of calpain and apoptosis following cerebral ischemia] causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/1706637/ Suppressive effect of E-64c on ischemic degradation of cerebral proteins following occlusion of the middle cerebral artery in rats. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/7477738/ Calpain as a novel target for treating acute neurodegenerative disorders. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8522983/ Brain mu-calpain autolysis during global cerebral ischemia. causal interaction 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8898691/ Microtubular proteolysis in focal cerebral ischemia. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9282922/ Neuronal nitric oxide synthase and calmodulin-dependent protein kinase IIalpha undergo neurotoxin-induced proteolysis. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/11421581/ Calpain activity in the rat brain after transient forebrain ischemia. causal interaction 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/12427474/ Decrease of PKC precedes other cellular signs of calpain activation in area CA1 of the hippocampus after transient cerebral ischemia. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/12828932/ Ischemic neuronal death in the rat hippocampus: the calpain-calpastatin-caspase hypothesis. causal interaction 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/16495451/ Calpain-cleaved collapsin response mediator protein-3 induces neuronal death after glutamate toxicity and cerebral ischemia. causal interaction 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17593948/ Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17728442/ Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. causal interaction 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18353231/ [Protective effect of calpain inhibitor-3 on hypoxic-ischemic brain damage of neonatal rats] causal interaction 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18544498/ Permissive and repulsive cues and signalling pathways of axonal outgrowth and regeneration. causal interaction 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. causal interaction 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/22118687/ Hsp70.1 and related lysosomal factors for necrotic neuronal death. causal interaction 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/26093380/ Calpain-Dependent ErbB4 Cleavage Is Involved in Brain Ischemia-Induced Neuronal Death. causal interaction 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/32689584/ Dapsone prolong delayed excitotoxic neuronal cell death by interacting with proapoptotic/survival signaling proteins. causal interaction 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/16763180/ Cathepsin and calpain inhibitor E64d attenuates matrix metalloproteinase-9 activity after focal cerebral ischemia in rats. diagnostic usage 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8207497/ Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. diagnostic usage 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8522983/ Brain mu-calpain autolysis during global cerebral ischemia. diagnostic usage 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18157632/ Cross-talk Between Calpain and Caspase-3 in Penumbra and Core During Focal Cerebral Ischemia-reperfusion. diagnostic usage 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. diagnostic usage 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/7974554/ Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8128523/ Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8946783/ Calpain as proposed target for neuroprotective treatment of brain ischemia. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9445345/ Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9701348/ Calpain mediates eukaryotic initiation factor 4G degradation during global brain ischemia. therapeutic application 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/10208584/ Increased intracellular calpain detection in experimental focal cerebral ischemia. therapeutic application 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/15036603/ Delayed moderate hypothermia reduces calpain activity and breakdown of its substrate in experimental focal cerebral ischemia in rats. therapeutic application 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/15978171/ Calpain inhibitor A-558693 in experimental focal cerebral ischemia in rats. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/16763180/ Cathepsin and calpain inhibitor E64d attenuates matrix metalloproteinase-9 activity after focal cerebral ischemia in rats. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/16805817/ Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia. therapeutic application 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17168715/ Currently evaluated calpain and caspase inhibitors for neuroprotection in experimental brain ischemia. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17712625/ Neuroprotective mechanism of taurine due to up-regulating calpastatin and down-regulating calpain and caspase-3 during focal cerebral ischemia. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18338260/ Activation of calpain, cathepsin-b and caspase-3 during transient focal cerebral ischemia in rat model. therapeutic application 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/19947509/ [Study advancement of calpain and apoptosis following cerebral ischemia] therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/28190474/ Salvianolic acid A inhibits calpain activation and eNOS uncoupling during focal cerebral ischemia in mice. therapeutic application 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/1706637/ Suppressive effect of E-64c on ischemic degradation of cerebral proteins following occlusion of the middle cerebral artery in rats. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/7477738/ Calpain as a novel target for treating acute neurodegenerative disorders. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8207497/ Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. therapeutic application 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8508322/ Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8522983/ Brain mu-calpain autolysis during global cerebral ischemia. therapeutic application 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8898691/ Microtubular proteolysis in focal cerebral ischemia. therapeutic application 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9637399/ Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. therapeutic application 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/10082855/ Calpain inhibitor entrapped in liposome rescues ischemic neuronal damage. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/12270691/ Comparison of calpain and caspase activities in the adult rat brain after transient forebrain ischemia. therapeutic application 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/12427474/ Decrease of PKC precedes other cellular signs of calpain activation in area CA1 of the hippocampus after transient cerebral ischemia. therapeutic application 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/12828932/ Ischemic neuronal death in the rat hippocampus: the calpain-calpastatin-caspase hypothesis. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. therapeutic application 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/15804424/ Spatial resolution of calpain-catalyzed proteolysis in focal cerebral ischemia. therapeutic application 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/16495451/ Calpain-cleaved collapsin response mediator protein-3 induces neuronal death after glutamate toxicity and cerebral ischemia. therapeutic application 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17683803/ Hippocampal CA1 cell loss in a non-human primate model of transient global ischemia: a pilot study. therapeutic application 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17728442/ Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18353231/ [Protective effect of calpain inhibitor-3 on hypoxic-ischemic brain damage of neonatal rats] therapeutic application 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18544498/ Permissive and repulsive cues and signalling pathways of axonal outgrowth and regeneration. therapeutic application 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18835333/ A novel calpain inhibitor, ((1S)-1((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester, protects neuronal cells from cerebral ischemia-induced damage in mice. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. therapeutic application 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/21430162/ Cleavage of the Vesicular GABA Transporter under Excitotoxic Conditions Is Followed by Accumulation of the Truncated Transporter in Nonsynaptic Sites. therapeutic application 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. therapeutic application 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/26093380/ Calpain-Dependent ErbB4 Cleavage Is Involved in Brain Ischemia-Induced Neuronal Death. therapeutic application 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/32689584/ Dapsone prolong delayed excitotoxic neuronal cell death by interacting with proapoptotic/survival signaling proteins. therapeutic application 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/7974554/ Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration. ongoing research 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8128523/ Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia. ongoing research 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9445345/ Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. ongoing research 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/10208584/ Increased intracellular calpain detection in experimental focal cerebral ischemia. ongoing research 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/11372450/ [Effects of 3-N-butylphthalide on cortical calcineurin and calpain activities in focal cerebral ischemia rats] ongoing research 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/15036603/ Delayed moderate hypothermia reduces calpain activity and breakdown of its substrate in experimental focal cerebral ischemia in rats. ongoing research 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/15978171/ Calpain inhibitor A-558693 in experimental focal cerebral ischemia in rats. ongoing research 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/16805817/ Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia. ongoing research 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17712625/ Neuroprotective mechanism of taurine due to up-regulating calpastatin and down-regulating calpain and caspase-3 during focal cerebral ischemia. ongoing research 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18338260/ Activation of calpain, cathepsin-b and caspase-3 during transient focal cerebral ischemia in rat model. ongoing research 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/19947509/ [Study advancement of calpain and apoptosis following cerebral ischemia] ongoing research 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/28190474/ Salvianolic acid A inhibits calpain activation and eNOS uncoupling during focal cerebral ischemia in mice. ongoing research 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8207497/ Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. ongoing research 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8522983/ Brain mu-calpain autolysis during global cerebral ischemia. ongoing research 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9637399/ Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. ongoing research 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/10082086/ Species differences in fodrin proteolysis in the ischemic brain. ongoing research 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. ongoing research 2 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/15804424/ Spatial resolution of calpain-catalyzed proteolysis in focal cerebral ischemia. ongoing research 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18157632/ Cross-talk Between Calpain and Caspase-3 in Penumbra and Core During Focal Cerebral Ischemia-reperfusion. ongoing research 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18353231/ [Protective effect of calpain inhibitor-3 on hypoxic-ischemic brain damage of neonatal rats] ongoing research 1 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. ongoing research 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/21430162/ Cleavage of the Vesicular GABA Transporter under Excitotoxic Conditions Is Followed by Accumulation of the Truncated Transporter in Nonsynaptic Sites. ongoing research 3 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. ongoing research 4 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/7974554/ Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8128523/ Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8946783/ Calpain as proposed target for neuroprotective treatment of brain ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/10208584/ Increased intracellular calpain detection in experimental focal cerebral ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/16805817/ Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/28190474/ Salvianolic acid A inhibits calpain activation and eNOS uncoupling during focal cerebral ischemia in mice. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8207497/ Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8508322/ Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9637399/ Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/10082086/ Species differences in fodrin proteolysis in the ischemic brain. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/10082855/ Calpain inhibitor entrapped in liposome rescues ischemic neuronal damage. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/10372919/ Ischemia-induced modifications of protein components of rat brain postsynaptic densities. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/12270691/ Comparison of calpain and caspase activities in the adult rat brain after transient forebrain ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/12957494/ Huntingtin is degraded to small fragments by calpain after ischemic injury. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/15804424/ Spatial resolution of calpain-catalyzed proteolysis in focal cerebral ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17672855/ Calpain cleavage of collapsin response mediator proteins in ischemic mouse brain. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17683803/ Hippocampal CA1 cell loss in a non-human primate model of transient global ischemia: a pilot study. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18157632/ Cross-talk Between Calpain and Caspase-3 in Penumbra and Core During Focal Cerebral Ischemia-reperfusion. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18835333/ A novel calpain inhibitor, ((1S)-1((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester, protects neuronal cells from cerebral ischemia-induced damage in mice. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/21430162/ Cleavage of the Vesicular GABA Transporter under Excitotoxic Conditions Is Followed by Accumulation of the Truncated Transporter in Nonsynaptic Sites. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9445345/ Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9701348/ Calpain mediates eukaryotic initiation factor 4G degradation during global brain ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/11372450/ [Effects of 3-N-butylphthalide on cortical calcineurin and calpain activities in focal cerebral ischemia rats] unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/15036603/ Delayed moderate hypothermia reduces calpain activity and breakdown of its substrate in experimental focal cerebral ischemia in rats. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/15978171/ Calpain inhibitor A-558693 in experimental focal cerebral ischemia in rats. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17168715/ Currently evaluated calpain and caspase inhibitors for neuroprotection in experimental brain ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17712625/ Neuroprotective mechanism of taurine due to up-regulating calpastatin and down-regulating calpain and caspase-3 during focal cerebral ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18338260/ Activation of calpain, cathepsin-b and caspase-3 during transient focal cerebral ischemia in rat model. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/19947509/ [Study advancement of calpain and apoptosis following cerebral ischemia] unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/1706637/ Suppressive effect of E-64c on ischemic degradation of cerebral proteins following occlusion of the middle cerebral artery in rats. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/7477738/ Calpain as a novel target for treating acute neurodegenerative disorders. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/8898691/ Microtubular proteolysis in focal cerebral ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/9282922/ Neuronal nitric oxide synthase and calmodulin-dependent protein kinase IIalpha undergo neurotoxin-induced proteolysis. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/11421581/ Calpain activity in the rat brain after transient forebrain ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/12427474/ Decrease of PKC precedes other cellular signs of calpain activation in area CA1 of the hippocampus after transient cerebral ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/12828932/ Ischemic neuronal death in the rat hippocampus: the calpain-calpastatin-caspase hypothesis. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/16495451/ Calpain-cleaved collapsin response mediator protein-3 induces neuronal death after glutamate toxicity and cerebral ischemia. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17593948/ Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/17728442/ Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18353231/ [Protective effect of calpain inhibitor-3 on hypoxic-ischemic brain damage of neonatal rats] unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18544498/ Permissive and repulsive cues and signalling pathways of axonal outgrowth and regeneration. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/22118687/ Hsp70.1 and related lysosomal factors for necrotic neuronal death. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/26093380/ Calpain-Dependent ErbB4 Cleavage Is Involved in Brain Ischemia-Induced Neuronal Death. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/32689584/ Dapsone prolong delayed excitotoxic neuronal cell death by interacting with proapoptotic/survival signaling proteins. unassigned - 3.4.22.B28 Brain Ischemia https://pubmed.ncbi.nlm.nih.gov/16763180/ Cathepsin and calpain inhibitor E64d attenuates matrix metalloproteinase-9 activity after focal cerebral ischemia in rats. unassigned - 3.4.22.B28 Brain Neoplasms https://pubmed.ncbi.nlm.nih.gov/12111801/ Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. causal interaction 4 3.4.22.B28 Brain Neoplasms https://pubmed.ncbi.nlm.nih.gov/30959065/ A new human calpastatin skipped of the inhibitory region protects calpain-1 from inactivation and degradation. therapeutic application 1 3.4.22.B28 Brain Neoplasms https://pubmed.ncbi.nlm.nih.gov/12111801/ Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. ongoing research 2 3.4.22.B28 Brain Neoplasms https://pubmed.ncbi.nlm.nih.gov/30959065/ A new human calpastatin skipped of the inhibitory region protects calpain-1 from inactivation and degradation. ongoing research 4 3.4.22.B28 Brain Neoplasms https://pubmed.ncbi.nlm.nih.gov/30959065/ A new human calpastatin skipped of the inhibitory region protects calpain-1 from inactivation and degradation. unassigned - 3.4.22.B28 Brain Neoplasms https://pubmed.ncbi.nlm.nih.gov/12111801/ Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/8687127/ Possible involvement of calpain in the growth of estrogen receptor positive breast cancer cells. causal interaction 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/12072431/ Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. causal interaction 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/17848600/ Mitochondria, calcium, and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946330/ Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/22745213/ Calpain system protein expression in basal-like and triple-negative invasive breast cancer. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/26330354/ Calpain in Breast Cancer: Role in Disease Progression and Treatment Response. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/26771715/ Calpain restrains the stem cells compartment in breast cancer. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27323818/ The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. causal interaction 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/28521486/ Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/9353308/ Regulation of cyclin D1 by calpain protease. causal interaction 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. causal interaction 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/11091548/ Ca²+;-Dependent Neutral Protease (Calpain) Activity in Breast Cancer Tissue and Estrogen Receptor Status. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. causal interaction 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/15225813/ Calcium as a mediator of 1,25-dihydroxyvitamin D3-induced apoptosis. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/16322214/ Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/18332219/ Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. causal interaction 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/20659425/ I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway. causal interaction 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. causal interaction 2 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27798717/ Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/28536704/ Calpain-1 Expression in Triple-Negative Breast Cancer: A Potential Prognostic Factor Independent of the Proliferative/Apoptotic Index. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/32825941/ The expression of calpain-1 and androgen receptor in breast cancer and their correlation with clinicopathological characteristics: An immunohistochemical retrospective study. causal interaction 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/8687127/ Possible involvement of calpain in the growth of estrogen receptor positive breast cancer cells. diagnostic usage 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/12569370/ Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain. diagnostic usage 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946330/ Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. diagnostic usage 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/22745213/ Calpain system protein expression in basal-like and triple-negative invasive breast cancer. diagnostic usage 2 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27323818/ The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. diagnostic usage 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/11091548/ Ca²+;-Dependent Neutral Protease (Calpain) Activity in Breast Cancer Tissue and Estrogen Receptor Status. diagnostic usage 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. diagnostic usage 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/15591784/ TransMiner: mining transitive associations among biological objects from text. diagnostic usage 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/16322214/ Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. diagnostic usage 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/20659425/ I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway. diagnostic usage 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/21531560/ Calpastatin is associated with lymphovascular invasion in breast cancer. diagnostic usage 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/23684705/ Modulation by Syk of Bcl-2, calcium and the calpain-calpastatin proteolytic system in human breast cancer cells. diagnostic usage 2 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27798717/ Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. diagnostic usage 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/28536704/ Calpain-1 Expression in Triple-Negative Breast Cancer: A Potential Prognostic Factor Independent of the Proliferative/Apoptotic Index. diagnostic usage 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/32825941/ The expression of calpain-1 and androgen receptor in breast cancer and their correlation with clinicopathological characteristics: An immunohistochemical retrospective study. diagnostic usage 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/12569370/ Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946330/ Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. therapeutic application 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/22745213/ Calpain system protein expression in basal-like and triple-negative invasive breast cancer. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/26246600/ Ezrin regulates focal adhesion and invadopodia dynamics by altering calpain activity to promote breast cancer cell invasion. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/26330354/ Calpain in Breast Cancer: Role in Disease Progression and Treatment Response. therapeutic application 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/26771715/ Calpain restrains the stem cells compartment in breast cancer. therapeutic application 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27323818/ The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/28521486/ Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. therapeutic application 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/9353308/ Regulation of cyclin D1 by calpain protease. therapeutic application 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/11091548/ Ca²+;-Dependent Neutral Protease (Calpain) Activity in Breast Cancer Tissue and Estrogen Receptor Status. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. therapeutic application 2 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/15225813/ Calcium as a mediator of 1,25-dihydroxyvitamin D3-induced apoptosis. therapeutic application 2 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/16322214/ Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. therapeutic application 2 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/16891067/ The induction of CYP1A1 by oltipraz is mediated through calcium-dependent-calpain. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/18332219/ Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/20659425/ I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/21531560/ Calpastatin is associated with lymphovascular invasion in breast cancer. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/24553345/ Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ?PK oncolytic activity in melanoma. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/25436724/ Regulation of apoptosis in adipocytes and breast cancer cells by 1,25-dihydroxyvitamin D3: a link between obesity and breast cancer. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. therapeutic application 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/30959065/ A new human calpastatin skipped of the inhibitory region protects calpain-1 from inactivation and degradation. therapeutic application 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/32825941/ The expression of calpain-1 and androgen receptor in breast cancer and their correlation with clinicopathological characteristics: An immunohistochemical retrospective study. therapeutic application 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/8687127/ Possible involvement of calpain in the growth of estrogen receptor positive breast cancer cells. ongoing research 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946330/ Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. ongoing research 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/22745213/ Calpain system protein expression in basal-like and triple-negative invasive breast cancer. ongoing research 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/26330354/ Calpain in Breast Cancer: Role in Disease Progression and Treatment Response. ongoing research 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/26771715/ Calpain restrains the stem cells compartment in breast cancer. ongoing research 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27323818/ The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. ongoing research 2 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/28521486/ Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. ongoing research 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/9216645/ Mechanism of growth inhibition by calpain inhibitor in MCF-7 cells. ongoing research 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. ongoing research 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/11091548/ Ca²+;-Dependent Neutral Protease (Calpain) Activity in Breast Cancer Tissue and Estrogen Receptor Status. ongoing research 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. ongoing research 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. ongoing research 2 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/18332219/ Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. ongoing research 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. ongoing research 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/21531560/ Calpastatin is associated with lymphovascular invasion in breast cancer. ongoing research 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/22449977/ 17beta-estradiol induces both up-regulation and processing of cyclin E in a calpain-dependent manner in MCF-7 breast cancer cells. ongoing research 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. ongoing research 3 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27798717/ Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. ongoing research 1 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/30959065/ A new human calpastatin skipped of the inhibitory region protects calpain-1 from inactivation and degradation. ongoing research 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/32825941/ The expression of calpain-1 and androgen receptor in breast cancer and their correlation with clinicopathological characteristics: An immunohistochemical retrospective study. ongoing research 4 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/12569370/ Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/26246600/ Ezrin regulates focal adhesion and invadopodia dynamics by altering calpain activity to promote breast cancer cell invasion. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/9216645/ Mechanism of growth inhibition by calpain inhibitor in MCF-7 cells. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/15591784/ TransMiner: mining transitive associations among biological objects from text. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/16891067/ The induction of CYP1A1 by oltipraz is mediated through calcium-dependent-calpain. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/21531560/ Calpastatin is associated with lymphovascular invasion in breast cancer. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/22449977/ 17beta-estradiol induces both up-regulation and processing of cyclin E in a calpain-dependent manner in MCF-7 breast cancer cells. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/23684705/ Modulation by Syk of Bcl-2, calcium and the calpain-calpastatin proteolytic system in human breast cancer cells. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/24440569/ Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/24553345/ Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ?PK oncolytic activity in melanoma. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/25436724/ Regulation of apoptosis in adipocytes and breast cancer cells by 1,25-dihydroxyvitamin D3: a link between obesity and breast cancer. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/30959065/ A new human calpastatin skipped of the inhibitory region protects calpain-1 from inactivation and degradation. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/12072431/ Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/17848600/ Mitochondria, calcium, and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/26330354/ Calpain in Breast Cancer: Role in Disease Progression and Treatment Response. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/26771715/ Calpain restrains the stem cells compartment in breast cancer. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/28521486/ Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/9353308/ Regulation of cyclin D1 by calpain protease. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/15225813/ Calcium as a mediator of 1,25-dihydroxyvitamin D3-induced apoptosis. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/18332219/ Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/8687127/ Possible involvement of calpain in the growth of estrogen receptor positive breast cancer cells. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27798717/ Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/28536704/ Calpain-1 Expression in Triple-Negative Breast Cancer: A Potential Prognostic Factor Independent of the Proliferative/Apoptotic Index. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/16322214/ Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. unassigned - 3.4.22.B28 Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/20659425/ I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway. unassigned - 3.4.22.B28 Burkitt Lymphoma https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. causal interaction 4 3.4.22.B28 Burkitt Lymphoma https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. diagnostic usage 3 3.4.22.B28 Burkitt Lymphoma https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. therapeutic application 4 3.4.22.B28 Burkitt Lymphoma https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. ongoing research 4 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/30617810/ Genetic Models of Calpain Deficiency and Ectopic Expression. causal interaction 3 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/17332428/ Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. causal interaction 4 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/9655129/ Pseudometabolic expression and phenotypic variability of calpain deficiency in two siblings. causal interaction 4 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. causal interaction 4 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/21030783/ Expanding members and roles of the calpain superfamily and their genetically modified animals. causal interaction 4 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/11731278/ Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. causal interaction 3 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/12461690/ Clinical variability in calpainopathy: what makes the difference? causal interaction 3 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/21670566/ Calpain chronicle--an enzyme family under multidisciplinary characterization. causal interaction 1 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/12721303/ Calpains mediate p53 activation and neuronal death evoked by DNA damage. causal interaction 3 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/22825607/ Analysis of calpain-3 protein in muscle biopsies of different muscular dystrophies from India. causal interaction 2 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. causal interaction 4 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. causal interaction 3 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/16597616/ Ubiquitous calpains promote caspase-12 and JNK activation during endoplasmic reticulum stress-induced apoptosis. causal interaction 3 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/17101693/ Calpain is required for macroautophagy in mammalian cells. causal interaction 4 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/19258295/ Partial epilepsy in an adolescent male with limb-girdle muscular dystrophy 1B. causal interaction 4 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/11731278/ Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. diagnostic usage 2 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/22825607/ Analysis of calpain-3 protein in muscle biopsies of different muscular dystrophies from India. diagnostic usage 3 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/17332428/ Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. therapeutic application 1 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. therapeutic application 1 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/21610046/ Impact of genetic insights into calpain biology. therapeutic application 1 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/22825607/ Analysis of calpain-3 protein in muscle biopsies of different muscular dystrophies from India. therapeutic application 1 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. therapeutic application 1 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/10101785/ [Alterations in functional proteins. Calpaine-3 deficiency] therapeutic application 1 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/30617810/ Genetic Models of Calpain Deficiency and Ectopic Expression. ongoing research 3 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. ongoing research 2 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/22825607/ Analysis of calpain-3 protein in muscle biopsies of different muscular dystrophies from India. ongoing research 3 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. ongoing research 2 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/21610046/ Impact of genetic insights into calpain biology. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/10101785/ [Alterations in functional proteins. Calpaine-3 deficiency] unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/30617810/ Genetic Models of Calpain Deficiency and Ectopic Expression. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/17332428/ Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/9655129/ Pseudometabolic expression and phenotypic variability of calpain deficiency in two siblings. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/26966280/ Leukocyte Calpain Deficiency Reduces Angiotensin II-Induced Inflammation and Atherosclerosis But Not Abdominal Aortic Aneurysms in Mice. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/21030783/ Expanding members and roles of the calpain superfamily and their genetically modified animals. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/12461690/ Clinical variability in calpainopathy: what makes the difference? unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/21670566/ Calpain chronicle--an enzyme family under multidisciplinary characterization. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/12721303/ Calpains mediate p53 activation and neuronal death evoked by DNA damage. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/16597616/ Ubiquitous calpains promote caspase-12 and JNK activation during endoplasmic reticulum stress-induced apoptosis. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/17101693/ Calpain is required for macroautophagy in mammalian cells. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/19258295/ Partial epilepsy in an adolescent male with limb-girdle muscular dystrophy 1B. unassigned - 3.4.22.B28 calpain 8 deficiency https://pubmed.ncbi.nlm.nih.gov/11731278/ Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/10906334/ Antisense RNA-mediated deficiency of the calpain protease, nCL-4, in NIH3T3 cells is associated with neoplastic transformation and tumorigenesis. causal interaction 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. causal interaction 2 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/9701243/ The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. causal interaction 2 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/9988224/ Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. causal interaction 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. causal interaction 2 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. causal interaction 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. causal interaction 3 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. causal interaction 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/21030783/ Expanding members and roles of the calpain superfamily and their genetically modified animals. causal interaction 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/21508973/ The calpain system and cancer. causal interaction 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. causal interaction 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/27798717/ Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. causal interaction 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. causal interaction 3 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/33470511/ Calpain-calpastatin system and cancer progression. causal interaction 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/33719969/ Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer. causal interaction 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/9988224/ Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. diagnostic usage 3 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. diagnostic usage 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. diagnostic usage 1 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. diagnostic usage 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/20686710/ Calpain 8/nCL-2 and calpain 9/nCL-4 constitute an active protease complex, G-calpain, involved in gastric mucosal defense. diagnostic usage 1 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/21508973/ The calpain system and cancer. diagnostic usage 3 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/27798717/ Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. diagnostic usage 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. diagnostic usage 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/10906334/ Antisense RNA-mediated deficiency of the calpain protease, nCL-4, in NIH3T3 cells is associated with neoplastic transformation and tumorigenesis. therapeutic application 1 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. therapeutic application 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/9988224/ Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. therapeutic application 3 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. therapeutic application 1 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. therapeutic application 1 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/21508973/ The calpain system and cancer. therapeutic application 1 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. therapeutic application 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. therapeutic application 3 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/33470511/ Calpain-calpastatin system and cancer progression. therapeutic application 2 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. ongoing research 3 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/9988224/ Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. ongoing research 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. ongoing research 1 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. ongoing research 4 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. ongoing research 2 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/21508973/ The calpain system and cancer. ongoing research 3 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. ongoing research 1 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/27798717/ Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. ongoing research 1 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. ongoing research 3 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/12054425/ Evidence for involvement of calpain in c-Myc proteolysis in vivo. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/20686710/ Calpain 8/nCL-2 and calpain 9/nCL-4 constitute an active protease complex, G-calpain, involved in gastric mucosal defense. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/10906334/ Antisense RNA-mediated deficiency of the calpain protease, nCL-4, in NIH3T3 cells is associated with neoplastic transformation and tumorigenesis. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/9701243/ The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/21030783/ Expanding members and roles of the calpain superfamily and their genetically modified animals. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/33470511/ Calpain-calpastatin system and cancer progression. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/33719969/ Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. unassigned - 3.4.22.B28 Carcinogenesis https://pubmed.ncbi.nlm.nih.gov/27798717/ Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. unassigned - 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. causal interaction 3 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/23269488/ Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities. causal interaction 1 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/29518545/ The study of the calpain and caspase-1 expression in ultrastructural dynamics of Ehrlich ascites carcinoma necrosis. causal interaction 4 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/33552245/ Inhibition of mitochondrial and cytosolic calpain attenuates atrophy in myotubes co-cultured with colon carcinoma cells. causal interaction 4 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. causal interaction 1 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. causal interaction 4 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. causal interaction 3 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/22510412/ The tyrosine phosphatase HD-PTP (PTPN23) is degraded by calpains in a calcium-dependent manner. causal interaction 4 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/24514433/ Capn4 mRNA level is correlated with tumour progression and clinical outcome in clear cell renal cell carcinoma. causal interaction 4 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/30737623/ Expression of Syk and MAP4 proteins in ovarian cancer. causal interaction 4 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. diagnostic usage 1 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/23140395/ Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla. diagnostic usage 3 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/23269488/ Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities. diagnostic usage 2 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/29518545/ The study of the calpain and caspase-1 expression in ultrastructural dynamics of Ehrlich ascites carcinoma necrosis. diagnostic usage 3 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. diagnostic usage 3 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/24514433/ Capn4 mRNA level is correlated with tumour progression and clinical outcome in clear cell renal cell carcinoma. diagnostic usage 4 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/30737623/ Expression of Syk and MAP4 proteins in ovarian cancer. diagnostic usage 3 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. therapeutic application 1 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. therapeutic application 4 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. therapeutic application 1 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/22510412/ The tyrosine phosphatase HD-PTP (PTPN23) is degraded by calpains in a calcium-dependent manner. therapeutic application 3 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. ongoing research 4 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/23269488/ Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities. ongoing research 3 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/29518545/ The study of the calpain and caspase-1 expression in ultrastructural dynamics of Ehrlich ascites carcinoma necrosis. ongoing research 1 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. ongoing research 3 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. ongoing research 4 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/17630920/ Nicotine, lung and cancer. ongoing research 2 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. ongoing research 1 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/24514433/ Capn4 mRNA level is correlated with tumour progression and clinical outcome in clear cell renal cell carcinoma. ongoing research 2 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/30737623/ Expression of Syk and MAP4 proteins in ovarian cancer. ongoing research 4 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/23140395/ Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla. unassigned - 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/17630920/ Nicotine, lung and cancer. unassigned - 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/33552245/ Inhibition of mitochondrial and cytosolic calpain attenuates atrophy in myotubes co-cultured with colon carcinoma cells. unassigned - 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. unassigned - 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. unassigned - 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/22510412/ The tyrosine phosphatase HD-PTP (PTPN23) is degraded by calpains in a calcium-dependent manner. unassigned - 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. unassigned - 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/23269488/ Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities. unassigned - 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/29518545/ The study of the calpain and caspase-1 expression in ultrastructural dynamics of Ehrlich ascites carcinoma necrosis. unassigned - 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/24514433/ Capn4 mRNA level is correlated with tumour progression and clinical outcome in clear cell renal cell carcinoma. unassigned - 3.4.22.B28 Carcinoma https://pubmed.ncbi.nlm.nih.gov/30737623/ Expression of Syk and MAP4 proteins in ovarian cancer. unassigned - 3.4.22.B28 Carcinoma, Basal Cell https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. causal interaction 3 3.4.22.B28 Carcinoma, Basal Cell https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. diagnostic usage 1 3.4.22.B28 Carcinoma, Basal Cell https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. ongoing research 4 3.4.22.B28 Carcinoma, Basal Cell https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. unassigned - 3.4.22.B28 Carcinoma, Embryonal https://pubmed.ncbi.nlm.nih.gov/10674630/ Activation of calpain precedes morphological alterations during hydrogen peroxide-induced apoptosis in neuronally differentiated mouse embryonal carcinoma P19 cell line. ongoing research 2 3.4.22.B28 Carcinoma, Embryonal https://pubmed.ncbi.nlm.nih.gov/10674630/ Activation of calpain precedes morphological alterations during hydrogen peroxide-induced apoptosis in neuronally differentiated mouse embryonal carcinoma P19 cell line. unassigned - 3.4.22.B28 Carcinoma, Hepatocellular https://pubmed.ncbi.nlm.nih.gov/17400802/ Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling. causal interaction 3 3.4.22.B28 Carcinoma, Hepatocellular https://pubmed.ncbi.nlm.nih.gov/17400802/ Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling. therapeutic application 1 3.4.22.B28 Carcinoma, Hepatocellular https://pubmed.ncbi.nlm.nih.gov/16891617/ Calpain mediates the dioxin-induced activation and down-regulation of the aryl hydrocarbon receptor. therapeutic application 2 3.4.22.B28 Carcinoma, Hepatocellular https://pubmed.ncbi.nlm.nih.gov/17400802/ Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling. ongoing research 1 3.4.22.B28 Carcinoma, Hepatocellular https://pubmed.ncbi.nlm.nih.gov/26351921/ Phenobarbital inhibits calpain activity and expression in mouse hepatoma cells. ongoing research 4 3.4.22.B28 Carcinoma, Hepatocellular https://pubmed.ncbi.nlm.nih.gov/26634820/ SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity. ongoing research 4 3.4.22.B28 Carcinoma, Hepatocellular https://pubmed.ncbi.nlm.nih.gov/8655597/ Hepatocellular carcinoma cells resist necrosis during anoxia by preventing phospholipase-mediated calpain activation. unassigned - 3.4.22.B28 Carcinoma, Hepatocellular https://pubmed.ncbi.nlm.nih.gov/26351921/ Phenobarbital inhibits calpain activity and expression in mouse hepatoma cells. unassigned - 3.4.22.B28 Carcinoma, Hepatocellular https://pubmed.ncbi.nlm.nih.gov/16891617/ Calpain mediates the dioxin-induced activation and down-regulation of the aryl hydrocarbon receptor. unassigned - 3.4.22.B28 Carcinoma, Hepatocellular https://pubmed.ncbi.nlm.nih.gov/26634820/ SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity. unassigned - 3.4.22.B28 Carcinoma, Hepatocellular https://pubmed.ncbi.nlm.nih.gov/17400802/ Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling. unassigned - 3.4.22.B28 Carcinoma, Non-Small-Cell Lung https://pubmed.ncbi.nlm.nih.gov/32069035/ Noninvasive Early Detection of Calpain 2-Enriched Non-Small Cell Lung Cancer Using a Human Serum Albumin-Bounded Calpain 2 Nanosensor. causal interaction 4 3.4.22.B28 Carcinoma, Non-Small-Cell Lung https://pubmed.ncbi.nlm.nih.gov/15471877/ Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. causal interaction 4 3.4.22.B28 Carcinoma, Non-Small-Cell Lung https://pubmed.ncbi.nlm.nih.gov/32069035/ Noninvasive Early Detection of Calpain 2-Enriched Non-Small Cell Lung Cancer Using a Human Serum Albumin-Bounded Calpain 2 Nanosensor. diagnostic usage 3 3.4.22.B28 Carcinoma, Non-Small-Cell Lung https://pubmed.ncbi.nlm.nih.gov/32069035/ Noninvasive Early Detection of Calpain 2-Enriched Non-Small Cell Lung Cancer Using a Human Serum Albumin-Bounded Calpain 2 Nanosensor. therapeutic application 1 3.4.22.B28 Carcinoma, Non-Small-Cell Lung https://pubmed.ncbi.nlm.nih.gov/15471877/ Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. ongoing research 1 3.4.22.B28 Carcinoma, Non-Small-Cell Lung https://pubmed.ncbi.nlm.nih.gov/15471877/ Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. unassigned - 3.4.22.B28 Carcinoma, Non-Small-Cell Lung https://pubmed.ncbi.nlm.nih.gov/32069035/ Noninvasive Early Detection of Calpain 2-Enriched Non-Small Cell Lung Cancer Using a Human Serum Albumin-Bounded Calpain 2 Nanosensor. unassigned - 3.4.22.B28 Carcinoma, Renal Cell https://pubmed.ncbi.nlm.nih.gov/24514433/ Capn4 mRNA level is correlated with tumour progression and clinical outcome in clear cell renal cell carcinoma. causal interaction 4 3.4.22.B28 Carcinoma, Renal Cell https://pubmed.ncbi.nlm.nih.gov/24514433/ Capn4 mRNA level is correlated with tumour progression and clinical outcome in clear cell renal cell carcinoma. diagnostic usage 4 3.4.22.B28 Carcinoma, Renal Cell https://pubmed.ncbi.nlm.nih.gov/24514433/ Capn4 mRNA level is correlated with tumour progression and clinical outcome in clear cell renal cell carcinoma. ongoing research 2 3.4.22.B28 Carcinoma, Renal Cell https://pubmed.ncbi.nlm.nih.gov/17989922/ The interaction of superoxide with nitric oxide destabilizes hypoxia-inducible factor-1alpha. unassigned - 3.4.22.B28 Carcinoma, Renal Cell https://pubmed.ncbi.nlm.nih.gov/24514433/ Capn4 mRNA level is correlated with tumour progression and clinical outcome in clear cell renal cell carcinoma. unassigned - 3.4.22.B28 Carcinoma, Squamous Cell https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. causal interaction 3 3.4.22.B28 Carcinoma, Squamous Cell https://pubmed.ncbi.nlm.nih.gov/23269488/ Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities. causal interaction 1 3.4.22.B28 Carcinoma, Squamous Cell https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. diagnostic usage 1 3.4.22.B28 Carcinoma, Squamous Cell https://pubmed.ncbi.nlm.nih.gov/23269488/ Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities. diagnostic usage 2 3.4.22.B28 Carcinoma, Squamous Cell https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. ongoing research 4 3.4.22.B28 Carcinoma, Squamous Cell https://pubmed.ncbi.nlm.nih.gov/23269488/ Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities. ongoing research 3 3.4.22.B28 Carcinoma, Squamous Cell https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. unassigned - 3.4.22.B28 Carcinoma, Squamous Cell https://pubmed.ncbi.nlm.nih.gov/23269488/ Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities. unassigned - 3.4.22.B28 Cardiac Output, Low https://pubmed.ncbi.nlm.nih.gov/10071251/ Ultrastructural changes in myocardial cells of rats fed a low protein diet. unassigned - 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/32768940/ ?-adrenergic activation may promote myosin light chain kinase degradation through calpain in pressure overload-induced cardiac hypertrophy: ?-adrenergic activation results in MLCK degradation. causal interaction 4 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/9406168/ A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy. causal interaction 4 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/18487434/ In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. causal interaction 3 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/21817165/ Tear me down: role of calpain in the development of cardiac ventricular hypertrophy. causal interaction 4 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/26489456/ Calpains and Coronary Vascular Disease. causal interaction 4 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/26597853/ Expression of nuclear factor of activated T cells (NFAT) and downstream muscle-specific proteins in ground squirrel skeletal and heart muscle during hibernation. causal interaction 1 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/30915659/ Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2. causal interaction 4 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/9406168/ A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy. diagnostic usage 3 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/30915659/ Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2. diagnostic usage 4 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/32768940/ ?-adrenergic activation may promote myosin light chain kinase degradation through calpain in pressure overload-induced cardiac hypertrophy: ?-adrenergic activation results in MLCK degradation. therapeutic application 2 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/18487434/ In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. therapeutic application 4 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/21817165/ Tear me down: role of calpain in the development of cardiac ventricular hypertrophy. therapeutic application 4 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/26489456/ Calpains and Coronary Vascular Disease. therapeutic application 3 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/30915659/ Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2. therapeutic application 1 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/9406168/ A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy. ongoing research 3 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/18487434/ In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. ongoing research 3 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/32768940/ ?-adrenergic activation may promote myosin light chain kinase degradation through calpain in pressure overload-induced cardiac hypertrophy: ?-adrenergic activation results in MLCK degradation. unassigned - 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/18487434/ In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. unassigned - 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/21817165/ Tear me down: role of calpain in the development of cardiac ventricular hypertrophy. unassigned - 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/26489456/ Calpains and Coronary Vascular Disease. unassigned - 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/26597853/ Expression of nuclear factor of activated T cells (NFAT) and downstream muscle-specific proteins in ground squirrel skeletal and heart muscle during hibernation. unassigned - 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/9406168/ A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy. unassigned - 3.4.22.B28 Cardiomegaly https://pubmed.ncbi.nlm.nih.gov/30915659/ Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2. unassigned - 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/24996291/ Protective effect of calpain inhibitor N-acetyl-L-leucyl-L-leucyl-L-norleucinal on acute alcohol consumption related cardiomyopathy. causal interaction 3 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/27880847/ Activation of Both the Calpain and Ubiquitin-Proteasome Systems Contributes to Septic Cardiomyopathy through Dystrophin Loss/Disruption and mTOR Inhibition. causal interaction 2 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/21946105/ Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. causal interaction 3 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/30915659/ Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2. causal interaction 4 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/27880847/ Activation of Both the Calpain and Ubiquitin-Proteasome Systems Contributes to Septic Cardiomyopathy through Dystrophin Loss/Disruption and mTOR Inhibition. diagnostic usage 3 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/30915659/ Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2. diagnostic usage 4 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/24996291/ Protective effect of calpain inhibitor N-acetyl-L-leucyl-L-leucyl-L-norleucinal on acute alcohol consumption related cardiomyopathy. therapeutic application 3 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/27880847/ Activation of Both the Calpain and Ubiquitin-Proteasome Systems Contributes to Septic Cardiomyopathy through Dystrophin Loss/Disruption and mTOR Inhibition. therapeutic application 1 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/21946105/ Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. therapeutic application 4 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/30915659/ Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2. therapeutic application 1 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/24996291/ Protective effect of calpain inhibitor N-acetyl-L-leucyl-L-leucyl-L-norleucinal on acute alcohol consumption related cardiomyopathy. ongoing research 3 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/24996291/ Protective effect of calpain inhibitor N-acetyl-L-leucyl-L-leucyl-L-norleucinal on acute alcohol consumption related cardiomyopathy. unassigned - 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/21946105/ Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. unassigned - 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/27880847/ Activation of Both the Calpain and Ubiquitin-Proteasome Systems Contributes to Septic Cardiomyopathy through Dystrophin Loss/Disruption and mTOR Inhibition. unassigned - 3.4.22.B28 Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/30915659/ Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2. unassigned - 3.4.22.B28 Cardiomyopathy, Dilated https://pubmed.ncbi.nlm.nih.gov/17332428/ Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. causal interaction 4 3.4.22.B28 Cardiomyopathy, Dilated https://pubmed.ncbi.nlm.nih.gov/17332428/ Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. therapeutic application 1 3.4.22.B28 Cardiomyopathy, Dilated https://pubmed.ncbi.nlm.nih.gov/17332428/ Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. unassigned - 3.4.22.B28 Cardiotoxicity https://pubmed.ncbi.nlm.nih.gov/23455548/ Over-expression of calpastatin aggravates cardiotoxicity induced by doxorubicin. therapeutic application 2 3.4.22.B28 Cardiotoxicity https://pubmed.ncbi.nlm.nih.gov/23455548/ Over-expression of calpastatin aggravates cardiotoxicity induced by doxorubicin. unassigned - 3.4.22.B28 Cardiovascular Diseases https://pubmed.ncbi.nlm.nih.gov/12824289/ A novel role for calpains in the endothelial dysfunction of hyperglycemia. causal interaction 4 3.4.22.B28 Cardiovascular Diseases https://pubmed.ncbi.nlm.nih.gov/31319178/ Calpain regulates CVB3 induced viral myocarditis by promoting autophagic flux upon infection. causal interaction 3 3.4.22.B28 Cardiovascular Diseases https://pubmed.ncbi.nlm.nih.gov/12824289/ A novel role for calpains in the endothelial dysfunction of hyperglycemia. therapeutic application 3 3.4.22.B28 Cardiovascular Diseases https://pubmed.ncbi.nlm.nih.gov/31319178/ Calpain regulates CVB3 induced viral myocarditis by promoting autophagic flux upon infection. therapeutic application 4 3.4.22.B28 Cardiovascular Diseases https://pubmed.ncbi.nlm.nih.gov/12824289/ A novel role for calpains in the endothelial dysfunction of hyperglycemia. ongoing research 3 3.4.22.B28 Cardiovascular Diseases https://pubmed.ncbi.nlm.nih.gov/21887410/ Conventional calpains and programmed cell death. unassigned - 3.4.22.B28 Cardiovascular Diseases https://pubmed.ncbi.nlm.nih.gov/32375599/ RNA-sequencing analysis of differential gene expression associated with arterial stiffness. unassigned - 3.4.22.B28 Cardiovascular Diseases https://pubmed.ncbi.nlm.nih.gov/12824289/ A novel role for calpains in the endothelial dysfunction of hyperglycemia. unassigned - 3.4.22.B28 Cardiovascular Diseases https://pubmed.ncbi.nlm.nih.gov/31319178/ Calpain regulates CVB3 induced viral myocarditis by promoting autophagic flux upon infection. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1440613/ Comparison of cell-permeable calpain inhibitors and E64 in reduction of cataract in cultured rat lenses. causal interaction 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1608594/ Hydration and elevated calcium alone do not produce xylose nuclear cataract: role of proteolysis by calpain. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/7720403/ Proteolysis by calpain is an underlying mechanism for formation of sugar cataract in rat lens. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/8319493/ Role of calpain in hydrogen peroxide induced cataract. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/8420967/ Sequence analysis of lens beta-crystallins suggests involvement of calpain in cataract formation. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9375805/ SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: amelioration of cataract in cultured rat lenses. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9434095/ Evidence for the involvement of calpain in cataractogenesis in Shumiya cataract rat (SCR). causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9739461/ Modelling cortical cataractogenesis. XXIX. Calpain proteolysis of lens fodrin in cataract. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11095908/ Cataract formation by a semiquinone metabolite of acetaminophen in mice: possible involvement of Ca(2+)and calpain activation. causal interaction 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11462167/ Calpain inhibitor, SJA6017, reduces the rate of formation of selenite cataract in rats. causal interaction 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11572469/ Naphthoquinone-Induced cataract in mice: possible involvement of Ca2+ release and calpain activation. causal interaction 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15101113/ Expression and proteolytic activity of calpain in lens epithelial cells of oxidative cataract. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/16303960/ Calpain may contribute to hereditary cataract formation in sheep. causal interaction 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/25583491/ Altered ubiquitin causes perturbed calcium homeostasis, hyperactivation of calpain, dysregulated differentiation, and cataract. causal interaction 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/25628419/ Correction for Liu et al., Altered ubiquitin causes perturbed calcium homeostasis, hyperactivation of calpain, dysregulated differentiation, and cataract. causal interaction 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/27130368/ Calpain and Caspase-12 Expression in Lens Epithelial Cells of Diabetic Cataracts. causal interaction 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1848210/ Amelioration of cataracts and proteolysis in cultured lenses by cysteine protease inhibitor E64. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1914502/ Cysteine protease inhibitor E64 reduces the rate of formation of selenite cataract in the whole animal. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2998702/ Age-related changes of calpain II and alpha-crystallin in the lens of hereditary cataract (Nakano) mouse. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/7847693/ Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/7855906/ Calpain inhibition: an overview of its therapeutic potential. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9196396/ Changes in calpain II mRNA in young rat lens during maturation and cataract formation. causal interaction 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9243307/ Immunohistochemical study of calpain-mediated alpha-crystallin proteolysis in the UPL rat hereditary cataract. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9894158/ Calpain inhibitors reduce the cornified cell envelope formation by inhibiting proteolytic processing of transglutaminase 1. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/10415455/ Oxidation enhances calpain-induced turbidity in young rat lenses. causal interaction 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11725957/ Effect of calpain on hereditary cataractous rat, ICR/f. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/12457873/ Contribution of ubiquitous calpains to cataractogenesis in the spontaneous diabetic WBN/Kob rat. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/12500971/ Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/12658553/ Comparison of Lp82- and m-calpain-mediated proteolysis during cataractogenesis in Shumiya cataract rat (SCR). causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/14601627/ Cellular events preceding acetaminophen cataractogenesis studied by confocal fluorescence microscopy. causal interaction 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/16312145/ Developments in the design and synthesis of calpain inhibitors. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/18326725/ Susceptibility of ovine lens crystallins to proteolytic cleavage during formation of hereditary cataract. causal interaction 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/18702462/ Cocrystal structures of primed side-extending alpha-ketoamide inhibitors reveal novel calpain-inhibitor aromatic interactions. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/19094987/ Vitex negundo attenuates calpain activation and cataractogenesis in selenite models. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/21978083/ Eye lens in aging and diabetes: effect of quercetin. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/23428743/ Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract: In vivo and in vitro evaluation. causal interaction 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/27168717/ Regulatory effect of chrysin on expression of lenticular calcium transporters, calpains, and apoptotic-cascade components in selenite-induced cataract. causal interaction 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/28759231/ Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides. causal interaction 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1608594/ Hydration and elevated calcium alone do not produce xylose nuclear cataract: role of proteolysis by calpain. diagnostic usage 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15101113/ Expression and proteolytic activity of calpain in lens epithelial cells of oxidative cataract. diagnostic usage 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/16303960/ Calpain may contribute to hereditary cataract formation in sheep. diagnostic usage 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/27130368/ Calpain and Caspase-12 Expression in Lens Epithelial Cells of Diabetic Cataracts. diagnostic usage 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2209751/ Calpain II in two in vivo models of sugar cataract. diagnostic usage 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2820891/ Regional distribution of free calcium in selenite cataract: relation to calpain II. diagnostic usage 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/7847693/ Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. diagnostic usage 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9196396/ Changes in calpain II mRNA in young rat lens during maturation and cataract formation. diagnostic usage 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9663852/ Nuclear cataract and light scattering in cultured lenses from guinea pig and rabbit. diagnostic usage 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. diagnostic usage 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1440613/ Comparison of cell-permeable calpain inhibitors and E64 in reduction of cataract in cultured rat lenses. therapeutic application 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1608594/ Hydration and elevated calcium alone do not produce xylose nuclear cataract: role of proteolysis by calpain. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1644187/ Involvement of calpain in diamide-induced cataract in cultured lenses. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/8319493/ Role of calpain in hydrogen peroxide induced cataract. therapeutic application 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9375805/ SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: amelioration of cataract in cultured rat lenses. therapeutic application 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9434095/ Evidence for the involvement of calpain in cataractogenesis in Shumiya cataract rat (SCR). therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11095908/ Cataract formation by a semiquinone metabolite of acetaminophen in mice: possible involvement of Ca(2+)and calpain activation. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11262616/ Comparison of various calpain inhibitors in reduction of light scattering, protein precipitation and nuclear cataract in vitro. therapeutic application 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11462167/ Calpain inhibitor, SJA6017, reduces the rate of formation of selenite cataract in rats. therapeutic application 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/16303960/ Calpain may contribute to hereditary cataract formation in sheep. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/19278481/ Evaluation of a novel calpain inhibitor as a treatment for cataract. therapeutic application 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/23211821/ A macrocyclic calpain inhibitor slows the development of inherited cortical cataracts in a sheep model. therapeutic application 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/25628419/ Correction for Liu et al., Altered ubiquitin causes perturbed calcium homeostasis, hyperactivation of calpain, dysregulated differentiation, and cataract. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/27130368/ Calpain and Caspase-12 Expression in Lens Epithelial Cells of Diabetic Cataracts. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1463773/ Superior prevention of calcium ionophore cataract by E64d. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1848210/ Amelioration of cataracts and proteolysis in cultured lenses by cysteine protease inhibitor E64. therapeutic application 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1914502/ Cysteine protease inhibitor E64 reduces the rate of formation of selenite cataract in the whole animal. therapeutic application 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2209751/ Calpain II in two in vivo models of sugar cataract. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2820891/ Regional distribution of free calcium in selenite cataract: relation to calpain II. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2998702/ Age-related changes of calpain II and alpha-crystallin in the lens of hereditary cataract (Nakano) mouse. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/7855906/ Calpain inhibition: an overview of its therapeutic potential. therapeutic application 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11725957/ Effect of calpain on hereditary cataractous rat, ICR/f. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/12500971/ Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15362500/ The in vitro retardation of porcine cataractogenesis by the calpain inhibitor, SJA6017. therapeutic application 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. therapeutic application 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/16312145/ Developments in the design and synthesis of calpain inhibitors. therapeutic application 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/16684519/ Low activity by the calpain system in primate lenses causes resistance to calcium-induced proteolysis. therapeutic application 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/28759231/ Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides. therapeutic application 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1440613/ Comparison of cell-permeable calpain inhibitors and E64 in reduction of cataract in cultured rat lenses. ongoing research 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1608594/ Hydration and elevated calcium alone do not produce xylose nuclear cataract: role of proteolysis by calpain. ongoing research 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1644187/ Involvement of calpain in diamide-induced cataract in cultured lenses. ongoing research 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9375805/ SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: amelioration of cataract in cultured rat lenses. ongoing research 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9846621/ Lp82 calpain during rat lens maturation and cataract formation. ongoing research 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11095908/ Cataract formation by a semiquinone metabolite of acetaminophen in mice: possible involvement of Ca(2+)and calpain activation. ongoing research 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11262616/ Comparison of various calpain inhibitors in reduction of light scattering, protein precipitation and nuclear cataract in vitro. ongoing research 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11462167/ Calpain inhibitor, SJA6017, reduces the rate of formation of selenite cataract in rats. ongoing research 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11572469/ Naphthoquinone-Induced cataract in mice: possible involvement of Ca2+ release and calpain activation. ongoing research 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15101113/ Expression and proteolytic activity of calpain in lens epithelial cells of oxidative cataract. ongoing research 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/19278481/ Evaluation of a novel calpain inhibitor as a treatment for cataract. ongoing research 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/23211821/ A macrocyclic calpain inhibitor slows the development of inherited cortical cataracts in a sheep model. ongoing research 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/27130368/ Calpain and Caspase-12 Expression in Lens Epithelial Cells of Diabetic Cataracts. ongoing research 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1848210/ Amelioration of cataracts and proteolysis in cultured lenses by cysteine protease inhibitor E64. ongoing research 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2209751/ Calpain II in two in vivo models of sugar cataract. ongoing research 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2820891/ Regional distribution of free calcium in selenite cataract: relation to calpain II. ongoing research 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2998702/ Age-related changes of calpain II and alpha-crystallin in the lens of hereditary cataract (Nakano) mouse. ongoing research 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/7847693/ Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. ongoing research 1 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/8395520/ alpha-Crystallin chaperone activity is reduced by calpain II in vitro and in selenite cataract. ongoing research 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9196396/ Changes in calpain II mRNA in young rat lens during maturation and cataract formation. ongoing research 3 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9663852/ Nuclear cataract and light scattering in cultured lenses from guinea pig and rabbit. ongoing research 2 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/16684519/ Low activity by the calpain system in primate lenses causes resistance to calcium-induced proteolysis. ongoing research 4 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1644187/ Involvement of calpain in diamide-induced cataract in cultured lenses. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/3036741/ Origin of urea-soluble protein in the selenite cataract. Role of beta-crystallin proteolysis and calpain II. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/8579611/ Calcium ionophore induced proteolysis and cataract: inhibition by cell permeable calpain antagonists. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9846621/ Lp82 calpain during rat lens maturation and cataract formation. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11262616/ Comparison of various calpain inhibitors in reduction of light scattering, protein precipitation and nuclear cataract in vitro. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/19278481/ Evaluation of a novel calpain inhibitor as a treatment for cataract. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/23211821/ A macrocyclic calpain inhibitor slows the development of inherited cortical cataracts in a sheep model. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/26863613/ CRY?A3/A1-Crystallin Knockout Develops Nuclear Cataract and Causes Impaired Lysosomal Cargo Clearance and Calpain Activation. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1463773/ Superior prevention of calcium ionophore cataract by E64d. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2209751/ Calpain II in two in vivo models of sugar cataract. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2820891/ Regional distribution of free calcium in selenite cataract: relation to calpain II. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/8395520/ alpha-Crystallin chaperone activity is reduced by calpain II in vitro and in selenite cataract. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9618719/ Calcium-dependent proteolysis in rabbit lens epithelium after oxidative stress. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9663852/ Nuclear cataract and light scattering in cultured lenses from guinea pig and rabbit. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11904300/ Characterization and regulation of lens-specific calpain Lp82. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11934353/ Lens epithelial cell apoptosis and intracellular Ca2+ increase in the presence of xanthurenic acid. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15362500/ The in vitro retardation of porcine cataractogenesis by the calpain inhibitor, SJA6017. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/16684519/ Low activity by the calpain system in primate lenses causes resistance to calcium-induced proteolysis. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/21434837/ Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/27524245/ Lens transcriptome profile during cataract development in Mip-null mice. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1440613/ Comparison of cell-permeable calpain inhibitors and E64 in reduction of cataract in cultured rat lenses. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/7720403/ Proteolysis by calpain is an underlying mechanism for formation of sugar cataract in rat lens. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/8319493/ Role of calpain in hydrogen peroxide induced cataract. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/8420967/ Sequence analysis of lens beta-crystallins suggests involvement of calpain in cataract formation. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9375805/ SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: amelioration of cataract in cultured rat lenses. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9434095/ Evidence for the involvement of calpain in cataractogenesis in Shumiya cataract rat (SCR). unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9739461/ Modelling cortical cataractogenesis. XXIX. Calpain proteolysis of lens fodrin in cataract. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11095908/ Cataract formation by a semiquinone metabolite of acetaminophen in mice: possible involvement of Ca(2+)and calpain activation. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11462167/ Calpain inhibitor, SJA6017, reduces the rate of formation of selenite cataract in rats. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11572469/ Naphthoquinone-Induced cataract in mice: possible involvement of Ca2+ release and calpain activation. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/25583491/ Altered ubiquitin causes perturbed calcium homeostasis, hyperactivation of calpain, dysregulated differentiation, and cataract. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/25628419/ Correction for Liu et al., Altered ubiquitin causes perturbed calcium homeostasis, hyperactivation of calpain, dysregulated differentiation, and cataract. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1848210/ Amelioration of cataracts and proteolysis in cultured lenses by cysteine protease inhibitor E64. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/1914502/ Cysteine protease inhibitor E64 reduces the rate of formation of selenite cataract in the whole animal. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/2998702/ Age-related changes of calpain II and alpha-crystallin in the lens of hereditary cataract (Nakano) mouse. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/7855906/ Calpain inhibition: an overview of its therapeutic potential. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9243307/ Immunohistochemical study of calpain-mediated alpha-crystallin proteolysis in the UPL rat hereditary cataract. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9894158/ Calpain inhibitors reduce the cornified cell envelope formation by inhibiting proteolytic processing of transglutaminase 1. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/10415455/ Oxidation enhances calpain-induced turbidity in young rat lenses. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/11725957/ Effect of calpain on hereditary cataractous rat, ICR/f. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/12457873/ Contribution of ubiquitous calpains to cataractogenesis in the spontaneous diabetic WBN/Kob rat. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/12500971/ Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/12658553/ Comparison of Lp82- and m-calpain-mediated proteolysis during cataractogenesis in Shumiya cataract rat (SCR). unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/14601627/ Cellular events preceding acetaminophen cataractogenesis studied by confocal fluorescence microscopy. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/16312145/ Developments in the design and synthesis of calpain inhibitors. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/18326725/ Susceptibility of ovine lens crystallins to proteolytic cleavage during formation of hereditary cataract. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/18702462/ Cocrystal structures of primed side-extending alpha-ketoamide inhibitors reveal novel calpain-inhibitor aromatic interactions. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/19094987/ Vitex negundo attenuates calpain activation and cataractogenesis in selenite models. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/21978083/ Eye lens in aging and diabetes: effect of quercetin. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/23428743/ Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract: In vivo and in vitro evaluation. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/27168717/ Regulatory effect of chrysin on expression of lenticular calcium transporters, calpains, and apoptotic-cascade components in selenite-induced cataract. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/28759231/ Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/15101113/ Expression and proteolytic activity of calpain in lens epithelial cells of oxidative cataract. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/7847693/ Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/9196396/ Changes in calpain II mRNA in young rat lens during maturation and cataract formation. unassigned - 3.4.22.B28 Cataract https://pubmed.ncbi.nlm.nih.gov/16303960/ Calpain may contribute to hereditary cataract formation in sheep. unassigned - 3.4.22.B28 Cerebral Infarction https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. causal interaction 4 3.4.22.B28 Cerebral Infarction https://pubmed.ncbi.nlm.nih.gov/19947509/ [Study advancement of calpain and apoptosis following cerebral ischemia] causal interaction 4 3.4.22.B28 Cerebral Infarction https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. therapeutic application 3 3.4.22.B28 Cerebral Infarction https://pubmed.ncbi.nlm.nih.gov/19947509/ [Study advancement of calpain and apoptosis following cerebral ischemia] therapeutic application 4 3.4.22.B28 Cerebral Infarction https://pubmed.ncbi.nlm.nih.gov/19947509/ [Study advancement of calpain and apoptosis following cerebral ischemia] ongoing research 2 3.4.22.B28 Cerebral Infarction https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. unassigned - 3.4.22.B28 Cerebral Infarction https://pubmed.ncbi.nlm.nih.gov/19947509/ [Study advancement of calpain and apoptosis following cerebral ischemia] unassigned - 3.4.22.B28 Chediak-Higashi Syndrome https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. causal interaction 1 3.4.22.B28 Chediak-Higashi Syndrome https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. therapeutic application 1 3.4.22.B28 Chediak-Higashi Syndrome https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. ongoing research 2 3.4.22.B28 Chediak-Higashi Syndrome https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. unassigned - 3.4.22.B28 Cholera https://pubmed.ncbi.nlm.nih.gov/10769177/ Persistent activation of Gsalpha through limited proteolysis by calpain. causal interaction 1 3.4.22.B28 Cholera https://pubmed.ncbi.nlm.nih.gov/10769177/ Persistent activation of Gsalpha through limited proteolysis by calpain. therapeutic application 4 3.4.22.B28 Cholera https://pubmed.ncbi.nlm.nih.gov/10769177/ Persistent activation of Gsalpha through limited proteolysis by calpain. unassigned - 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/11247891/ Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. causal interaction 4 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/22381211/ Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. causal interaction 4 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/25642769/ Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. causal interaction 1 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/22381211/ Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. diagnostic usage 1 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/25642769/ Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. diagnostic usage 3 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/11247891/ Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. therapeutic application 4 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/22381211/ Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. therapeutic application 1 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/11247891/ Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. ongoing research 4 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/25642769/ Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. ongoing research 3 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/11247891/ Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. unassigned - 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/25642769/ Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. unassigned - 3.4.22.B28 Colitis https://pubmed.ncbi.nlm.nih.gov/22381211/ Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. unassigned - 3.4.22.B28 Colitis, Ulcerative https://pubmed.ncbi.nlm.nih.gov/22381211/ Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. causal interaction 4 3.4.22.B28 Colitis, Ulcerative https://pubmed.ncbi.nlm.nih.gov/22381211/ Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. diagnostic usage 1 3.4.22.B28 Colitis, Ulcerative https://pubmed.ncbi.nlm.nih.gov/22381211/ Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. therapeutic application 1 3.4.22.B28 Colitis, Ulcerative https://pubmed.ncbi.nlm.nih.gov/22381211/ Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. unassigned - 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/25629974/ Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain. causal interaction 4 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/30695567/ [Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis]. causal interaction 1 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/32668972/ Cryptotanshinone-Induced p53-Dependent Sensitization of Colon Cancer Cells to Apoptotic Drive by Regulation of Calpain and Calcium Homeostasis. causal interaction 4 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/15120327/ Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. causal interaction 2 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/25629974/ Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain. diagnostic usage 1 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/30695567/ [Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis]. diagnostic usage 4 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/32668972/ Cryptotanshinone-Induced p53-Dependent Sensitization of Colon Cancer Cells to Apoptotic Drive by Regulation of Calpain and Calcium Homeostasis. diagnostic usage 3 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/25629974/ Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain. therapeutic application 1 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/32668972/ Cryptotanshinone-Induced p53-Dependent Sensitization of Colon Cancer Cells to Apoptotic Drive by Regulation of Calpain and Calcium Homeostasis. therapeutic application 4 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/15120327/ Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. therapeutic application 4 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/25319833/ Astragalus saponins modulates colon cancer development by regulating calpain-mediated glucose-regulated protein expression. therapeutic application 1 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/16530191/ N-myristoyltransferase 2 expression in human colon cancer: cross-talk between the calpain and caspase system. ongoing research 4 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/17390089/ Role of calpain and caspase system in the regulation of N-myristoyltransferase in human colon cancer (Review). ongoing research 4 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/25629974/ Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain. ongoing research 3 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/32668972/ Cryptotanshinone-Induced p53-Dependent Sensitization of Colon Cancer Cells to Apoptotic Drive by Regulation of Calpain and Calcium Homeostasis. ongoing research 2 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/25319833/ Astragalus saponins modulates colon cancer development by regulating calpain-mediated glucose-regulated protein expression. ongoing research 3 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/33210606/ Magnesium deficiency with high calcium-to-magnesium ratio promotes a metastatic phenotype in the CT26 colon cancer cell line. ongoing research 4 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/16530191/ N-myristoyltransferase 2 expression in human colon cancer: cross-talk between the calpain and caspase system. unassigned - 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/17390089/ Role of calpain and caspase system in the regulation of N-myristoyltransferase in human colon cancer (Review). unassigned - 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/25319833/ Astragalus saponins modulates colon cancer development by regulating calpain-mediated glucose-regulated protein expression. unassigned - 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/33210606/ Magnesium deficiency with high calcium-to-magnesium ratio promotes a metastatic phenotype in the CT26 colon cancer cell line. unassigned - 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/15120327/ Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. unassigned - 3.4.22.B28 Colonic Neoplasms https://pubmed.ncbi.nlm.nih.gov/30695567/ [Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis]. unassigned - 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/25207720/ Luteolin induces apoptosis in BE colorectal cancer cells by downregulating calpain, UHRF1, and DNMT1 expressions. causal interaction 2 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. causal interaction 4 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/29507677/ New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. causal interaction 4 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/34055617/ Calcium Channel Protein ORAI1 Mediates TGF-? Induced Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cells. causal interaction 2 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/25342484/ Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. diagnostic usage 4 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. diagnostic usage 4 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/29507677/ New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. diagnostic usage 3 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/22069124/ Calpain 2-dependent I?B? degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts. therapeutic application 1 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/24828012/ Limoniastrum guyonianum aqueous gall extract induces apoptosis in colorectal cancer cells by inhibiting calpain activity. therapeutic application 1 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/25207720/ Luteolin induces apoptosis in BE colorectal cancer cells by downregulating calpain, UHRF1, and DNMT1 expressions. therapeutic application 4 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/29262595/ Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway. therapeutic application 1 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/29928496/ Correction: Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway. therapeutic application 1 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. therapeutic application 1 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/34055617/ Calcium Channel Protein ORAI1 Mediates TGF-? Induced Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cells. therapeutic application 1 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/25342484/ Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. ongoing research 3 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/29262595/ Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway. ongoing research 3 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/29928496/ Correction: Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway. ongoing research 3 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. ongoing research 4 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/29507677/ New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. ongoing research 2 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/22069124/ Calpain 2-dependent I?B? degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts. unassigned - 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/24828012/ Limoniastrum guyonianum aqueous gall extract induces apoptosis in colorectal cancer cells by inhibiting calpain activity. unassigned - 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/25342484/ Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. unassigned - 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/29262595/ Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway. unassigned - 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/29928496/ Correction: Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway. unassigned - 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/25207720/ Luteolin induces apoptosis in BE colorectal cancer cells by downregulating calpain, UHRF1, and DNMT1 expressions. unassigned - 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/34055617/ Calcium Channel Protein ORAI1 Mediates TGF-? Induced Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cells. unassigned - 3.4.22.B28 Colorectal Neoplasms https://pubmed.ncbi.nlm.nih.gov/29507677/ New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. unassigned - 3.4.22.B28 Confusion https://pubmed.ncbi.nlm.nih.gov/11328585/ The structure of calpain. therapeutic application 1 3.4.22.B28 Confusion https://pubmed.ncbi.nlm.nih.gov/11328585/ The structure of calpain. unassigned - 3.4.22.B28 Congenital Abnormalities https://pubmed.ncbi.nlm.nih.gov/31464433/ Calcium Alleviates Fluoride-Induced Bone Damage by Inhibiting Endoplasmic Reticulum Stress and Mitochondrial Dysfunction. unassigned - 3.4.22.B28 Contracture https://pubmed.ncbi.nlm.nih.gov/23284963/ Different roles for contracture and calpain in calcium paradox-induced heart injury. causal interaction 4 3.4.22.B28 Contracture https://pubmed.ncbi.nlm.nih.gov/23284963/ Different roles for contracture and calpain in calcium paradox-induced heart injury. diagnostic usage 3 3.4.22.B28 Contracture https://pubmed.ncbi.nlm.nih.gov/23221958/ Activation of proteases and changes in Na+-K+-ATPase subunits in hearts subjected to ischemia-reperfusion. therapeutic application 3 3.4.22.B28 Contracture https://pubmed.ncbi.nlm.nih.gov/23221958/ Activation of proteases and changes in Na+-K+-ATPase subunits in hearts subjected to ischemia-reperfusion. unassigned - 3.4.22.B28 Contracture https://pubmed.ncbi.nlm.nih.gov/23284963/ Different roles for contracture and calpain in calcium paradox-induced heart injury. unassigned - 3.4.22.B28 Coronary Artery Disease https://pubmed.ncbi.nlm.nih.gov/32359903/ Calpain inhibition decreases myocardial fibrosis in chronically ischemic hypercholesterolemic swine. causal interaction 4 3.4.22.B28 Coronary Artery Disease https://pubmed.ncbi.nlm.nih.gov/32359903/ Calpain inhibition decreases myocardial fibrosis in chronically ischemic hypercholesterolemic swine. therapeutic application 4 3.4.22.B28 Coronary Artery Disease https://pubmed.ncbi.nlm.nih.gov/32359903/ Calpain inhibition decreases myocardial fibrosis in chronically ischemic hypercholesterolemic swine. unassigned - 3.4.22.B28 Coronary Occlusion https://pubmed.ncbi.nlm.nih.gov/24702751/ Protection Against Myocardial Ischemia-Reperfusion Injury in Clinical Practice. causal interaction 1 3.4.22.B28 Coronary Occlusion https://pubmed.ncbi.nlm.nih.gov/24774733/ Protection against myocardial ischemia-reperfusion injury in clinical practice. causal interaction 1 3.4.22.B28 Coronary Occlusion https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. causal interaction 4 3.4.22.B28 Coronary Occlusion https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. therapeutic application 4 3.4.22.B28 Coronary Occlusion https://pubmed.ncbi.nlm.nih.gov/24702751/ Protection Against Myocardial Ischemia-Reperfusion Injury in Clinical Practice. ongoing research 1 3.4.22.B28 Coronary Occlusion https://pubmed.ncbi.nlm.nih.gov/24774733/ Protection against myocardial ischemia-reperfusion injury in clinical practice. ongoing research 1 3.4.22.B28 Coronary Occlusion https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. ongoing research 2 3.4.22.B28 Coronary Occlusion https://pubmed.ncbi.nlm.nih.gov/26113472/ Mitochondrial m-calpain opens the mitochondrial permeability transition pore in ischemia-reperfusion. unassigned - 3.4.22.B28 Coronary Occlusion https://pubmed.ncbi.nlm.nih.gov/24702751/ Protection Against Myocardial Ischemia-Reperfusion Injury in Clinical Practice. unassigned - 3.4.22.B28 Coronary Occlusion https://pubmed.ncbi.nlm.nih.gov/24774733/ Protection against myocardial ischemia-reperfusion injury in clinical practice. unassigned - 3.4.22.B28 Coronary Occlusion https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. unassigned - 3.4.22.B28 Craniocerebral Trauma https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. causal interaction 4 3.4.22.B28 Craniocerebral Trauma https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. therapeutic application 4 3.4.22.B28 Craniocerebral Trauma https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. ongoing research 2 3.4.22.B28 Craniocerebral Trauma https://pubmed.ncbi.nlm.nih.gov/11721741/ The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. unassigned - 3.4.22.B28 Cystic Fibrosis https://pubmed.ncbi.nlm.nih.gov/23785472/ Calpain inhibition promotes the rescue of F(508)del-CFTR in PBMC from cystic fibrosis patients. causal interaction 1 3.4.22.B28 Cystic Fibrosis https://pubmed.ncbi.nlm.nih.gov/23785472/ Calpain inhibition promotes the rescue of F(508)del-CFTR in PBMC from cystic fibrosis patients. therapeutic application 1 3.4.22.B28 Cystic Fibrosis https://pubmed.ncbi.nlm.nih.gov/27349634/ Abnormal activation of calpain and protein kinase C? promotes a constitutive release of matrix metalloproteinase 9 in peripheral blood mononuclear cells from cystic fibrosis patients. therapeutic application 1 3.4.22.B28 Cystic Fibrosis https://pubmed.ncbi.nlm.nih.gov/27349634/ Abnormal activation of calpain and protein kinase C? promotes a constitutive release of matrix metalloproteinase 9 in peripheral blood mononuclear cells from cystic fibrosis patients. ongoing research 2 3.4.22.B28 Cystic Fibrosis https://pubmed.ncbi.nlm.nih.gov/27349634/ Abnormal activation of calpain and protein kinase C? promotes a constitutive release of matrix metalloproteinase 9 in peripheral blood mononuclear cells from cystic fibrosis patients. unassigned - 3.4.22.B28 Cystic Fibrosis https://pubmed.ncbi.nlm.nih.gov/21983488/ Evidence for alteration of calpain/calpastatin system in PBMC of cystic fibrosis patients. unassigned - 3.4.22.B28 Cystic Fibrosis https://pubmed.ncbi.nlm.nih.gov/23785472/ Calpain inhibition promotes the rescue of F(508)del-CFTR in PBMC from cystic fibrosis patients. unassigned - 3.4.22.B28 Cysts https://pubmed.ncbi.nlm.nih.gov/2113367/ Cyst fluid proteases. causal interaction 4 3.4.22.B28 Cysts https://pubmed.ncbi.nlm.nih.gov/2113367/ Cyst fluid proteases. therapeutic application 3 3.4.22.B28 Cysts https://pubmed.ncbi.nlm.nih.gov/2113367/ Cyst fluid proteases. unassigned - 3.4.22.B28 Deafness https://pubmed.ncbi.nlm.nih.gov/32885237/ Biallelic variants in the small optic lobe calpain CAPN15 are associated with congenital eye anomalies, deafness and other neurodevelopmental deficits. therapeutic application 1 3.4.22.B28 Deafness https://pubmed.ncbi.nlm.nih.gov/32885237/ Biallelic variants in the small optic lobe calpain CAPN15 are associated with congenital eye anomalies, deafness and other neurodevelopmental deficits. ongoing research 3 3.4.22.B28 Deafness https://pubmed.ncbi.nlm.nih.gov/32885237/ Biallelic variants in the small optic lobe calpain CAPN15 are associated with congenital eye anomalies, deafness and other neurodevelopmental deficits. unassigned - 3.4.22.B28 Death, Sudden, Cardiac https://pubmed.ncbi.nlm.nih.gov/27502273/ The Human Ether-a-go-go-Related Gene (hERG) Potassium Channel Represents an Unusual Target for Protease-mediated Damage. causal interaction 2 3.4.22.B28 Death, Sudden, Cardiac https://pubmed.ncbi.nlm.nih.gov/23390828/ Calpain expression in the brain cortex after traumatic brain injury. diagnostic usage 1 3.4.22.B28 Death, Sudden, Cardiac https://pubmed.ncbi.nlm.nih.gov/23390828/ Calpain expression in the brain cortex after traumatic brain injury. ongoing research 4 3.4.22.B28 Death, Sudden, Cardiac https://pubmed.ncbi.nlm.nih.gov/23390828/ Calpain expression in the brain cortex after traumatic brain injury. unassigned - 3.4.22.B28 Death, Sudden, Cardiac https://pubmed.ncbi.nlm.nih.gov/27502273/ The Human Ether-a-go-go-Related Gene (hERG) Potassium Channel Represents an Unusual Target for Protease-mediated Damage. unassigned - 3.4.22.B28 Deficiency Diseases https://pubmed.ncbi.nlm.nih.gov/21030783/ Expanding members and roles of the calpain superfamily and their genetically modified animals. causal interaction 4 3.4.22.B28 Deficiency Diseases https://pubmed.ncbi.nlm.nih.gov/21030783/ Expanding members and roles of the calpain superfamily and their genetically modified animals. unassigned - 3.4.22.B28 Dehydration https://pubmed.ncbi.nlm.nih.gov/22063280/ Changes in calpain and calpastatin activities of osmotically dehydrated bovine muscle during storage after treatment with calcium. ongoing research 1 3.4.22.B28 Dehydration https://pubmed.ncbi.nlm.nih.gov/100124599/ Changes in calpain and calpastatin activities of osmotically dehydrated bovine muscle during storage after treatment with calcium. ongoing research 1 3.4.22.B28 Dehydration https://pubmed.ncbi.nlm.nih.gov/22063280/ Changes in calpain and calpastatin activities of osmotically dehydrated bovine muscle during storage after treatment with calcium. unassigned - 3.4.22.B28 Dehydration https://pubmed.ncbi.nlm.nih.gov/100124599/ Changes in calpain and calpastatin activities of osmotically dehydrated bovine muscle during storage after treatment with calcium. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/9630523/ Upregulation of calpain activity and expression in experimental allergic encephalomyelitis: a putative role for calpain in demyelination. causal interaction 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. causal interaction 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10212825/ A putative role for calpain in demyelination associated with optic neuritis. causal interaction 3 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. causal interaction 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/7852311/ Calpain expression in lymphoid cells. Increased mRNA and protein levels after cell activation. causal interaction 3 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/8568927/ Calpain secreted by activated human lymphoid cells degrades myelin. causal interaction 3 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/9576959/ Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. causal interaction 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. causal interaction 2 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/18725211/ Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. causal interaction 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10212825/ A putative role for calpain in demyelination associated with optic neuritis. diagnostic usage 2 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. diagnostic usage 3 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. diagnostic usage 1 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/12161014/ Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. diagnostic usage 3 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. therapeutic application 3 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/17551984/ Coherent anti-stokes Raman scattering imaging of myelin degradation reveals a calcium-dependent pathway in lyso-PtdCho-induced demyelination. therapeutic application 2 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/20414110/ New drug therapies for multiple sclerosis. therapeutic application 3 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/21671839/ Cannabinoid treatment renders neurons less vulnerable than oligodendrocytes in experimental autoimmune encephalomyelitis. therapeutic application 1 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/9630523/ Upregulation of calpain activity and expression in experimental allergic encephalomyelitis: a putative role for calpain in demyelination. ongoing research 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. ongoing research 2 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10212825/ A putative role for calpain in demyelination associated with optic neuritis. ongoing research 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. ongoing research 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/18673215/ Activation of calpain and caspase pathways in demyelination and neurodegeneration in animal model of multiple sclerosis. ongoing research 2 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/7690115/ Differential distribution of calpain in human lymphoid cells. ongoing research 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/9576959/ Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. ongoing research 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. ongoing research 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/12161014/ Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. ongoing research 4 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/11519732/ Mechanism of myelin breakdown in experimental demyelination: a putative role for calpain. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/18673215/ Activation of calpain and caspase pathways in demyelination and neurodegeneration in animal model of multiple sclerosis. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/7690115/ Differential distribution of calpain in human lymphoid cells. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/12161014/ Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/17551984/ Coherent anti-stokes Raman scattering imaging of myelin degradation reveals a calcium-dependent pathway in lyso-PtdCho-induced demyelination. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/20414110/ New drug therapies for multiple sclerosis. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/21671839/ Cannabinoid treatment renders neurons less vulnerable than oligodendrocytes in experimental autoimmune encephalomyelitis. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/9630523/ Upregulation of calpain activity and expression in experimental allergic encephalomyelitis: a putative role for calpain in demyelination. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/7852311/ Calpain expression in lymphoid cells. Increased mRNA and protein levels after cell activation. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/8568927/ Calpain secreted by activated human lymphoid cells degrades myelin. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/9576959/ Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/18725211/ Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10212825/ A putative role for calpain in demyelination associated with optic neuritis. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. unassigned - 3.4.22.B28 Demyelinating Diseases https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. unassigned - 3.4.22.B28 Diabetes Complications https://pubmed.ncbi.nlm.nih.gov/18212479/ Down-regulation of brain-pancreas relative protein in diabetic rats and by high glucose in PC12 cells: prevention by calpain inhibitors. causal interaction 2 3.4.22.B28 Diabetes Complications https://pubmed.ncbi.nlm.nih.gov/22805611/ Advanced glycation end-products induce calpain-mediated degradation of ezrin. causal interaction 2 3.4.22.B28 Diabetes Complications https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. causal interaction 4 3.4.22.B28 Diabetes Complications https://pubmed.ncbi.nlm.nih.gov/18212479/ Down-regulation of brain-pancreas relative protein in diabetic rats and by high glucose in PC12 cells: prevention by calpain inhibitors. therapeutic application 1 3.4.22.B28 Diabetes Complications https://pubmed.ncbi.nlm.nih.gov/22805611/ Advanced glycation end-products induce calpain-mediated degradation of ezrin. therapeutic application 3 3.4.22.B28 Diabetes Complications https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. ongoing research 4 3.4.22.B28 Diabetes Complications https://pubmed.ncbi.nlm.nih.gov/18212479/ Down-regulation of brain-pancreas relative protein in diabetic rats and by high glucose in PC12 cells: prevention by calpain inhibitors. unassigned - 3.4.22.B28 Diabetes Complications https://pubmed.ncbi.nlm.nih.gov/22805611/ Advanced glycation end-products induce calpain-mediated degradation of ezrin. unassigned - 3.4.22.B28 Diabetes Complications https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. unassigned - 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. causal interaction 4 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/11375982/ Characterization and expression of calpain 10. A novel ubiquitous calpain with nuclear localization. causal interaction 3 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. causal interaction 3 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/25944670/ Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. causal interaction 3 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/30425305/ Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B. causal interaction 3 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/25944670/ Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. diagnostic usage 3 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. therapeutic application 1 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/25944670/ Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. therapeutic application 2 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. ongoing research 4 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. unassigned - 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/11375982/ Characterization and expression of calpain 10. A novel ubiquitous calpain with nuclear localization. unassigned - 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. unassigned - 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/30425305/ Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B. unassigned - 3.4.22.B28 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/25944670/ Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 1 https://pubmed.ncbi.nlm.nih.gov/21911754/ Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. causal interaction 4 3.4.22.B28 Diabetes Mellitus, Type 1 https://pubmed.ncbi.nlm.nih.gov/24630865/ The calpain system and diabetes. causal interaction 4 3.4.22.B28 Diabetes Mellitus, Type 1 https://pubmed.ncbi.nlm.nih.gov/26470784/ Mitochondrial Calpain-1 Disrupts ATP Synthase and Induces Superoxide Generation in Type 1 Diabetic Hearts: A Novel Mechanism Contributing to Diabetic Cardiomyopathy. causal interaction 3 3.4.22.B28 Diabetes Mellitus, Type 1 https://pubmed.ncbi.nlm.nih.gov/21911754/ Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. therapeutic application 4 3.4.22.B28 Diabetes Mellitus, Type 1 https://pubmed.ncbi.nlm.nih.gov/21911754/ Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. ongoing research 3 3.4.22.B28 Diabetes Mellitus, Type 1 https://pubmed.ncbi.nlm.nih.gov/24630865/ The calpain system and diabetes. ongoing research 2 3.4.22.B28 Diabetes Mellitus, Type 1 https://pubmed.ncbi.nlm.nih.gov/26470784/ Mitochondrial Calpain-1 Disrupts ATP Synthase and Induces Superoxide Generation in Type 1 Diabetic Hearts: A Novel Mechanism Contributing to Diabetic Cardiomyopathy. ongoing research 2 3.4.22.B28 Diabetes Mellitus, Type 1 https://pubmed.ncbi.nlm.nih.gov/21911754/ Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 1 https://pubmed.ncbi.nlm.nih.gov/24630865/ The calpain system and diabetes. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 1 https://pubmed.ncbi.nlm.nih.gov/26470784/ Mitochondrial Calpain-1 Disrupts ATP Synthase and Induces Superoxide Generation in Type 1 Diabetic Hearts: A Novel Mechanism Contributing to Diabetic Cardiomyopathy. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/15793253/ The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. causal interaction 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/12079852/ Genetic and molecular analyses of complex metabolic disorders: genetic linkage. causal interaction 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/12759879/ A 48-hour exposure of pancreatic islets to calpain inhibitors impairs mitochondrial fuel metabolism and the exocytosis of insulin. causal interaction 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] causal interaction 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/12974673/ Calpain facilitates GLUT4 vesicle translocation during insulin-stimulated glucose uptake in adipocytes. causal interaction 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/14749260/ Structure, activation, and biology of calpain. causal interaction 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/14749261/ Linkage of calpain 10 to type 2 diabetes: the biological rationale. causal interaction 1 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/15862281/ Calpain inhibition and insulin action in cultured human muscle cells. causal interaction 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. causal interaction 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/17400802/ Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling. causal interaction 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/18193633/ Calpains and human disease. causal interaction 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/18452715/ Characterization of endogenous and recombinant human calpain-10. causal interaction 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/20933204/ The role of calpain in diabetes-associated platelet hyperactivation. causal interaction 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/22665935/ Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. causal interaction 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/24630865/ The calpain system and diabetes. causal interaction 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/25773692/ New evidence for the role of calpain 10 in autosomal recessive intellectual disability: identification of two novel nonsense variants by exome sequencing in Iranian families. causal interaction 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/30425305/ Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B. causal interaction 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. causal interaction 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/34497520/ Effects of Naringin on Cardiomyocytes From a Rodent Model of Type 2 Diabetes. causal interaction 1 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/15862281/ Calpain inhibition and insulin action in cultured human muscle cells. diagnostic usage 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. diagnostic usage 2 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] therapeutic application 1 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/14749260/ Structure, activation, and biology of calpain. therapeutic application 1 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/14749261/ Linkage of calpain 10 to type 2 diabetes: the biological rationale. therapeutic application 1 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/15862281/ Calpain inhibition and insulin action in cultured human muscle cells. therapeutic application 2 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. therapeutic application 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/17400802/ Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling. therapeutic application 1 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/18193633/ Calpains and human disease. therapeutic application 2 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/18452715/ Characterization of endogenous and recombinant human calpain-10. therapeutic application 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/22665935/ Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. therapeutic application 2 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/25773692/ New evidence for the role of calpain 10 in autosomal recessive intellectual disability: identification of two novel nonsense variants by exome sequencing in Iranian families. therapeutic application 1 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. therapeutic application 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/15793253/ The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. ongoing research 1 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/12759879/ A 48-hour exposure of pancreatic islets to calpain inhibitors impairs mitochondrial fuel metabolism and the exocytosis of insulin. ongoing research 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/14749261/ Linkage of calpain 10 to type 2 diabetes: the biological rationale. ongoing research 2 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/15862281/ Calpain inhibition and insulin action in cultured human muscle cells. ongoing research 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/17400802/ Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling. ongoing research 1 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/22665935/ Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. ongoing research 3 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/24630865/ The calpain system and diabetes. ongoing research 2 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. ongoing research 4 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/11814478/ Changes in membrane microenvironment and signal transduction in platelets from NIDDM patients-a pilot study. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/15793253/ The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/12079852/ Genetic and molecular analyses of complex metabolic disorders: genetic linkage. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/12759879/ A 48-hour exposure of pancreatic islets to calpain inhibitors impairs mitochondrial fuel metabolism and the exocytosis of insulin. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/12974673/ Calpain facilitates GLUT4 vesicle translocation during insulin-stimulated glucose uptake in adipocytes. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/14749260/ Structure, activation, and biology of calpain. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/14749261/ Linkage of calpain 10 to type 2 diabetes: the biological rationale. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/17400802/ Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/18193633/ Calpains and human disease. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/18452715/ Characterization of endogenous and recombinant human calpain-10. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/20933204/ The role of calpain in diabetes-associated platelet hyperactivation. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/22665935/ Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/24630865/ The calpain system and diabetes. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/25773692/ New evidence for the role of calpain 10 in autosomal recessive intellectual disability: identification of two novel nonsense variants by exome sequencing in Iranian families. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/30425305/ Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/34497520/ Effects of Naringin on Cardiomyocytes From a Rodent Model of Type 2 Diabetes. unassigned - 3.4.22.B28 Diabetes Mellitus, Type 2 https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. unassigned - 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. causal interaction 3 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/19505932/ Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. causal interaction 4 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. causal interaction 4 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/26470784/ Mitochondrial Calpain-1 Disrupts ATP Synthase and Induces Superoxide Generation in Type 1 Diabetic Hearts: A Novel Mechanism Contributing to Diabetic Cardiomyopathy. causal interaction 3 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. therapeutic application 4 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/19505932/ Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. therapeutic application 4 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. ongoing research 4 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. ongoing research 4 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/26470784/ Mitochondrial Calpain-1 Disrupts ATP Synthase and Induces Superoxide Generation in Type 1 Diabetic Hearts: A Novel Mechanism Contributing to Diabetic Cardiomyopathy. ongoing research 2 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. unassigned - 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/19505932/ Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. unassigned - 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. unassigned - 3.4.22.B28 Diabetic Cardiomyopathies https://pubmed.ncbi.nlm.nih.gov/26470784/ Mitochondrial Calpain-1 Disrupts ATP Synthase and Induces Superoxide Generation in Type 1 Diabetic Hearts: A Novel Mechanism Contributing to Diabetic Cardiomyopathy. unassigned - 3.4.22.B28 Diabetic Nephropathies https://pubmed.ncbi.nlm.nih.gov/20424485/ Local Delivery of Angiotensin II Receptor Blockers into the Kidney Passively Attenuates Inflammatory Reactions during the Early Phases of Streptozotocin-Induced Diabetic Nephropathy through Inhibition of Calpain Activity. causal interaction 1 3.4.22.B28 Diabetic Nephropathies https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. causal interaction 4 3.4.22.B28 Diabetic Nephropathies https://pubmed.ncbi.nlm.nih.gov/20424485/ Local Delivery of Angiotensin II Receptor Blockers into the Kidney Passively Attenuates Inflammatory Reactions during the Early Phases of Streptozotocin-Induced Diabetic Nephropathy through Inhibition of Calpain Activity. therapeutic application 4 3.4.22.B28 Diabetic Nephropathies https://pubmed.ncbi.nlm.nih.gov/20424485/ Local Delivery of Angiotensin II Receptor Blockers into the Kidney Passively Attenuates Inflammatory Reactions during the Early Phases of Streptozotocin-Induced Diabetic Nephropathy through Inhibition of Calpain Activity. ongoing research 1 3.4.22.B28 Diabetic Nephropathies https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. ongoing research 4 3.4.22.B28 Diabetic Nephropathies https://pubmed.ncbi.nlm.nih.gov/20424485/ Local Delivery of Angiotensin II Receptor Blockers into the Kidney Passively Attenuates Inflammatory Reactions during the Early Phases of Streptozotocin-Induced Diabetic Nephropathy through Inhibition of Calpain Activity. unassigned - 3.4.22.B28 Diabetic Nephropathies https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. unassigned - 3.4.22.B28 Diabetic Neuropathies https://pubmed.ncbi.nlm.nih.gov/26087461/ Calpain inhibitor, MDL 28170 confer electrophysiological, nociceptive and biochemical improvement in diabetic neuropathy. causal interaction 3 3.4.22.B28 Diabetic Neuropathies https://pubmed.ncbi.nlm.nih.gov/26087461/ Calpain inhibitor, MDL 28170 confer electrophysiological, nociceptive and biochemical improvement in diabetic neuropathy. therapeutic application 3 3.4.22.B28 Diabetic Neuropathies https://pubmed.ncbi.nlm.nih.gov/26087461/ Calpain inhibitor, MDL 28170 confer electrophysiological, nociceptive and biochemical improvement in diabetic neuropathy. unassigned - 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/22967911/ Metabolic stress response implicated in diabetic retinopathy: The role of calpain, and the therapeutic impact of calpain inhibitor. causal interaction 4 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/34214506/ Photoreceptor Cell Calcium Dysregulation and Calpain Activation Promote Pathogenic Photoreceptor Oxidative Stress and Inflammation in Prodromal Diabetic Retinopathy. causal interaction 3 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/21757584/ Calpain, not caspase, is the causative protease for hypoxic damage in cultured monkey retinal cells. causal interaction 1 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. causal interaction 4 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/27130368/ Calpain and Caspase-12 Expression in Lens Epithelial Cells of Diabetic Cataracts. causal interaction 1 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/27130368/ Calpain and Caspase-12 Expression in Lens Epithelial Cells of Diabetic Cataracts. diagnostic usage 3 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/22967911/ Metabolic stress response implicated in diabetic retinopathy: The role of calpain, and the therapeutic impact of calpain inhibitor. therapeutic application 3 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/34214506/ Photoreceptor Cell Calcium Dysregulation and Calpain Activation Promote Pathogenic Photoreceptor Oxidative Stress and Inflammation in Prodromal Diabetic Retinopathy. therapeutic application 4 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/27130368/ Calpain and Caspase-12 Expression in Lens Epithelial Cells of Diabetic Cataracts. therapeutic application 1 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/22967911/ Metabolic stress response implicated in diabetic retinopathy: The role of calpain, and the therapeutic impact of calpain inhibitor. ongoing research 2 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/21757584/ Calpain, not caspase, is the causative protease for hypoxic damage in cultured monkey retinal cells. ongoing research 1 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. ongoing research 4 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/27130368/ Calpain and Caspase-12 Expression in Lens Epithelial Cells of Diabetic Cataracts. ongoing research 4 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/22967911/ Metabolic stress response implicated in diabetic retinopathy: The role of calpain, and the therapeutic impact of calpain inhibitor. unassigned - 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/34214506/ Photoreceptor Cell Calcium Dysregulation and Calpain Activation Promote Pathogenic Photoreceptor Oxidative Stress and Inflammation in Prodromal Diabetic Retinopathy. unassigned - 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/21757584/ Calpain, not caspase, is the causative protease for hypoxic damage in cultured monkey retinal cells. unassigned - 3.4.22.B28 Diabetic Retinopathy https://pubmed.ncbi.nlm.nih.gov/26349983/ Role of the calpain on the development of diabetes mellitus and its chronic complications. unassigned - 3.4.22.B28 DiGeorge Syndrome https://pubmed.ncbi.nlm.nih.gov/25699712/ Stress Induces p38 MAPK-Mediated Phosphorylation and Inhibition of Drosha-Dependent Cell Survival. ongoing research 1 3.4.22.B28 DiGeorge Syndrome https://pubmed.ncbi.nlm.nih.gov/25699712/ Stress Induces p38 MAPK-Mediated Phosphorylation and Inhibition of Drosha-Dependent Cell Survival. unassigned - 3.4.22.B28 Disseminated Intravascular Coagulation https://pubmed.ncbi.nlm.nih.gov/22268136/ Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release. causal interaction 4 3.4.22.B28 Disseminated Intravascular Coagulation https://pubmed.ncbi.nlm.nih.gov/22268136/ Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release. therapeutic application 2 3.4.22.B28 Disseminated Intravascular Coagulation https://pubmed.ncbi.nlm.nih.gov/22268136/ Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release. ongoing research 4 3.4.22.B28 Disseminated Intravascular Coagulation https://pubmed.ncbi.nlm.nih.gov/22268136/ Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release. unassigned - 3.4.22.B28 Down Syndrome https://pubmed.ncbi.nlm.nih.gov/20032300/ Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: requirement for tau and APP. causal interaction 1 3.4.22.B28 Down Syndrome https://pubmed.ncbi.nlm.nih.gov/20032300/ Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: requirement for tau and APP. unassigned - 3.4.22.B28 Dysentery, Bacillary https://pubmed.ncbi.nlm.nih.gov/22423964/ Calpain activation by the Shigella flexneri effector VirA regulates key steps in the formation and life of the bacterium's epithelial niche. causal interaction 4 3.4.22.B28 Dysentery, Bacillary https://pubmed.ncbi.nlm.nih.gov/22423964/ Calpain activation by the Shigella flexneri effector VirA regulates key steps in the formation and life of the bacterium's epithelial niche. therapeutic application 1 3.4.22.B28 Dysentery, Bacillary https://pubmed.ncbi.nlm.nih.gov/22423964/ Calpain activation by the Shigella flexneri effector VirA regulates key steps in the formation and life of the bacterium's epithelial niche. unassigned - 3.4.22.B28 Dyslipidemias https://pubmed.ncbi.nlm.nih.gov/27161420/ Grape seed and skin extract as an adjunct to xenical therapy reduces obesity, brain lipotoxicity and oxidative stress in high fat diet fed rats. unassigned - 3.4.22.B28 Embolism https://pubmed.ncbi.nlm.nih.gov/22580607/ The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin. causal interaction 1 3.4.22.B28 Embolism https://pubmed.ncbi.nlm.nih.gov/16467455/ 3-[2-[4-(3-Chloro-2-methylphenylmethyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydro-chloride 3.5 hydrate (DY-9760e) is neuroprotective in rat microsphere embolism: role of the cross-talk between calpain and caspase-3 through calpastatin. unassigned - 3.4.22.B28 Embolism https://pubmed.ncbi.nlm.nih.gov/22580607/ The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin. unassigned - 3.4.22.B28 Encephalitis https://pubmed.ncbi.nlm.nih.gov/16088944/ E2F1 induces cell death, calpain activation, and MDMX degradation in a transcription independent manner implicating a novel role for E2F1 in neuronal loss in SIV encephalitis. causal interaction 1 3.4.22.B28 Encephalitis https://pubmed.ncbi.nlm.nih.gov/16088944/ E2F1 induces cell death, calpain activation, and MDMX degradation in a transcription independent manner implicating a novel role for E2F1 in neuronal loss in SIV encephalitis. unassigned - 3.4.22.B28 Encephalitis, Viral https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. causal interaction 4 3.4.22.B28 Encephalitis, Viral https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. therapeutic application 4 3.4.22.B28 Encephalitis, Viral https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. ongoing research 3 3.4.22.B28 Encephalitis, Viral https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. unassigned - 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. causal interaction 4 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/18725211/ Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. causal interaction 4 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. causal interaction 1 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/24707444/ The Involvement of Calpain in CD4(+) T Helper Cell Bias in Multple Sclerosis. causal interaction 3 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. causal interaction 4 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. therapeutic application 4 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/20414110/ New drug therapies for multiple sclerosis. therapeutic application 3 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. therapeutic application 4 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/24707444/ The Involvement of Calpain in CD4(+) T Helper Cell Bias in Multple Sclerosis. therapeutic application 3 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. therapeutic application 4 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/27513991/ Calpain Inhibition Reduces Structural and Functional Impairment of Retinal Ganglion Cells in Experimental Optic Neuritis. therapeutic application 4 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/30251207/ The Role of Calpain and Proteasomes in the Degradation of Carbonylated Neuronal Cytoskeletal Proteins in Acute Experimental Autoimmune Encephalomyelitis. ongoing research 3 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. ongoing research 4 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. ongoing research 3 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/27513991/ Calpain Inhibition Reduces Structural and Functional Impairment of Retinal Ganglion Cells in Experimental Optic Neuritis. ongoing research 4 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/15952172/ Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis. unassigned - 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/30251207/ The Role of Calpain and Proteasomes in the Degradation of Carbonylated Neuronal Cytoskeletal Proteins in Acute Experimental Autoimmune Encephalomyelitis. unassigned - 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/20414110/ New drug therapies for multiple sclerosis. unassigned - 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/27513991/ Calpain Inhibition Reduces Structural and Functional Impairment of Retinal Ganglion Cells in Experimental Optic Neuritis. unassigned - 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. unassigned - 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/18725211/ Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. unassigned - 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. unassigned - 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/24707444/ The Involvement of Calpain in CD4(+) T Helper Cell Bias in Multple Sclerosis. unassigned - 3.4.22.B28 Encephalomyelitis https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9576959/ Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. causal interaction 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9630523/ Upregulation of calpain activity and expression in experimental allergic encephalomyelitis: a putative role for calpain in demyelination. causal interaction 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/10496171/ Calpain activity and expression are increased in splenic inflammatory cells associated with experimental allergic encephalomyelitis. causal interaction 3 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. causal interaction 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/18725211/ Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. causal interaction 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9518658/ Increased calpain expression in experimental demyelinating optic neuritis: an immunocytochemical study. causal interaction 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. causal interaction 2 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. causal interaction 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. causal interaction 1 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/24707444/ The Involvement of Calpain in CD4(+) T Helper Cell Bias in Multple Sclerosis. causal interaction 3 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/10496171/ Calpain activity and expression are increased in splenic inflammatory cells associated with experimental allergic encephalomyelitis. diagnostic usage 3 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/12161014/ Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. diagnostic usage 3 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. diagnostic usage 1 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/26535670/ Effects of beta 2 adrenergic agonists on axonal injury and mitochondrial metabolism in experimental autoimmune encephalomyelitis rats. diagnostic usage 2 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. therapeutic application 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/22715087/ Calpain inhibition attenuated morphological and molecular changes in skeletal muscle of experimental allergic encephalomyelitis rats. therapeutic application 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. therapeutic application 3 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/20414110/ New drug therapies for multiple sclerosis. therapeutic application 3 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. therapeutic application 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/24707444/ The Involvement of Calpain in CD4(+) T Helper Cell Bias in Multple Sclerosis. therapeutic application 3 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/27513991/ Calpain Inhibition Reduces Structural and Functional Impairment of Retinal Ganglion Cells in Experimental Optic Neuritis. therapeutic application 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9576959/ Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. ongoing research 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9630523/ Upregulation of calpain activity and expression in experimental allergic encephalomyelitis: a putative role for calpain in demyelination. ongoing research 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/10496171/ Calpain activity and expression are increased in splenic inflammatory cells associated with experimental allergic encephalomyelitis. ongoing research 3 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/12161014/ Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. ongoing research 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/21318550/ Calpain Activity in Spinal Cord Cells from Rats with Experimental Allergic Encephalomyelitis of Different Grades. ongoing research 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/22715087/ Calpain inhibition attenuated morphological and molecular changes in skeletal muscle of experimental allergic encephalomyelitis rats. ongoing research 3 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/30251207/ The Role of Calpain and Proteasomes in the Degradation of Carbonylated Neuronal Cytoskeletal Proteins in Acute Experimental Autoimmune Encephalomyelitis. ongoing research 3 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9518658/ Increased calpain expression in experimental demyelinating optic neuritis: an immunocytochemical study. ongoing research 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. ongoing research 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. ongoing research 2 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. ongoing research 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/26535670/ Effects of beta 2 adrenergic agonists on axonal injury and mitochondrial metabolism in experimental autoimmune encephalomyelitis rats. ongoing research 3 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/27513991/ Calpain Inhibition Reduces Structural and Functional Impairment of Retinal Ganglion Cells in Experimental Optic Neuritis. ongoing research 4 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/12161014/ Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/21318550/ Calpain Activity in Spinal Cord Cells from Rats with Experimental Allergic Encephalomyelitis of Different Grades. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/22715087/ Calpain inhibition attenuated morphological and molecular changes in skeletal muscle of experimental allergic encephalomyelitis rats. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/30251207/ The Role of Calpain and Proteasomes in the Degradation of Carbonylated Neuronal Cytoskeletal Proteins in Acute Experimental Autoimmune Encephalomyelitis. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/20414110/ New drug therapies for multiple sclerosis. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/26535670/ Effects of beta 2 adrenergic agonists on axonal injury and mitochondrial metabolism in experimental autoimmune encephalomyelitis rats. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/27513991/ Calpain Inhibition Reduces Structural and Functional Impairment of Retinal Ganglion Cells in Experimental Optic Neuritis. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9576959/ Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9630523/ Upregulation of calpain activity and expression in experimental allergic encephalomyelitis: a putative role for calpain in demyelination. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/18725211/ Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9518658/ Increased calpain expression in experimental demyelinating optic neuritis: an immunocytochemical study. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/24707444/ The Involvement of Calpain in CD4(+) T Helper Cell Bias in Multple Sclerosis. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/10496171/ Calpain activity and expression are increased in splenic inflammatory cells associated with experimental allergic encephalomyelitis. unassigned - 3.4.22.B28 Encephalomyelitis, Autoimmune, Experimental https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. unassigned - 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/17162536/ Calpain inhibition attenuates iNOS production and midzonal hepatic necrosis in a repeat dose model of endotoxemia in rats. causal interaction 1 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/26246018/ Deletion of capn4 Protects the Heart Against Endotoxemic Injury by Preventing ATP Synthase Disruption and Inhibiting Mitochondrial Superoxide Generation. causal interaction 4 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/26246018/ Deletion of capn4 Protects the Heart Against Endotoxemic Injury by Preventing ATP Synthase Disruption and Inhibiting Mitochondrial Superoxide Generation. diagnostic usage 3 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/17162536/ Calpain inhibition attenuates iNOS production and midzonal hepatic necrosis in a repeat dose model of endotoxemia in rats. therapeutic application 2 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/26246018/ Deletion of capn4 Protects the Heart Against Endotoxemic Injury by Preventing ATP Synthase Disruption and Inhibiting Mitochondrial Superoxide Generation. therapeutic application 4 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/32346126/ Protective role of endothelial calpain knockout in lipopolysaccharide-induced acute kidney injury via attenuation of the p38-iNOS pathway and NO/ROS production. therapeutic application 1 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/17162536/ Calpain inhibition attenuates iNOS production and midzonal hepatic necrosis in a repeat dose model of endotoxemia in rats. ongoing research 4 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/26246018/ Deletion of capn4 Protects the Heart Against Endotoxemic Injury by Preventing ATP Synthase Disruption and Inhibiting Mitochondrial Superoxide Generation. ongoing research 4 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/32346126/ Protective role of endothelial calpain knockout in lipopolysaccharide-induced acute kidney injury via attenuation of the p38-iNOS pathway and NO/ROS production. ongoing research 2 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/32346126/ Protective role of endothelial calpain knockout in lipopolysaccharide-induced acute kidney injury via attenuation of the p38-iNOS pathway and NO/ROS production. unassigned - 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/33567713/ Suppression of Hypoxia-Inducible Factor 1? by Low-Molecular-Weight Heparin Mitigates Ventilation-Induced Diaphragm Dysfunction in a Murine Endotoxemia Model. unassigned - 3.4.22.B28 Endotoxemia https://pubmed.ncbi.nlm.nih.gov/17162536/ Calpain inhibition attenuates iNOS production and midzonal hepatic necrosis in a repeat dose model of endotoxemia in rats. unassigned - 3.4.22.B28 Eosinophilic Esophagitis https://pubmed.ncbi.nlm.nih.gov/28131390/ Calpain-14 and its association with eosinophilic esophagitis. causal interaction 4 3.4.22.B28 Eosinophilic Esophagitis https://pubmed.ncbi.nlm.nih.gov/27158675/ Eosinophilic esophagitis-linked calpain 14 is an IL-13-induced protease that mediates esophageal epithelial barrier impairment. unassigned - 3.4.22.B28 Eosinophilic Esophagitis https://pubmed.ncbi.nlm.nih.gov/28131390/ Calpain-14 and its association with eosinophilic esophagitis. unassigned - 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. causal interaction 3 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. causal interaction 4 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. causal interaction 3 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/18088374/ Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus. causal interaction 4 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/19258295/ Partial epilepsy in an adolescent male with limb-girdle muscular dystrophy 1B. causal interaction 4 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/30186110/ M-Calpain Activation Facilitates Seizure Induced KCC2 Down Regulation. causal interaction 3 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/33132163/ Calpain-2 activation in mouse hippocampus plays a critical role in seizure-induced neuropathology. causal interaction 4 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. diagnostic usage 1 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. therapeutic application 4 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. therapeutic application 4 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/16954597/ Calpain and synaptic function. therapeutic application 3 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/18088374/ Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus. therapeutic application 1 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/33132163/ Calpain-2 activation in mouse hippocampus plays a critical role in seizure-induced neuropathology. therapeutic application 4 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. ongoing research 4 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. ongoing research 2 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/30186110/ M-Calpain Activation Facilitates Seizure Induced KCC2 Down Regulation. ongoing research 2 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/33132163/ Calpain-2 activation in mouse hippocampus plays a critical role in seizure-induced neuropathology. ongoing research 3 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/16954597/ Calpain and synaptic function. unassigned - 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/17234699/ Calpain regulation of AMPA receptor channels in cortical pyramidal neurons. unassigned - 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/20231455/ Targeted deletion of betaIII spectrin impairs synaptogenesis and generates ataxic and seizure phenotypes. unassigned - 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. unassigned - 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. unassigned - 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/18088374/ Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus. unassigned - 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/19258295/ Partial epilepsy in an adolescent male with limb-girdle muscular dystrophy 1B. unassigned - 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/30186110/ M-Calpain Activation Facilitates Seizure Induced KCC2 Down Regulation. unassigned - 3.4.22.B28 Epilepsy https://pubmed.ncbi.nlm.nih.gov/33132163/ Calpain-2 activation in mouse hippocampus plays a critical role in seizure-induced neuropathology. unassigned - 3.4.22.B28 Epilepsy, Absence https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. causal interaction 3 3.4.22.B28 Epilepsy, Absence https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. ongoing research 2 3.4.22.B28 Epilepsy, Absence https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. unassigned - 3.4.22.B28 Epilepsy, Generalized https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. causal interaction 3 3.4.22.B28 Epilepsy, Generalized https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. ongoing research 2 3.4.22.B28 Epilepsy, Generalized https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. unassigned - 3.4.22.B28 Epilepsy, Temporal Lobe https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. causal interaction 3 3.4.22.B28 Epilepsy, Temporal Lobe https://pubmed.ncbi.nlm.nih.gov/18088374/ Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus. causal interaction 4 3.4.22.B28 Epilepsy, Temporal Lobe https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. diagnostic usage 1 3.4.22.B28 Epilepsy, Temporal Lobe https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. therapeutic application 4 3.4.22.B28 Epilepsy, Temporal Lobe https://pubmed.ncbi.nlm.nih.gov/18088374/ Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus. therapeutic application 1 3.4.22.B28 Epilepsy, Temporal Lobe https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. ongoing research 4 3.4.22.B28 Epilepsy, Temporal Lobe https://pubmed.ncbi.nlm.nih.gov/18088374/ Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus. unassigned - 3.4.22.B28 Erectile Dysfunction https://pubmed.ncbi.nlm.nih.gov/29319007/ Calpain inhibition improves erectile function in diabetic mice via upregulating endothelial nitric oxide synthase expression and reducing apoptosis. ongoing research 4 3.4.22.B28 Erectile Dysfunction https://pubmed.ncbi.nlm.nih.gov/29319007/ Calpain inhibition improves erectile function in diabetic mice via upregulating endothelial nitric oxide synthase expression and reducing apoptosis. unassigned - 3.4.22.B28 Essential Hypertension https://pubmed.ncbi.nlm.nih.gov/2847982/ Erythrocyte deficiency in calpain inhibitor activity in essential hypertension. causal interaction 4 3.4.22.B28 Essential Hypertension https://pubmed.ncbi.nlm.nih.gov/2065100/ The calpastatin defect in hypertension is possibly due to a specific degradation by calpain. causal interaction 3 3.4.22.B28 Essential Hypertension https://pubmed.ncbi.nlm.nih.gov/9488238/ Erythrocyte calpain activity and left ventricular mass in essential hypertension. therapeutic application 1 3.4.22.B28 Essential Hypertension https://pubmed.ncbi.nlm.nih.gov/2065100/ The calpastatin defect in hypertension is possibly due to a specific degradation by calpain. therapeutic application 1 3.4.22.B28 Essential Hypertension https://pubmed.ncbi.nlm.nih.gov/2145987/ Comparative action of calpain on erythrocyte Ca2(+)-pumping ATPase in sickle cell anaemia, essential hypertension and kwashiorkor. ongoing research 3 3.4.22.B28 Essential Hypertension https://pubmed.ncbi.nlm.nih.gov/9488238/ Erythrocyte calpain activity and left ventricular mass in essential hypertension. ongoing research 4 3.4.22.B28 Essential Hypertension https://pubmed.ncbi.nlm.nih.gov/2145987/ Comparative action of calpain on erythrocyte Ca2(+)-pumping ATPase in sickle cell anaemia, essential hypertension and kwashiorkor. unassigned - 3.4.22.B28 Essential Hypertension https://pubmed.ncbi.nlm.nih.gov/9488238/ Erythrocyte calpain activity and left ventricular mass in essential hypertension. unassigned - 3.4.22.B28 Essential Hypertension https://pubmed.ncbi.nlm.nih.gov/2847982/ Erythrocyte deficiency in calpain inhibitor activity in essential hypertension. unassigned - 3.4.22.B28 Essential Hypertension https://pubmed.ncbi.nlm.nih.gov/2065100/ The calpastatin defect in hypertension is possibly due to a specific degradation by calpain. unassigned - 3.4.22.B28 Essential Tremor https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. causal interaction 1 3.4.22.B28 Essential Tremor https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. diagnostic usage 4 3.4.22.B28 Essential Tremor https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. ongoing research 4 3.4.22.B28 Essential Tremor https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. unassigned - 3.4.22.B28 Eye Diseases https://pubmed.ncbi.nlm.nih.gov/23055945/ Calpain-5 mutations cause autoimmune uveitis, retinal neovascularization, and photoreceptor degeneration. causal interaction 4 3.4.22.B28 Eye Diseases https://pubmed.ncbi.nlm.nih.gov/23055945/ Calpain-5 mutations cause autoimmune uveitis, retinal neovascularization, and photoreceptor degeneration. unassigned - 3.4.22.B28 Favism https://pubmed.ncbi.nlm.nih.gov/3024566/ Oxidative inactivation of the calcium-stimulated neutral proteinase from human red blood cells by divicine and intracellular protection by reduced glutathione. ongoing research 2 3.4.22.B28 Favism https://pubmed.ncbi.nlm.nih.gov/3024566/ Oxidative inactivation of the calcium-stimulated neutral proteinase from human red blood cells by divicine and intracellular protection by reduced glutathione. unassigned - 3.4.22.B28 Fetal Growth Retardation https://pubmed.ncbi.nlm.nih.gov/32852077/ The investigation of calpain in human placenta with fetal growth restriction. ongoing research 4 3.4.22.B28 Fetal Growth Retardation https://pubmed.ncbi.nlm.nih.gov/32852077/ The investigation of calpain in human placenta with fetal growth restriction. unassigned - 3.4.22.B28 Fibrosarcoma https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. causal interaction 2 3.4.22.B28 Fibrosarcoma https://pubmed.ncbi.nlm.nih.gov/11865195/ Calpeptin suppresses tumor necrosis factor-alpha-induced death and accumulation of p53 in L929 mouse sarcoma cells. therapeutic application 3 3.4.22.B28 Fibrosarcoma https://pubmed.ncbi.nlm.nih.gov/11865195/ Calpeptin suppresses tumor necrosis factor-alpha-induced death and accumulation of p53 in L929 mouse sarcoma cells. ongoing research 4 3.4.22.B28 Fibrosarcoma https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. ongoing research 1 3.4.22.B28 Fibrosarcoma https://pubmed.ncbi.nlm.nih.gov/11865195/ Calpeptin suppresses tumor necrosis factor-alpha-induced death and accumulation of p53 in L929 mouse sarcoma cells. unassigned - 3.4.22.B28 Fibrosarcoma https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. unassigned - 3.4.22.B28 Foodborne Diseases https://pubmed.ncbi.nlm.nih.gov/31848291/ RIP1, RIP3, and MLKL Contribute to Cell Death Caused by Clostridium perfringens Enterotoxin. causal interaction 4 3.4.22.B28 Foodborne Diseases https://pubmed.ncbi.nlm.nih.gov/31848291/ RIP1, RIP3, and MLKL Contribute to Cell Death Caused by Clostridium perfringens Enterotoxin. therapeutic application 4 3.4.22.B28 Foodborne Diseases https://pubmed.ncbi.nlm.nih.gov/31848291/ RIP1, RIP3, and MLKL Contribute to Cell Death Caused by Clostridium perfringens Enterotoxin. unassigned - 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/20107181/ Calpain activation in experimental glaucoma. causal interaction 3 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/15979593/ Proteolysis of neuronal cytoskeletal proteins by calpain contributes to rat retinal cell death induced by hypoxia. causal interaction 3 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/16528750/ Presence of calpain-induced proteolysis in retinal degeneration and dysfunction in a rat model of acute ocular hypertension. causal interaction 4 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/17122138/ Calpain-specific proteolysis in primate retina: Contribution of calpains in cell death. causal interaction 4 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/22118687/ Hsp70.1 and related lysosomal factors for necrotic neuronal death. causal interaction 2 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/20107181/ Calpain activation in experimental glaucoma. diagnostic usage 1 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/20107181/ Calpain activation in experimental glaucoma. therapeutic application 3 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/15979593/ Proteolysis of neuronal cytoskeletal proteins by calpain contributes to rat retinal cell death induced by hypoxia. therapeutic application 4 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/16528750/ Presence of calpain-induced proteolysis in retinal degeneration and dysfunction in a rat model of acute ocular hypertension. therapeutic application 4 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/17122138/ Calpain-specific proteolysis in primate retina: Contribution of calpains in cell death. therapeutic application 1 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/20107181/ Calpain activation in experimental glaucoma. ongoing research 2 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/15979593/ Proteolysis of neuronal cytoskeletal proteins by calpain contributes to rat retinal cell death induced by hypoxia. unassigned - 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/16528750/ Presence of calpain-induced proteolysis in retinal degeneration and dysfunction in a rat model of acute ocular hypertension. unassigned - 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/17122138/ Calpain-specific proteolysis in primate retina: Contribution of calpains in cell death. unassigned - 3.4.22.B28 Glaucoma https://pubmed.ncbi.nlm.nih.gov/22118687/ Hsp70.1 and related lysosomal factors for necrotic neuronal death. unassigned - 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/12111801/ Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. causal interaction 4 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/29581866/ Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. causal interaction 4 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/18258589/ Phosphoinositide binding to the substrate regulates susceptibility to proteolysis by calpain. causal interaction 1 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/20730561/ Calpain 2 is required for glioblastoma cell invasion: regulation of matrix metalloproteinase 2. causal interaction 3 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/28760640/ Sialidase NEU3 defines invasive potential of human glioblastoma cells by regulating calpain-mediated proteolysis of focal adhesion proteins. causal interaction 4 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/29581866/ Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. diagnostic usage 3 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/19285047/ N-(4-Hydroxyphenyl) retinamide potentiated paclitaxel for cell cycle arrest and apoptosis in glioblastoma C6 and RG2 cells. diagnostic usage 3 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/29581866/ Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. therapeutic application 1 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/17562168/ Curcumin Suppressed Anti-apoptotic Signals and Activated Cysteine Proteases for Apoptosis in Human Malignant Glioblastoma U87MG Cells. therapeutic application 4 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/18357521/ Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. therapeutic application 1 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/19285047/ N-(4-Hydroxyphenyl) retinamide potentiated paclitaxel for cell cycle arrest and apoptosis in glioblastoma C6 and RG2 cells. therapeutic application 1 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/19848398/ Dehydroeburicoic Acid Induces Calcium- and Calpain-Dependent Necrosis in Human U87MG Glioblastomas. therapeutic application 2 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/20730561/ Calpain 2 is required for glioblastoma cell invasion: regulation of matrix metalloproteinase 2. therapeutic application 2 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/28760640/ Sialidase NEU3 defines invasive potential of human glioblastoma cells by regulating calpain-mediated proteolysis of focal adhesion proteins. therapeutic application 4 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/12111801/ Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. ongoing research 2 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/32103382/ Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A. ongoing research 3 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/18357521/ Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. ongoing research 3 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/19848398/ Dehydroeburicoic Acid Induces Calcium- and Calpain-Dependent Necrosis in Human U87MG Glioblastomas. ongoing research 1 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/20730561/ Calpain 2 is required for glioblastoma cell invasion: regulation of matrix metalloproteinase 2. ongoing research 3 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/28760640/ Sialidase NEU3 defines invasive potential of human glioblastoma cells by regulating calpain-mediated proteolysis of focal adhesion proteins. ongoing research 2 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/32103382/ Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A. unassigned - 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/17562168/ Curcumin Suppressed Anti-apoptotic Signals and Activated Cysteine Proteases for Apoptosis in Human Malignant Glioblastoma U87MG Cells. unassigned - 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/18357521/ Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. unassigned - 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/19285047/ N-(4-Hydroxyphenyl) retinamide potentiated paclitaxel for cell cycle arrest and apoptosis in glioblastoma C6 and RG2 cells. unassigned - 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/19848398/ Dehydroeburicoic Acid Induces Calcium- and Calpain-Dependent Necrosis in Human U87MG Glioblastomas. unassigned - 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/12111801/ Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. unassigned - 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/18258589/ Phosphoinositide binding to the substrate regulates susceptibility to proteolysis by calpain. unassigned - 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/20730561/ Calpain 2 is required for glioblastoma cell invasion: regulation of matrix metalloproteinase 2. unassigned - 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/28760640/ Sialidase NEU3 defines invasive potential of human glioblastoma cells by regulating calpain-mediated proteolysis of focal adhesion proteins. unassigned - 3.4.22.B28 Glioblastoma https://pubmed.ncbi.nlm.nih.gov/29581866/ Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. unassigned - 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10350526/ Diverse stimuli induce calpain overexpression and apoptosis in C6 glioma cells. causal interaction 1 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/30273051/ Crocus sativus L. Causes a Non Apoptotic Calpain Dependent Death in C6 Rat Glioma Cells, Exhibiting a Synergistic Effect with Temozolomide. causal interaction 1 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10424775/ Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors. causal interaction 1 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10494025/ Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. causal interaction 4 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/21501525/ Silibinin induces apoptosis via calpain-dependent AIF nuclear translocation in U87MG human glioma cell death. causal interaction 1 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/24771611/ A protease storm cleaves a cell-cell adhesion molecule in cancer: multiple proteases converge to regulate PTPmu in glioma cells. causal interaction 3 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10350526/ Diverse stimuli induce calpain overexpression and apoptosis in C6 glioma cells. therapeutic application 1 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10424775/ Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors. therapeutic application 2 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10494025/ Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. therapeutic application 4 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/21501525/ Silibinin induces apoptosis via calpain-dependent AIF nuclear translocation in U87MG human glioma cell death. therapeutic application 3 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/24771611/ A protease storm cleaves a cell-cell adhesion molecule in cancer: multiple proteases converge to regulate PTPmu in glioma cells. therapeutic application 1 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10350526/ Diverse stimuli induce calpain overexpression and apoptosis in C6 glioma cells. ongoing research 2 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/30273051/ Crocus sativus L. Causes a Non Apoptotic Calpain Dependent Death in C6 Rat Glioma Cells, Exhibiting a Synergistic Effect with Temozolomide. ongoing research 1 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10424775/ Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors. ongoing research 4 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10494025/ Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. ongoing research 2 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/21501525/ Silibinin induces apoptosis via calpain-dependent AIF nuclear translocation in U87MG human glioma cell death. ongoing research 4 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10350526/ Diverse stimuli induce calpain overexpression and apoptosis in C6 glioma cells. unassigned - 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/30273051/ Crocus sativus L. Causes a Non Apoptotic Calpain Dependent Death in C6 Rat Glioma Cells, Exhibiting a Synergistic Effect with Temozolomide. unassigned - 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10424775/ Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors. unassigned - 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/10494025/ Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. unassigned - 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/21501525/ Silibinin induces apoptosis via calpain-dependent AIF nuclear translocation in U87MG human glioma cell death. unassigned - 3.4.22.B28 Glioma https://pubmed.ncbi.nlm.nih.gov/24771611/ A protease storm cleaves a cell-cell adhesion molecule in cancer: multiple proteases converge to regulate PTPmu in glioma cells. unassigned - 3.4.22.B28 Glomerulonephritis https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. causal interaction 1 3.4.22.B28 Glomerulonephritis https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. diagnostic usage 2 3.4.22.B28 Glomerulonephritis https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. ongoing research 3 3.4.22.B28 Glomerulonephritis https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. unassigned - 3.4.22.B28 Head Injuries, Closed https://pubmed.ncbi.nlm.nih.gov/24691765/ Citicoline Protects Brain Against Closed Head Injury in Rats Through Suppressing Oxidative Stress and Calpain Over-Activation. causal interaction 1 3.4.22.B28 Head Injuries, Closed https://pubmed.ncbi.nlm.nih.gov/27188531/ PrP(C) expression and calpain activity independently mediate the effects of closed head injury in mice. causal interaction 4 3.4.22.B28 Head Injuries, Closed https://pubmed.ncbi.nlm.nih.gov/24691765/ Citicoline Protects Brain Against Closed Head Injury in Rats Through Suppressing Oxidative Stress and Calpain Over-Activation. therapeutic application 3 3.4.22.B28 Head Injuries, Closed https://pubmed.ncbi.nlm.nih.gov/27188531/ PrP(C) expression and calpain activity independently mediate the effects of closed head injury in mice. ongoing research 3 3.4.22.B28 Head Injuries, Closed https://pubmed.ncbi.nlm.nih.gov/24691765/ Citicoline Protects Brain Against Closed Head Injury in Rats Through Suppressing Oxidative Stress and Calpain Over-Activation. unassigned - 3.4.22.B28 Head Injuries, Closed https://pubmed.ncbi.nlm.nih.gov/27188531/ PrP(C) expression and calpain activity independently mediate the effects of closed head injury in mice. unassigned - 3.4.22.B28 Hearing Loss https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. causal interaction 4 3.4.22.B28 Hearing Loss https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. causal interaction 3 3.4.22.B28 Hearing Loss https://pubmed.ncbi.nlm.nih.gov/29472286/ A novel de novo CAPN5 mutation in a patient with inflammatory vitreoretinopathy, hearing loss, and developmental delay. causal interaction 4 3.4.22.B28 Hearing Loss https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. therapeutic application 4 3.4.22.B28 Hearing Loss https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. therapeutic application 4 3.4.22.B28 Hearing Loss https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. ongoing research 3 3.4.22.B28 Hearing Loss https://pubmed.ncbi.nlm.nih.gov/31814894/ Cisplatin induces calcium ion accumulation and hearing loss by causing functional alterations in calcium channels and exocytosis. unassigned - 3.4.22.B28 Hearing Loss https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. unassigned - 3.4.22.B28 Hearing Loss https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. unassigned - 3.4.22.B28 Hearing Loss https://pubmed.ncbi.nlm.nih.gov/29472286/ A novel de novo CAPN5 mutation in a patient with inflammatory vitreoretinopathy, hearing loss, and developmental delay. unassigned - 3.4.22.B28 Hearing Loss, Noise-Induced https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. causal interaction 3 3.4.22.B28 Hearing Loss, Noise-Induced https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. causal interaction 4 3.4.22.B28 Hearing Loss, Noise-Induced https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. causal interaction 4 3.4.22.B28 Hearing Loss, Noise-Induced https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. therapeutic application 4 3.4.22.B28 Hearing Loss, Noise-Induced https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. therapeutic application 4 3.4.22.B28 Hearing Loss, Noise-Induced https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. ongoing research 3 3.4.22.B28 Hearing Loss, Noise-Induced https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. unassigned - 3.4.22.B28 Hearing Loss, Noise-Induced https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. unassigned - 3.4.22.B28 Hearing Loss, Noise-Induced https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. unassigned - 3.4.22.B28 Hearing Loss, Sensorineural https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. causal interaction 4 3.4.22.B28 Hearing Loss, Sensorineural https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. therapeutic application 4 3.4.22.B28 Hearing Loss, Sensorineural https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. ongoing research 3 3.4.22.B28 Hearing Loss, Sensorineural https://pubmed.ncbi.nlm.nih.gov/28366808/ Calpain inhibitor alleviates permanent hearing loss induced by intense noise by preventing disruption of gap junction-mediated intercellular communication in the cochlear spiral ligament. unassigned - 3.4.22.B28 Heart Arrest https://pubmed.ncbi.nlm.nih.gov/19966051/ Cardioprotective effects of a novel calpain inhibitor SNJ-1945 for reperfusion injury after cardioplegic cardiac arrest. causal interaction 1 3.4.22.B28 Heart Arrest https://pubmed.ncbi.nlm.nih.gov/16823696/ Changes of cytoskeletal proteins in ischaemic brain under cardiac arrest and reperfusion conditions. causal interaction 2 3.4.22.B28 Heart Arrest https://pubmed.ncbi.nlm.nih.gov/19966051/ Cardioprotective effects of a novel calpain inhibitor SNJ-1945 for reperfusion injury after cardioplegic cardiac arrest. therapeutic application 4 3.4.22.B28 Heart Arrest https://pubmed.ncbi.nlm.nih.gov/19966051/ Cardioprotective effects of a novel calpain inhibitor SNJ-1945 for reperfusion injury after cardioplegic cardiac arrest. ongoing research 1 3.4.22.B28 Heart Arrest https://pubmed.ncbi.nlm.nih.gov/16823696/ Changes of cytoskeletal proteins in ischaemic brain under cardiac arrest and reperfusion conditions. ongoing research 2 3.4.22.B28 Heart Arrest https://pubmed.ncbi.nlm.nih.gov/19966051/ Cardioprotective effects of a novel calpain inhibitor SNJ-1945 for reperfusion injury after cardioplegic cardiac arrest. unassigned - 3.4.22.B28 Heart Arrest https://pubmed.ncbi.nlm.nih.gov/16823696/ Changes of cytoskeletal proteins in ischaemic brain under cardiac arrest and reperfusion conditions. unassigned - 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/17593948/ Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. causal interaction 4 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/19505932/ Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. causal interaction 4 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/24519662/ [Upstream therapy for atrial fibrillation]. causal interaction 1 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/27730362/ Dantrolene improves in vitro structural changes induced by serum from Trypanosoma cruzi-infected mice. causal interaction 4 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/29945255/ Expression and effect of Calpain9 gene genetic polymorphism on slaughter indicators and intramuscular fat content in chickens. causal interaction 1 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/34440793/ Calpain-Mediated Mitochondrial Damage: An Emerging Mechanism Contributing to Cardiac Disease. causal interaction 2 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/19505932/ Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. therapeutic application 4 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/24519662/ [Upstream therapy for atrial fibrillation]. therapeutic application 1 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/27730362/ Dantrolene improves in vitro structural changes induced by serum from Trypanosoma cruzi-infected mice. therapeutic application 4 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/17593948/ Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. unassigned - 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/19505932/ Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. unassigned - 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/24519662/ [Upstream therapy for atrial fibrillation]. unassigned - 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/27730362/ Dantrolene improves in vitro structural changes induced by serum from Trypanosoma cruzi-infected mice. unassigned - 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/29945255/ Expression and effect of Calpain9 gene genetic polymorphism on slaughter indicators and intramuscular fat content in chickens. unassigned - 3.4.22.B28 Heart Diseases https://pubmed.ncbi.nlm.nih.gov/34440793/ Calpain-Mediated Mitochondrial Damage: An Emerging Mechanism Contributing to Cardiac Disease. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/15929823/ [Calpain involved in signal transduction of myocardial remodeling in patients with congestive heart failure] causal interaction 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/16633084/ Possible involvement of calpain activation in pathogenesis of chronic heart failure after acute myocardial infarction. causal interaction 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/20514436/ Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure. causal interaction 3 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/22582173/ Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. causal interaction 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/23596505/ Calpain inhibition reduces amplitude and accelerates decay of the late sodium current in ventricular myocytes from dogs with chronic heart failure. causal interaction 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/30175275/ Unraveling the Mechanisms by Which Calpain Inhibition Prevents Heart Failure Development. causal interaction 2 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/15532451/ [Calpains and cardiac diseases] causal interaction 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/15639474/ Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart. causal interaction 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/19889795/ Inhibition of dystrophin breakdown and endothelial nitric-oxide synthase uncoupling accounts for cytoprotection by 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) in left ventricular hypertrophied Mice. causal interaction 3 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/21108772/ Physiologic and Pathophysiologic Role of Calpain: Implications for the Occurrence of Atrial Fibrillation. causal interaction 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/21162207/ [The role of angiotension II receptor and calpain in myocardium remodeling]. causal interaction 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/22843702/ Cooperation between proteolytic systems in cardiomyocyte recycling. causal interaction 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. causal interaction 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/30175274/ Targeting Calpain for Heart Failure Therapy: Implications From Multiple Murine Models. causal interaction 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/31958767/ Crosstalk between endothelial cell-specific calpain inhibition and the endothelial-mesenchymal transition via the HSP90/Akt signaling pathway. causal interaction 3 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/32968209/ Targeted inhibition of calpain in mitochondria alleviates oxidative stress-induced myocardial injury. causal interaction 3 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/34524407/ Calpain-2 Specifically Cleaves Junctophilin-2 at the Same Site as Calpain-1 but with Less Efficacy. causal interaction 3 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/15929823/ [Calpain involved in signal transduction of myocardial remodeling in patients with congestive heart failure] diagnostic usage 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/16633084/ Possible involvement of calpain activation in pathogenesis of chronic heart failure after acute myocardial infarction. diagnostic usage 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/20514436/ Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure. diagnostic usage 2 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/21108772/ Physiologic and Pathophysiologic Role of Calpain: Implications for the Occurrence of Atrial Fibrillation. diagnostic usage 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/21162207/ [The role of angiotension II receptor and calpain in myocardium remodeling]. diagnostic usage 2 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/15929823/ [Calpain involved in signal transduction of myocardial remodeling in patients with congestive heart failure] therapeutic application 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/16633084/ Possible involvement of calpain activation in pathogenesis of chronic heart failure after acute myocardial infarction. therapeutic application 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/22582173/ Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. therapeutic application 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/23596505/ Calpain inhibition reduces amplitude and accelerates decay of the late sodium current in ventricular myocytes from dogs with chronic heart failure. therapeutic application 2 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/25336645/ Molecular basis of calpain cleavage and inactivation of the sodium-calcium exchanger 1 in heart failure. therapeutic application 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/30175275/ Unraveling the Mechanisms by Which Calpain Inhibition Prevents Heart Failure Development. therapeutic application 2 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/15532451/ [Calpains and cardiac diseases] therapeutic application 3 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/15639474/ Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart. therapeutic application 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/16054019/ A novel scheme of dystrophin disruption for the progression of advanced heart failure. therapeutic application 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/21108772/ Physiologic and Pathophysiologic Role of Calpain: Implications for the Occurrence of Atrial Fibrillation. therapeutic application 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/21162207/ [The role of angiotension II receptor and calpain in myocardium remodeling]. therapeutic application 2 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. therapeutic application 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/30175274/ Targeting Calpain for Heart Failure Therapy: Implications From Multiple Murine Models. therapeutic application 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/31958767/ Crosstalk between endothelial cell-specific calpain inhibition and the endothelial-mesenchymal transition via the HSP90/Akt signaling pathway. therapeutic application 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/34524407/ Calpain-2 Specifically Cleaves Junctophilin-2 at the Same Site as Calpain-1 but with Less Efficacy. therapeutic application 3 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/15929823/ [Calpain involved in signal transduction of myocardial remodeling in patients with congestive heart failure] ongoing research 2 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/23596505/ Calpain inhibition reduces amplitude and accelerates decay of the late sodium current in ventricular myocytes from dogs with chronic heart failure. ongoing research 2 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/15639474/ Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart. ongoing research 4 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/21162207/ [The role of angiotension II receptor and calpain in myocardium remodeling]. ongoing research 1 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/22843702/ Cooperation between proteolytic systems in cardiomyocyte recycling. ongoing research 2 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. ongoing research 2 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/25336645/ Molecular basis of calpain cleavage and inactivation of the sodium-calcium exchanger 1 in heart failure. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/16054019/ A novel scheme of dystrophin disruption for the progression of advanced heart failure. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/22778271/ Ankyrin-B Protein in Heart Failure: IDENTIFICATION OF A NEW COMPONENT OF METAZOAN CARDIOPROTECTION. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/30409805/ E-C coupling structural protein junctophilin-2 encodes a stress-adaptive transcription regulator. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/22582173/ Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/23596505/ Calpain inhibition reduces amplitude and accelerates decay of the late sodium current in ventricular myocytes from dogs with chronic heart failure. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/30175275/ Unraveling the Mechanisms by Which Calpain Inhibition Prevents Heart Failure Development. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/15532451/ [Calpains and cardiac diseases] unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/15639474/ Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/19889795/ Inhibition of dystrophin breakdown and endothelial nitric-oxide synthase uncoupling accounts for cytoprotection by 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) in left ventricular hypertrophied Mice. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/22843702/ Cooperation between proteolytic systems in cardiomyocyte recycling. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/30175274/ Targeting Calpain for Heart Failure Therapy: Implications From Multiple Murine Models. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/31958767/ Crosstalk between endothelial cell-specific calpain inhibition and the endothelial-mesenchymal transition via the HSP90/Akt signaling pathway. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/32968209/ Targeted inhibition of calpain in mitochondria alleviates oxidative stress-induced myocardial injury. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/34524407/ Calpain-2 Specifically Cleaves Junctophilin-2 at the Same Site as Calpain-1 but with Less Efficacy. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/20514436/ Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/16633084/ Possible involvement of calpain activation in pathogenesis of chronic heart failure after acute myocardial infarction. unassigned - 3.4.22.B28 Heart Failure https://pubmed.ncbi.nlm.nih.gov/21108772/ Physiologic and Pathophysiologic Role of Calpain: Implications for the Occurrence of Atrial Fibrillation. unassigned - 3.4.22.B28 Hemorrhagic Stroke https://pubmed.ncbi.nlm.nih.gov/24583080/ A neuroproteomic and systems biology analysis of rat brain post intracerebral hemorrhagic stroke. unassigned - 3.4.22.B28 Hepatic Encephalopathy https://pubmed.ncbi.nlm.nih.gov/28828727/ Concurrent assessment of calpain and caspase3 activities in brains of mice with acetaminophen-induced acute hepatic encephalopathy. ongoing research 3 3.4.22.B28 Hepatic Encephalopathy https://pubmed.ncbi.nlm.nih.gov/28828727/ Concurrent assessment of calpain and caspase3 activities in brains of mice with acetaminophen-induced acute hepatic encephalopathy. unassigned - 3.4.22.B28 Hepatitis https://pubmed.ncbi.nlm.nih.gov/17162536/ Calpain inhibition attenuates iNOS production and midzonal hepatic necrosis in a repeat dose model of endotoxemia in rats. causal interaction 1 3.4.22.B28 Hepatitis https://pubmed.ncbi.nlm.nih.gov/17162536/ Calpain inhibition attenuates iNOS production and midzonal hepatic necrosis in a repeat dose model of endotoxemia in rats. therapeutic application 2 3.4.22.B28 Hepatitis https://pubmed.ncbi.nlm.nih.gov/17162536/ Calpain inhibition attenuates iNOS production and midzonal hepatic necrosis in a repeat dose model of endotoxemia in rats. ongoing research 4 3.4.22.B28 Hepatitis https://pubmed.ncbi.nlm.nih.gov/17162536/ Calpain inhibition attenuates iNOS production and midzonal hepatic necrosis in a repeat dose model of endotoxemia in rats. unassigned - 3.4.22.B28 Hepatitis C https://pubmed.ncbi.nlm.nih.gov/12909638/ Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease. causal interaction 2 3.4.22.B28 Hepatitis C https://pubmed.ncbi.nlm.nih.gov/15479828/ Calcium-dependent calpain proteases are implicated in processing of the hepatitis C virus NS5A protein. causal interaction 2 3.4.22.B28 Hepatitis C https://pubmed.ncbi.nlm.nih.gov/19711428/ Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway. causal interaction 4 3.4.22.B28 Hepatitis C https://pubmed.ncbi.nlm.nih.gov/12909638/ Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease. therapeutic application 1 3.4.22.B28 Hepatitis C https://pubmed.ncbi.nlm.nih.gov/19711428/ Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway. therapeutic application 1 3.4.22.B28 Hepatitis C https://pubmed.ncbi.nlm.nih.gov/30593533/ Withdrawal: Hepatitis C virus NS5A and subgenomic replicon activate NF- ? B via tyrosine phosphorylation of I ? B ? and its degradation by calpain protease. unassigned - 3.4.22.B28 Hepatitis C https://pubmed.ncbi.nlm.nih.gov/12909638/ Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease. unassigned - 3.4.22.B28 Hepatitis C https://pubmed.ncbi.nlm.nih.gov/15479828/ Calcium-dependent calpain proteases are implicated in processing of the hepatitis C virus NS5A protein. unassigned - 3.4.22.B28 Hepatitis C https://pubmed.ncbi.nlm.nih.gov/19711428/ Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway. unassigned - 3.4.22.B28 Hepatoblastoma https://pubmed.ncbi.nlm.nih.gov/22613727/ Calpain induces N-terminal truncation of ?-catenin in normal murine liver development: diagnostic implications in hepatoblastomas. ongoing research 2 3.4.22.B28 Hepatoblastoma https://pubmed.ncbi.nlm.nih.gov/22613727/ Calpain induces N-terminal truncation of ?-catenin in normal murine liver development: diagnostic implications in hepatoblastomas. unassigned - 3.4.22.B28 Hernia, Umbilical https://pubmed.ncbi.nlm.nih.gov/30746724/ Genome-wide association study identifies variants in the CAPN9 gene associated with umbilical hernia in pigs. ongoing research 1 3.4.22.B28 Hernia, Umbilical https://pubmed.ncbi.nlm.nih.gov/30746724/ Genome-wide association study identifies variants in the CAPN9 gene associated with umbilical hernia in pigs. unassigned - 3.4.22.B28 High Pressure Neurological Syndrome https://pubmed.ncbi.nlm.nih.gov/24287800/ Protective effect of S-allyl-L-cysteine against endoplasmic reticulum stress-induced neuronal death is mediated by inhibition of calpain. ongoing research 2 3.4.22.B28 High Pressure Neurological Syndrome https://pubmed.ncbi.nlm.nih.gov/24287800/ Protective effect of S-allyl-L-cysteine against endoplasmic reticulum stress-induced neuronal death is mediated by inhibition of calpain. unassigned - 3.4.22.B28 HIV Infections https://pubmed.ncbi.nlm.nih.gov/8021517/ Inhibition of activation-induced programmed cell death and restoration of defective immune responses of HIV+ donors by cysteine protease inhibitors. causal interaction 3 3.4.22.B28 HIV Infections https://pubmed.ncbi.nlm.nih.gov/8021517/ Inhibition of activation-induced programmed cell death and restoration of defective immune responses of HIV+ donors by cysteine protease inhibitors. therapeutic application 4 3.4.22.B28 HIV Infections https://pubmed.ncbi.nlm.nih.gov/8021517/ Inhibition of activation-induced programmed cell death and restoration of defective immune responses of HIV+ donors by cysteine protease inhibitors. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/12832525/ Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. causal interaction 3 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/16959224/ Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. causal interaction 3 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. causal interaction 3 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/25257175/ Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity. causal interaction 3 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/12832525/ Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. therapeutic application 3 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/21304966/ Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1. therapeutic application 1 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/25257175/ Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity. therapeutic application 4 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/27141414/ The calpain-suppressing effects of olesoxime in Huntington's disease. therapeutic application 1 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/16959224/ Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. ongoing research 2 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/19036965/ Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. ongoing research 2 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/22523092/ Calpain and STriatal-Enriched protein tyrosine Phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model. ongoing research 1 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/24588402/ Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model. ongoing research 2 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/29355642/ Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease. ongoing research 3 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/12077181/ Calpain activation in Huntington's disease. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/19036965/ Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/22523092/ Calpain and STriatal-Enriched protein tyrosine Phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/21304966/ Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/24588402/ Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/26490331/ Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/27141414/ The calpain-suppressing effects of olesoxime in Huntington's disease. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/29355642/ Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/12832525/ Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/16959224/ Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. unassigned - 3.4.22.B28 Huntington Disease https://pubmed.ncbi.nlm.nih.gov/25257175/ Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity. unassigned - 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/25150005/ Calpain-2 contributes to neuropathic pain following motor nerve injury via up-regulating interleukin-6 in DRG neurons. causal interaction 3 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/28039003/ Neurotropin(®) inhibits calpain activity upregulated by specific alternation of rhythm in temperature in the mesencephalon of rats. causal interaction 1 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/15275793/ The calpain inhibitor MDL 28170 prevents inflammation-induced neurofilament light chain breakdown in the spinal cord and reduces thermal hyperalgesia. therapeutic application 3 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/20236225/ Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain. therapeutic application 4 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/20420580/ Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain. therapeutic application 4 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/25150005/ Calpain-2 contributes to neuropathic pain following motor nerve injury via up-regulating interleukin-6 in DRG neurons. therapeutic application 1 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/28039003/ Neurotropin(®) inhibits calpain activity upregulated by specific alternation of rhythm in temperature in the mesencephalon of rats. therapeutic application 2 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/28714350/ Activation and expression of ?-calpain in dorsal root contributes to RTX-induced mechanical allodynia. therapeutic application 2 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/28714350/ Activation and expression of ?-calpain in dorsal root contributes to RTX-induced mechanical allodynia. ongoing research 4 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/34006144/ Intracellular versus extracellular inhibition of calpain I causes differential effects on pain in a rat model of joint inflammation. ongoing research 4 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/15275793/ The calpain inhibitor MDL 28170 prevents inflammation-induced neurofilament light chain breakdown in the spinal cord and reduces thermal hyperalgesia. unassigned - 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/20236225/ Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain. unassigned - 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/20420580/ Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain. unassigned - 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/28714350/ Activation and expression of ?-calpain in dorsal root contributes to RTX-induced mechanical allodynia. unassigned - 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/34006144/ Intracellular versus extracellular inhibition of calpain I causes differential effects on pain in a rat model of joint inflammation. unassigned - 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/25150005/ Calpain-2 contributes to neuropathic pain following motor nerve injury via up-regulating interleukin-6 in DRG neurons. unassigned - 3.4.22.B28 Hyperalgesia https://pubmed.ncbi.nlm.nih.gov/28039003/ Neurotropin(®) inhibits calpain activity upregulated by specific alternation of rhythm in temperature in the mesencephalon of rats. unassigned - 3.4.22.B28 Hypercalcemia https://pubmed.ncbi.nlm.nih.gov/16865232/ The gene expression and activity of calpains and the muscle wasting-associated ubiquitin ligases, atrogin-1 and MuRF1, are not altered in patients with primary hyperparathyroidism. causal interaction 1 3.4.22.B28 Hypercalcemia https://pubmed.ncbi.nlm.nih.gov/16865232/ The gene expression and activity of calpains and the muscle wasting-associated ubiquitin ligases, atrogin-1 and MuRF1, are not altered in patients with primary hyperparathyroidism. diagnostic usage 1 3.4.22.B28 Hypercalcemia https://pubmed.ncbi.nlm.nih.gov/16865232/ The gene expression and activity of calpains and the muscle wasting-associated ubiquitin ligases, atrogin-1 and MuRF1, are not altered in patients with primary hyperparathyroidism. therapeutic application 1 3.4.22.B28 Hypercalcemia https://pubmed.ncbi.nlm.nih.gov/16865232/ The gene expression and activity of calpains and the muscle wasting-associated ubiquitin ligases, atrogin-1 and MuRF1, are not altered in patients with primary hyperparathyroidism. unassigned - 3.4.22.B28 Hypercholesterolemia https://pubmed.ncbi.nlm.nih.gov/26047104/ Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL. causal interaction 4 3.4.22.B28 Hypercholesterolemia https://pubmed.ncbi.nlm.nih.gov/26047104/ Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL. therapeutic application 1 3.4.22.B28 Hypercholesterolemia https://pubmed.ncbi.nlm.nih.gov/26478238/ Calpain inhibition improves collateral-dependent perfusion in a hypercholesterolemic swine model of chronic myocardial ischemia. therapeutic application 1 3.4.22.B28 Hypercholesterolemia https://pubmed.ncbi.nlm.nih.gov/26047104/ Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL. ongoing research 3 3.4.22.B28 Hypercholesterolemia https://pubmed.ncbi.nlm.nih.gov/26478238/ Calpain inhibition improves collateral-dependent perfusion in a hypercholesterolemic swine model of chronic myocardial ischemia. ongoing research 2 3.4.22.B28 Hypercholesterolemia https://pubmed.ncbi.nlm.nih.gov/26478238/ Calpain inhibition improves collateral-dependent perfusion in a hypercholesterolemic swine model of chronic myocardial ischemia. unassigned - 3.4.22.B28 Hypercholesterolemia https://pubmed.ncbi.nlm.nih.gov/26047104/ Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL. unassigned - 3.4.22.B28 Hyperglycemia https://pubmed.ncbi.nlm.nih.gov/12824289/ A novel role for calpains in the endothelial dysfunction of hyperglycemia. causal interaction 4 3.4.22.B28 Hyperglycemia https://pubmed.ncbi.nlm.nih.gov/22967911/ Metabolic stress response implicated in diabetic retinopathy: The role of calpain, and the therapeutic impact of calpain inhibitor. causal interaction 4 3.4.22.B28 Hyperglycemia https://pubmed.ncbi.nlm.nih.gov/30799273/ Calpain Inhibition Restores Autophagy and Prevents Mitochondrial Fragmentation in a Human iPSC Model of Diabetic Endotheliopathy. causal interaction 3 3.4.22.B28 Hyperglycemia https://pubmed.ncbi.nlm.nih.gov/12824289/ A novel role for calpains in the endothelial dysfunction of hyperglycemia. therapeutic application 3 3.4.22.B28 Hyperglycemia https://pubmed.ncbi.nlm.nih.gov/22967911/ Metabolic stress response implicated in diabetic retinopathy: The role of calpain, and the therapeutic impact of calpain inhibitor. therapeutic application 3 3.4.22.B28 Hyperglycemia https://pubmed.ncbi.nlm.nih.gov/12824289/ A novel role for calpains in the endothelial dysfunction of hyperglycemia. ongoing research 3 3.4.22.B28 Hyperglycemia https://pubmed.ncbi.nlm.nih.gov/22967911/ Metabolic stress response implicated in diabetic retinopathy: The role of calpain, and the therapeutic impact of calpain inhibitor. ongoing research 2 3.4.22.B28 Hyperglycemia https://pubmed.ncbi.nlm.nih.gov/21071702/ Protein kinase C upregulates intercellular adhesion molecule-1 and leukocyte-endothelium interactions in hyperglycemia via activation of endothelial expressed calpain. unassigned - 3.4.22.B28 Hyperglycemia https://pubmed.ncbi.nlm.nih.gov/12824289/ A novel role for calpains in the endothelial dysfunction of hyperglycemia. unassigned - 3.4.22.B28 Hyperglycemia https://pubmed.ncbi.nlm.nih.gov/22967911/ Metabolic stress response implicated in diabetic retinopathy: The role of calpain, and the therapeutic impact of calpain inhibitor. unassigned - 3.4.22.B28 Hyperglycemia https://pubmed.ncbi.nlm.nih.gov/30799273/ Calpain Inhibition Restores Autophagy and Prevents Mitochondrial Fragmentation in a Human iPSC Model of Diabetic Endotheliopathy. unassigned - 3.4.22.B28 Hyperhomocysteinemia https://pubmed.ncbi.nlm.nih.gov/19059382/ Effect of hyperhomocysteinemia on the protein kinase DYRK1A in liver of mice. therapeutic application 1 3.4.22.B28 Hyperhomocysteinemia https://pubmed.ncbi.nlm.nih.gov/19059382/ Effect of hyperhomocysteinemia on the protein kinase DYRK1A in liver of mice. ongoing research 4 3.4.22.B28 Hyperhomocysteinemia https://pubmed.ncbi.nlm.nih.gov/19059382/ Effect of hyperhomocysteinemia on the protein kinase DYRK1A in liver of mice. unassigned - 3.4.22.B28 Hyperlipidemias https://pubmed.ncbi.nlm.nih.gov/26560635/ Grape seed and skin extract protects against arsenic trioxide induced oxidative stress in rat heart. causal interaction 3 3.4.22.B28 Hyperlipidemias https://pubmed.ncbi.nlm.nih.gov/26560635/ Grape seed and skin extract protects against arsenic trioxide induced oxidative stress in rat heart. diagnostic usage 3 3.4.22.B28 Hyperlipidemias https://pubmed.ncbi.nlm.nih.gov/26560635/ Grape seed and skin extract protects against arsenic trioxide induced oxidative stress in rat heart. unassigned - 3.4.22.B28 Hypersensitivity https://pubmed.ncbi.nlm.nih.gov/28131390/ Calpain-14 and its association with eosinophilic esophagitis. causal interaction 4 3.4.22.B28 Hypersensitivity https://pubmed.ncbi.nlm.nih.gov/34394070/ Cross-Linking Cellular Prion Protein Induces Neuronal Type 2-Like Hypersensitivity. causal interaction 4 3.4.22.B28 Hypersensitivity https://pubmed.ncbi.nlm.nih.gov/28131390/ Calpain-14 and its association with eosinophilic esophagitis. unassigned - 3.4.22.B28 Hypersensitivity https://pubmed.ncbi.nlm.nih.gov/34394070/ Cross-Linking Cellular Prion Protein Induces Neuronal Type 2-Like Hypersensitivity. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/2065100/ The calpastatin defect in hypertension is possibly due to a specific degradation by calpain. causal interaction 3 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/2279616/ Calpains (intracellular calcium-activated cysteine proteinases): structure-activity relationships and involvement in normal and abnormal cellular metabolism. causal interaction 4 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/7709342/ A genetic deficiency in calpastatin and isovalerylcarnitine treatment is associated with enhanced hippocampal long-term potentiation. causal interaction 4 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/8547842/ Calpain activity of hypertrophic hearts from hypertensive rats. causal interaction 4 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/12631067/ Calpain is activated in experimental uremia: is calpain a mediator of uremia-induced myocardial injury? causal interaction 4 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. causal interaction 3 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/16843603/ Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester. causal interaction 4 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/17593948/ Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. causal interaction 4 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. causal interaction 4 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. causal interaction 4 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/29945255/ Expression and effect of Calpain9 gene genetic polymorphism on slaughter indicators and intramuscular fat content in chickens. causal interaction 1 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/12358155/ Screening the proteins that interact with calpain in a human heart cDNA library using a yeast two-hybrid system. diagnostic usage 3 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. diagnostic usage 3 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/2065100/ The calpastatin defect in hypertension is possibly due to a specific degradation by calpain. therapeutic application 1 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/2279616/ Calpains (intracellular calcium-activated cysteine proteinases): structure-activity relationships and involvement in normal and abnormal cellular metabolism. therapeutic application 1 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/9488238/ Erythrocyte calpain activity and left ventricular mass in essential hypertension. therapeutic application 1 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/12631067/ Calpain is activated in experimental uremia: is calpain a mediator of uremia-induced myocardial injury? therapeutic application 1 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. therapeutic application 1 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/16843603/ Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester. therapeutic application 4 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. therapeutic application 3 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. therapeutic application 2 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/9488238/ Erythrocyte calpain activity and left ventricular mass in essential hypertension. ongoing research 4 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/12358155/ Screening the proteins that interact with calpain in a human heart cDNA library using a yeast two-hybrid system. ongoing research 3 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/16843603/ Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester. ongoing research 3 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. ongoing research 4 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/9488238/ Erythrocyte calpain activity and left ventricular mass in essential hypertension. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/12358155/ Screening the proteins that interact with calpain in a human heart cDNA library using a yeast two-hybrid system. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/33675847/ Calpastatin prevents Angiotensin II-mediated podocyte injury through maintenance of autophagy. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/2065100/ The calpastatin defect in hypertension is possibly due to a specific degradation by calpain. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/2279616/ Calpains (intracellular calcium-activated cysteine proteinases): structure-activity relationships and involvement in normal and abnormal cellular metabolism. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/7709342/ A genetic deficiency in calpastatin and isovalerylcarnitine treatment is associated with enhanced hippocampal long-term potentiation. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/8547842/ Calpain activity of hypertrophic hearts from hypertensive rats. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/12631067/ Calpain is activated in experimental uremia: is calpain a mediator of uremia-induced myocardial injury? unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/16843603/ Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/17593948/ Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/29945255/ Expression and effect of Calpain9 gene genetic polymorphism on slaughter indicators and intramuscular fat content in chickens. unassigned - 3.4.22.B28 Hypertension https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. unassigned - 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/15753756/ Calpain inhibition decreases endothelin-1 levels and pulmonary hypertension after cardiopulmonary bypass with deep hypothermic circulatory arrest. causal interaction 4 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. causal interaction 4 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/22582173/ Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. causal interaction 4 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. causal interaction 4 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. causal interaction 4 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/27640791/ [Calpain mediated pulmonary vascular remodeling in hypoxia induced pulmonary hypertension]. causal interaction 2 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/31088299/ Reactive Oxygen Species-Dependent Calpain Activation Contributes to Airway and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease. causal interaction 4 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. diagnostic usage 3 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/31088299/ Reactive Oxygen Species-Dependent Calpain Activation Contributes to Airway and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease. diagnostic usage 2 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/15753756/ Calpain inhibition decreases endothelin-1 levels and pulmonary hypertension after cardiopulmonary bypass with deep hypothermic circulatory arrest. therapeutic application 1 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. therapeutic application 3 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/22582173/ Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. therapeutic application 4 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. therapeutic application 1 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. therapeutic application 2 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/27640791/ [Calpain mediated pulmonary vascular remodeling in hypoxia induced pulmonary hypertension]. therapeutic application 1 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/31088299/ Reactive Oxygen Species-Dependent Calpain Activation Contributes to Airway and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease. therapeutic application 4 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. ongoing research 4 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/27099352/ Calpain-2 activates Akt via TGF-?1-mTORC2 pathway in pulmonary artery smooth muscle cells. ongoing research 2 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/27099352/ Calpain-2 activates Akt via TGF-?1-mTORC2 pathway in pulmonary artery smooth muscle cells. unassigned - 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/15753756/ Calpain inhibition decreases endothelin-1 levels and pulmonary hypertension after cardiopulmonary bypass with deep hypothermic circulatory arrest. unassigned - 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. unassigned - 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/22582173/ Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. unassigned - 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. unassigned - 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/27640791/ [Calpain mediated pulmonary vascular remodeling in hypoxia induced pulmonary hypertension]. unassigned - 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. unassigned - 3.4.22.B28 Hypertension, Pulmonary https://pubmed.ncbi.nlm.nih.gov/31088299/ Reactive Oxygen Species-Dependent Calpain Activation Contributes to Airway and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease. unassigned - 3.4.22.B28 Hypertrophy, Left Ventricular https://pubmed.ncbi.nlm.nih.gov/8547842/ Calpain activity of hypertrophic hearts from hypertensive rats. causal interaction 4 3.4.22.B28 Hypertrophy, Left Ventricular https://pubmed.ncbi.nlm.nih.gov/9488238/ Erythrocyte calpain activity and left ventricular mass in essential hypertension. therapeutic application 1 3.4.22.B28 Hypertrophy, Left Ventricular https://pubmed.ncbi.nlm.nih.gov/9488238/ Erythrocyte calpain activity and left ventricular mass in essential hypertension. ongoing research 4 3.4.22.B28 Hypertrophy, Left Ventricular https://pubmed.ncbi.nlm.nih.gov/9488238/ Erythrocyte calpain activity and left ventricular mass in essential hypertension. unassigned - 3.4.22.B28 Hypertrophy, Left Ventricular https://pubmed.ncbi.nlm.nih.gov/8547842/ Calpain activity of hypertrophic hearts from hypertensive rats. unassigned - 3.4.22.B28 Hypertrophy, Right Ventricular https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. causal interaction 4 3.4.22.B28 Hypertrophy, Right Ventricular https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. therapeutic application 3 3.4.22.B28 Hypertrophy, Right Ventricular https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. ongoing research 4 3.4.22.B28 Hypertrophy, Right Ventricular https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. unassigned - 3.4.22.B28 Hypoglycemia https://pubmed.ncbi.nlm.nih.gov/12787063/ Cyclosporin A prevents calpain activation despite increased intracellular calcium concentrations, as well as translocation of apoptosis-inducing factor, cytochrome c and caspase-3 activation in neurons exposed to transient hypoglycemia. causal interaction 1 3.4.22.B28 Hypoglycemia https://pubmed.ncbi.nlm.nih.gov/12787063/ Cyclosporin A prevents calpain activation despite increased intracellular calcium concentrations, as well as translocation of apoptosis-inducing factor, cytochrome c and caspase-3 activation in neurons exposed to transient hypoglycemia. therapeutic application 1 3.4.22.B28 Hypoglycemia https://pubmed.ncbi.nlm.nih.gov/12787063/ Cyclosporin A prevents calpain activation despite increased intracellular calcium concentrations, as well as translocation of apoptosis-inducing factor, cytochrome c and caspase-3 activation in neurons exposed to transient hypoglycemia. ongoing research 2 3.4.22.B28 Hypoglycemia https://pubmed.ncbi.nlm.nih.gov/12787063/ Cyclosporin A prevents calpain activation despite increased intracellular calcium concentrations, as well as translocation of apoptosis-inducing factor, cytochrome c and caspase-3 activation in neurons exposed to transient hypoglycemia. unassigned - 3.4.22.B28 Hypoxia-Ischemia, Brain https://pubmed.ncbi.nlm.nih.gov/10318818/ Calpastatin is up-regulated in response to hypoxia and is a suicide substrate to calpain after neonatal cerebral hypoxia-ischemia. causal interaction 3 3.4.22.B28 Hypoxia-Ischemia, Brain https://pubmed.ncbi.nlm.nih.gov/11124942/ Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia: a mechanism of "pathological apoptosis"? causal interaction 3 3.4.22.B28 Hypoxia-Ischemia, Brain https://pubmed.ncbi.nlm.nih.gov/11124942/ Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia: a mechanism of "pathological apoptosis"? therapeutic application 1 3.4.22.B28 Hypoxia-Ischemia, Brain https://pubmed.ncbi.nlm.nih.gov/10318818/ Calpastatin is up-regulated in response to hypoxia and is a suicide substrate to calpain after neonatal cerebral hypoxia-ischemia. unassigned - 3.4.22.B28 Hypoxia-Ischemia, Brain https://pubmed.ncbi.nlm.nih.gov/11124942/ Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia: a mechanism of "pathological apoptosis"? unassigned - 3.4.22.B28 Idiopathic Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/34231213/ Pleural mesothelial cell migration into lung parenchyma by calpain contributes to idiopathic pulmonary fibrosis. therapeutic application 1 3.4.22.B28 Idiopathic Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/34231213/ Pleural mesothelial cell migration into lung parenchyma by calpain contributes to idiopathic pulmonary fibrosis. ongoing research 3 3.4.22.B28 Idiopathic Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/34231213/ Pleural mesothelial cell migration into lung parenchyma by calpain contributes to idiopathic pulmonary fibrosis. unassigned - 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. causal interaction 4 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/15036603/ Delayed moderate hypothermia reduces calpain activity and breakdown of its substrate in experimental focal cerebral ischemia in rats. causal interaction 1 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. diagnostic usage 1 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/7593358/ Time-related neuronal changes following middle cerebral artery occlusion: implications for therapeutic intervention and the role of calpain. therapeutic application 4 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. therapeutic application 3 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/15036603/ Delayed moderate hypothermia reduces calpain activity and breakdown of its substrate in experimental focal cerebral ischemia in rats. therapeutic application 2 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/16805817/ Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia. therapeutic application 2 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/21430162/ Cleavage of the Vesicular GABA Transporter under Excitotoxic Conditions Is Followed by Accumulation of the Truncated Transporter in Nonsynaptic Sites. therapeutic application 3 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/23435869/ Neuroprotective Effect of Resveratrol on Ischemia/Reperfusion Injury in Rats Through TRPC6/CREB Pathways. therapeutic application 2 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. therapeutic application 1 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/15036603/ Delayed moderate hypothermia reduces calpain activity and breakdown of its substrate in experimental focal cerebral ischemia in rats. ongoing research 4 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/16805817/ Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia. ongoing research 2 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/21430162/ Cleavage of the Vesicular GABA Transporter under Excitotoxic Conditions Is Followed by Accumulation of the Truncated Transporter in Nonsynaptic Sites. ongoing research 3 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/23435869/ Neuroprotective Effect of Resveratrol on Ischemia/Reperfusion Injury in Rats Through TRPC6/CREB Pathways. ongoing research 4 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. ongoing research 4 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/32707070/ Calpain-mediated cleavage of Fbxw7 during excitotoxicity. ongoing research 2 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/7593358/ Time-related neuronal changes following middle cerebral artery occlusion: implications for therapeutic intervention and the role of calpain. unassigned - 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/16805817/ Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia. unassigned - 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/21430162/ Cleavage of the Vesicular GABA Transporter under Excitotoxic Conditions Is Followed by Accumulation of the Truncated Transporter in Nonsynaptic Sites. unassigned - 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/23435869/ Neuroprotective Effect of Resveratrol on Ischemia/Reperfusion Injury in Rats Through TRPC6/CREB Pathways. unassigned - 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. unassigned - 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/30158515/ Zinc induces CDK5 activation and neuronal death through CDK5-Tyr15 phosphorylation in ischemic stroke. unassigned - 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/32707070/ Calpain-mediated cleavage of Fbxw7 during excitotoxicity. unassigned - 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. unassigned - 3.4.22.B28 Infarction, Middle Cerebral Artery https://pubmed.ncbi.nlm.nih.gov/15036603/ Delayed moderate hypothermia reduces calpain activity and breakdown of its substrate in experimental focal cerebral ischemia in rats. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/24177271/ Coxsackievirus B3-induced calpain activation facilitates the progeny virus replication via a likely mechanism related with both autophagy enhancement and apoptosis inhibition in the early phase of infection: an in vitro study in H9c2 cells. causal interaction 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/31319178/ Calpain regulates CVB3 induced viral myocarditis by promoting autophagic flux upon infection. causal interaction 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/2195187/ [Calpain and calpastatin] causal interaction 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/11264351/ Degradation of p21cip1 in cells productively infected with human cytomegalovirus. causal interaction 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/12625933/ The role of calpain and calpastatin in the catabolism of erythrocyte-membrane proteins during anaemia in hamsters (Mesocricetus auretus) infected with Leishmania donovani. causal interaction 4 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/12798631/ Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. causal interaction 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/15081949/ Research on calpain of Schistosoma japonicum as a vaccine candidate. causal interaction 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/16236382/ Activation of calpains, calpastatin and spectrin cleavage in the brain during the pathology of fatal murine cerebral malaria. causal interaction 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/19158511/ Autophagy in coxsackievirus-infected neurons. causal interaction 4 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. causal interaction 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/19329553/ Calpain Activation Contributes to Endotoxin Induced Diaphragmatic Dysfunction. causal interaction 4 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/20194588/ Listeriolysin O-dependent bacterial entry into the cytoplasm is required for calpain activation and interleukin-1 alpha secretion in macrophages infected with Listeria monocytogenes. causal interaction 4 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/20345487/ The bacterial effectors EspG and EspG2 induce a destructive calpain activity that is kept in check by the co-delivered Tir effector. causal interaction 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/20457672/ Effects of the calpain inhibitor MDL28170 on the clinically relevant forms of Trypanosoma cruzi in vitro. causal interaction 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/21087681/ Involvement of host calpain in the invasion of Cryptosporidium parvum. causal interaction 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/22684480/ Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNF? causal interaction 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/23264129/ Mycobacterium kansasii-induced death of murine macrophages involves endoplasmic reticulum stress responses mediated by reactive oxygen species generation or calpain activation. causal interaction 4 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/26968769/ Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction. causal interaction 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/28701483/ The Shigella type III effector IpgD recodes Ca(2+) signals during invasion of epithelial cells. causal interaction 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/28789934/ Targeting calpains: A novel immunomodulatory approach for microbial infections. causal interaction 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/32855235/ Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition. causal interaction 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/34234076/ Inhibition of Calpain Alleviates Apoptosis in Coxsackievirus B3-induced Acute Virus Myocarditis Through Suppressing Endoplasmic Reticulum Stress. causal interaction 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/34365571/ Inhibition of calpain reduces cell apoptosis by suppressing mitochondrial fission in acute viral myocarditis. causal interaction 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/2195187/ [Calpain and calpastatin] diagnostic usage 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/11227763/ Cloning and molecular characterization of calpain, a calcium-activated neutral proteinase, from different strains of Schistosoma japonicum. diagnostic usage 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/12499268/ Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. diagnostic usage 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/12625933/ The role of calpain and calpastatin in the catabolism of erythrocyte-membrane proteins during anaemia in hamsters (Mesocricetus auretus) infected with Leishmania donovani. diagnostic usage 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/20457672/ Effects of the calpain inhibitor MDL28170 on the clinically relevant forms of Trypanosoma cruzi in vitro. diagnostic usage 4 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/21084306/ Streptolysin S contributes to group A streptococcal translocation across an epithelial barrier. diagnostic usage 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/32855235/ Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition. diagnostic usage 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/9364694/ Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. therapeutic application 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/24177271/ Coxsackievirus B3-induced calpain activation facilitates the progeny virus replication via a likely mechanism related with both autophagy enhancement and apoptosis inhibition in the early phase of infection: an in vitro study in H9c2 cells. therapeutic application 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/31319178/ Calpain regulates CVB3 induced viral myocarditis by promoting autophagic flux upon infection. therapeutic application 4 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/11227763/ Cloning and molecular characterization of calpain, a calcium-activated neutral proteinase, from different strains of Schistosoma japonicum. therapeutic application 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/11264351/ Degradation of p21cip1 in cells productively infected with human cytomegalovirus. therapeutic application 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/12625933/ The role of calpain and calpastatin in the catabolism of erythrocyte-membrane proteins during anaemia in hamsters (Mesocricetus auretus) infected with Leishmania donovani. therapeutic application 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/15081949/ Research on calpain of Schistosoma japonicum as a vaccine candidate. therapeutic application 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/16236382/ Activation of calpains, calpastatin and spectrin cleavage in the brain during the pathology of fatal murine cerebral malaria. therapeutic application 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/18032503/ Calpain 1 and 2 are required for RNA replication of echovirus 1. therapeutic application 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/19158511/ Autophagy in coxsackievirus-infected neurons. therapeutic application 4 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. therapeutic application 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/19329553/ Calpain Activation Contributes to Endotoxin Induced Diaphragmatic Dysfunction. therapeutic application 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/20457672/ Effects of the calpain inhibitor MDL28170 on the clinically relevant forms of Trypanosoma cruzi in vitro. therapeutic application 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/23264129/ Mycobacterium kansasii-induced death of murine macrophages involves endoplasmic reticulum stress responses mediated by reactive oxygen species generation or calpain activation. therapeutic application 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/26747784/ Targeting host calpain proteases decreases influenza A virus infection. therapeutic application 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/26968769/ Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction. therapeutic application 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/28789934/ Targeting calpains: A novel immunomodulatory approach for microbial infections. therapeutic application 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/29026995/ Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium. therapeutic application 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/29739616/ Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons. therapeutic application 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/34234076/ Inhibition of Calpain Alleviates Apoptosis in Coxsackievirus B3-induced Acute Virus Myocarditis Through Suppressing Endoplasmic Reticulum Stress. therapeutic application 3 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/34365571/ Inhibition of calpain reduces cell apoptosis by suppressing mitochondrial fission in acute viral myocarditis. therapeutic application 4 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/9364694/ Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. ongoing research 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/11227763/ Cloning and molecular characterization of calpain, a calcium-activated neutral proteinase, from different strains of Schistosoma japonicum. ongoing research 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/12625933/ The role of calpain and calpastatin in the catabolism of erythrocyte-membrane proteins during anaemia in hamsters (Mesocricetus auretus) infected with Leishmania donovani. ongoing research 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/12798631/ Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. ongoing research 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/15081949/ Research on calpain of Schistosoma japonicum as a vaccine candidate. ongoing research 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/16236382/ Activation of calpains, calpastatin and spectrin cleavage in the brain during the pathology of fatal murine cerebral malaria. ongoing research 4 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. ongoing research 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/21084306/ Streptolysin S contributes to group A streptococcal translocation across an epithelial barrier. ongoing research 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/22073041/ Calpain mediates epithelial cell microvillar effacement by enterohemorrhagic Escherichia coli. ongoing research 1 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/26968769/ Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction. ongoing research 4 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/29026995/ Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium. ongoing research 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/29739616/ Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons. ongoing research 2 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/9364694/ Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/11227763/ Cloning and molecular characterization of calpain, a calcium-activated neutral proteinase, from different strains of Schistosoma japonicum. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/12499268/ Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/18032503/ Calpain 1 and 2 are required for RNA replication of echovirus 1. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/18787008/ Internal deletions of IE2 86 and loss of the late IE2 60 and IE2 40 proteins encoded by human cytomegalovirus affect the levels of UL84 protein but not the amount of UL84 mRNA or the loading and distribution of the mRNA on polysomes. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/20452455/ Innate immunogenicity and in vitro protective potential of Schistosoma mansoni lung schistosomula excretory--secretory candidate vaccine antigens. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/21084306/ Streptolysin S contributes to group A streptococcal translocation across an epithelial barrier. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/22073041/ Calpain mediates epithelial cell microvillar effacement by enterohemorrhagic Escherichia coli. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/23903654/ The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/26747784/ Targeting host calpain proteases decreases influenza A virus infection. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/29026995/ Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/29739616/ Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/24177271/ Coxsackievirus B3-induced calpain activation facilitates the progeny virus replication via a likely mechanism related with both autophagy enhancement and apoptosis inhibition in the early phase of infection: an in vitro study in H9c2 cells. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/31319178/ Calpain regulates CVB3 induced viral myocarditis by promoting autophagic flux upon infection. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/11264351/ Degradation of p21cip1 in cells productively infected with human cytomegalovirus. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/12798631/ Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/15081949/ Research on calpain of Schistosoma japonicum as a vaccine candidate. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/16236382/ Activation of calpains, calpastatin and spectrin cleavage in the brain during the pathology of fatal murine cerebral malaria. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/19158511/ Autophagy in coxsackievirus-infected neurons. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/19329553/ Calpain Activation Contributes to Endotoxin Induced Diaphragmatic Dysfunction. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/20194588/ Listeriolysin O-dependent bacterial entry into the cytoplasm is required for calpain activation and interleukin-1 alpha secretion in macrophages infected with Listeria monocytogenes. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/20345487/ The bacterial effectors EspG and EspG2 induce a destructive calpain activity that is kept in check by the co-delivered Tir effector. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/21087681/ Involvement of host calpain in the invasion of Cryptosporidium parvum. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/22684480/ Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNF? unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/23264129/ Mycobacterium kansasii-induced death of murine macrophages involves endoplasmic reticulum stress responses mediated by reactive oxygen species generation or calpain activation. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/26968769/ Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/28701483/ The Shigella type III effector IpgD recodes Ca(2+) signals during invasion of epithelial cells. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/28789934/ Targeting calpains: A novel immunomodulatory approach for microbial infections. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/34234076/ Inhibition of Calpain Alleviates Apoptosis in Coxsackievirus B3-induced Acute Virus Myocarditis Through Suppressing Endoplasmic Reticulum Stress. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/34365571/ Inhibition of calpain reduces cell apoptosis by suppressing mitochondrial fission in acute viral myocarditis. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/2195187/ [Calpain and calpastatin] unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/32855235/ Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition. unassigned - 3.4.22.B28 Infections https://pubmed.ncbi.nlm.nih.gov/20457672/ Effects of the calpain inhibitor MDL28170 on the clinically relevant forms of Trypanosoma cruzi in vitro. unassigned - 3.4.22.B28 Inflammatory Bowel Diseases https://pubmed.ncbi.nlm.nih.gov/11247891/ Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. causal interaction 4 3.4.22.B28 Inflammatory Bowel Diseases https://pubmed.ncbi.nlm.nih.gov/11247891/ Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. therapeutic application 4 3.4.22.B28 Inflammatory Bowel Diseases https://pubmed.ncbi.nlm.nih.gov/11247891/ Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. ongoing research 4 3.4.22.B28 Inflammatory Bowel Diseases https://pubmed.ncbi.nlm.nih.gov/23986533/ Calpastatin Prevents NF-?B-Mediated Hyperactivation of Macrophages and Attenuates Colitis. unassigned - 3.4.22.B28 Inflammatory Bowel Diseases https://pubmed.ncbi.nlm.nih.gov/11247891/ Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. unassigned - 3.4.22.B28 Influenza, Human https://pubmed.ncbi.nlm.nih.gov/26747784/ Targeting host calpain proteases decreases influenza A virus infection. therapeutic application 2 3.4.22.B28 Influenza, Human https://pubmed.ncbi.nlm.nih.gov/26747784/ Targeting host calpain proteases decreases influenza A virus infection. unassigned - 3.4.22.B28 Insulin Resistance https://pubmed.ncbi.nlm.nih.gov/15862281/ Calpain inhibition and insulin action in cultured human muscle cells. causal interaction 3 3.4.22.B28 Insulin Resistance https://pubmed.ncbi.nlm.nih.gov/15862281/ Calpain inhibition and insulin action in cultured human muscle cells. diagnostic usage 3 3.4.22.B28 Insulin Resistance https://pubmed.ncbi.nlm.nih.gov/15862281/ Calpain inhibition and insulin action in cultured human muscle cells. therapeutic application 2 3.4.22.B28 Insulin Resistance https://pubmed.ncbi.nlm.nih.gov/15862281/ Calpain inhibition and insulin action in cultured human muscle cells. ongoing research 4 3.4.22.B28 Insulinoma https://pubmed.ncbi.nlm.nih.gov/15909116/ Effect of PK11195, a peripheral benzodiazepine receptor agonist, on insulinoma cell death and insulin secretion. causal interaction 4 3.4.22.B28 Insulinoma https://pubmed.ncbi.nlm.nih.gov/15153522/ Role of calcium in pancreatic islet cell death by IFN-gamma/TNF-alpha. therapeutic application 1 3.4.22.B28 Insulinoma https://pubmed.ncbi.nlm.nih.gov/15909116/ Effect of PK11195, a peripheral benzodiazepine receptor agonist, on insulinoma cell death and insulin secretion. therapeutic application 1 3.4.22.B28 Insulinoma https://pubmed.ncbi.nlm.nih.gov/15153522/ Role of calcium in pancreatic islet cell death by IFN-gamma/TNF-alpha. unassigned - 3.4.22.B28 Insulinoma https://pubmed.ncbi.nlm.nih.gov/15909116/ Effect of PK11195, a peripheral benzodiazepine receptor agonist, on insulinoma cell death and insulin secretion. unassigned - 3.4.22.B28 Intermittent Claudication https://pubmed.ncbi.nlm.nih.gov/24445084/ A randomised controlled trial of supervised exercise regimens and their impact on walking performance, skeletal muscle mass and calpain activity in patients with intermittent claudication. therapeutic application 1 3.4.22.B28 Intermittent Claudication https://pubmed.ncbi.nlm.nih.gov/24445084/ A randomised controlled trial of supervised exercise regimens and their impact on walking performance, skeletal muscle mass and calpain activity in patients with intermittent claudication. ongoing research 3 3.4.22.B28 Intermittent Claudication https://pubmed.ncbi.nlm.nih.gov/24445084/ A randomised controlled trial of supervised exercise regimens and their impact on walking performance, skeletal muscle mass and calpain activity in patients with intermittent claudication. unassigned - 3.4.22.B28 Intracranial Hypertension https://pubmed.ncbi.nlm.nih.gov/16210142/ Left ventricular dysfunction after acute intracranial hypertension is associated with increased hydroxyl free radical production, cardiac ryanodine hyperphosphorylation, and troponin I degradation. ongoing research 1 3.4.22.B28 Intracranial Hypertension https://pubmed.ncbi.nlm.nih.gov/16210142/ Left ventricular dysfunction after acute intracranial hypertension is associated with increased hydroxyl free radical production, cardiac ryanodine hyperphosphorylation, and troponin I degradation. unassigned - 3.4.22.B28 Ischemic Attack, Transient https://pubmed.ncbi.nlm.nih.gov/12427474/ Decrease of PKC precedes other cellular signs of calpain activation in area CA1 of the hippocampus after transient cerebral ischemia. causal interaction 4 3.4.22.B28 Ischemic Attack, Transient https://pubmed.ncbi.nlm.nih.gov/12427474/ Decrease of PKC precedes other cellular signs of calpain activation in area CA1 of the hippocampus after transient cerebral ischemia. therapeutic application 1 3.4.22.B28 Ischemic Attack, Transient https://pubmed.ncbi.nlm.nih.gov/16464234/ Aminoguanidine inhibits caspase-3 and calpain activation without affecting microglial activation following neonatal transient cerebral ischemia. therapeutic application 1 3.4.22.B28 Ischemic Attack, Transient https://pubmed.ncbi.nlm.nih.gov/16464234/ Aminoguanidine inhibits caspase-3 and calpain activation without affecting microglial activation following neonatal transient cerebral ischemia. unassigned - 3.4.22.B28 Ischemic Attack, Transient https://pubmed.ncbi.nlm.nih.gov/2911839/ Nilvadipine attenuates ischemic degradation of gerbil brain cytoskeletal proteins. unassigned - 3.4.22.B28 Ischemic Attack, Transient https://pubmed.ncbi.nlm.nih.gov/12427474/ Decrease of PKC precedes other cellular signs of calpain activation in area CA1 of the hippocampus after transient cerebral ischemia. unassigned - 3.4.22.B28 Ischemic Stroke https://pubmed.ncbi.nlm.nih.gov/15282090/ Epimerization study of the L,L- and L,D-diastereoisomers of the calpain inhibitor MDL 28170 by capillary electrophoresis. causal interaction 3 3.4.22.B28 Ischemic Stroke https://pubmed.ncbi.nlm.nih.gov/15979564/ Identification of a novel calpain inhibitor using phage display. causal interaction 3 3.4.22.B28 Ischemic Stroke https://pubmed.ncbi.nlm.nih.gov/28069373/ Memantine attenuates cell apoptosis by suppressing the calpain-caspase-3 pathway in an experimental model of ischemic stroke. causal interaction 3 3.4.22.B28 Ischemic Stroke https://pubmed.ncbi.nlm.nih.gov/15282090/ Epimerization study of the L,L- and L,D-diastereoisomers of the calpain inhibitor MDL 28170 by capillary electrophoresis. therapeutic application 4 3.4.22.B28 Ischemic Stroke https://pubmed.ncbi.nlm.nih.gov/15979564/ Identification of a novel calpain inhibitor using phage display. therapeutic application 4 3.4.22.B28 Ischemic Stroke https://pubmed.ncbi.nlm.nih.gov/15282090/ Epimerization study of the L,L- and L,D-diastereoisomers of the calpain inhibitor MDL 28170 by capillary electrophoresis. unassigned - 3.4.22.B28 Ischemic Stroke https://pubmed.ncbi.nlm.nih.gov/15979564/ Identification of a novel calpain inhibitor using phage display. unassigned - 3.4.22.B28 Ischemic Stroke https://pubmed.ncbi.nlm.nih.gov/28069373/ Memantine attenuates cell apoptosis by suppressing the calpain-caspase-3 pathway in an experimental model of ischemic stroke. unassigned - 3.4.22.B28 Keloid https://pubmed.ncbi.nlm.nih.gov/15086770/ Keloid fibroblast responsiveness to epidermal growth factor and activation of downstream intracellular signaling pathways. ongoing research 4 3.4.22.B28 Keloid https://pubmed.ncbi.nlm.nih.gov/15086770/ Keloid fibroblast responsiveness to epidermal growth factor and activation of downstream intracellular signaling pathways. unassigned - 3.4.22.B28 Kidney Diseases https://pubmed.ncbi.nlm.nih.gov/29945255/ Expression and effect of Calpain9 gene genetic polymorphism on slaughter indicators and intramuscular fat content in chickens. causal interaction 1 3.4.22.B28 Kidney Diseases https://pubmed.ncbi.nlm.nih.gov/29945255/ Expression and effect of Calpain9 gene genetic polymorphism on slaughter indicators and intramuscular fat content in chickens. unassigned - 3.4.22.B28 Kidney Neoplasms https://pubmed.ncbi.nlm.nih.gov/27165064/ Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. causal interaction 4 3.4.22.B28 Kidney Neoplasms https://pubmed.ncbi.nlm.nih.gov/27165064/ Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. diagnostic usage 1 3.4.22.B28 Kidney Neoplasms https://pubmed.ncbi.nlm.nih.gov/27165064/ Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. ongoing research 4 3.4.22.B28 Kidney Neoplasms https://pubmed.ncbi.nlm.nih.gov/27165064/ Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. unassigned - 3.4.22.B28 Kwashiorkor https://pubmed.ncbi.nlm.nih.gov/2145987/ Comparative action of calpain on erythrocyte Ca2(+)-pumping ATPase in sickle cell anaemia, essential hypertension and kwashiorkor. ongoing research 3 3.4.22.B28 Kwashiorkor https://pubmed.ncbi.nlm.nih.gov/2145987/ Comparative action of calpain on erythrocyte Ca2(+)-pumping ATPase in sickle cell anaemia, essential hypertension and kwashiorkor. unassigned - 3.4.22.B28 Leishmaniasis https://pubmed.ncbi.nlm.nih.gov/29728827/ Susceptibility of promastigotes and intracellular amastigotes from distinct Leishmania species to the calpain inhibitor MDL28170. causal interaction 4 3.4.22.B28 Leishmaniasis https://pubmed.ncbi.nlm.nih.gov/27869056/ Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis? therapeutic application 4 3.4.22.B28 Leishmaniasis https://pubmed.ncbi.nlm.nih.gov/29728827/ Susceptibility of promastigotes and intracellular amastigotes from distinct Leishmania species to the calpain inhibitor MDL28170. therapeutic application 4 3.4.22.B28 Leishmaniasis https://pubmed.ncbi.nlm.nih.gov/27869056/ Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis? unassigned - 3.4.22.B28 Leishmaniasis https://pubmed.ncbi.nlm.nih.gov/29728827/ Susceptibility of promastigotes and intracellular amastigotes from distinct Leishmania species to the calpain inhibitor MDL28170. unassigned - 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/10914553/ Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. causal interaction 3 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/12121983/ Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. causal interaction 4 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. causal interaction 1 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. causal interaction 4 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/26358320/ GAS2-Calpain2 axis contributes to the growth of leukemic cells. causal interaction 1 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/10914553/ Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. diagnostic usage 3 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/17458879/ Flow cytometric measurement of calpain activity in living cells. diagnostic usage 3 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/26358320/ GAS2-Calpain2 axis contributes to the growth of leukemic cells. diagnostic usage 3 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/10914553/ Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. therapeutic application 4 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/12121983/ Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. therapeutic application 3 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. therapeutic application 2 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. therapeutic application 4 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/27769062/ Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain. therapeutic application 3 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/10914553/ Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. ongoing research 1 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. ongoing research 3 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. ongoing research 4 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/17458879/ Flow cytometric measurement of calpain activity in living cells. ongoing research 4 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/20644512/ Measuring calpain activity in fixed and living cells by flow cytometry. ongoing research 1 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/10499538/ Vitamin D analogs, 20-Epi-22-oxa-24a,26a,27a,-trihomo-1alpha,25(OH)2-vitamin D3, 1,24(OH)2-22-ene-24-cyclopropyl-vitamin D3 and 1alpha,25(OH)2-lumisterol3 prime NB4 leukemia cells for monocytic differentiation via nongenomic signaling pathways, involving calcium and calpain. unassigned - 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/17458879/ Flow cytometric measurement of calpain activity in living cells. unassigned - 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/20644512/ Measuring calpain activity in fixed and living cells by flow cytometry. unassigned - 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/27769062/ Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain. unassigned - 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/12121983/ Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. unassigned - 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. unassigned - 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. unassigned - 3.4.22.B28 Leukemia https://pubmed.ncbi.nlm.nih.gov/26358320/ GAS2-Calpain2 axis contributes to the growth of leukemic cells. unassigned - 3.4.22.B28 Leukemia, Erythroblastic, Acute https://pubmed.ncbi.nlm.nih.gov/2256952/ Murine erythroleukemia cell differentiation: possible involvement of a calcium dependent neutral proteinase. causal interaction 1 3.4.22.B28 Leukemia, Erythroblastic, Acute https://pubmed.ncbi.nlm.nih.gov/7925435/ Modulation of the intracellular Ca(2+)-dependent proteolytic system is critically correlated with the kinetics of differentiation of murine erythroleukemia cells. causal interaction 3 3.4.22.B28 Leukemia, Erythroblastic, Acute https://pubmed.ncbi.nlm.nih.gov/7925435/ Modulation of the intracellular Ca(2+)-dependent proteolytic system is critically correlated with the kinetics of differentiation of murine erythroleukemia cells. therapeutic application 1 3.4.22.B28 Leukemia, Erythroblastic, Acute https://pubmed.ncbi.nlm.nih.gov/2256952/ Murine erythroleukemia cell differentiation: possible involvement of a calcium dependent neutral proteinase. ongoing research 4 3.4.22.B28 Leukemia, Erythroblastic, Acute https://pubmed.ncbi.nlm.nih.gov/2256952/ Murine erythroleukemia cell differentiation: possible involvement of a calcium dependent neutral proteinase. unassigned - 3.4.22.B28 Leukemia, Erythroblastic, Acute https://pubmed.ncbi.nlm.nih.gov/7925435/ Modulation of the intracellular Ca(2+)-dependent proteolytic system is critically correlated with the kinetics of differentiation of murine erythroleukemia cells. unassigned - 3.4.22.B28 Leukemia, Lymphocytic, Chronic, B-Cell https://pubmed.ncbi.nlm.nih.gov/18165173/ Ex vivo measurement of calpain activation in human peripheral blood lymphocytes by detection of immunoreactive products of calpastatin degradation. diagnostic usage 3 3.4.22.B28 Leukemia, Lymphocytic, Chronic, B-Cell https://pubmed.ncbi.nlm.nih.gov/18165173/ Ex vivo measurement of calpain activation in human peripheral blood lymphocytes by detection of immunoreactive products of calpastatin degradation. therapeutic application 1 3.4.22.B28 Leukemia, Lymphocytic, Chronic, B-Cell https://pubmed.ncbi.nlm.nih.gov/18165173/ Ex vivo measurement of calpain activation in human peripheral blood lymphocytes by detection of immunoreactive products of calpastatin degradation. ongoing research 3 3.4.22.B28 Leukemia, Lymphocytic, Chronic, B-Cell https://pubmed.ncbi.nlm.nih.gov/18165173/ Ex vivo measurement of calpain activation in human peripheral blood lymphocytes by detection of immunoreactive products of calpastatin degradation. unassigned - 3.4.22.B28 Leukemia, Myelogenous, Chronic, BCR-ABL Positive https://pubmed.ncbi.nlm.nih.gov/28881589/ Decreased calpain activity in chronic myeloid leukemia impairs apoptosis by increasing survivin in myeloid progenitors and xiap1 in differentiating granulocytes. causal interaction 2 3.4.22.B28 Leukemia, Myelogenous, Chronic, BCR-ABL Positive https://pubmed.ncbi.nlm.nih.gov/28881589/ Decreased calpain activity in chronic myeloid leukemia impairs apoptosis by increasing survivin in myeloid progenitors and xiap1 in differentiating granulocytes. diagnostic usage 1 3.4.22.B28 Leukemia, Myelogenous, Chronic, BCR-ABL Positive https://pubmed.ncbi.nlm.nih.gov/28881589/ Decreased calpain activity in chronic myeloid leukemia impairs apoptosis by increasing survivin in myeloid progenitors and xiap1 in differentiating granulocytes. unassigned - 3.4.22.B28 Leukemia, Myeloid, Acute https://pubmed.ncbi.nlm.nih.gov/22829235/ Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression. causal interaction 4 3.4.22.B28 Leukemia, Myeloid, Acute https://pubmed.ncbi.nlm.nih.gov/26358320/ GAS2-Calpain2 axis contributes to the growth of leukemic cells. causal interaction 1 3.4.22.B28 Leukemia, Myeloid, Acute https://pubmed.ncbi.nlm.nih.gov/27294874/ A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. causal interaction 1 3.4.22.B28 Leukemia, Myeloid, Acute https://pubmed.ncbi.nlm.nih.gov/22829235/ Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression. diagnostic usage 3 3.4.22.B28 Leukemia, Myeloid, Acute https://pubmed.ncbi.nlm.nih.gov/26358320/ GAS2-Calpain2 axis contributes to the growth of leukemic cells. diagnostic usage 3 3.4.22.B28 Leukemia, Myeloid, Acute https://pubmed.ncbi.nlm.nih.gov/22829235/ Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression. ongoing research 4 3.4.22.B28 Leukemia, Myeloid, Acute https://pubmed.ncbi.nlm.nih.gov/27294874/ A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. unassigned - 3.4.22.B28 Leukemia, Myeloid, Acute https://pubmed.ncbi.nlm.nih.gov/22829235/ Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression. unassigned - 3.4.22.B28 Leukemia, Myeloid, Acute https://pubmed.ncbi.nlm.nih.gov/26358320/ GAS2-Calpain2 axis contributes to the growth of leukemic cells. unassigned - 3.4.22.B28 Leukemia, Neutrophilic, Chronic https://pubmed.ncbi.nlm.nih.gov/12121983/ Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. causal interaction 4 3.4.22.B28 Leukemia, Neutrophilic, Chronic https://pubmed.ncbi.nlm.nih.gov/12121983/ Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. therapeutic application 3 3.4.22.B28 Leukemia, Neutrophilic, Chronic https://pubmed.ncbi.nlm.nih.gov/12121983/ Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. unassigned - 3.4.22.B28 Lissencephaly https://pubmed.ncbi.nlm.nih.gov/19734909/ Inhibition of calpain increases LIS1 expression and partially rescues in vivo phenotypes in a mouse model of lissencephaly. causal interaction 3 3.4.22.B28 Lissencephaly https://pubmed.ncbi.nlm.nih.gov/21030783/ Expanding members and roles of the calpain superfamily and their genetically modified animals. causal interaction 4 3.4.22.B28 Lissencephaly https://pubmed.ncbi.nlm.nih.gov/19734909/ Inhibition of calpain increases LIS1 expression and partially rescues in vivo phenotypes in a mouse model of lissencephaly. diagnostic usage 1 3.4.22.B28 Lissencephaly https://pubmed.ncbi.nlm.nih.gov/19734909/ Inhibition of calpain increases LIS1 expression and partially rescues in vivo phenotypes in a mouse model of lissencephaly. therapeutic application 4 3.4.22.B28 Lissencephaly https://pubmed.ncbi.nlm.nih.gov/23390575/ Post-natal treatment by a blood-brain-barrier permeable calpain inhibitor, SNJ1945 rescued defective function in lissencephaly. therapeutic application 4 3.4.22.B28 Lissencephaly https://pubmed.ncbi.nlm.nih.gov/19734909/ Inhibition of calpain increases LIS1 expression and partially rescues in vivo phenotypes in a mouse model of lissencephaly. ongoing research 2 3.4.22.B28 Lissencephaly https://pubmed.ncbi.nlm.nih.gov/23390575/ Post-natal treatment by a blood-brain-barrier permeable calpain inhibitor, SNJ1945 rescued defective function in lissencephaly. ongoing research 2 3.4.22.B28 Lissencephaly https://pubmed.ncbi.nlm.nih.gov/23390575/ Post-natal treatment by a blood-brain-barrier permeable calpain inhibitor, SNJ1945 rescued defective function in lissencephaly. unassigned - 3.4.22.B28 Lissencephaly https://pubmed.ncbi.nlm.nih.gov/21030783/ Expanding members and roles of the calpain superfamily and their genetically modified animals. unassigned - 3.4.22.B28 Liver Cirrhosis https://pubmed.ncbi.nlm.nih.gov/31316008/ Calpain 9 as a therapeutic target in TGF?-induced mesenchymal transition and fibrosis. therapeutic application 1 3.4.22.B28 Liver Cirrhosis https://pubmed.ncbi.nlm.nih.gov/31316008/ Calpain 9 as a therapeutic target in TGF?-induced mesenchymal transition and fibrosis. unassigned - 3.4.22.B28 Liver Failure, Acute https://pubmed.ncbi.nlm.nih.gov/15316131/ Protective effect of MDL28170 against thioacetamide-induced acute liver failure in mice. causal interaction 4 3.4.22.B28 Liver Failure, Acute https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. causal interaction 3 3.4.22.B28 Liver Failure, Acute https://pubmed.ncbi.nlm.nih.gov/15316131/ Protective effect of MDL28170 against thioacetamide-induced acute liver failure in mice. therapeutic application 2 3.4.22.B28 Liver Failure, Acute https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. therapeutic application 4 3.4.22.B28 Liver Failure, Acute https://pubmed.ncbi.nlm.nih.gov/15316131/ Protective effect of MDL28170 against thioacetamide-induced acute liver failure in mice. unassigned - 3.4.22.B28 Liver Failure, Acute https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. unassigned - 3.4.22.B28 Lung Diseases https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. causal interaction 4 3.4.22.B28 Lung Diseases https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. therapeutic application 4 3.4.22.B28 Lung Diseases https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. unassigned - 3.4.22.B28 Lung Diseases, Interstitial https://pubmed.ncbi.nlm.nih.gov/32393322/ Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis. causal interaction 3 3.4.22.B28 Lung Diseases, Interstitial https://pubmed.ncbi.nlm.nih.gov/32393322/ Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis. diagnostic usage 4 3.4.22.B28 Lung Diseases, Interstitial https://pubmed.ncbi.nlm.nih.gov/32393322/ Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis. unassigned - 3.4.22.B28 Lung Injury https://pubmed.ncbi.nlm.nih.gov/30338266/ Calpain inhibition ameliorates scald burn-induced acute lung injury in rats. causal interaction 4 3.4.22.B28 Lung Injury https://pubmed.ncbi.nlm.nih.gov/30338266/ Calpain inhibition ameliorates scald burn-induced acute lung injury in rats. therapeutic application 2 3.4.22.B28 Lung Injury https://pubmed.ncbi.nlm.nih.gov/30338266/ Calpain inhibition ameliorates scald burn-induced acute lung injury in rats. ongoing research 3 3.4.22.B28 Lung Injury https://pubmed.ncbi.nlm.nih.gov/30338266/ Calpain inhibition ameliorates scald burn-induced acute lung injury in rats. unassigned - 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/32069035/ Noninvasive Early Detection of Calpain 2-Enriched Non-Small Cell Lung Cancer Using a Human Serum Albumin-Bounded Calpain 2 Nanosensor. causal interaction 4 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/15471877/ Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. causal interaction 4 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/16361262/ Protein Kinase C{iota} Promotes Nicotine-induced Migration and Invasion of Cancer Cells via Phosphorylation of {micro}- and m-Calpains. causal interaction 3 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. causal interaction 2 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/28061464/ MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering. causal interaction 4 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/30683309/ Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. causal interaction 4 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/32069035/ Noninvasive Early Detection of Calpain 2-Enriched Non-Small Cell Lung Cancer Using a Human Serum Albumin-Bounded Calpain 2 Nanosensor. diagnostic usage 3 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/30683309/ Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. diagnostic usage 3 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/32069035/ Noninvasive Early Detection of Calpain 2-Enriched Non-Small Cell Lung Cancer Using a Human Serum Albumin-Bounded Calpain 2 Nanosensor. therapeutic application 1 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. therapeutic application 1 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/30683309/ Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. therapeutic application 1 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/24878626/ Capsaicin induces apoptosis in human small cell lung cancer via the TRPV6 receptor and the calpain pathway. ongoing research 2 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/28104436/ Capsaicin synergizes with camptothecin to induce increased apoptosis in human small cell lung cancers via the calpain pathway. ongoing research 1 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/15471877/ Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. ongoing research 1 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. ongoing research 2 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/30683309/ Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. ongoing research 4 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/24878626/ Capsaicin induces apoptosis in human small cell lung cancer via the TRPV6 receptor and the calpain pathway. unassigned - 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/28104436/ Capsaicin synergizes with camptothecin to induce increased apoptosis in human small cell lung cancers via the calpain pathway. unassigned - 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/15471877/ Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. unassigned - 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/16361262/ Protein Kinase C{iota} Promotes Nicotine-induced Migration and Invasion of Cancer Cells via Phosphorylation of {micro}- and m-Calpains. unassigned - 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. unassigned - 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/28061464/ MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering. unassigned - 3.4.22.B28 Lung Neoplasms https://pubmed.ncbi.nlm.nih.gov/32069035/ Noninvasive Early Detection of Calpain 2-Enriched Non-Small Cell Lung Cancer Using a Human Serum Albumin-Bounded Calpain 2 Nanosensor. unassigned - 3.4.22.B28 Lymphocytosis https://pubmed.ncbi.nlm.nih.gov/32544313/ Excessive amount and activity of ?-calpain affects apoptotic machinery in chronic B-cell leukemia cells and influences the course of the disease. diagnostic usage 4 3.4.22.B28 Lymphocytosis https://pubmed.ncbi.nlm.nih.gov/32544313/ Excessive amount and activity of ?-calpain affects apoptotic machinery in chronic B-cell leukemia cells and influences the course of the disease. ongoing research 4 3.4.22.B28 Lymphocytosis https://pubmed.ncbi.nlm.nih.gov/32544313/ Excessive amount and activity of ?-calpain affects apoptotic machinery in chronic B-cell leukemia cells and influences the course of the disease. unassigned - 3.4.22.B28 Lymphoma https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. causal interaction 4 3.4.22.B28 Lymphoma https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. diagnostic usage 3 3.4.22.B28 Lymphoma https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. therapeutic application 4 3.4.22.B28 Lymphoma https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. ongoing research 4 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/11745502/ Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells. causal interaction 4 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. causal interaction 4 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/26229452/ Oral treatment with herbal formula B307 alleviates cardiac failure in aging R6/2 mice with Huntington's disease via suppressing oxidative stress, inflammation, and apoptosis. causal interaction 1 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/26609226/ Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice. causal interaction 3 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. diagnostic usage 3 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/11745502/ Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells. therapeutic application 4 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. therapeutic application 4 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/26060405/ Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis. therapeutic application 2 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/26229452/ Oral treatment with herbal formula B307 alleviates cardiac failure in aging R6/2 mice with Huntington's disease via suppressing oxidative stress, inflammation, and apoptosis. therapeutic application 1 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/26609226/ Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice. therapeutic application 2 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/11745502/ Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells. ongoing research 2 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/22366408/ Induction of apoptosis in E?-myc lymphoma cells in vitro and in vivo through calpain inhibition. ongoing research 4 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/26060405/ Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis. unassigned - 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/11745502/ Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells. unassigned - 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/26229452/ Oral treatment with herbal formula B307 alleviates cardiac failure in aging R6/2 mice with Huntington's disease via suppressing oxidative stress, inflammation, and apoptosis. unassigned - 3.4.22.B28 Lymphoma, B-Cell https://pubmed.ncbi.nlm.nih.gov/26609226/ Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice. unassigned - 3.4.22.B28 Lymphoma, Non-Hodgkin https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. causal interaction 3 3.4.22.B28 Lymphoma, Non-Hodgkin https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. therapeutic application 4 3.4.22.B28 Lymphoma, Non-Hodgkin https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. ongoing research 4 3.4.22.B28 Lymphoma, Non-Hodgkin https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. unassigned - 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/28334907/ A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3. causal interaction 3 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/28687604/ Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy. causal interaction 4 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/28687604/ Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy. diagnostic usage 2 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/24817574/ Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease. therapeutic application 2 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/28334907/ A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3. therapeutic application 4 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/28687604/ Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy. therapeutic application 3 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/22843411/ Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. ongoing research 2 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/24817574/ Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease. unassigned - 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/34191270/ Variants in Genes of Calpain System as Modifiers of Spinocerebellar Ataxia Type 3 Phenotype. unassigned - 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/21653538/ N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. unassigned - 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/22843411/ Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. unassigned - 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/28334907/ A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3. unassigned - 3.4.22.B28 Machado-Joseph Disease https://pubmed.ncbi.nlm.nih.gov/28687604/ Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy. unassigned - 3.4.22.B28 Macular Degeneration https://pubmed.ncbi.nlm.nih.gov/19857102/ Calpain inhibitor SNJ-1945 attenuates events prior to angiogenesis in cultured human retinal endothelial cells. therapeutic application 4 3.4.22.B28 Macular Degeneration https://pubmed.ncbi.nlm.nih.gov/19857102/ Calpain inhibitor SNJ-1945 attenuates events prior to angiogenesis in cultured human retinal endothelial cells. unassigned - 3.4.22.B28 Malaria https://pubmed.ncbi.nlm.nih.gov/12106878/ Erythrocyte calpain is dispensable for malaria parasite invasion and growth. causal interaction 3 3.4.22.B28 Malaria https://pubmed.ncbi.nlm.nih.gov/17359359/ Cerebral calpain in fatal falciparum malaria. causal interaction 2 3.4.22.B28 Malaria https://pubmed.ncbi.nlm.nih.gov/17359359/ Cerebral calpain in fatal falciparum malaria. therapeutic application 1 3.4.22.B28 Malaria https://pubmed.ncbi.nlm.nih.gov/17583361/ BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria. therapeutic application 4 3.4.22.B28 Malaria https://pubmed.ncbi.nlm.nih.gov/17359359/ Cerebral calpain in fatal falciparum malaria. ongoing research 4 3.4.22.B28 Malaria https://pubmed.ncbi.nlm.nih.gov/17583361/ BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria. unassigned - 3.4.22.B28 Malaria https://pubmed.ncbi.nlm.nih.gov/12106878/ Erythrocyte calpain is dispensable for malaria parasite invasion and growth. unassigned - 3.4.22.B28 Malaria https://pubmed.ncbi.nlm.nih.gov/17359359/ Cerebral calpain in fatal falciparum malaria. unassigned - 3.4.22.B28 Malaria, Cerebral https://pubmed.ncbi.nlm.nih.gov/24995009/ Systemic and Cerebral Vascular Endothelial Growth Factor Levels Increase in Murine Cerebral Malaria along with Increased Calpain and Caspase Activity and Can be Reduced by Erythropoietin Treatment. causal interaction 1 3.4.22.B28 Malaria, Cerebral https://pubmed.ncbi.nlm.nih.gov/16236382/ Activation of calpains, calpastatin and spectrin cleavage in the brain during the pathology of fatal murine cerebral malaria. causal interaction 1 3.4.22.B28 Malaria, Cerebral https://pubmed.ncbi.nlm.nih.gov/24995009/ Systemic and Cerebral Vascular Endothelial Growth Factor Levels Increase in Murine Cerebral Malaria along with Increased Calpain and Caspase Activity and Can be Reduced by Erythropoietin Treatment. therapeutic application 4 3.4.22.B28 Malaria, Cerebral https://pubmed.ncbi.nlm.nih.gov/16236382/ Activation of calpains, calpastatin and spectrin cleavage in the brain during the pathology of fatal murine cerebral malaria. therapeutic application 2 3.4.22.B28 Malaria, Cerebral https://pubmed.ncbi.nlm.nih.gov/16236382/ Activation of calpains, calpastatin and spectrin cleavage in the brain during the pathology of fatal murine cerebral malaria. ongoing research 4 3.4.22.B28 Malaria, Cerebral https://pubmed.ncbi.nlm.nih.gov/24995009/ Systemic and Cerebral Vascular Endothelial Growth Factor Levels Increase in Murine Cerebral Malaria along with Increased Calpain and Caspase Activity and Can be Reduced by Erythropoietin Treatment. unassigned - 3.4.22.B28 Malaria, Cerebral https://pubmed.ncbi.nlm.nih.gov/16236382/ Activation of calpains, calpastatin and spectrin cleavage in the brain during the pathology of fatal murine cerebral malaria. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/17130844/ Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: a major role of calpain inhibition in cell death protection and p53 status. causal interaction 1 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/10597248/ Regulation of BRCA1 by protein degradation. causal interaction 3 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/11940658/ Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. causal interaction 4 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/19798049/ The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. causal interaction 3 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/20955350/ Loss Of Klotho During Melanoma Progression Leads To Increased Filamin Cleavage, Increased Wnt5A Expression and Enhanced Melanoma Cell Motility. causal interaction 3 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. causal interaction 4 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/26506473/ Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1? in an AIM2 inflammasome-dependent manner. causal interaction 4 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. causal interaction 2 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/30131853/ CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma. causal interaction 4 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/15225804/ Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. diagnostic usage 3 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/26506473/ Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1? in an AIM2 inflammasome-dependent manner. diagnostic usage 3 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/16885359/ Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. therapeutic application 1 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/17130844/ Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: a major role of calpain inhibition in cell death protection and p53 status. therapeutic application 1 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/31425704/ Preventing Calpain Externalization by Reducing ABCA1 Activity with Probenecid Limits Melanoma Angiogenesis and Development. therapeutic application 1 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/10597248/ Regulation of BRCA1 by protein degradation. therapeutic application 1 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/11940658/ Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. therapeutic application 1 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. therapeutic application 4 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/24553345/ Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ?PK oncolytic activity in melanoma. therapeutic application 1 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/30131853/ CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma. therapeutic application 4 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/16885359/ Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. ongoing research 4 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/17130844/ Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: a major role of calpain inhibition in cell death protection and p53 status. ongoing research 3 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/10597248/ Regulation of BRCA1 by protein degradation. ongoing research 2 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/11940658/ Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. ongoing research 4 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/15225804/ Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. ongoing research 4 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/19798049/ The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. ongoing research 2 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. ongoing research 1 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. ongoing research 1 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/14517853/ Vitamin D-induced apoptosis and melanoma: does calpain represent the major execution protease rather than caspases? unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/16885359/ Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/31425704/ Preventing Calpain Externalization by Reducing ABCA1 Activity with Probenecid Limits Melanoma Angiogenesis and Development. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/15225804/ Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/24553345/ Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ?PK oncolytic activity in melanoma. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/17130844/ Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: a major role of calpain inhibition in cell death protection and p53 status. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/10597248/ Regulation of BRCA1 by protein degradation. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/11940658/ Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/19798049/ The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/20955350/ Loss Of Klotho During Melanoma Progression Leads To Increased Filamin Cleavage, Increased Wnt5A Expression and Enhanced Melanoma Cell Motility. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/30131853/ CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma. unassigned - 3.4.22.B28 Melanoma https://pubmed.ncbi.nlm.nih.gov/26506473/ Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1? in an AIM2 inflammasome-dependent manner. unassigned - 3.4.22.B28 Melanoma, Experimental https://pubmed.ncbi.nlm.nih.gov/16335789/ Involvement of calpain in melanogenesis of mouse B16 melanoma cells. causal interaction 4 3.4.22.B28 Melanoma, Experimental https://pubmed.ncbi.nlm.nih.gov/16335789/ Involvement of calpain in melanogenesis of mouse B16 melanoma cells. ongoing research 4 3.4.22.B28 Melanoma, Experimental https://pubmed.ncbi.nlm.nih.gov/16335789/ Involvement of calpain in melanogenesis of mouse B16 melanoma cells. unassigned - 3.4.22.B28 Memory Disorders https://pubmed.ncbi.nlm.nih.gov/9851910/ The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part IV: can calpain act as alpha-secretase? causal interaction 3 3.4.22.B28 Memory Disorders https://pubmed.ncbi.nlm.nih.gov/18596919/ Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. causal interaction 4 3.4.22.B28 Memory Disorders https://pubmed.ncbi.nlm.nih.gov/21544067/ The involvement of Cdk5 Activator p35 in social isolation-triggered onset of early alzheimer's disease-related cognitive deficit in the transgenic mice. causal interaction 2 3.4.22.B28 Memory Disorders https://pubmed.ncbi.nlm.nih.gov/18596919/ Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. diagnostic usage 3 3.4.22.B28 Memory Disorders https://pubmed.ncbi.nlm.nih.gov/18596919/ Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. therapeutic application 3 3.4.22.B28 Memory Disorders https://pubmed.ncbi.nlm.nih.gov/9851910/ The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part IV: can calpain act as alpha-secretase? unassigned - 3.4.22.B28 Memory Disorders https://pubmed.ncbi.nlm.nih.gov/21544067/ The involvement of Cdk5 Activator p35 in social isolation-triggered onset of early alzheimer's disease-related cognitive deficit in the transgenic mice. unassigned - 3.4.22.B28 Memory Disorders https://pubmed.ncbi.nlm.nih.gov/18596919/ Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. unassigned - 3.4.22.B28 Meningioma https://pubmed.ncbi.nlm.nih.gov/9701243/ The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. causal interaction 2 3.4.22.B28 Meningioma https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. causal interaction 2 3.4.22.B28 Meningioma https://pubmed.ncbi.nlm.nih.gov/11745202/ Calpain-dependent proteolysis of merlin occurs by oxidative stress in meningiomas: a novel hypothesis of tumorigenesis. causal interaction 4 3.4.22.B28 Meningioma https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. therapeutic application 1 3.4.22.B28 Meningioma https://pubmed.ncbi.nlm.nih.gov/11745202/ Calpain-dependent proteolysis of merlin occurs by oxidative stress in meningiomas: a novel hypothesis of tumorigenesis. therapeutic application 1 3.4.22.B28 Meningioma https://pubmed.ncbi.nlm.nih.gov/9701243/ The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. unassigned - 3.4.22.B28 Meningioma https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. unassigned - 3.4.22.B28 Meningioma https://pubmed.ncbi.nlm.nih.gov/11745202/ Calpain-dependent proteolysis of merlin occurs by oxidative stress in meningiomas: a novel hypothesis of tumorigenesis. unassigned - 3.4.22.B28 Meningitis, Pneumococcal https://pubmed.ncbi.nlm.nih.gov/11023466/ Pharmacologic interference with NF-kappaB activation attenuates central nervous system complications in experimental Pneumococcal meningitis. therapeutic application 2 3.4.22.B28 Meningitis, Pneumococcal https://pubmed.ncbi.nlm.nih.gov/11023466/ Pharmacologic interference with NF-kappaB activation attenuates central nervous system complications in experimental Pneumococcal meningitis. unassigned - 3.4.22.B28 Mesothelioma https://pubmed.ncbi.nlm.nih.gov/16458112/ Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. causal interaction 3 3.4.22.B28 Mesothelioma https://pubmed.ncbi.nlm.nih.gov/16458112/ Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. diagnostic usage 2 3.4.22.B28 Mesothelioma https://pubmed.ncbi.nlm.nih.gov/16458112/ Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. therapeutic application 4 3.4.22.B28 Mesothelioma https://pubmed.ncbi.nlm.nih.gov/16458112/ Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. ongoing research 4 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. causal interaction 4 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/27986275/ Calpain inhibition modulates glycogen synthase kinase 3? pathways in ischemic myocardium: A proteomic and mechanistic analysis. causal interaction 2 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. causal interaction 4 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. diagnostic usage 2 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. therapeutic application 4 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/25991048/ Calpain inhibition decreases myocardial apoptosis in a swine model of chronic myocardial ischemia. therapeutic application 1 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/27986275/ Calpain inhibition modulates glycogen synthase kinase 3? pathways in ischemic myocardium: A proteomic and mechanistic analysis. therapeutic application 3 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. therapeutic application 4 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/25991048/ Calpain inhibition decreases myocardial apoptosis in a swine model of chronic myocardial ischemia. ongoing research 1 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. ongoing research 1 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/8088401/ Involvement of calpain in myonephropathic metabolic syndrome (MNMS). unassigned - 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/25991048/ Calpain inhibition decreases myocardial apoptosis in a swine model of chronic myocardial ischemia. unassigned - 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/27986275/ Calpain inhibition modulates glycogen synthase kinase 3? pathways in ischemic myocardium: A proteomic and mechanistic analysis. unassigned - 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. unassigned - 3.4.22.B28 Metabolic Syndrome https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. unassigned - 3.4.22.B28 Mitochondrial Diseases https://pubmed.ncbi.nlm.nih.gov/32195756/ Inhibition of GPR35 Preserves Mitochondrial Function after Myocardial Infarction by Targeting Calpain 1/2. causal interaction 2 3.4.22.B28 Mitochondrial Diseases https://pubmed.ncbi.nlm.nih.gov/32195756/ Inhibition of GPR35 Preserves Mitochondrial Function after Myocardial Infarction by Targeting Calpain 1/2. therapeutic application 3 3.4.22.B28 Mitochondrial Diseases https://pubmed.ncbi.nlm.nih.gov/32195756/ Inhibition of GPR35 Preserves Mitochondrial Function after Myocardial Infarction by Targeting Calpain 1/2. unassigned - 3.4.22.B28 mitogen-activated protein kinase kinase kinase deficiency https://pubmed.ncbi.nlm.nih.gov/12839996/ MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts. causal interaction 3 3.4.22.B28 mitogen-activated protein kinase kinase kinase deficiency https://pubmed.ncbi.nlm.nih.gov/12839996/ MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts. therapeutic application 1 3.4.22.B28 mitogen-activated protein kinase kinase kinase deficiency https://pubmed.ncbi.nlm.nih.gov/12839996/ MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts. unassigned - 3.4.22.B28 Motor Neuron Disease https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. causal interaction 3 3.4.22.B28 Motor Neuron Disease https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. unassigned - 3.4.22.B28 Movement Disorders https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. causal interaction 1 3.4.22.B28 Movement Disorders https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. diagnostic usage 4 3.4.22.B28 Movement Disorders https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. ongoing research 4 3.4.22.B28 Movement Disorders https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. unassigned - 3.4.22.B28 MPTP Poisoning https://pubmed.ncbi.nlm.nih.gov/12105103/ Calpain upregulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice. causal interaction 1 3.4.22.B28 MPTP Poisoning https://pubmed.ncbi.nlm.nih.gov/12105103/ Calpain upregulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice. ongoing research 2 3.4.22.B28 MPTP Poisoning https://pubmed.ncbi.nlm.nih.gov/12105103/ Calpain upregulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice. unassigned - 3.4.22.B28 Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/16391721/ Chronicles in drug discovery. causal interaction 3 3.4.22.B28 Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/16391721/ Chronicles in drug discovery. therapeutic application 4 3.4.22.B28 Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/31915234/ Combination lenalidomide/bortezomib treatment synergistically induces calpain-dependent Ikaros cleavage and apoptosis in myeloma cells. therapeutic application 1 3.4.22.B28 Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/31915234/ Combination lenalidomide/bortezomib treatment synergistically induces calpain-dependent Ikaros cleavage and apoptosis in myeloma cells. unassigned - 3.4.22.B28 Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/16391721/ Chronicles in drug discovery. unassigned - 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. causal interaction 4 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. causal interaction 1 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. causal interaction 4 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/14992597/ The beta- and gamma-CH2 of B27-WT's Leu11 and Ile18 side chains play a direct role in calpain inhibition. causal interaction 4 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. causal interaction 4 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. causal interaction 3 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. diagnostic usage 3 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/12161014/ Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. diagnostic usage 3 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. therapeutic application 4 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. therapeutic application 3 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/14992597/ The beta- and gamma-CH2 of B27-WT's Leu11 and Ile18 side chains play a direct role in calpain inhibition. therapeutic application 2 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. therapeutic application 4 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. ongoing research 4 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/18673215/ Activation of calpain and caspase pathways in demyelination and neurodegeneration in animal model of multiple sclerosis. ongoing research 2 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. ongoing research 4 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. ongoing research 2 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/12161014/ Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. ongoing research 4 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/18673215/ Activation of calpain and caspase pathways in demyelination and neurodegeneration in animal model of multiple sclerosis. unassigned - 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/12161014/ Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. unassigned - 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/24447070/ Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. unassigned - 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/10082076/ Pathophysiological role of calpain in experimental demyelination. unassigned - 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/14992597/ The beta- and gamma-CH2 of B27-WT's Leu11 and Ile18 side chains play a direct role in calpain inhibition. unassigned - 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. unassigned - 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. unassigned - 3.4.22.B28 Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/10500203/ A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. unassigned - 3.4.22.B28 Muscle Spasticity https://pubmed.ncbi.nlm.nih.gov/9347985/ Generation of the catalytic fragment of protein kinase C alpha in spastic canine basilar artery. diagnostic usage 3 3.4.22.B28 Muscle Spasticity https://pubmed.ncbi.nlm.nih.gov/1370069/ Effects of inhibitors of protein kinase C and calpain in experimental delayed cerebral vasospasm. therapeutic application 4 3.4.22.B28 Muscle Spasticity https://pubmed.ncbi.nlm.nih.gov/9347985/ Generation of the catalytic fragment of protein kinase C alpha in spastic canine basilar artery. therapeutic application 4 3.4.22.B28 Muscle Spasticity https://pubmed.ncbi.nlm.nih.gov/1370069/ Effects of inhibitors of protein kinase C and calpain in experimental delayed cerebral vasospasm. ongoing research 1 3.4.22.B28 Muscle Spasticity https://pubmed.ncbi.nlm.nih.gov/1370069/ Effects of inhibitors of protein kinase C and calpain in experimental delayed cerebral vasospasm. unassigned - 3.4.22.B28 Muscle Spasticity https://pubmed.ncbi.nlm.nih.gov/9347985/ Generation of the catalytic fragment of protein kinase C alpha in spastic canine basilar artery. unassigned - 3.4.22.B28 Muscle Weakness https://pubmed.ncbi.nlm.nih.gov/26138644/ Neutral sphingomyelinase 2 is required for cytokine-induced skeletal muscle calpain activation. causal interaction 3 3.4.22.B28 Muscle Weakness https://pubmed.ncbi.nlm.nih.gov/26968769/ Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction. causal interaction 3 3.4.22.B28 Muscle Weakness https://pubmed.ncbi.nlm.nih.gov/19892928/ Inhibition of calpain prevents muscle weakness and disruption of sarcomere structure during hindlimb suspension. therapeutic application 2 3.4.22.B28 Muscle Weakness https://pubmed.ncbi.nlm.nih.gov/26138644/ Neutral sphingomyelinase 2 is required for cytokine-induced skeletal muscle calpain activation. therapeutic application 3 3.4.22.B28 Muscle Weakness https://pubmed.ncbi.nlm.nih.gov/26968769/ Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction. therapeutic application 2 3.4.22.B28 Muscle Weakness https://pubmed.ncbi.nlm.nih.gov/26968769/ Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction. ongoing research 4 3.4.22.B28 Muscle Weakness https://pubmed.ncbi.nlm.nih.gov/19892928/ Inhibition of calpain prevents muscle weakness and disruption of sarcomere structure during hindlimb suspension. unassigned - 3.4.22.B28 Muscle Weakness https://pubmed.ncbi.nlm.nih.gov/26138644/ Neutral sphingomyelinase 2 is required for cytokine-induced skeletal muscle calpain activation. unassigned - 3.4.22.B28 Muscle Weakness https://pubmed.ncbi.nlm.nih.gov/26968769/ Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/23471945/ Calpain and capase-3 play required roles in immobilization-induced limb muscle atrophy. causal interaction 4 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/12171431/ Effect of different dietary protein composition on skeletal muscle atrophy by suspension hypokinesia/hypodynamia in rats. causal interaction 3 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/17182728/ Differential localization of autolyzed calpains 1 and 2 in slow and fast skeletal muscles in the early phase of atrophy. causal interaction 3 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/17272355/ Calpain activation causes a proteasome-dependent increase in protein degradation and inhibits the Akt signalling pathway in rat diaphragm muscle. causal interaction 4 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. causal interaction 3 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/20860623/ A new pathway encompassing calpain 3 and its newly identified substrate cardiac ankyrin repeat protein is involved in the regulation of the nuclear factor-?B pathway in skeletal muscle. causal interaction 2 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/23766499/ Immobilization-induced activation of key proteolytic systems in skeletal muscles is prevented by a mitochondria-targeted antioxidant. causal interaction 4 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/26297661/ Calpain-dependent regulation of the skeletal muscle atrophy following unloading. causal interaction 1 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/26569227/ Calpain 3 Expression Pattern during Gastrocnemius Muscle Atrophy and Regeneration Following Sciatic Nerve Injury in Rats. causal interaction 4 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/27609832/ Skeletal Muscle Alterations Are Exacerbated in Heart Failure With Reduced Compared With Preserved Ejection Fraction: Mediated by Circulating Cytokines? causal interaction 2 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/30039299/ Muscle-specific activation of calpain system in hindlimb unloading rats and hibernating Daurian ground squirrels: a comparison between artificial and natural disuse. causal interaction 1 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/30992050/ RNA-sequencing reveals altered skeletal muscle contraction, E3 ligases, autophagy, apoptosis, and chaperone expression in patients with critical illness myopathy. causal interaction 1 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/31219776/ Differential activation of the calpain system involved in individualized adaptation of different fast-twitch muscles in hibernating Daurian ground squirrels. causal interaction 3 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/32451848/ Superoxide-mediated oxidative stress accelerates skeletal muscle atrophy by synchronous activation of proteolytic systems. causal interaction 3 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/33279868/ Calpains play an essential role in mechanical ventilation-induced diaphragmatic weakness and mitochondrial dysfunction. causal interaction 2 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/28290154/ The role of calpains in ventilator-induced diaphragm atrophy. diagnostic usage 2 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/30992050/ RNA-sequencing reveals altered skeletal muscle contraction, E3 ligases, autophagy, apoptosis, and chaperone expression in patients with critical illness myopathy. diagnostic usage 1 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/23471945/ Calpain and capase-3 play required roles in immobilization-induced limb muscle atrophy. therapeutic application 3 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/29032335/ Identification of the optimal dose and calpain system regulation of tetramethylpyrazine on the prevention of skeletal muscle atrophy in hindlimb unloading rats. therapeutic application 2 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/30393967/ Inhibition of calpain delays early muscle atrophy after rotator cuff tendon release in sheep. therapeutic application 1 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/17182728/ Differential localization of autolyzed calpains 1 and 2 in slow and fast skeletal muscles in the early phase of atrophy. therapeutic application 2 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. therapeutic application 4 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/20860623/ A new pathway encompassing calpain 3 and its newly identified substrate cardiac ankyrin repeat protein is involved in the regulation of the nuclear factor-?B pathway in skeletal muscle. therapeutic application 1 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/23766499/ Immobilization-induced activation of key proteolytic systems in skeletal muscles is prevented by a mitochondria-targeted antioxidant. therapeutic application 3 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/26297661/ Calpain-dependent regulation of the skeletal muscle atrophy following unloading. therapeutic application 1 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/26569227/ Calpain 3 Expression Pattern during Gastrocnemius Muscle Atrophy and Regeneration Following Sciatic Nerve Injury in Rats. therapeutic application 4 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/26988155/ The molecular mechanisms of calpains on muscle atrophy. therapeutic application 1 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/28290154/ The role of calpains in ventilator-induced diaphragm atrophy. therapeutic application 3 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/30039299/ Muscle-specific activation of calpain system in hindlimb unloading rats and hibernating Daurian ground squirrels: a comparison between artificial and natural disuse. therapeutic application 1 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/31219776/ Differential activation of the calpain system involved in individualized adaptation of different fast-twitch muscles in hibernating Daurian ground squirrels. therapeutic application 3 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/33279868/ Calpains play an essential role in mechanical ventilation-induced diaphragmatic weakness and mitochondrial dysfunction. therapeutic application 1 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/29032335/ Identification of the optimal dose and calpain system regulation of tetramethylpyrazine on the prevention of skeletal muscle atrophy in hindlimb unloading rats. ongoing research 2 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. ongoing research 1 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/26569227/ Calpain 3 Expression Pattern during Gastrocnemius Muscle Atrophy and Regeneration Following Sciatic Nerve Injury in Rats. ongoing research 4 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/29032335/ Identification of the optimal dose and calpain system regulation of tetramethylpyrazine on the prevention of skeletal muscle atrophy in hindlimb unloading rats. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/30393967/ Inhibition of calpain delays early muscle atrophy after rotator cuff tendon release in sheep. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/17928995/ Ventilator-induced diaphragm dysfunction: the clinical relevance of animal models. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/25415668/ Fibrosis, adipogenesis, and muscle atrophy in congenital muscular torticollis. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/26988155/ The molecular mechanisms of calpains on muscle atrophy. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/28290154/ The role of calpains in ventilator-induced diaphragm atrophy. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/34386092/ Differential Protein Metabolism and Regeneration in Gastrocnemius Muscles in High-fat Diet Fed Mice and Pre-hibernation Daurian Ground Squirrels: A Comparison between Pathological and Healthy Obesity. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/23471945/ Calpain and capase-3 play required roles in immobilization-induced limb muscle atrophy. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/12171431/ Effect of different dietary protein composition on skeletal muscle atrophy by suspension hypokinesia/hypodynamia in rats. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/17182728/ Differential localization of autolyzed calpains 1 and 2 in slow and fast skeletal muscles in the early phase of atrophy. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/17272355/ Calpain activation causes a proteasome-dependent increase in protein degradation and inhibits the Akt signalling pathway in rat diaphragm muscle. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/20860623/ A new pathway encompassing calpain 3 and its newly identified substrate cardiac ankyrin repeat protein is involved in the regulation of the nuclear factor-?B pathway in skeletal muscle. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/23766499/ Immobilization-induced activation of key proteolytic systems in skeletal muscles is prevented by a mitochondria-targeted antioxidant. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/26297661/ Calpain-dependent regulation of the skeletal muscle atrophy following unloading. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/26569227/ Calpain 3 Expression Pattern during Gastrocnemius Muscle Atrophy and Regeneration Following Sciatic Nerve Injury in Rats. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/27609832/ Skeletal Muscle Alterations Are Exacerbated in Heart Failure With Reduced Compared With Preserved Ejection Fraction: Mediated by Circulating Cytokines? unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/30039299/ Muscle-specific activation of calpain system in hindlimb unloading rats and hibernating Daurian ground squirrels: a comparison between artificial and natural disuse. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/31219776/ Differential activation of the calpain system involved in individualized adaptation of different fast-twitch muscles in hibernating Daurian ground squirrels. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/32451848/ Superoxide-mediated oxidative stress accelerates skeletal muscle atrophy by synchronous activation of proteolytic systems. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/33279868/ Calpains play an essential role in mechanical ventilation-induced diaphragmatic weakness and mitochondrial dysfunction. unassigned - 3.4.22.B28 Muscular Atrophy https://pubmed.ncbi.nlm.nih.gov/30992050/ RNA-sequencing reveals altered skeletal muscle contraction, E3 ligases, autophagy, apoptosis, and chaperone expression in patients with critical illness myopathy. unassigned - 3.4.22.B28 Muscular Atrophy, Spinal https://pubmed.ncbi.nlm.nih.gov/32587237/ Calpain system is altered in survival motor neuron-reduced cells from in vitro and in vivo spinal muscular atrophy models. causal interaction 1 3.4.22.B28 Muscular Atrophy, Spinal https://pubmed.ncbi.nlm.nih.gov/30327977/ Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice. ongoing research 1 3.4.22.B28 Muscular Atrophy, Spinal https://pubmed.ncbi.nlm.nih.gov/32587237/ Calpain system is altered in survival motor neuron-reduced cells from in vitro and in vivo spinal muscular atrophy models. ongoing research 2 3.4.22.B28 Muscular Atrophy, Spinal https://pubmed.ncbi.nlm.nih.gov/30327977/ Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice. unassigned - 3.4.22.B28 Muscular Atrophy, Spinal https://pubmed.ncbi.nlm.nih.gov/32587237/ Calpain system is altered in survival motor neuron-reduced cells from in vitro and in vivo spinal muscular atrophy models. unassigned - 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/25643692/ Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy. causal interaction 3 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. causal interaction 1 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/11731278/ Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. causal interaction 3 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/27957058/ Atrial Calpains: Mediators of Atrialmyopathies in Atrial Fibrillation. causal interaction 2 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. diagnostic usage 4 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/10687099/ [Polymorphism of exon 4 in the CANP-3 gene in patients with primary myopathies] diagnostic usage 1 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/11731278/ Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. diagnostic usage 2 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/15948206/ Calpain-dependent alpha-fodrin cleavage at the sarcolemma in muscle diseases. therapeutic application 2 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. ongoing research 3 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/10687099/ [Polymorphism of exon 4 in the CANP-3 gene in patients with primary myopathies] ongoing research 2 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/10687099/ [Polymorphism of exon 4 in the CANP-3 gene in patients with primary myopathies] unassigned - 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/15948206/ Calpain-dependent alpha-fodrin cleavage at the sarcolemma in muscle diseases. unassigned - 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/25680228/ Quickly progressive amyotrophy of the thigh: An unusual cause of rapid chondrolysis of the knee. unassigned - 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/25643692/ Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy. unassigned - 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/27957058/ Atrial Calpains: Mediators of Atrialmyopathies in Atrial Fibrillation. unassigned - 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. unassigned - 3.4.22.B28 Muscular Diseases https://pubmed.ncbi.nlm.nih.gov/11731278/ Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. unassigned - 3.4.22.B28 Muscular Disorders, Atrophic https://pubmed.ncbi.nlm.nih.gov/23471945/ Calpain and capase-3 play required roles in immobilization-induced limb muscle atrophy. causal interaction 4 3.4.22.B28 Muscular Disorders, Atrophic https://pubmed.ncbi.nlm.nih.gov/23471945/ Calpain and capase-3 play required roles in immobilization-induced limb muscle atrophy. therapeutic application 3 3.4.22.B28 Muscular Disorders, Atrophic https://pubmed.ncbi.nlm.nih.gov/23471945/ Calpain and capase-3 play required roles in immobilization-induced limb muscle atrophy. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/7618437/ Immunohistochemical study of calpain and its endogenous inhibitor in the skeletal muscle of muscular dystrophy. causal interaction 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/16185867/ Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy. causal interaction 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/21826685/ Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy. causal interaction 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/2279616/ Calpains (intracellular calcium-activated cysteine proteinases): structure-activity relationships and involvement in normal and abnormal cellular metabolism. causal interaction 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/7855906/ Calpain inhibition: an overview of its therapeutic potential. causal interaction 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. causal interaction 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/9894158/ Calpain inhibitors reduce the cornified cell envelope formation by inhibiting proteolytic processing of transglutaminase 1. causal interaction 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10661889/ Calpains and muscular dystrophies. causal interaction 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10723861/ Disease taxonomy--monogenic muscular dystrophy. causal interaction 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. causal interaction 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/11078210/ Proteasome expression in the skeletal muscles of patients with muscular dystrophy. causal interaction 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/12173413/ The calpain system in human placenta. causal interaction 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/15336956/ Calpain-related diseases. causal interaction 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. causal interaction 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/16453164/ Possible functions of p94 in connectin-mediated signaling pathways in skeletal muscle cells. causal interaction 2 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. causal interaction 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. causal interaction 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/19258295/ Partial epilepsy in an adolescent male with limb-girdle muscular dystrophy 1B. causal interaction 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/21030783/ Expanding members and roles of the calpain superfamily and their genetically modified animals. causal interaction 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/21670566/ Calpain chronicle--an enzyme family under multidisciplinary characterization. causal interaction 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/22291646/ Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy. causal interaction 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. causal interaction 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/26569227/ Calpain 3 Expression Pattern during Gastrocnemius Muscle Atrophy and Regeneration Following Sciatic Nerve Injury in Rats. causal interaction 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/27506543/ Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts. causal interaction 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/30075226/ Translating genetic, biochemical and structural information to the calpain view of development. causal interaction 2 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/7618437/ Immunohistochemical study of calpain and its endogenous inhibitor in the skeletal muscle of muscular dystrophy. diagnostic usage 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/11579578/ [Muscular dystrophy and calpain] diagnostic usage 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/21826685/ Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy. diagnostic usage 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. diagnostic usage 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10687099/ [Polymorphism of exon 4 in the CANP-3 gene in patients with primary myopathies] diagnostic usage 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/11078210/ Proteasome expression in the skeletal muscles of patients with muscular dystrophy. diagnostic usage 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. diagnostic usage 2 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/27506543/ Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts. diagnostic usage 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/7618437/ Immunohistochemical study of calpain and its endogenous inhibitor in the skeletal muscle of muscular dystrophy. therapeutic application 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/16185867/ Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy. therapeutic application 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/21826685/ Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy. therapeutic application 2 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/34298987/ Allosteric Modulation of GSK-3? as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. therapeutic application 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/2279616/ Calpains (intracellular calcium-activated cysteine proteinases): structure-activity relationships and involvement in normal and abnormal cellular metabolism. therapeutic application 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/7855906/ Calpain inhibition: an overview of its therapeutic potential. therapeutic application 2 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10101785/ [Alterations in functional proteins. Calpaine-3 deficiency] therapeutic application 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10661889/ Calpains and muscular dystrophies. therapeutic application 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/11078210/ Proteasome expression in the skeletal muscles of patients with muscular dystrophy. therapeutic application 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/11813630/ [Muscular dystrophies detected by immunophenotyping and genotype analysis (mRNA and DNA)] therapeutic application 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. therapeutic application 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/16453164/ Possible functions of p94 in connectin-mediated signaling pathways in skeletal muscle cells. therapeutic application 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. therapeutic application 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/21610046/ Impact of genetic insights into calpain biology. therapeutic application 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/22291646/ Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy. therapeutic application 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. therapeutic application 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/26569227/ Calpain 3 Expression Pattern during Gastrocnemius Muscle Atrophy and Regeneration Following Sciatic Nerve Injury in Rats. therapeutic application 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/27506543/ Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts. therapeutic application 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/7618437/ Immunohistochemical study of calpain and its endogenous inhibitor in the skeletal muscle of muscular dystrophy. ongoing research 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/11579578/ [Muscular dystrophy and calpain] ongoing research 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/21826685/ Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy. ongoing research 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. ongoing research 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10687099/ [Polymorphism of exon 4 in the CANP-3 gene in patients with primary myopathies] ongoing research 2 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/11078210/ Proteasome expression in the skeletal muscles of patients with muscular dystrophy. ongoing research 3 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. ongoing research 2 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. ongoing research 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/22291646/ Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy. ongoing research 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/26569227/ Calpain 3 Expression Pattern during Gastrocnemius Muscle Atrophy and Regeneration Following Sciatic Nerve Injury in Rats. ongoing research 4 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/27506543/ Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts. ongoing research 1 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/11579578/ [Muscular dystrophy and calpain] unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/34298987/ Allosteric Modulation of GSK-3? as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10101785/ [Alterations in functional proteins. Calpaine-3 deficiency] unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10687099/ [Polymorphism of exon 4 in the CANP-3 gene in patients with primary myopathies] unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/11813630/ [Muscular dystrophies detected by immunophenotyping and genotype analysis (mRNA and DNA)] unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/14645524/ Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/17646163/ Stomach-specific calpain, nCL-2/calpain 8, is active without calpain regulatory subunit and oligomerizes through C2-like domains. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/21434837/ Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/21610046/ Impact of genetic insights into calpain biology. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/16185867/ Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/2279616/ Calpains (intracellular calcium-activated cysteine proteinases): structure-activity relationships and involvement in normal and abnormal cellular metabolism. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/7855906/ Calpain inhibition: an overview of its therapeutic potential. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/9894158/ Calpain inhibitors reduce the cornified cell envelope formation by inhibiting proteolytic processing of transglutaminase 1. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10661889/ Calpains and muscular dystrophies. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10723861/ Disease taxonomy--monogenic muscular dystrophy. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/12173413/ The calpain system in human placenta. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/15336956/ Calpain-related diseases. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/16453164/ Possible functions of p94 in connectin-mediated signaling pathways in skeletal muscle cells. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/19258295/ Partial epilepsy in an adolescent male with limb-girdle muscular dystrophy 1B. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/21030783/ Expanding members and roles of the calpain superfamily and their genetically modified animals. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/21670566/ Calpain chronicle--an enzyme family under multidisciplinary characterization. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/22291646/ Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/23259318/ Implications of calpains in health and diseases. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/26569227/ Calpain 3 Expression Pattern during Gastrocnemius Muscle Atrophy and Regeneration Following Sciatic Nerve Injury in Rats. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/30075226/ Translating genetic, biochemical and structural information to the calpain view of development. unassigned - 3.4.22.B28 Muscular Dystrophies https://pubmed.ncbi.nlm.nih.gov/9562261/ Expression of three calpain isoform genes in human skeletal muscles. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/11245732/ Normal calpain expression in genetically confirmed limb-girdle muscular dystrophy type 2A. causal interaction 4 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/9396712/ Structure and physiological function of calpains. causal interaction 2 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/9642272/ Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A. causal interaction 3 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/9655129/ Pseudometabolic expression and phenotypic variability of calpain deficiency in two siblings. causal interaction 4 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/10639725/ New aspect of the research on limb-girdle muscular dystrophy 2A: a molecular biologic and biochemical approach to pathology. causal interaction 1 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/10661889/ Calpains and muscular dystrophies. causal interaction 4 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/10723861/ Disease taxonomy--monogenic muscular dystrophy. causal interaction 3 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/12801918/ Localization of calpain 3 in human skeletal muscle and its alteration in limb-girdle muscular dystrophy 2A muscle. causal interaction 1 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] causal interaction 3 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/15336956/ Calpain-related diseases. causal interaction 1 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/16453164/ Possible functions of p94 in connectin-mediated signaling pathways in skeletal muscle cells. causal interaction 2 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. causal interaction 3 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/19258295/ Partial epilepsy in an adolescent male with limb-girdle muscular dystrophy 1B. causal interaction 4 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/10102422/ Calpain III mutation analysis of a heterogeneous limb-girdle muscular dystrophy population. diagnostic usage 2 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/11245732/ Normal calpain expression in genetically confirmed limb-girdle muscular dystrophy type 2A. diagnostic usage 3 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/9577386/ Abnormal merosin in adults. A new form of late onset muscular dystrophy not linked to chromosome 6q2. diagnostic usage 2 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/34298987/ Allosteric Modulation of GSK-3? as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. therapeutic application 4 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/10661889/ Calpains and muscular dystrophies. therapeutic application 1 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] therapeutic application 1 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/16453164/ Possible functions of p94 in connectin-mediated signaling pathways in skeletal muscle cells. therapeutic application 1 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/10102422/ Calpain III mutation analysis of a heterogeneous limb-girdle muscular dystrophy population. ongoing research 2 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/11245732/ Normal calpain expression in genetically confirmed limb-girdle muscular dystrophy type 2A. ongoing research 1 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/12801918/ Localization of calpain 3 in human skeletal muscle and its alteration in limb-girdle muscular dystrophy 2A muscle. ongoing research 4 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. ongoing research 2 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/10102422/ Calpain III mutation analysis of a heterogeneous limb-girdle muscular dystrophy population. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/34298987/ Allosteric Modulation of GSK-3? as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/9577386/ Abnormal merosin in adults. A new form of late onset muscular dystrophy not linked to chromosome 6q2. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/14645524/ Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/25206500/ Limb-girdle muscular dystrophy subtypes: First-reported cohort from northeastern China. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/31991774/ Calpainopathy: Description of a Novel Mutation and Clinical Presentation with Early Severe Contractures. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/9396712/ Structure and physiological function of calpains. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/9642272/ Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/9655129/ Pseudometabolic expression and phenotypic variability of calpain deficiency in two siblings. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/10639725/ New aspect of the research on limb-girdle muscular dystrophy 2A: a molecular biologic and biochemical approach to pathology. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/10661889/ Calpains and muscular dystrophies. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/10723861/ Disease taxonomy--monogenic muscular dystrophy. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/12801918/ Localization of calpain 3 in human skeletal muscle and its alteration in limb-girdle muscular dystrophy 2A muscle. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/12843569/ [Calpain and pathology in view of structure-function relationships] unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/15336956/ Calpain-related diseases. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/16453164/ Possible functions of p94 in connectin-mediated signaling pathways in skeletal muscle cells. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/19258295/ Partial epilepsy in an adolescent male with limb-girdle muscular dystrophy 1B. unassigned - 3.4.22.B28 Muscular Dystrophies, Limb-Girdle https://pubmed.ncbi.nlm.nih.gov/11245732/ Normal calpain expression in genetically confirmed limb-girdle muscular dystrophy type 2A. unassigned - 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/22291646/ Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy. causal interaction 1 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/7618437/ Immunohistochemical study of calpain and its endogenous inhibitor in the skeletal muscle of muscular dystrophy. causal interaction 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/9687572/ Neuronal nitric oxide synthase isoforms alpha and mu are closely related calpain-sensitive proteins. causal interaction 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/10590413/ Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition. causal interaction 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/10661889/ Calpains and muscular dystrophies. causal interaction 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16185867/ Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy. causal interaction 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16391721/ Chronicles in drug discovery. causal interaction 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. causal interaction 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/19258295/ Partial epilepsy in an adolescent male with limb-girdle muscular dystrophy 1B. causal interaction 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/20844259/ Leupeptin-based inhibitors do not improve the mdx phenotype. causal interaction 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/21826685/ Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy. causal interaction 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/27506543/ Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts. causal interaction 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/9798335/ Deletion analysis & calpain status for carrier detection in a family with Duchenne muscular dystrophy. diagnostic usage 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/7618437/ Immunohistochemical study of calpain and its endogenous inhibitor in the skeletal muscle of muscular dystrophy. diagnostic usage 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16815350/ Altered expression, intracellular distribution and activity of lymphocyte calpain II in Duchenne muscular dystrophy. diagnostic usage 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/21826685/ Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy. diagnostic usage 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/27506543/ Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts. diagnostic usage 1 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/22291646/ Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy. therapeutic application 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/7618437/ Immunohistochemical study of calpain and its endogenous inhibitor in the skeletal muscle of muscular dystrophy. therapeutic application 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/10590413/ Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition. therapeutic application 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/10661889/ Calpains and muscular dystrophies. therapeutic application 1 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16185867/ Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy. therapeutic application 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16391721/ Chronicles in drug discovery. therapeutic application 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/20844259/ Leupeptin-based inhibitors do not improve the mdx phenotype. therapeutic application 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/21826685/ Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy. therapeutic application 2 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/27506543/ Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts. therapeutic application 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/22291646/ Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy. ongoing research 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/7618437/ Immunohistochemical study of calpain and its endogenous inhibitor in the skeletal muscle of muscular dystrophy. ongoing research 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. ongoing research 2 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16815350/ Altered expression, intracellular distribution and activity of lymphocyte calpain II in Duchenne muscular dystrophy. ongoing research 3 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/21826685/ Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy. ongoing research 4 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/27506543/ Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts. ongoing research 1 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/9798335/ Deletion analysis & calpain status for carrier detection in a family with Duchenne muscular dystrophy. unassigned - 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16815350/ Altered expression, intracellular distribution and activity of lymphocyte calpain II in Duchenne muscular dystrophy. unassigned - 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/22291646/ Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy. unassigned - 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/9687572/ Neuronal nitric oxide synthase isoforms alpha and mu are closely related calpain-sensitive proteins. unassigned - 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/10590413/ Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition. unassigned - 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/10661889/ Calpains and muscular dystrophies. unassigned - 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16185867/ Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy. unassigned - 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16391721/ Chronicles in drug discovery. unassigned - 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. unassigned - 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/19258295/ Partial epilepsy in an adolescent male with limb-girdle muscular dystrophy 1B. unassigned - 3.4.22.B28 Muscular Dystrophy, Duchenne https://pubmed.ncbi.nlm.nih.gov/20844259/ Leupeptin-based inhibitors do not improve the mdx phenotype. unassigned - 3.4.22.B28 Mycobacterium Infections https://pubmed.ncbi.nlm.nih.gov/27660000/ Potential of Ca(2+) in Mycobacterium tuberculosis H37Rv Pathogenesis and Survival. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/16633084/ Possible involvement of calpain activation in pathogenesis of chronic heart failure after acute myocardial infarction. causal interaction 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/32195756/ Inhibition of GPR35 Preserves Mitochondrial Function after Myocardial Infarction by Targeting Calpain 1/2. causal interaction 2 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/8548709/ Inhibiting calpain, rescuing cells. causal interaction 1 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/10218728/ Calpain inhibitor-1 reduces infarct size and DNA fragmentation of myocardium in ischemic/reperfused rat heart. causal interaction 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/12843408/ The calpain system. causal interaction 1 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/16956607/ Inhibition of calpain-mediated cell death by a novel peptide inhibitor. causal interaction 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/22753411/ Deficiency of Capn4 Gene Inhibits Nuclear Factor-?B (NF-?B) Protein Signaling/Inflammation and Reduces Remodeling after Myocardial Infarction. causal interaction 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. causal interaction 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/26453333/ Calpastatin overexpression impairs postinfarct scar healing in mice by compromising reparative immune cell recruitment and activation. causal interaction 3 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. causal interaction 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/12393065/ Calcium channel blockade limits transcriptional, translational and functional up-regulation of the cardiac calpain system after myocardial infarction. diagnostic usage 3 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/16633084/ Possible involvement of calpain activation in pathogenesis of chronic heart failure after acute myocardial infarction. diagnostic usage 1 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/22753411/ Deficiency of Capn4 Gene Inhibits Nuclear Factor-?B (NF-?B) Protein Signaling/Inflammation and Reduces Remodeling after Myocardial Infarction. diagnostic usage 1 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. diagnostic usage 3 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/10722243/ Activation of calpain in myocardial infarction: an immunohistochemical study using a calpain antibody raised against active site histidine-containing peptide. therapeutic application 2 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/12393065/ Calcium channel blockade limits transcriptional, translational and functional up-regulation of the cardiac calpain system after myocardial infarction. therapeutic application 2 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/15576328/ Reduction of myocardial infarction by calpain inhibitors A-705239 and A-705253 in isolated perfused rabbit hearts. therapeutic application 3 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/16633084/ Possible involvement of calpain activation in pathogenesis of chronic heart failure after acute myocardial infarction. therapeutic application 1 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/18844452/ Reduction of myocardial infarction by postischemic administration of the calpain inhibitor A-705253 in comparison to the Na(+)/H(+) exchange inhibitor Cariporide in isolated perfused rabbit hearts. therapeutic application 3 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/19734364/ Calpain inhibition preserves myocardial structure and function following myocardial infarction. therapeutic application 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/32195756/ Inhibition of GPR35 Preserves Mitochondrial Function after Myocardial Infarction by Targeting Calpain 1/2. therapeutic application 3 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/8548709/ Inhibiting calpain, rescuing cells. therapeutic application 1 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/12843408/ The calpain system. therapeutic application 1 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/14995081/ Calpain and caspase-3 inhibitors reduce infarct size and post-ischemic apoptosis in rat heart without modifying contractile recovery. therapeutic application 2 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/16956607/ Inhibition of calpain-mediated cell death by a novel peptide inhibitor. therapeutic application 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/22753411/ Deficiency of Capn4 Gene Inhibits Nuclear Factor-?B (NF-?B) Protein Signaling/Inflammation and Reduces Remodeling after Myocardial Infarction. therapeutic application 3 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. therapeutic application 3 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/25786109/ Over-expression of calpastatin inhibits calpain activation and attenuates post-infarction myocardial remodeling. therapeutic application 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. therapeutic application 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/30416776/ Over-expression of calpastatin attenuates myocardial injury following myocardial infarction by inhibiting endoplasmic reticulum stress. therapeutic application 3 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/10722243/ Activation of calpain in myocardial infarction: an immunohistochemical study using a calpain antibody raised against active site histidine-containing peptide. ongoing research 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/14995081/ Calpain and caspase-3 inhibitors reduce infarct size and post-ischemic apoptosis in rat heart without modifying contractile recovery. ongoing research 2 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/24891510/ Calpain-dependent cleavage of N-cadherin is involved in the progression of post-myocardial infarction remodeling. ongoing research 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. ongoing research 2 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/30416776/ Over-expression of calpastatin attenuates myocardial injury following myocardial infarction by inhibiting endoplasmic reticulum stress. ongoing research 4 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/10722243/ Activation of calpain in myocardial infarction: an immunohistochemical study using a calpain antibody raised against active site histidine-containing peptide. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/12393065/ Calcium channel blockade limits transcriptional, translational and functional up-regulation of the cardiac calpain system after myocardial infarction. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/15576328/ Reduction of myocardial infarction by calpain inhibitors A-705239 and A-705253 in isolated perfused rabbit hearts. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/18844452/ Reduction of myocardial infarction by postischemic administration of the calpain inhibitor A-705253 in comparison to the Na(+)/H(+) exchange inhibitor Cariporide in isolated perfused rabbit hearts. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/19734364/ Calpain inhibition preserves myocardial structure and function following myocardial infarction. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/14995081/ Calpain and caspase-3 inhibitors reduce infarct size and post-ischemic apoptosis in rat heart without modifying contractile recovery. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/24891510/ Calpain-dependent cleavage of N-cadherin is involved in the progression of post-myocardial infarction remodeling. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/25786109/ Over-expression of calpastatin inhibits calpain activation and attenuates post-infarction myocardial remodeling. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/30416776/ Over-expression of calpastatin attenuates myocardial injury following myocardial infarction by inhibiting endoplasmic reticulum stress. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/32195756/ Inhibition of GPR35 Preserves Mitochondrial Function after Myocardial Infarction by Targeting Calpain 1/2. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/8548709/ Inhibiting calpain, rescuing cells. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/10218728/ Calpain inhibitor-1 reduces infarct size and DNA fragmentation of myocardium in ischemic/reperfused rat heart. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/12843408/ The calpain system. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/16956607/ Inhibition of calpain-mediated cell death by a novel peptide inhibitor. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/26453333/ Calpastatin overexpression impairs postinfarct scar healing in mice by compromising reparative immune cell recruitment and activation. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/28460013/ Delayed, oral pharmacological inhibition of calpains attenuates adverse post-infarction remodelling. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/16633084/ Possible involvement of calpain activation in pathogenesis of chronic heart failure after acute myocardial infarction. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/22753411/ Deficiency of Capn4 Gene Inhibits Nuclear Factor-?B (NF-?B) Protein Signaling/Inflammation and Reduces Remodeling after Myocardial Infarction. unassigned - 3.4.22.B28 Myocardial Infarction https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. unassigned - 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. causal interaction 4 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. causal interaction 4 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/31926683/ Commentary: Calpain inhibition: A novel strategy to treat chronic myocardial ischemia. causal interaction 4 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/11404357/ Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. causal interaction 3 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/22575511/ Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. causal interaction 2 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/27986275/ Calpain inhibition modulates glycogen synthase kinase 3? pathways in ischemic myocardium: A proteomic and mechanistic analysis. causal interaction 2 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. diagnostic usage 3 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. therapeutic application 3 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/25991048/ Calpain inhibition decreases myocardial apoptosis in a swine model of chronic myocardial ischemia. therapeutic application 1 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/26478238/ Calpain inhibition improves collateral-dependent perfusion in a hypercholesterolemic swine model of chronic myocardial ischemia. therapeutic application 1 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. therapeutic application 4 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/31926683/ Commentary: Calpain inhibition: A novel strategy to treat chronic myocardial ischemia. therapeutic application 4 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/16981728/ Selective Deletion of the NH(2)-Terminal Variable Region of Cardiac Troponin T in Ischemia Reperfusion by Myofibril-Associated mu-Calpain Cleavage. therapeutic application 3 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/22575511/ Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. therapeutic application 4 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/27986275/ Calpain inhibition modulates glycogen synthase kinase 3? pathways in ischemic myocardium: A proteomic and mechanistic analysis. therapeutic application 3 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/25991048/ Calpain inhibition decreases myocardial apoptosis in a swine model of chronic myocardial ischemia. ongoing research 1 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/26478238/ Calpain inhibition improves collateral-dependent perfusion in a hypercholesterolemic swine model of chronic myocardial ischemia. ongoing research 2 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. ongoing research 1 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/25991048/ Calpain inhibition decreases myocardial apoptosis in a swine model of chronic myocardial ischemia. unassigned - 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/26478238/ Calpain inhibition improves collateral-dependent perfusion in a hypercholesterolemic swine model of chronic myocardial ischemia. unassigned - 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/16981728/ Selective Deletion of the NH(2)-Terminal Variable Region of Cardiac Troponin T in Ischemia Reperfusion by Myofibril-Associated mu-Calpain Cleavage. unassigned - 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. unassigned - 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/31926683/ Commentary: Calpain inhibition: A novel strategy to treat chronic myocardial ischemia. unassigned - 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/11404357/ Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. unassigned - 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/22575511/ Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. unassigned - 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/27986275/ Calpain inhibition modulates glycogen synthase kinase 3? pathways in ischemic myocardium: A proteomic and mechanistic analysis. unassigned - 3.4.22.B28 Myocardial Ischemia https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. unassigned - 3.4.22.B28 Myocardial Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/26489456/ Calpains and Coronary Vascular Disease. causal interaction 4 3.4.22.B28 Myocardial Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/26489456/ Calpains and Coronary Vascular Disease. therapeutic application 3 3.4.22.B28 Myocardial Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/26489456/ Calpains and Coronary Vascular Disease. unassigned - 3.4.22.B28 Myocardial Stunning https://pubmed.ncbi.nlm.nih.gov/12646718/ Glucocorticoids preserve calpastatin and troponin I during cardiopulmonary bypass in immature pigs. causal interaction 3 3.4.22.B28 Myocardial Stunning https://pubmed.ncbi.nlm.nih.gov/26489456/ Calpains and Coronary Vascular Disease. causal interaction 4 3.4.22.B28 Myocardial Stunning https://pubmed.ncbi.nlm.nih.gov/26489456/ Calpains and Coronary Vascular Disease. therapeutic application 3 3.4.22.B28 Myocardial Stunning https://pubmed.ncbi.nlm.nih.gov/12646718/ Glucocorticoids preserve calpastatin and troponin I during cardiopulmonary bypass in immature pigs. unassigned - 3.4.22.B28 Myocardial Stunning https://pubmed.ncbi.nlm.nih.gov/26489456/ Calpains and Coronary Vascular Disease. unassigned - 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/27472894/ Dual roles of calpain in facilitating Coxsackievirus B3 replication and prompting inflammation in acute myocarditis. causal interaction 3 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/31319178/ Calpain regulates CVB3 induced viral myocarditis by promoting autophagic flux upon infection. causal interaction 3 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/32509190/ Inhibition of calpain alleviates coxsackievirus B3-induced myocarditis through suppressing the canonical NLRP3 inflammasome/caspase-1-mediated and noncanonical caspase-11-mediated pyroptosis pathways. causal interaction 1 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/34234076/ Inhibition of Calpain Alleviates Apoptosis in Coxsackievirus B3-induced Acute Virus Myocarditis Through Suppressing Endoplasmic Reticulum Stress. causal interaction 2 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/34365571/ Inhibition of calpain reduces cell apoptosis by suppressing mitochondrial fission in acute viral myocarditis. causal interaction 2 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/24177271/ Coxsackievirus B3-induced calpain activation facilitates the progeny virus replication via a likely mechanism related with both autophagy enhancement and apoptosis inhibition in the early phase of infection: an in vitro study in H9c2 cells. causal interaction 2 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/27730362/ Dantrolene improves in vitro structural changes induced by serum from Trypanosoma cruzi-infected mice. causal interaction 4 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/27472894/ Dual roles of calpain in facilitating Coxsackievirus B3 replication and prompting inflammation in acute myocarditis. therapeutic application 4 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/31319178/ Calpain regulates CVB3 induced viral myocarditis by promoting autophagic flux upon infection. therapeutic application 4 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/32509190/ Inhibition of calpain alleviates coxsackievirus B3-induced myocarditis through suppressing the canonical NLRP3 inflammasome/caspase-1-mediated and noncanonical caspase-11-mediated pyroptosis pathways. therapeutic application 2 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/34234076/ Inhibition of Calpain Alleviates Apoptosis in Coxsackievirus B3-induced Acute Virus Myocarditis Through Suppressing Endoplasmic Reticulum Stress. therapeutic application 3 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/34365571/ Inhibition of calpain reduces cell apoptosis by suppressing mitochondrial fission in acute viral myocarditis. therapeutic application 4 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/24177271/ Coxsackievirus B3-induced calpain activation facilitates the progeny virus replication via a likely mechanism related with both autophagy enhancement and apoptosis inhibition in the early phase of infection: an in vitro study in H9c2 cells. therapeutic application 1 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/27730362/ Dantrolene improves in vitro structural changes induced by serum from Trypanosoma cruzi-infected mice. therapeutic application 4 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/32509190/ Inhibition of calpain alleviates coxsackievirus B3-induced myocarditis through suppressing the canonical NLRP3 inflammasome/caspase-1-mediated and noncanonical caspase-11-mediated pyroptosis pathways. ongoing research 4 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/27472894/ Dual roles of calpain in facilitating Coxsackievirus B3 replication and prompting inflammation in acute myocarditis. unassigned - 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/31319178/ Calpain regulates CVB3 induced viral myocarditis by promoting autophagic flux upon infection. unassigned - 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/32509190/ Inhibition of calpain alleviates coxsackievirus B3-induced myocarditis through suppressing the canonical NLRP3 inflammasome/caspase-1-mediated and noncanonical caspase-11-mediated pyroptosis pathways. unassigned - 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/34234076/ Inhibition of Calpain Alleviates Apoptosis in Coxsackievirus B3-induced Acute Virus Myocarditis Through Suppressing Endoplasmic Reticulum Stress. unassigned - 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/34365571/ Inhibition of calpain reduces cell apoptosis by suppressing mitochondrial fission in acute viral myocarditis. unassigned - 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/24177271/ Coxsackievirus B3-induced calpain activation facilitates the progeny virus replication via a likely mechanism related with both autophagy enhancement and apoptosis inhibition in the early phase of infection: an in vitro study in H9c2 cells. unassigned - 3.4.22.B28 Myocarditis https://pubmed.ncbi.nlm.nih.gov/27730362/ Dantrolene improves in vitro structural changes induced by serum from Trypanosoma cruzi-infected mice. unassigned - 3.4.22.B28 Myositis https://pubmed.ncbi.nlm.nih.gov/9137928/ Calpain and cathepsins in the skeletal muscle of inflammatory myopathies. causal interaction 4 3.4.22.B28 Myositis https://pubmed.ncbi.nlm.nih.gov/28602176/ Calpainopathy with macrophage-rich, regional inflammatory infiltrates. causal interaction 4 3.4.22.B28 Myositis https://pubmed.ncbi.nlm.nih.gov/9137928/ Calpain and cathepsins in the skeletal muscle of inflammatory myopathies. therapeutic application 2 3.4.22.B28 Myositis https://pubmed.ncbi.nlm.nih.gov/9137928/ Calpain and cathepsins in the skeletal muscle of inflammatory myopathies. ongoing research 2 3.4.22.B28 Myositis https://pubmed.ncbi.nlm.nih.gov/9137928/ Calpain and cathepsins in the skeletal muscle of inflammatory myopathies. unassigned - 3.4.22.B28 Myositis https://pubmed.ncbi.nlm.nih.gov/28602176/ Calpainopathy with macrophage-rich, regional inflammatory infiltrates. unassigned - 3.4.22.B28 Myotonic Dystrophy https://pubmed.ncbi.nlm.nih.gov/15634230/ Expression of late myogenic differentiation markers in sarcoplasmic masses of patients with myotonic dystrophy. diagnostic usage 3 3.4.22.B28 Myotonic Dystrophy https://pubmed.ncbi.nlm.nih.gov/15634230/ Expression of late myogenic differentiation markers in sarcoplasmic masses of patients with myotonic dystrophy. ongoing research 4 3.4.22.B28 Myotonic Dystrophy https://pubmed.ncbi.nlm.nih.gov/15634230/ Expression of late myogenic differentiation markers in sarcoplasmic masses of patients with myotonic dystrophy. unassigned - 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/30695567/ [Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis]. causal interaction 1 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. causal interaction 2 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/21244345/ Calpains as potential anti-cancer targets. causal interaction 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/22580607/ The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin. causal interaction 1 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. causal interaction 1 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/26757261/ E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. causal interaction 3 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. causal interaction 2 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/28521486/ Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. causal interaction 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/31938163/ High expression of Capn4 is associated with metastasis and poor prognosis in esophageal squamous cell carcinoma. causal interaction 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/33470511/ Calpain-calpastatin system and cancer progression. causal interaction 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/30695567/ [Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis]. diagnostic usage 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/25342484/ Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. diagnostic usage 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. diagnostic usage 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/26757261/ E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. diagnostic usage 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/31938163/ High expression of Capn4 is associated with metastasis and poor prognosis in esophageal squamous cell carcinoma. diagnostic usage 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. therapeutic application 1 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/21244345/ Calpains as potential anti-cancer targets. therapeutic application 2 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/26514342/ Melatonin set out to ER stress signaling thwarts epithelial mesenchymal transition and peritoneal dissemination via calpain-mediated C/EBP? and NF?B cleavage. therapeutic application 1 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/26757261/ E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. therapeutic application 1 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. therapeutic application 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/28521486/ Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. therapeutic application 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/31938163/ High expression of Capn4 is associated with metastasis and poor prognosis in esophageal squamous cell carcinoma. therapeutic application 1 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/33470511/ Calpain-calpastatin system and cancer progression. therapeutic application 2 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. ongoing research 2 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/25342484/ Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. ongoing research 3 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. ongoing research 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/26757261/ E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. ongoing research 3 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. ongoing research 3 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/28521486/ Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. ongoing research 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/31938163/ High expression of Capn4 is associated with metastasis and poor prognosis in esophageal squamous cell carcinoma. ongoing research 4 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/34426913/ Relationship Estimation of Cell Mobility Proteins Level with Processes of Proteolysis and Lymphogenic Metastasis in Breast Cancer. ongoing research 1 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/25342484/ Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. unassigned - 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/26514342/ Melatonin set out to ER stress signaling thwarts epithelial mesenchymal transition and peritoneal dissemination via calpain-mediated C/EBP? and NF?B cleavage. unassigned - 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/34426913/ Relationship Estimation of Cell Mobility Proteins Level with Processes of Proteolysis and Lymphogenic Metastasis in Breast Cancer. unassigned - 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. unassigned - 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/21244345/ Calpains as potential anti-cancer targets. unassigned - 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/22580607/ The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin. unassigned - 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. unassigned - 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/28521486/ Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. unassigned - 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/33470511/ Calpain-calpastatin system and cancer progression. unassigned - 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/30695567/ [Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis]. unassigned - 3.4.22.B28 Neoplasm Metastasis https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10845425/ Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15363254/ [The effect of pre-operative chemotherapy on calpain in cells of gastrointestinal malignant tumors] causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946123/ ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21177867/ Calpain activation by Wingless-type murine mammary tumor virus integration site family, member 5A (Wnt5a) promotes axonal growth. causal interaction 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21508973/ The calpain system and cancer. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27323818/ The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29388704/ A novel anti-cancer agent, FPDHP, induces anoikis in various human cancer cells through activation of calpain, and downregulation of anoikis-related molecules. causal interaction 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. causal interaction 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31440276/ Precise Prediction of Calpain Cleavage Sites and Their Aberrance Caused by Mutations in Cancer. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/34238324/ MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer. causal interaction 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9109377/ On the involvement of calpains in the degradation of the tumor suppressor protein p53. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9701243/ The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. causal interaction 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9988224/ Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10640428/ Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10914553/ Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11091548/ Ca²+;-Dependent Neutral Protease (Calpain) Activity in Breast Cancer Tissue and Estrogen Receptor Status. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. causal interaction 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11195789/ Calpain-mediated proteolytic cleavage of troponin I induced by hypoxia or metabolic inhibition in cultured neonatal cardiomyocytes. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11313873/ Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12111801/ Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12121983/ Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12379276/ Calpain: a role in cell transformation and migration. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15068671/ Calpain activity is generally elevated during transformation but has oncogene-specific biological functions. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15375607/ Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16574073/ mu-Calpain is involved in the regulation of TNF-alpha-induced matrix metalloproteinase-3 release in a rheumatoid synovial cell line. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16632474/ Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16809781/ Spatial localization of m-calpain to the plasma membrane by phosphoinositide biphosphate binding during epidermal growth factor receptor-mediated activation. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16913717/ Synthesis, calpain inhibitory activity, and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl alpha-ketoamides. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. causal interaction 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17264674/ The calpain system as a modulator of stress/damage response. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17909000/ Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19266085/ Aspirin Has Antitumor Effects via Expression of Calpain Gene in Cervical Cancer Cells. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19540315/ Combination of N-(4-hydroxyphenyl) retinamide and genistein increased apoptosis in neuroblastoma SK-N-BE2 and SH-SY5Y xenografts. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19798049/ The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946330/ Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/20193680/ Calpains: Markers of tumor aggressiveness? causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21140455/ Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21244345/ Calpains as potential anti-cancer targets. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21290412/ Calpeptin attenuated apoptosis and intracellular inflammatory changes in muscle cells. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21305563/ CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/22335024/ Immunhistochemical analysis for expression of calpain 1, calpain 2 and calpastatin in ovarian cancer. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/22580607/ The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23329366/ Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23379852/ Targeting calpain in synaptic plasticity. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23389291/ Regulation of proteolytic cleavage of retinoid X receptor-? by GSK-3? causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25399719/ An updated patent review of calpain inhibitors (2012 - 2014). causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25629974/ Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25714701/ Targeting Microparticle Biogenesis: A Novel Approach to the Circumvention of Cancer Multidrug Resistance. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25720282/ [Expression and activity of proteases in metastasis of ovarian cancer]. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26138287/ The flavonoid beverage Haelan 951 induces growth arrest and apoptosis in pancreatic carcinoma cell lines in vitro. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26229452/ Oral treatment with herbal formula B307 alleviates cardiac failure in aging R6/2 mice with Huntington's disease via suppressing oxidative stress, inflammation, and apoptosis. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26496999/ Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26506473/ Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1? in an AIM2 inflammasome-dependent manner. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26548718/ The hyaluronic acid inhibitor 4-methylumbelliferone is an NSMase2 activator-role of Ceramide in MU anti-tumor activity. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26757261/ E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26771715/ Calpain restrains the stem cells compartment in breast cancer. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27165064/ Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. causal interaction 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27878263/ Capn4 promotes epithelial-mesenchymal transition in human melanoma cells through activation of the Wnt/?-catenin pathway. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28112357/ Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28285348/ N-Adamantyl-4-Methylthiazol-2-Amine Attenuates Glutamate-Induced Oxidative Stress and Inflammation in the Brain. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28366876/ Endothelial cell calpain as a critical modulator of angiogenesis. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28588694/ High level of calpain1 promotes cancer cell invasion and migration in oral squamous cell carcinoma. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29507677/ New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29518545/ The study of the calpain and caspase-1 expression in ultrastructural dynamics of Ehrlich ascites carcinoma necrosis. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29581866/ Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/30683309/ Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/30695567/ [Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis]. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31938163/ High expression of Capn4 is associated with metastasis and poor prognosis in esophageal squamous cell carcinoma. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32668972/ Cryptotanshinone-Induced p53-Dependent Sensitization of Colon Cancer Cells to Apoptotic Drive by Regulation of Calpain and Calcium Homeostasis. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32777225/ Capn4 contributes to tumor invasion and metastasis in gastric cancer via activation of the Wnt/?-catenin/MMP9 signalling pathways. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/33109785/ Acylated and unacylated ghrelin relieve cancer cachexia in mice through multiple mechanisms. causal interaction 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/33470511/ Calpain-calpastatin system and cancer progression. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/33719969/ Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer. causal interaction 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/34282564/ Neuroinflammation and Tinnitus. causal interaction 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10845425/ Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. diagnostic usage 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15363254/ [The effect of pre-operative chemotherapy on calpain in cells of gastrointestinal malignant tumors] diagnostic usage 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. diagnostic usage 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21508973/ The calpain system and cancer. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27323818/ The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. diagnostic usage 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31440276/ Precise Prediction of Calpain Cleavage Sites and Their Aberrance Caused by Mutations in Cancer. diagnostic usage 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/34238324/ MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer. diagnostic usage 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9988224/ Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10914553/ Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11091548/ Ca²+;-Dependent Neutral Protease (Calpain) Activity in Breast Cancer Tissue and Estrogen Receptor Status. diagnostic usage 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11288141/ TNF-alpha stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures. diagnostic usage 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11313873/ Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. diagnostic usage 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12569370/ Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. diagnostic usage 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15068671/ Calpain activity is generally elevated during transformation but has oncogene-specific biological functions. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. diagnostic usage 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16632474/ Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli. diagnostic usage 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19540315/ Combination of N-(4-hydroxyphenyl) retinamide and genistein increased apoptosis in neuroblastoma SK-N-BE2 and SH-SY5Y xenografts. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946330/ Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. diagnostic usage 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/20193680/ Calpains: Markers of tumor aggressiveness? diagnostic usage 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21140455/ Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21305563/ CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/22335024/ Immunhistochemical analysis for expression of calpain 1, calpain 2 and calpastatin in ovarian cancer. diagnostic usage 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23329366/ Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25629974/ Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain. diagnostic usage 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25720282/ [Expression and activity of proteases in metastasis of ovarian cancer]. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. diagnostic usage 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26138287/ The flavonoid beverage Haelan 951 induces growth arrest and apoptosis in pancreatic carcinoma cell lines in vitro. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26496999/ Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26506473/ Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1? in an AIM2 inflammasome-dependent manner. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26757261/ E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. diagnostic usage 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27165064/ Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. diagnostic usage 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27878263/ Capn4 promotes epithelial-mesenchymal transition in human melanoma cells through activation of the Wnt/?-catenin pathway. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28112357/ Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28479722/ Influence of Capsaicin on Inflammatory Cytokines Induced by Lipopolysaccharide in Myoblast Cells Under In vitro Environment. diagnostic usage 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28512118/ Epstein-Barr virus-encoded LMP2A stimulates migration of nasopharyngeal carcinoma cells via the EGFR/Ca(2+)/calpain/ITG?4 axis. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28588694/ High level of calpain1 promotes cancer cell invasion and migration in oral squamous cell carcinoma. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. diagnostic usage 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29507677/ New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29518545/ The study of the calpain and caspase-1 expression in ultrastructural dynamics of Ehrlich ascites carcinoma necrosis. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29581866/ Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/30683309/ Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/30695567/ [Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis]. diagnostic usage 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31938163/ High expression of Capn4 is associated with metastasis and poor prognosis in esophageal squamous cell carcinoma. diagnostic usage 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. diagnostic usage 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32627970/ Calpain-2 plays a pivotal role in the inhibitory effects of propofol against TNF-?-induced autophagy in mouse hippocampal neurons. diagnostic usage 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32668972/ Cryptotanshinone-Induced p53-Dependent Sensitization of Colon Cancer Cells to Apoptotic Drive by Regulation of Calpain and Calcium Homeostasis. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32777225/ Capn4 contributes to tumor invasion and metastasis in gastric cancer via activation of the Wnt/?-catenin/MMP9 signalling pathways. diagnostic usage 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10845425/ Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15363254/ [The effect of pre-operative chemotherapy on calpain in cells of gastrointestinal malignant tumors] therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946123/ ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21508973/ The calpain system and cancer. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/22753709/ Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27323818/ The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29388704/ A novel anti-cancer agent, FPDHP, induces anoikis in various human cancer cells through activation of calpain, and downregulation of anoikis-related molecules. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31440276/ Precise Prediction of Calpain Cleavage Sites and Their Aberrance Caused by Mutations in Cancer. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9109377/ On the involvement of calpains in the degradation of the tumor suppressor protein p53. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9988224/ Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10403824/ CAPN 8: isolation of a new mouse calpain-isoenzyme. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10914553/ Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11091548/ Ca²+;-Dependent Neutral Protease (Calpain) Activity in Breast Cancer Tissue and Estrogen Receptor Status. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12121983/ Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12569370/ Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. therapeutic application 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/14607845/ Requirement of protein kinase C micro activation and calpain-mediated proteolysis for arachidonic acid-stimulated adhesion of MDA-MB-435 human mammary carcinoma cells to collagen type IV. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15068671/ Calpain activity is generally elevated during transformation but has oncogene-specific biological functions. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16632474/ Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16913717/ Synthesis, calpain inhibitory activity, and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl alpha-ketoamides. therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17180042/ Activation and possible involvement of calpain, a calcium-activated cysteine protease, in down-regulation of apoptosis of human monoblast U937 cells. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17264674/ The calpain system as a modulator of stress/damage response. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17909000/ Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/18498295/ Complex effects of IL1A polymorphism and calpain inhibitors on interleukin 1 alpha (IL-1 alpha) mRNA levels and secretion of IL-1 alpha protein. therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19266085/ Aspirin Has Antitumor Effects via Expression of Calpain Gene in Cervical Cancer Cells. therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19540315/ Combination of N-(4-hydroxyphenyl) retinamide and genistein increased apoptosis in neuroblastoma SK-N-BE2 and SH-SY5Y xenografts. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946330/ Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/20193680/ Calpains: Markers of tumor aggressiveness? therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21140455/ Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21244345/ Calpains as potential anti-cancer targets. therapeutic application 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21290412/ Calpeptin attenuated apoptosis and intracellular inflammatory changes in muscle cells. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21666767/ Activation of Multiple Molecular Mechanisms for Increasing Apoptosis in Human Glioblastoma T98G Xenograft. therapeutic application 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/22335024/ Immunhistochemical analysis for expression of calpain 1, calpain 2 and calpastatin in ovarian cancer. therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/22673732/ Regulation of IL-33 Expression by IFN-? and Tumor Necrosis Factor-? in Normal Human Epidermal Keratinocytes. therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23027830/ Fermentation Product of Soybean, Black Bean, and Green Bean Mixture Induces Apoptosis in a Wide Variety of Cancer Cells. therapeutic application 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23329366/ Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23379852/ Targeting calpain in synaptic plasticity. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23389291/ Regulation of proteolytic cleavage of retinoid X receptor-? by GSK-3? therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/24198074/ Autophagy Induced by Tumor Necrosis Factor ? Mediates Intrinsic Apoptosis in Trophoblastic Cells. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25399719/ An updated patent review of calpain inhibitors (2012 - 2014). therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25629974/ Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25714701/ Targeting Microparticle Biogenesis: A Novel Approach to the Circumvention of Cancer Multidrug Resistance. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25720282/ [Expression and activity of proteases in metastasis of ovarian cancer]. therapeutic application 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26060405/ Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis. therapeutic application 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26138287/ The flavonoid beverage Haelan 951 induces growth arrest and apoptosis in pancreatic carcinoma cell lines in vitro. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26229452/ Oral treatment with herbal formula B307 alleviates cardiac failure in aging R6/2 mice with Huntington's disease via suppressing oxidative stress, inflammation, and apoptosis. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26496999/ Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study. therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26548718/ The hyaluronic acid inhibitor 4-methylumbelliferone is an NSMase2 activator-role of Ceramide in MU anti-tumor activity. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26757261/ E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26771715/ Calpain restrains the stem cells compartment in breast cancer. therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27878263/ Capn4 promotes epithelial-mesenchymal transition in human melanoma cells through activation of the Wnt/?-catenin pathway. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27894956/ Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28112357/ Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28285348/ N-Adamantyl-4-Methylthiazol-2-Amine Attenuates Glutamate-Induced Oxidative Stress and Inflammation in the Brain. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28366876/ Endothelial cell calpain as a critical modulator of angiogenesis. therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28588694/ High level of calpain1 promotes cancer cell invasion and migration in oral squamous cell carcinoma. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. therapeutic application 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29581866/ Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29997872/ Oncosis-inducing cyclometalated iridium(iii) complexes. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/30683309/ Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31425704/ Preventing Calpain Externalization by Reducing ABCA1 Activity with Probenecid Limits Melanoma Angiogenesis and Development. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31938163/ High expression of Capn4 is associated with metastasis and poor prognosis in esophageal squamous cell carcinoma. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32627970/ Calpain-2 plays a pivotal role in the inhibitory effects of propofol against TNF-?-induced autophagy in mouse hippocampal neurons. therapeutic application 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32668972/ Cryptotanshinone-Induced p53-Dependent Sensitization of Colon Cancer Cells to Apoptotic Drive by Regulation of Calpain and Calcium Homeostasis. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32777225/ Capn4 contributes to tumor invasion and metastasis in gastric cancer via activation of the Wnt/?-catenin/MMP9 signalling pathways. therapeutic application 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/33109785/ Acylated and unacylated ghrelin relieve cancer cachexia in mice through multiple mechanisms. therapeutic application 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/33470511/ Calpain-calpastatin system and cancer progression. therapeutic application 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/34282564/ Neuroinflammation and Tinnitus. therapeutic application 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10845425/ Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15363254/ [The effect of pre-operative chemotherapy on calpain in cells of gastrointestinal malignant tumors] ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16397758/ Tumor necrosis factor- [Formula: see text] induces caspase-independent cell death in human neutrophils via reactive oxidants and associated with calpain activity. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/18632617/ SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946123/ ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/20484155/ Calpain and caspase orchestrated death signal to accomplish apoptosis induced by resveratrol and its novel analog hydroxystilbene-1 [correction of hydroxstilbene-1] in cancer cells. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21508973/ The calpain system and cancer. ongoing research 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/22753709/ Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27323818/ The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29388704/ A novel anti-cancer agent, FPDHP, induces anoikis in various human cancer cells through activation of calpain, and downregulation of anoikis-related molecules. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/1420319/ Secretagogue-induced proteolysis of lung spectrin in alveolar epithelial type II cells. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. ongoing research 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9988224/ Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10914553/ Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11091548/ Ca²+;-Dependent Neutral Protease (Calpain) Activity in Breast Cancer Tissue and Estrogen Receptor Status. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11288141/ TNF-alpha stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12111801/ Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12379276/ Calpain: a role in cell transformation and migration. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. ongoing research 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/14607845/ Requirement of protein kinase C micro activation and calpain-mediated proteolysis for arachidonic acid-stimulated adhesion of MDA-MB-435 human mammary carcinoma cells to collagen type IV. ongoing research 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15466976/ Overexpression of m-calpain in human colorectal adenocarcinomas. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17180042/ Activation and possible involvement of calpain, a calcium-activated cysteine protease, in down-regulation of apoptosis of human monoblast U937 cells. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17630920/ Nicotine, lung and cancer. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/18408750/ Mechanistic insight into taxol-induced cell death. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19266085/ Aspirin Has Antitumor Effects via Expression of Calpain Gene in Cervical Cancer Cells. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19798049/ The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946330/ Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21140455/ Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21305563/ CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/22335024/ Immunhistochemical analysis for expression of calpain 1, calpain 2 and calpastatin in ovarian cancer. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23329366/ Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/24198074/ Autophagy Induced by Tumor Necrosis Factor ? Mediates Intrinsic Apoptosis in Trophoblastic Cells. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25629974/ Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain. ongoing research 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25720282/ [Expression and activity of proteases in metastasis of ovarian cancer]. ongoing research 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26138287/ The flavonoid beverage Haelan 951 induces growth arrest and apoptosis in pancreatic carcinoma cell lines in vitro. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26757261/ E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. ongoing research 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26771715/ Calpain restrains the stem cells compartment in breast cancer. ongoing research 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27165064/ Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. ongoing research 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27878263/ Capn4 promotes epithelial-mesenchymal transition in human melanoma cells through activation of the Wnt/?-catenin pathway. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27894956/ Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28512118/ Epstein-Barr virus-encoded LMP2A stimulates migration of nasopharyngeal carcinoma cells via the EGFR/Ca(2+)/calpain/ITG?4 axis. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28588694/ High level of calpain1 promotes cancer cell invasion and migration in oral squamous cell carcinoma. ongoing research 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. ongoing research 3 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29507677/ New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29518545/ The study of the calpain and caspase-1 expression in ultrastructural dynamics of Ehrlich ascites carcinoma necrosis. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29997872/ Oncosis-inducing cyclometalated iridium(iii) complexes. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/30683309/ Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31938163/ High expression of Capn4 is associated with metastasis and poor prognosis in esophageal squamous cell carcinoma. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32627970/ Calpain-2 plays a pivotal role in the inhibitory effects of propofol against TNF-?-induced autophagy in mouse hippocampal neurons. ongoing research 4 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32668972/ Cryptotanshinone-Induced p53-Dependent Sensitization of Colon Cancer Cells to Apoptotic Drive by Regulation of Calpain and Calcium Homeostasis. ongoing research 2 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/33109785/ Acylated and unacylated ghrelin relieve cancer cachexia in mice through multiple mechanisms. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/34426913/ Relationship Estimation of Cell Mobility Proteins Level with Processes of Proteolysis and Lymphogenic Metastasis in Breast Cancer. ongoing research 1 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16397758/ Tumor necrosis factor- [Formula: see text] induces caspase-independent cell death in human neutrophils via reactive oxidants and associated with calpain activity. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/18632617/ SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19107625/ Chlorella powder inhibits the activities of peptidase cathepsin S, PLA2, cyclooxygenase-2, thromboxane synthase, tyrosine phosphatases, tumor necrosis factor-alpha converting enzyme, calpain and kinases. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/20484155/ Calpain and caspase orchestrated death signal to accomplish apoptosis induced by resveratrol and its novel analog hydroxystilbene-1 [correction of hydroxstilbene-1] in cancer cells. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/22753709/ Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/1420319/ Secretagogue-induced proteolysis of lung spectrin in alveolar epithelial type II cells. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10403824/ CAPN 8: isolation of a new mouse calpain-isoenzyme. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11286475/ Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11288141/ TNF-alpha stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12569370/ Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/14607845/ Requirement of protein kinase C micro activation and calpain-mediated proteolysis for arachidonic acid-stimulated adhesion of MDA-MB-435 human mammary carcinoma cells to collagen type IV. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17180042/ Activation and possible involvement of calpain, a calcium-activated cysteine protease, in down-regulation of apoptosis of human monoblast U937 cells. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17630920/ Nicotine, lung and cancer. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17646163/ Stomach-specific calpain, nCL-2/calpain 8, is active without calpain regulatory subunit and oligomerizes through C2-like domains. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/18211896/ Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/18408750/ Mechanistic insight into taxol-induced cell death. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/18498295/ Complex effects of IL1A polymorphism and calpain inhibitors on interleukin 1 alpha (IL-1 alpha) mRNA levels and secretion of IL-1 alpha protein. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/20610477/ Expression of the interleukin-4 receptor alpha in human conjunctival epithelial cells. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21434837/ Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21666767/ Activation of Multiple Molecular Mechanisms for Increasing Apoptosis in Human Glioblastoma T98G Xenograft. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21704983/ Potential contribution of oxidative stress and inflammation to anxiety and hypertension. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/22673732/ Regulation of IL-33 Expression by IFN-? and Tumor Necrosis Factor-? in Normal Human Epidermal Keratinocytes. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23027830/ Fermentation Product of Soybean, Black Bean, and Green Bean Mixture Induces Apoptosis in a Wide Variety of Cancer Cells. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/24198074/ Autophagy Induced by Tumor Necrosis Factor ? Mediates Intrinsic Apoptosis in Trophoblastic Cells. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26060405/ Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26821268/ Effect of glutamate on lysosomal membrane permeabilization in primary cultured cortical neurons. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27894956/ Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28479722/ Influence of Capsaicin on Inflammatory Cytokines Induced by Lipopolysaccharide in Myoblast Cells Under In vitro Environment. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28512118/ Epstein-Barr virus-encoded LMP2A stimulates migration of nasopharyngeal carcinoma cells via the EGFR/Ca(2+)/calpain/ITG?4 axis. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29997872/ Oncosis-inducing cyclometalated iridium(iii) complexes. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31425704/ Preventing Calpain Externalization by Reducing ABCA1 Activity with Probenecid Limits Melanoma Angiogenesis and Development. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32627970/ Calpain-2 plays a pivotal role in the inhibitory effects of propofol against TNF-?-induced autophagy in mouse hippocampal neurons. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/34426913/ Relationship Estimation of Cell Mobility Proteins Level with Processes of Proteolysis and Lymphogenic Metastasis in Breast Cancer. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19946123/ ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21177867/ Calpain activation by Wingless-type murine mammary tumor virus integration site family, member 5A (Wnt5a) promotes axonal growth. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29388704/ A novel anti-cancer agent, FPDHP, induces anoikis in various human cancer cells through activation of calpain, and downregulation of anoikis-related molecules. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9109377/ On the involvement of calpains in the degradation of the tumor suppressor protein p53. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9701243/ The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/9735389/ Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/10640428/ Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11195789/ Calpain-mediated proteolytic cleavage of troponin I induced by hypoxia or metabolic inhibition in cultured neonatal cardiomyocytes. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12111801/ Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12121983/ Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12379276/ Calpain: a role in cell transformation and migration. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15375607/ Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16574073/ mu-Calpain is involved in the regulation of TNF-alpha-induced matrix metalloproteinase-3 release in a rheumatoid synovial cell line. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16809781/ Spatial localization of m-calpain to the plasma membrane by phosphoinositide biphosphate binding during epidermal growth factor receptor-mediated activation. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16913717/ Synthesis, calpain inhibitory activity, and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl alpha-ketoamides. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16982626/ Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17264674/ The calpain system as a modulator of stress/damage response. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/17909000/ Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19029949/ Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19266085/ Aspirin Has Antitumor Effects via Expression of Calpain Gene in Cervical Cancer Cells. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19798049/ The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21244345/ Calpains as potential anti-cancer targets. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21290412/ Calpeptin attenuated apoptosis and intracellular inflammatory changes in muscle cells. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/22580607/ The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23379852/ Targeting calpain in synaptic plasticity. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23389291/ Regulation of proteolytic cleavage of retinoid X receptor-? by GSK-3? unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/23565252/ The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25399719/ An updated patent review of calpain inhibitors (2012 - 2014). unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25714701/ Targeting Microparticle Biogenesis: A Novel Approach to the Circumvention of Cancer Multidrug Resistance. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26229452/ Oral treatment with herbal formula B307 alleviates cardiac failure in aging R6/2 mice with Huntington's disease via suppressing oxidative stress, inflammation, and apoptosis. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26548718/ The hyaluronic acid inhibitor 4-methylumbelliferone is an NSMase2 activator-role of Ceramide in MU anti-tumor activity. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26771715/ Calpain restrains the stem cells compartment in breast cancer. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27215381/ Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28024857/ Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28285348/ N-Adamantyl-4-Methylthiazol-2-Amine Attenuates Glutamate-Induced Oxidative Stress and Inflammation in the Brain. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28366876/ Endothelial cell calpain as a critical modulator of angiogenesis. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/33109785/ Acylated and unacylated ghrelin relieve cancer cachexia in mice through multiple mechanisms. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/33470511/ Calpain-calpastatin system and cancer progression. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/33719969/ Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/34282564/ Neuroinflammation and Tinnitus. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/34238324/ MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/11313873/ Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/12635142/ Different expression patterns of calpain isozymes 1 and 2 (CAPN1 and 2) in squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) of human skin. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/21305563/ CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26506473/ Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1? in an AIM2 inflammasome-dependent manner. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/27165064/ Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29507677/ New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29518545/ The study of the calpain and caspase-1 expression in ultrastructural dynamics of Ehrlich ascites carcinoma necrosis. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/30695567/ [Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis]. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/31440276/ Precise Prediction of Calpain Cleavage Sites and Their Aberrance Caused by Mutations in Cancer. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/15068671/ Calpain activity is generally elevated during transformation but has oncogene-specific biological functions. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/16632474/ Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/19540315/ Combination of N-(4-hydroxyphenyl) retinamide and genistein increased apoptosis in neuroblastoma SK-N-BE2 and SH-SY5Y xenografts. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/20193680/ Calpains: Markers of tumor aggressiveness? unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/26496999/ Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/28112357/ Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/29581866/ Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. unassigned - 3.4.22.B28 Neoplasms https://pubmed.ncbi.nlm.nih.gov/32777225/ Capn4 contributes to tumor invasion and metastasis in gastric cancer via activation of the Wnt/?-catenin/MMP9 signalling pathways. unassigned - 3.4.22.B28 Nephritis https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. causal interaction 1 3.4.22.B28 Nephritis https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. diagnostic usage 2 3.4.22.B28 Nephritis https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. ongoing research 3 3.4.22.B28 Nephritis https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. unassigned - 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/17160145/ The role of CDK5/P25 formation/inhibition in neurodegeneration. causal interaction 3 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/18396356/ Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. causal interaction 2 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/19041242/ Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. causal interaction 2 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/20595388/ Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. causal interaction 3 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/21504847/ Synthesis of cinnamoyl ketoamides as hybrid structures of antioxidants and calpain inhibitors. causal interaction 4 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/29623944/ Regulatory role of calpain in neuronal death. causal interaction 3 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/17160145/ The role of CDK5/P25 formation/inhibition in neurodegeneration. diagnostic usage 2 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/17160145/ The role of CDK5/P25 formation/inhibition in neurodegeneration. therapeutic application 4 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/18396356/ Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. therapeutic application 4 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/19041242/ Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. therapeutic application 4 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/21504847/ Synthesis of cinnamoyl ketoamides as hybrid structures of antioxidants and calpain inhibitors. therapeutic application 1 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/29623944/ Regulatory role of calpain in neuronal death. therapeutic application 2 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/20595388/ Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. ongoing research 1 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/21434837/ Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. unassigned - 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/18396356/ Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. unassigned - 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/19041242/ Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. unassigned - 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/20595388/ Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. unassigned - 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/21504847/ Synthesis of cinnamoyl ketoamides as hybrid structures of antioxidants and calpain inhibitors. unassigned - 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/29623944/ Regulatory role of calpain in neuronal death. unassigned - 3.4.22.B28 Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/17160145/ The role of CDK5/P25 formation/inhibition in neurodegeneration. unassigned - 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/22854961/ NMDA Receptor- and Calpain-mediated Proteolytic Cleavage of K+-Cl- Cotransporter-2 Disrupts Spinal Chloride Homeostasis in Neuropathic Pain. causal interaction 3 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/29477696/ Calpain-2 Regulates TNF-? Expression Associated with Neuropathic Pain Following Motor Nerve Injury. causal interaction 4 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/30145792/ Melatonin, a calpain inhibitor in the central nervous system: Current status and future perspectives. causal interaction 3 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/20236225/ Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain. therapeutic application 4 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/20420580/ Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain. therapeutic application 4 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/22854961/ NMDA Receptor- and Calpain-mediated Proteolytic Cleavage of K+-Cl- Cotransporter-2 Disrupts Spinal Chloride Homeostasis in Neuropathic Pain. therapeutic application 4 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/29477696/ Calpain-2 Regulates TNF-? Expression Associated with Neuropathic Pain Following Motor Nerve Injury. therapeutic application 4 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/20236225/ Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain. unassigned - 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/20420580/ Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain. unassigned - 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/24030012/ Nerve Injury Increases GluA2-lacking AMPA Receptor Prevalence in Spinal Cords: Functional Significance and Signaling Mechanisms. unassigned - 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/22854961/ NMDA Receptor- and Calpain-mediated Proteolytic Cleavage of K+-Cl- Cotransporter-2 Disrupts Spinal Chloride Homeostasis in Neuropathic Pain. unassigned - 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/29477696/ Calpain-2 Regulates TNF-? Expression Associated with Neuropathic Pain Following Motor Nerve Injury. unassigned - 3.4.22.B28 Neuralgia https://pubmed.ncbi.nlm.nih.gov/30145792/ Melatonin, a calpain inhibitor in the central nervous system: Current status and future perspectives. unassigned - 3.4.22.B28 Neuralgia, Postherpetic https://pubmed.ncbi.nlm.nih.gov/28714350/ Activation and expression of ?-calpain in dorsal root contributes to RTX-induced mechanical allodynia. therapeutic application 2 3.4.22.B28 Neuralgia, Postherpetic https://pubmed.ncbi.nlm.nih.gov/28714350/ Activation and expression of ?-calpain in dorsal root contributes to RTX-induced mechanical allodynia. ongoing research 4 3.4.22.B28 Neuralgia, Postherpetic https://pubmed.ncbi.nlm.nih.gov/28714350/ Activation and expression of ?-calpain in dorsal root contributes to RTX-induced mechanical allodynia. unassigned - 3.4.22.B28 Neurilemmoma https://pubmed.ncbi.nlm.nih.gov/9701243/ The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. causal interaction 2 3.4.22.B28 Neurilemmoma https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. causal interaction 2 3.4.22.B28 Neurilemmoma https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. therapeutic application 1 3.4.22.B28 Neurilemmoma https://pubmed.ncbi.nlm.nih.gov/9701243/ The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. unassigned - 3.4.22.B28 Neurilemmoma https://pubmed.ncbi.nlm.nih.gov/11132929/ Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/8954122/ NMDA and HIV-1 coat protein, GP120, produce necrotic but not apoptotic cell death in human CHP100 neuroblastoma cultures via a mechanism involving calpain. causal interaction 2 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/23688838/ Melatonin attenuates dexamethasone toxicity-induced oxidative stress, calpain and caspase activation in human neuroblastoma SH-SY5Y cells. causal interaction 1 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/27453331/ Calpastatin overexpression reduces oxidative stress-induced mitochondrial impairment and cell death in human neuroblastoma SH-SY5Y cells by decreasing calpain and calcineurin activation, induction of mitochondrial fission and destruction of mitochondrial fusion. causal interaction 3 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/22988235/ Inhibition of Paclitaxel-Induced Decreases in Calcium Signaling. causal interaction 2 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/32172509/ Phosphorylation of Serine 157 Protects the Rat Glycine Transporter GlyT2 from Calpain Cleavage. causal interaction 3 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/32329786/ Novel synthetic lipopeptides derived from Mycoplasma hyorhinis upregulate calpastatin in SH-SY5Y neuroblastoma cells and induce a neuroprotective effect against amyloid-?-peptide toxicity. causal interaction 1 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/9160241/ Calpains and calpastatin in SH-SY5Y neuroblastoma cells during retinoic acid-induced differentiation and neurite outgrowth: comparison with the human brain calpain system. diagnostic usage 3 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/16988947/ Mechanism of apoptosis with the involvement of calpain and caspase cascades in human malignant neuroblastoma SH-SY5Y cells exposed to flavonoids. diagnostic usage 3 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/22198100/ Comparative in vitro study of the inhibition of human and hen esterases by methamidophos enantiomers. diagnostic usage 3 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/8954122/ NMDA and HIV-1 coat protein, GP120, produce necrotic but not apoptotic cell death in human CHP100 neuroblastoma cultures via a mechanism involving calpain. therapeutic application 1 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/17219050/ Garlic compounds induced calpain and intrinsic caspase cascade for apoptosis in human malignant neuroblastoma SH-SY5Y cells. therapeutic application 1 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/22897874/ Calpastatin reduces calpain and caspase activation in methamphetamine-induced toxicity in human neuroblastoma SH-SY5Y cultured cells. therapeutic application 1 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/2119652/ Possible involvement of calpain in down-regulation of protein kinase C. therapeutic application 3 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/17488727/ Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. therapeutic application 1 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/22988235/ Inhibition of Paclitaxel-Induced Decreases in Calcium Signaling. therapeutic application 2 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/8660700/ Maitotoxin induces calpain activation in SH-SY5Y neuroblastoma cells and cerebrocortical cultures. ongoing research 2 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/8954122/ NMDA and HIV-1 coat protein, GP120, produce necrotic but not apoptotic cell death in human CHP100 neuroblastoma cultures via a mechanism involving calpain. ongoing research 1 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/9160241/ Calpains and calpastatin in SH-SY5Y neuroblastoma cells during retinoic acid-induced differentiation and neurite outgrowth: comparison with the human brain calpain system. ongoing research 4 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/9210524/ Restriction of microM-calcium-requiring calpain activation to the plasma membrane in human neuroblastoma cells: evidence for regionalized influence of a calpain activator protein. ongoing research 4 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/9685336/ Calcium/calmodulin-dependent protein kinase IV is cleaved by caspase-3 and calpain in SH-SY5Y human neuroblastoma cells undergoing apoptosis. ongoing research 3 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/15750211/ Proteasome or calpain inhibition does not alter cellular tau levels in neuroblastoma cells or primary neurons. ongoing research 4 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/16988947/ Mechanism of apoptosis with the involvement of calpain and caspase cascades in human malignant neuroblastoma SH-SY5Y cells exposed to flavonoids. ongoing research 3 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/17219050/ Garlic compounds induced calpain and intrinsic caspase cascade for apoptosis in human malignant neuroblastoma SH-SY5Y cells. ongoing research 3 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/22897874/ Calpastatin reduces calpain and caspase activation in methamphetamine-induced toxicity in human neuroblastoma SH-SY5Y cultured cells. ongoing research 4 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/23688838/ Melatonin attenuates dexamethasone toxicity-induced oxidative stress, calpain and caspase activation in human neuroblastoma SH-SY5Y cells. ongoing research 2 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/27453331/ Calpastatin overexpression reduces oxidative stress-induced mitochondrial impairment and cell death in human neuroblastoma SH-SY5Y cells by decreasing calpain and calcineurin activation, induction of mitochondrial fission and destruction of mitochondrial fusion. ongoing research 3 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/2119652/ Possible involvement of calpain in down-regulation of protein kinase C. ongoing research 1 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/7616205/ Enhancement of neurite outgrowth following calpain inhibition is mediated by protein kinase C. ongoing research 4 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/9582380/ Oxidative stress inhibits calpain activity in situ. ongoing research 4 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/10854849/ Differential degradation of calpastatin by mu- and m-calpain in Ca(2+)-enriched human neuroblastoma LAN-5 cells. ongoing research 3 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/12576481/ Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. ongoing research 4 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/17488727/ Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. ongoing research 2 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/22198100/ Comparative in vitro study of the inhibition of human and hen esterases by methamidophos enantiomers. ongoing research 4 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/25910916/ In vitro study of the neuropathic potential of the organophosphorus compounds fenamiphos and profenofos: Comparison with mipafox and paraoxon. ongoing research 4 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/8660700/ Maitotoxin induces calpain activation in SH-SY5Y neuroblastoma cells and cerebrocortical cultures. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/9160241/ Calpains and calpastatin in SH-SY5Y neuroblastoma cells during retinoic acid-induced differentiation and neurite outgrowth: comparison with the human brain calpain system. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/9210524/ Restriction of microM-calcium-requiring calpain activation to the plasma membrane in human neuroblastoma cells: evidence for regionalized influence of a calpain activator protein. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/9685336/ Calcium/calmodulin-dependent protein kinase IV is cleaved by caspase-3 and calpain in SH-SY5Y human neuroblastoma cells undergoing apoptosis. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/15750211/ Proteasome or calpain inhibition does not alter cellular tau levels in neuroblastoma cells or primary neurons. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/16988947/ Mechanism of apoptosis with the involvement of calpain and caspase cascades in human malignant neuroblastoma SH-SY5Y cells exposed to flavonoids. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/17219050/ Garlic compounds induced calpain and intrinsic caspase cascade for apoptosis in human malignant neuroblastoma SH-SY5Y cells. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/22897874/ Calpastatin reduces calpain and caspase activation in methamphetamine-induced toxicity in human neuroblastoma SH-SY5Y cultured cells. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/2119652/ Possible involvement of calpain in down-regulation of protein kinase C. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/7616205/ Enhancement of neurite outgrowth following calpain inhibition is mediated by protein kinase C. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/9582380/ Oxidative stress inhibits calpain activity in situ. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/10854849/ Differential degradation of calpastatin by mu- and m-calpain in Ca(2+)-enriched human neuroblastoma LAN-5 cells. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/12576481/ Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/15020222/ Stimulation of beta-amyloid precursor protein alpha-processing by phorbol ester involves calcium and calpain activation. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/17488727/ Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/22198100/ Comparative in vitro study of the inhibition of human and hen esterases by methamidophos enantiomers. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/25910916/ In vitro study of the neuropathic potential of the organophosphorus compounds fenamiphos and profenofos: Comparison with mipafox and paraoxon. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/8954122/ NMDA and HIV-1 coat protein, GP120, produce necrotic but not apoptotic cell death in human CHP100 neuroblastoma cultures via a mechanism involving calpain. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/23688838/ Melatonin attenuates dexamethasone toxicity-induced oxidative stress, calpain and caspase activation in human neuroblastoma SH-SY5Y cells. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/27453331/ Calpastatin overexpression reduces oxidative stress-induced mitochondrial impairment and cell death in human neuroblastoma SH-SY5Y cells by decreasing calpain and calcineurin activation, induction of mitochondrial fission and destruction of mitochondrial fusion. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/22988235/ Inhibition of Paclitaxel-Induced Decreases in Calcium Signaling. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/32172509/ Phosphorylation of Serine 157 Protects the Rat Glycine Transporter GlyT2 from Calpain Cleavage. unassigned - 3.4.22.B28 Neuroblastoma https://pubmed.ncbi.nlm.nih.gov/32329786/ Novel synthetic lipopeptides derived from Mycoplasma hyorhinis upregulate calpastatin in SH-SY5Y neuroblastoma cells and induce a neuroprotective effect against amyloid-?-peptide toxicity. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/7477738/ Calpain as a novel target for treating acute neurodegenerative disorders. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/10753367/ Calpain Inhibitors as Neuroprotective Agents in Neurodegenerative Disorders. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/12070670/ Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/14673209/ The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/15051518/ Immunofluorescent labeling of increased calpain expression and neuronal death in the spinal cord of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16054018/ Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16192386/ Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16504408/ Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16895584/ Calpain inhibitors and antioxidants act synergistically to prevent cell necrosis: effects of the novel dual inhibitors (cysteine protease inhibitor and antioxidant) BN 82204 and its pro-drug BN 82270. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16958987/ Involvement of calpain activation in neurodegenerative processes. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/17121855/ Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by site-specific phosphorylation. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/17261846/ Axons break in animals lacking beta-spectrin. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/17506859/ p25/cyclin-dependent kinase 5 promotes the progression of cell death in nucleus of endoplasmic reticulum-stressed neurons. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/18701765/ Inhibition of Calpain Prevents N-Methyl-D-aspartate-Induced Degeneration of the Nucleus Basalis and Associated Behavioral Dysfunction. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/19594409/ Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium. causal interaction 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/19689241/ Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium. causal interaction 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/19857555/ Downregulation of Kv4.2 channels mediated by NR2B-containing NMDA receptors in cultured hippocampal neurons. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/19880516/ Adaptive modifications in the calpain/calpastatin system in brain cells after persistent alteration in Ca2+ homeostasis. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/20107181/ Calpain activation in experimental glaucoma. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/21219955/ Neuroprotective effects of Mycoplasma hyorhinis against amyloid-?-peptide toxicity in SH-SY5Y human neuroblastoma cells are mediated by calpastatin upregulation in the mycoplasma-infected cells. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/21683092/ Neuroprotective effects of MAPK/ERK1/2 and calpain inhibitors on lactacystin-induced cell damage in primary cortical neurons. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/22613839/ The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/23305291/ Brain injury-induced proteolysis is reduced in a novel calpastatin-overexpressing transgenic mouse. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/23507938/ Role of calpain in apoptosis. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/24128662/ Calpain-mediated degradation of MDMx/MDM4 contributes to HIV-induced neuronal damage. causal interaction 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/24755075/ Valproic acid downregulates Cdk5 activity via the transcription of the p35 mRNA. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/25245568/ ?1-antitrypsin modulates microglial-mediated neuroinflammation and protects microglial cells from amyloid-?-induced toxicity. causal interaction 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/25399719/ An updated patent review of calpain inhibitors (2012 - 2014). causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/25661999/ Calpain Inhibition Improves Erectile Function in a Rat Model of Cavernous Nerve Injury. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/27453331/ Calpastatin overexpression reduces oxidative stress-induced mitochondrial impairment and cell death in human neuroblastoma SH-SY5Y cells by decreasing calpain and calcineurin activation, induction of mitochondrial fission and destruction of mitochondrial fusion. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/27529445/ Neuron-Microglia Interaction Induced Bi-directional Cytotoxicity Associated with Calpain Activation. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/27812546/ ? Cell-specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/28759231/ Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/30145792/ Melatonin, a calpain inhibitor in the central nervous system: Current status and future perspectives. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/30177812/ Isoform-specific hyperactivation of calpain-2 occurs presymptomatically at the synapse in Alzheimer's disease mice and correlates with memory deficits in human subjects. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31133534/ Discovery of ABT-957: 1-Benzyl-5-oxopyrrolidine-2-carboxamides as selective calpain inhibitors with enhanced metabolic stability. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31156179/ Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31804596/ Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces A? and P25 accumulation in 5XFAD mice. causal interaction 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/32594381/ MicroRNA-137-3p Protects PC12 Cells Against Oxidative Stress by Downregulation of Calpain-2 and nNOS. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/32840034/ Synthesis of ?-Ketoamide-Based Stereoselective Calpain-1 Inhibitors as Neuroprotective Agents. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/33790315/ Age-dependent ataxia and neurodegeneration caused by an ?II spectrin mutation with impaired regulation of its calpain sensitivity. causal interaction 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/34417060/ The calcium-dependent protease calpain in neuronal remodeling and neurodegeneration. causal interaction 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/12070670/ Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. diagnostic usage 2 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16504408/ Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate. diagnostic usage 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. diagnostic usage 2 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/20107181/ Calpain activation in experimental glaucoma. diagnostic usage 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. diagnostic usage 2 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/7477738/ Calpain as a novel target for treating acute neurodegenerative disorders. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/10753367/ Calpain Inhibitors as Neuroprotective Agents in Neurodegenerative Disorders. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/12070670/ Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. therapeutic application 2 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. therapeutic application 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/15275793/ The calpain inhibitor MDL 28170 prevents inflammation-induced neurofilament light chain breakdown in the spinal cord and reduces thermal hyperalgesia. therapeutic application 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16054018/ Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16504408/ Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate. therapeutic application 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16776830/ Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16958987/ Involvement of calpain activation in neurodegenerative processes. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/17121855/ Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by site-specific phosphorylation. therapeutic application 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/18701765/ Inhibition of Calpain Prevents N-Methyl-D-aspartate-Induced Degeneration of the Nucleus Basalis and Associated Behavioral Dysfunction. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/19880516/ Adaptive modifications in the calpain/calpastatin system in brain cells after persistent alteration in Ca2+ homeostasis. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/20107181/ Calpain activation in experimental glaucoma. therapeutic application 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/21219955/ Neuroprotective effects of Mycoplasma hyorhinis against amyloid-?-peptide toxicity in SH-SY5Y human neuroblastoma cells are mediated by calpastatin upregulation in the mycoplasma-infected cells. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/21683092/ Neuroprotective effects of MAPK/ERK1/2 and calpain inhibitors on lactacystin-induced cell damage in primary cortical neurons. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/22613839/ The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. therapeutic application 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/23305291/ Brain injury-induced proteolysis is reduced in a novel calpastatin-overexpressing transgenic mouse. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/23507938/ Role of calpain in apoptosis. therapeutic application 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/25245568/ ?1-antitrypsin modulates microglial-mediated neuroinflammation and protects microglial cells from amyloid-?-induced toxicity. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/25399719/ An updated patent review of calpain inhibitors (2012 - 2014). therapeutic application 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/27529445/ Neuron-Microglia Interaction Induced Bi-directional Cytotoxicity Associated with Calpain Activation. therapeutic application 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/27812546/ ? Cell-specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity. therapeutic application 2 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/28759231/ Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/29875647/ Analyzing the Behavior of Neuronal Pathways in Alzheimer's Disease Using Petri Net Modeling Approach. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31133534/ Discovery of ABT-957: 1-Benzyl-5-oxopyrrolidine-2-carboxamides as selective calpain inhibitors with enhanced metabolic stability. therapeutic application 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31156179/ Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31804596/ Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces A? and P25 accumulation in 5XFAD mice. therapeutic application 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. therapeutic application 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/32840034/ Synthesis of ?-Ketoamide-Based Stereoselective Calpain-1 Inhibitors as Neuroprotective Agents. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/33790315/ Age-dependent ataxia and neurodegeneration caused by an ?II spectrin mutation with impaired regulation of its calpain sensitivity. therapeutic application 2 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/34417060/ The calcium-dependent protease calpain in neuronal remodeling and neurodegeneration. therapeutic application 4 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/12070670/ Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. ongoing research 2 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/19594409/ Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium. ongoing research 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/19689241/ Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium. ongoing research 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/20107181/ Calpain activation in experimental glaucoma. ongoing research 2 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/21219955/ Neuroprotective effects of Mycoplasma hyorhinis against amyloid-?-peptide toxicity in SH-SY5Y human neuroblastoma cells are mediated by calpastatin upregulation in the mycoplasma-infected cells. ongoing research 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/25245568/ ?1-antitrypsin modulates microglial-mediated neuroinflammation and protects microglial cells from amyloid-?-induced toxicity. ongoing research 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/27453331/ Calpastatin overexpression reduces oxidative stress-induced mitochondrial impairment and cell death in human neuroblastoma SH-SY5Y cells by decreasing calpain and calcineurin activation, induction of mitochondrial fission and destruction of mitochondrial fusion. ongoing research 3 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/27812546/ ? Cell-specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity. ongoing research 2 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/30177812/ Isoform-specific hyperactivation of calpain-2 occurs presymptomatically at the synapse in Alzheimer's disease mice and correlates with memory deficits in human subjects. ongoing research 2 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31156179/ Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice. ongoing research 2 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. ongoing research 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/34417060/ The calcium-dependent protease calpain in neuronal remodeling and neurodegeneration. ongoing research 1 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/15275793/ The calpain inhibitor MDL 28170 prevents inflammation-induced neurofilament light chain breakdown in the spinal cord and reduces thermal hyperalgesia. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16776830/ Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/26490331/ Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/29875647/ Analyzing the Behavior of Neuronal Pathways in Alzheimer's Disease Using Petri Net Modeling Approach. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/7477738/ Calpain as a novel target for treating acute neurodegenerative disorders. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/10753367/ Calpain Inhibitors as Neuroprotective Agents in Neurodegenerative Disorders. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/14522243/ The calpains in aging and aging-related diseases. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/14673209/ The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/15051518/ Immunofluorescent labeling of increased calpain expression and neuronal death in the spinal cord of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16054018/ Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16192386/ Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16895584/ Calpain inhibitors and antioxidants act synergistically to prevent cell necrosis: effects of the novel dual inhibitors (cysteine protease inhibitor and antioxidant) BN 82204 and its pro-drug BN 82270. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16958987/ Involvement of calpain activation in neurodegenerative processes. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/17007940/ A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/17121855/ Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by site-specific phosphorylation. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/17261846/ Axons break in animals lacking beta-spectrin. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/17506859/ p25/cyclin-dependent kinase 5 promotes the progression of cell death in nucleus of endoplasmic reticulum-stressed neurons. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/18701765/ Inhibition of Calpain Prevents N-Methyl-D-aspartate-Induced Degeneration of the Nucleus Basalis and Associated Behavioral Dysfunction. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/19594409/ Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/19689241/ Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/19857555/ Downregulation of Kv4.2 channels mediated by NR2B-containing NMDA receptors in cultured hippocampal neurons. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/19880516/ Adaptive modifications in the calpain/calpastatin system in brain cells after persistent alteration in Ca2+ homeostasis. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/21219955/ Neuroprotective effects of Mycoplasma hyorhinis against amyloid-?-peptide toxicity in SH-SY5Y human neuroblastoma cells are mediated by calpastatin upregulation in the mycoplasma-infected cells. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/21683092/ Neuroprotective effects of MAPK/ERK1/2 and calpain inhibitors on lactacystin-induced cell damage in primary cortical neurons. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/22613839/ The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/23305291/ Brain injury-induced proteolysis is reduced in a novel calpastatin-overexpressing transgenic mouse. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/23507938/ Role of calpain in apoptosis. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/24128662/ Calpain-mediated degradation of MDMx/MDM4 contributes to HIV-induced neuronal damage. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/24755075/ Valproic acid downregulates Cdk5 activity via the transcription of the p35 mRNA. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/25245568/ ?1-antitrypsin modulates microglial-mediated neuroinflammation and protects microglial cells from amyloid-?-induced toxicity. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/25399719/ An updated patent review of calpain inhibitors (2012 - 2014). unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/25661999/ Calpain Inhibition Improves Erectile Function in a Rat Model of Cavernous Nerve Injury. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/27453331/ Calpastatin overexpression reduces oxidative stress-induced mitochondrial impairment and cell death in human neuroblastoma SH-SY5Y cells by decreasing calpain and calcineurin activation, induction of mitochondrial fission and destruction of mitochondrial fusion. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/27529445/ Neuron-Microglia Interaction Induced Bi-directional Cytotoxicity Associated with Calpain Activation. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/27812546/ ? Cell-specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/28759231/ Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/30145792/ Melatonin, a calpain inhibitor in the central nervous system: Current status and future perspectives. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/30177812/ Isoform-specific hyperactivation of calpain-2 occurs presymptomatically at the synapse in Alzheimer's disease mice and correlates with memory deficits in human subjects. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31133534/ Discovery of ABT-957: 1-Benzyl-5-oxopyrrolidine-2-carboxamides as selective calpain inhibitors with enhanced metabolic stability. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31156179/ Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/31804596/ Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces A? and P25 accumulation in 5XFAD mice. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/32594381/ MicroRNA-137-3p Protects PC12 Cells Against Oxidative Stress by Downregulation of Calpain-2 and nNOS. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/32840034/ Synthesis of ?-Ketoamide-Based Stereoselective Calpain-1 Inhibitors as Neuroprotective Agents. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/33790315/ Age-dependent ataxia and neurodegeneration caused by an ?II spectrin mutation with impaired regulation of its calpain sensitivity. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/34417060/ The calcium-dependent protease calpain in neuronal remodeling and neurodegeneration. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16504408/ Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate. unassigned - 3.4.22.B28 Neurodegenerative Diseases https://pubmed.ncbi.nlm.nih.gov/16997142/ The therapeutic potential of the calpain family: new aspects. unassigned - 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. causal interaction 4 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/31707035/ miR-124 and Parkinson's disease: A biomarker with therapeutic potential. causal interaction 1 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. causal interaction 4 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/31968260/ Structural Insights into the Unique Activation Mechanisms of a Non-classical Calpain and Its Disease-Causing Variants. causal interaction 1 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/33433724/ Sarm1 is Essential for Anesthesia-Induced Neuroinflammation and Cognitive Impairment in Aged Mice. causal interaction 2 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. diagnostic usage 2 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. therapeutic application 4 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. therapeutic application 1 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. ongoing research 3 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/31948437/ Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca2+/calpain might contribute to postoperative cognitive dysfunction in aging mice. ongoing research 1 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. unassigned - 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/31707035/ miR-124 and Parkinson's disease: A biomarker with therapeutic potential. unassigned - 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/31968260/ Structural Insights into the Unique Activation Mechanisms of a Non-classical Calpain and Its Disease-Causing Variants. unassigned - 3.4.22.B28 Neuroinflammatory Diseases https://pubmed.ncbi.nlm.nih.gov/33433724/ Sarm1 is Essential for Anesthesia-Induced Neuroinflammation and Cognitive Impairment in Aged Mice. unassigned - 3.4.22.B28 Neurologic Manifestations https://pubmed.ncbi.nlm.nih.gov/10490730/ Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. diagnostic usage 3 3.4.22.B28 Neurologic Manifestations https://pubmed.ncbi.nlm.nih.gov/10490730/ Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. therapeutic application 1 3.4.22.B28 Neurologic Manifestations https://pubmed.ncbi.nlm.nih.gov/10490730/ Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. unassigned - 3.4.22.B28 Optic Nerve Injuries https://pubmed.ncbi.nlm.nih.gov/27859240/ The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection. therapeutic application 1 3.4.22.B28 Optic Nerve Injuries https://pubmed.ncbi.nlm.nih.gov/27859240/ The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection. unassigned - 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/9518658/ Increased calpain expression in experimental demyelinating optic neuritis: an immunocytochemical study. causal interaction 4 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. causal interaction 2 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/10212825/ A putative role for calpain in demyelination associated with optic neuritis. causal interaction 3 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/16179508/ A role for calpain in optic neuritis. causal interaction 1 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/21613375/ Calpain inhibition attenuates apoptosis of retinal ganglion cells in acute optic neuritis. causal interaction 3 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/23106593/ Calpain inhibitor attenuated optic nerve damage in acute optic neuritis in rats. causal interaction 2 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/23860028/ Calcium influx and calpain activation mediate preclinical retinal neurodegeneration in autoimmune optic neuritis. causal interaction 4 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/9237860/ Calcium-mediated neurofilament protein degradation in rat optic nerve in vitro: activity and autolysis of calpain proenzyme. causal interaction 3 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. diagnostic usage 1 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/10212825/ A putative role for calpain in demyelination associated with optic neuritis. diagnostic usage 2 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/23860028/ Calcium influx and calpain activation mediate preclinical retinal neurodegeneration in autoimmune optic neuritis. diagnostic usage 3 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/16179508/ A role for calpain in optic neuritis. therapeutic application 4 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/21613375/ Calpain inhibition attenuates apoptosis of retinal ganglion cells in acute optic neuritis. therapeutic application 2 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/23860028/ Calcium influx and calpain activation mediate preclinical retinal neurodegeneration in autoimmune optic neuritis. therapeutic application 4 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/27513991/ Calpain Inhibition Reduces Structural and Functional Impairment of Retinal Ganglion Cells in Experimental Optic Neuritis. therapeutic application 4 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/9518658/ Increased calpain expression in experimental demyelinating optic neuritis: an immunocytochemical study. ongoing research 4 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. ongoing research 4 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/10212825/ A putative role for calpain in demyelination associated with optic neuritis. ongoing research 4 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/21613375/ Calpain inhibition attenuates apoptosis of retinal ganglion cells in acute optic neuritis. ongoing research 1 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/23106593/ Calpain inhibitor attenuated optic nerve damage in acute optic neuritis in rats. ongoing research 2 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/27513991/ Calpain Inhibition Reduces Structural and Functional Impairment of Retinal Ganglion Cells in Experimental Optic Neuritis. ongoing research 4 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/27513991/ Calpain Inhibition Reduces Structural and Functional Impairment of Retinal Ganglion Cells in Experimental Optic Neuritis. unassigned - 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/9518658/ Increased calpain expression in experimental demyelinating optic neuritis: an immunocytochemical study. unassigned - 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/16179508/ A role for calpain in optic neuritis. unassigned - 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/21613375/ Calpain inhibition attenuates apoptosis of retinal ganglion cells in acute optic neuritis. unassigned - 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/23106593/ Calpain inhibitor attenuated optic nerve damage in acute optic neuritis in rats. unassigned - 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/9237860/ Calcium-mediated neurofilament protein degradation in rat optic nerve in vitro: activity and autolysis of calpain proenzyme. unassigned - 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/9820787/ Putative role of calpain in the pathophysiology of experimental optic neuritis. unassigned - 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/10212825/ A putative role for calpain in demyelination associated with optic neuritis. unassigned - 3.4.22.B28 Optic Neuritis https://pubmed.ncbi.nlm.nih.gov/23860028/ Calcium influx and calpain activation mediate preclinical retinal neurodegeneration in autoimmune optic neuritis. unassigned - 3.4.22.B28 Osteoarthritis https://pubmed.ncbi.nlm.nih.gov/10600505/ Inflammatory cytokines induced down-regulation of m-calpain mRNA expression in fibroblastic synoviocytes from patients with osteoarthritis and rheumatoid arthritis. causal interaction 3 3.4.22.B28 Osteoarthritis https://pubmed.ncbi.nlm.nih.gov/10600505/ Inflammatory cytokines induced down-regulation of m-calpain mRNA expression in fibroblastic synoviocytes from patients with osteoarthritis and rheumatoid arthritis. diagnostic usage 3 3.4.22.B28 Osteoarthritis https://pubmed.ncbi.nlm.nih.gov/17963167/ Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. diagnostic usage 1 3.4.22.B28 Osteoarthritis https://pubmed.ncbi.nlm.nih.gov/10600505/ Inflammatory cytokines induced down-regulation of m-calpain mRNA expression in fibroblastic synoviocytes from patients with osteoarthritis and rheumatoid arthritis. ongoing research 2 3.4.22.B28 Osteoarthritis https://pubmed.ncbi.nlm.nih.gov/17963167/ Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. ongoing research 3 3.4.22.B28 Osteoarthritis https://pubmed.ncbi.nlm.nih.gov/17963167/ Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. unassigned - 3.4.22.B28 Osteoarthritis https://pubmed.ncbi.nlm.nih.gov/10600505/ Inflammatory cytokines induced down-regulation of m-calpain mRNA expression in fibroblastic synoviocytes from patients with osteoarthritis and rheumatoid arthritis. unassigned - 3.4.22.B28 Osteosarcoma https://pubmed.ncbi.nlm.nih.gov/19747555/ Silencing of calpain expression reduces the metastatic potential of human osteosarcoma cells. causal interaction 4 3.4.22.B28 Osteosarcoma https://pubmed.ncbi.nlm.nih.gov/19747555/ Silencing of calpain expression reduces the metastatic potential of human osteosarcoma cells. diagnostic usage 3 3.4.22.B28 Osteosarcoma https://pubmed.ncbi.nlm.nih.gov/19747555/ Silencing of calpain expression reduces the metastatic potential of human osteosarcoma cells. therapeutic application 1 3.4.22.B28 Osteosarcoma https://pubmed.ncbi.nlm.nih.gov/12037623/ Apoptosis may determine the release of skeletal alkaline phosphatase activity from human osteoblast-line cells. therapeutic application 1 3.4.22.B28 Osteosarcoma https://pubmed.ncbi.nlm.nih.gov/19747555/ Silencing of calpain expression reduces the metastatic potential of human osteosarcoma cells. ongoing research 4 3.4.22.B28 Osteosarcoma https://pubmed.ncbi.nlm.nih.gov/12037623/ Apoptosis may determine the release of skeletal alkaline phosphatase activity from human osteoblast-line cells. ongoing research 3 3.4.22.B28 Osteosarcoma https://pubmed.ncbi.nlm.nih.gov/12037623/ Apoptosis may determine the release of skeletal alkaline phosphatase activity from human osteoblast-line cells. unassigned - 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/25206508/ Calpain mediated cisplatin-induced ototoxicity in mice. causal interaction 3 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/15300786/ Calpain activity in the amikacin-damaged rat cochlea. causal interaction 3 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/12625566/ Neuroprotection of vestibular sensory cells from gentamicin ototoxicity obtained using nitric oxide synthase inhibitors, reactive oxygen species scavengers, brain-derived neurotrophic factors and calpain inhibitors. therapeutic application 3 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/12797578/ Calpain and caspase inhibitors protect vestibular sensory cells from gentamicin ototoxicity. therapeutic application 3 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/16707850/ Leupeptin, a calpain inhibitor, protects inner ear hair cells from aminoglycoside ototoxicity. therapeutic application 1 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/25206508/ Calpain mediated cisplatin-induced ototoxicity in mice. therapeutic application 1 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/11950531/ Leupeptin protects cochlear and vestibular hair cells from gentamicin ototoxicity. therapeutic application 1 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/12797578/ Calpain and caspase inhibitors protect vestibular sensory cells from gentamicin ototoxicity. ongoing research 4 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/16707850/ Leupeptin, a calpain inhibitor, protects inner ear hair cells from aminoglycoside ototoxicity. ongoing research 2 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/25206508/ Calpain mediated cisplatin-induced ototoxicity in mice. ongoing research 3 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/11950531/ Leupeptin protects cochlear and vestibular hair cells from gentamicin ototoxicity. ongoing research 2 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/21067520/ Involvement of calpain-I and microRNA34 in kanamycin-induced apoptosis of inner ear cells. ongoing research 4 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/12625566/ Neuroprotection of vestibular sensory cells from gentamicin ototoxicity obtained using nitric oxide synthase inhibitors, reactive oxygen species scavengers, brain-derived neurotrophic factors and calpain inhibitors. unassigned - 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/12797578/ Calpain and caspase inhibitors protect vestibular sensory cells from gentamicin ototoxicity. unassigned - 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/16707850/ Leupeptin, a calpain inhibitor, protects inner ear hair cells from aminoglycoside ototoxicity. unassigned - 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/11950531/ Leupeptin protects cochlear and vestibular hair cells from gentamicin ototoxicity. unassigned - 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/21067520/ Involvement of calpain-I and microRNA34 in kanamycin-induced apoptosis of inner ear cells. unassigned - 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/25206508/ Calpain mediated cisplatin-induced ototoxicity in mice. unassigned - 3.4.22.B28 Ototoxicity https://pubmed.ncbi.nlm.nih.gov/15300786/ Calpain activity in the amikacin-damaged rat cochlea. unassigned - 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/30448882/ Calpain system protein expression and activity in ovarian cancer. causal interaction 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/34238324/ MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer. causal interaction 2 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/11319608/ Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors. causal interaction 3 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/22335024/ Immunhistochemical analysis for expression of calpain 1, calpain 2 and calpastatin in ovarian cancer. causal interaction 1 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. causal interaction 1 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. causal interaction 3 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/30737623/ Expression of Syk and MAP4 proteins in ovarian cancer. causal interaction 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/27793894/ The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells. diagnostic usage 1 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/30448882/ Calpain system protein expression and activity in ovarian cancer. diagnostic usage 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/34238324/ MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer. diagnostic usage 1 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/22335024/ Immunhistochemical analysis for expression of calpain 1, calpain 2 and calpastatin in ovarian cancer. diagnostic usage 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. diagnostic usage 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. diagnostic usage 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/30737623/ Expression of Syk and MAP4 proteins in ovarian cancer. diagnostic usage 3 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/12175527/ Se-methylselenocysteine induces apoptosis through caspase activation and Bax cleavage mediated by calpain in SKOV-3 ovarian cancer cells. therapeutic application 1 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/27793894/ The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells. therapeutic application 2 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/11319608/ Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors. therapeutic application 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/22335024/ Immunhistochemical analysis for expression of calpain 1, calpain 2 and calpastatin in ovarian cancer. therapeutic application 3 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. therapeutic application 3 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/27793894/ The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells. ongoing research 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/30448882/ Calpain system protein expression and activity in ovarian cancer. ongoing research 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/11319608/ Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors. ongoing research 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/22335024/ Immunhistochemical analysis for expression of calpain 1, calpain 2 and calpastatin in ovarian cancer. ongoing research 2 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. ongoing research 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/28927135/ Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa. ongoing research 3 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/30737623/ Expression of Syk and MAP4 proteins in ovarian cancer. ongoing research 4 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/12175527/ Se-methylselenocysteine induces apoptosis through caspase activation and Bax cleavage mediated by calpain in SKOV-3 ovarian cancer cells. unassigned - 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/27793894/ The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells. unassigned - 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/11319608/ Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors. unassigned - 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/30448882/ Calpain system protein expression and activity in ovarian cancer. unassigned - 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/34238324/ MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer. unassigned - 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/25895370/ [Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer]. unassigned - 3.4.22.B28 Ovarian Neoplasms https://pubmed.ncbi.nlm.nih.gov/30737623/ Expression of Syk and MAP4 proteins in ovarian cancer. unassigned - 3.4.22.B28 Pancreatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/26138287/ The flavonoid beverage Haelan 951 induces growth arrest and apoptosis in pancreatic carcinoma cell lines in vitro. causal interaction 3 3.4.22.B28 Pancreatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/27487486/ The calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. diagnostic usage 3 3.4.22.B28 Pancreatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/26138287/ The flavonoid beverage Haelan 951 induces growth arrest and apoptosis in pancreatic carcinoma cell lines in vitro. diagnostic usage 3 3.4.22.B28 Pancreatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/27487486/ The calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. therapeutic application 2 3.4.22.B28 Pancreatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/26138287/ The flavonoid beverage Haelan 951 induces growth arrest and apoptosis in pancreatic carcinoma cell lines in vitro. therapeutic application 4 3.4.22.B28 Pancreatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/27487486/ The calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. ongoing research 4 3.4.22.B28 Pancreatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/26138287/ The flavonoid beverage Haelan 951 induces growth arrest and apoptosis in pancreatic carcinoma cell lines in vitro. ongoing research 4 3.4.22.B28 Pancreatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/27487486/ The calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. unassigned - 3.4.22.B28 Pancreatitis https://pubmed.ncbi.nlm.nih.gov/16154113/ Calpain activation contributes to oxidative stress-induced pancreatic acinar cell injury. causal interaction 4 3.4.22.B28 Pancreatitis https://pubmed.ncbi.nlm.nih.gov/19659897/ Calpain-mediated breakdown of cytoskeletal proteins contributes to cholecystokinin-induced damage of rat pancreatic acini. causal interaction 4 3.4.22.B28 Pancreatitis https://pubmed.ncbi.nlm.nih.gov/15132950/ Dysregulation of the calpain-calpastatin system plays a role in the development of cerulein-induced acute pancreatitis in the rat. diagnostic usage 3 3.4.22.B28 Pancreatitis https://pubmed.ncbi.nlm.nih.gov/15132950/ Dysregulation of the calpain-calpastatin system plays a role in the development of cerulein-induced acute pancreatitis in the rat. therapeutic application 3 3.4.22.B28 Pancreatitis https://pubmed.ncbi.nlm.nih.gov/16154113/ Calpain activation contributes to oxidative stress-induced pancreatic acinar cell injury. therapeutic application 2 3.4.22.B28 Pancreatitis https://pubmed.ncbi.nlm.nih.gov/19659897/ Calpain-mediated breakdown of cytoskeletal proteins contributes to cholecystokinin-induced damage of rat pancreatic acini. therapeutic application 3 3.4.22.B28 Pancreatitis https://pubmed.ncbi.nlm.nih.gov/15132950/ Dysregulation of the calpain-calpastatin system plays a role in the development of cerulein-induced acute pancreatitis in the rat. ongoing research 3 3.4.22.B28 Pancreatitis https://pubmed.ncbi.nlm.nih.gov/15132950/ Dysregulation of the calpain-calpastatin system plays a role in the development of cerulein-induced acute pancreatitis in the rat. unassigned - 3.4.22.B28 Pancreatitis https://pubmed.ncbi.nlm.nih.gov/16154113/ Calpain activation contributes to oxidative stress-induced pancreatic acinar cell injury. unassigned - 3.4.22.B28 Pancreatitis https://pubmed.ncbi.nlm.nih.gov/19659897/ Calpain-mediated breakdown of cytoskeletal proteins contributes to cholecystokinin-induced damage of rat pancreatic acini. unassigned - 3.4.22.B28 Parasitic Diseases https://pubmed.ncbi.nlm.nih.gov/16842979/ Antileishmanial activity of MDL 28170, a potent calpain inhibitor. causal interaction 3 3.4.22.B28 Parasitic Diseases https://pubmed.ncbi.nlm.nih.gov/16842979/ Antileishmanial activity of MDL 28170, a potent calpain inhibitor. therapeutic application 4 3.4.22.B28 Parasitic Diseases https://pubmed.ncbi.nlm.nih.gov/16842979/ Antileishmanial activity of MDL 28170, a potent calpain inhibitor. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/18673214/ Calpain as a potential therapeutic target in Parkinson's disease. causal interaction 4 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. causal interaction 1 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. causal interaction 4 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. causal interaction 3 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/22863139/ Calpain inhibitor nanocrystals prepared using Nano Spray Dryer B-90. causal interaction 3 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. diagnostic usage 4 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. diagnostic usage 2 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/18673214/ Calpain as a potential therapeutic target in Parkinson's disease. therapeutic application 4 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/23875735/ Critical role of calpain in spinal cord degeneration in Parkinson's disease. therapeutic application 1 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/22863139/ Calpain inhibitor nanocrystals prepared using Nano Spray Dryer B-90. therapeutic application 4 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/11085327/ Calpain upregulation in spinal cords of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease. ongoing research 2 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/20034566/ Dysfunctional mitochondria uphold calpain activation: contribution to Parkinson's disease pathology. ongoing research 2 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. ongoing research 4 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/11085327/ Calpain upregulation in spinal cords of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/20034566/ Dysfunctional mitochondria uphold calpain activation: contribution to Parkinson's disease pathology. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/23875735/ Critical role of calpain in spinal cord degeneration in Parkinson's disease. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/31601400/ Calpain in the cleavage of alpha-synuclein and the pathogenesis of Parkinson's disease. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/32302678/ Calpain mediated expansion of CD4+ cytotoxic T cells in rodent models of Parkinson's disease. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/23951044/ Calpastatin Gene (CAST) Is Not Associated with Late Onset Sporadic Parkinson's Disease in the Han Chinese Population. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/18673214/ Calpain as a potential therapeutic target in Parkinson's disease. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/18686046/ Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/22863139/ Calpain inhibitor nanocrystals prepared using Nano Spray Dryer B-90. unassigned - 3.4.22.B28 Parkinson Disease https://pubmed.ncbi.nlm.nih.gov/33729106/ Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. unassigned - 3.4.22.B28 Parkinsonian Disorders https://pubmed.ncbi.nlm.nih.gov/18673214/ Calpain as a potential therapeutic target in Parkinson's disease. causal interaction 4 3.4.22.B28 Parkinsonian Disorders https://pubmed.ncbi.nlm.nih.gov/17105932/ Calpain activation in apoptosis of motoneurons in cell culture models of experimental parkinsonism. therapeutic application 3 3.4.22.B28 Parkinsonian Disorders https://pubmed.ncbi.nlm.nih.gov/18673214/ Calpain as a potential therapeutic target in Parkinson's disease. therapeutic application 4 3.4.22.B28 Parkinsonian Disorders https://pubmed.ncbi.nlm.nih.gov/18991878/ Extranigral neurodegeneration in Parkinson's disease. therapeutic application 3 3.4.22.B28 Parkinsonian Disorders https://pubmed.ncbi.nlm.nih.gov/17105932/ Calpain activation in apoptosis of motoneurons in cell culture models of experimental parkinsonism. ongoing research 4 3.4.22.B28 Parkinsonian Disorders https://pubmed.ncbi.nlm.nih.gov/17367952/ The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. ongoing research 1 3.4.22.B28 Parkinsonian Disorders https://pubmed.ncbi.nlm.nih.gov/18991878/ Extranigral neurodegeneration in Parkinson's disease. ongoing research 3 3.4.22.B28 Parkinsonian Disorders https://pubmed.ncbi.nlm.nih.gov/17105932/ Calpain activation in apoptosis of motoneurons in cell culture models of experimental parkinsonism. unassigned - 3.4.22.B28 Parkinsonian Disorders https://pubmed.ncbi.nlm.nih.gov/17367952/ The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. unassigned - 3.4.22.B28 Parkinsonian Disorders https://pubmed.ncbi.nlm.nih.gov/18991878/ Extranigral neurodegeneration in Parkinson's disease. unassigned - 3.4.22.B28 Parkinsonian Disorders https://pubmed.ncbi.nlm.nih.gov/18673214/ Calpain as a potential therapeutic target in Parkinson's disease. unassigned - 3.4.22.B28 Peripheral Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/12937083/ Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. causal interaction 4 3.4.22.B28 Peripheral Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/22988235/ Inhibition of Paclitaxel-Induced Decreases in Calcium Signaling. causal interaction 2 3.4.22.B28 Peripheral Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/33318563/ Cisplatin induced neurotoxicity is mediated by Sarm1 and calpain activation. causal interaction 3 3.4.22.B28 Peripheral Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/12937083/ Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. diagnostic usage 3 3.4.22.B28 Peripheral Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/22988235/ Inhibition of Paclitaxel-Induced Decreases in Calcium Signaling. therapeutic application 2 3.4.22.B28 Peripheral Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/33318563/ Cisplatin induced neurotoxicity is mediated by Sarm1 and calpain activation. therapeutic application 4 3.4.22.B28 Peripheral Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/22988235/ Inhibition of Paclitaxel-Induced Decreases in Calcium Signaling. unassigned - 3.4.22.B28 Peripheral Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/33318563/ Cisplatin induced neurotoxicity is mediated by Sarm1 and calpain activation. unassigned - 3.4.22.B28 Peripheral Nervous System Diseases https://pubmed.ncbi.nlm.nih.gov/12937083/ Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. unassigned - 3.4.22.B28 Peritoneal Fibrosis https://pubmed.ncbi.nlm.nih.gov/33963721/ [Calpain activation promotes dialysis-associated peritoneal fibrosis in rats]. therapeutic application 2 3.4.22.B28 Peritoneal Fibrosis https://pubmed.ncbi.nlm.nih.gov/33963721/ [Calpain activation promotes dialysis-associated peritoneal fibrosis in rats]. unassigned - 3.4.22.B28 Peritonitis https://pubmed.ncbi.nlm.nih.gov/24375267/ Calpains promote neutrophil recruitment and bacterial clearance in an acute bacterial peritonitis model. causal interaction 4 3.4.22.B28 Peritonitis https://pubmed.ncbi.nlm.nih.gov/24375267/ Calpains promote neutrophil recruitment and bacterial clearance in an acute bacterial peritonitis model. therapeutic application 4 3.4.22.B28 Peritonitis https://pubmed.ncbi.nlm.nih.gov/24375267/ Calpains promote neutrophil recruitment and bacterial clearance in an acute bacterial peritonitis model. ongoing research 4 3.4.22.B28 Peritonitis https://pubmed.ncbi.nlm.nih.gov/26608921/ Calpains Released by T Lymphocytes Cleave TLR2 To Control IL-17 Expression. ongoing research 2 3.4.22.B28 Peritonitis https://pubmed.ncbi.nlm.nih.gov/26608921/ Calpains Released by T Lymphocytes Cleave TLR2 To Control IL-17 Expression. unassigned - 3.4.22.B28 Peritonitis https://pubmed.ncbi.nlm.nih.gov/24375267/ Calpains promote neutrophil recruitment and bacterial clearance in an acute bacterial peritonitis model. unassigned - 3.4.22.B28 Pheochromocytoma https://pubmed.ncbi.nlm.nih.gov/8041520/ Calpeptin, a calpain inhibitor, promotes neurite elongation in differentiating PC12 cells. causal interaction 1 3.4.22.B28 Pheochromocytoma https://pubmed.ncbi.nlm.nih.gov/8041520/ Calpeptin, a calpain inhibitor, promotes neurite elongation in differentiating PC12 cells. ongoing research 2 3.4.22.B28 Pheochromocytoma https://pubmed.ncbi.nlm.nih.gov/8041520/ Calpeptin, a calpain inhibitor, promotes neurite elongation in differentiating PC12 cells. unassigned - 3.4.22.B28 Picornaviridae Infections https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. causal interaction 4 3.4.22.B28 Picornaviridae Infections https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. therapeutic application 4 3.4.22.B28 Picornaviridae Infections https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. ongoing research 3 3.4.22.B28 Picornaviridae Infections https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. unassigned - 3.4.22.B28 Pituitary Neoplasms https://pubmed.ncbi.nlm.nih.gov/11192619/ Calpain inhibitor inhibits secretory granule maturation and secretion of GH. causal interaction 2 3.4.22.B28 Pituitary Neoplasms https://pubmed.ncbi.nlm.nih.gov/11192619/ Calpain inhibitor inhibits secretory granule maturation and secretion of GH. ongoing research 1 3.4.22.B28 Pituitary Neoplasms https://pubmed.ncbi.nlm.nih.gov/12238950/ Positive feedback of protein kinase C proteolytic activation during apoptosis. ongoing research 3 3.4.22.B28 Pituitary Neoplasms https://pubmed.ncbi.nlm.nih.gov/12238950/ Positive feedback of protein kinase C proteolytic activation during apoptosis. unassigned - 3.4.22.B28 Pituitary Neoplasms https://pubmed.ncbi.nlm.nih.gov/11192619/ Calpain inhibitor inhibits secretory granule maturation and secretion of GH. unassigned - 3.4.22.B28 Pleural Effusion https://pubmed.ncbi.nlm.nih.gov/29997916/ Calpain and spectrin breakdown products as potential biomarkers in tuberculous pleural effusion. causal interaction 4 3.4.22.B28 Pleural Effusion https://pubmed.ncbi.nlm.nih.gov/27261452/ Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis. causal interaction 3 3.4.22.B28 Pleural Effusion https://pubmed.ncbi.nlm.nih.gov/29997916/ Calpain and spectrin breakdown products as potential biomarkers in tuberculous pleural effusion. diagnostic usage 3 3.4.22.B28 Pleural Effusion https://pubmed.ncbi.nlm.nih.gov/27261452/ Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis. diagnostic usage 1 3.4.22.B28 Pleural Effusion https://pubmed.ncbi.nlm.nih.gov/29997916/ Calpain and spectrin breakdown products as potential biomarkers in tuberculous pleural effusion. therapeutic application 1 3.4.22.B28 Pleural Effusion https://pubmed.ncbi.nlm.nih.gov/29997916/ Calpain and spectrin breakdown products as potential biomarkers in tuberculous pleural effusion. ongoing research 1 3.4.22.B28 Pleural Effusion https://pubmed.ncbi.nlm.nih.gov/30233907/ Calpain and spectrin breakdown products in tuberculous pleural effusion. unassigned - 3.4.22.B28 Pleural Effusion https://pubmed.ncbi.nlm.nih.gov/27261452/ Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis. unassigned - 3.4.22.B28 Pleural Effusion, Malignant https://pubmed.ncbi.nlm.nih.gov/27261452/ Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis. causal interaction 3 3.4.22.B28 Pleural Effusion, Malignant https://pubmed.ncbi.nlm.nih.gov/27261452/ Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis. diagnostic usage 1 3.4.22.B28 Pleural Effusion, Malignant https://pubmed.ncbi.nlm.nih.gov/27261452/ Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis. unassigned - 3.4.22.B28 Pleurisy https://pubmed.ncbi.nlm.nih.gov/11106579/ Calpain inhibitor I reduces the development of acute and chronic inflammation. therapeutic application 2 3.4.22.B28 Pleurisy https://pubmed.ncbi.nlm.nih.gov/11106579/ Calpain inhibitor I reduces the development of acute and chronic inflammation. ongoing research 4 3.4.22.B28 Pleurisy https://pubmed.ncbi.nlm.nih.gov/11106579/ Calpain inhibitor I reduces the development of acute and chronic inflammation. unassigned - 3.4.22.B28 Pneumonia https://pubmed.ncbi.nlm.nih.gov/22140070/ Activation of calpains mediates early lung neutrophilic inflammation in ventilator-induced lung injury. causal interaction 4 3.4.22.B28 Pneumonia https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. causal interaction 4 3.4.22.B28 Pneumonia https://pubmed.ncbi.nlm.nih.gov/22140070/ Activation of calpains mediates early lung neutrophilic inflammation in ventilator-induced lung injury. therapeutic application 4 3.4.22.B28 Pneumonia https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. therapeutic application 4 3.4.22.B28 Pneumonia https://pubmed.ncbi.nlm.nih.gov/22140070/ Activation of calpains mediates early lung neutrophilic inflammation in ventilator-induced lung injury. ongoing research 3 3.4.22.B28 Pneumonia https://pubmed.ncbi.nlm.nih.gov/22140070/ Activation of calpains mediates early lung neutrophilic inflammation in ventilator-induced lung injury. unassigned - 3.4.22.B28 Pneumonia https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. unassigned - 3.4.22.B28 Polycystic Ovary Syndrome https://pubmed.ncbi.nlm.nih.gov/26376770/ Association of Calpain (CAPN) 10 (UCSNP-43, rs3792267) gene polymorphism with elevated serum androgens in young women with the most severe phenotype of polycystic ovary syndrome (PCOS). causal interaction 4 3.4.22.B28 Polycystic Ovary Syndrome https://pubmed.ncbi.nlm.nih.gov/26376770/ Association of Calpain (CAPN) 10 (UCSNP-43, rs3792267) gene polymorphism with elevated serum androgens in young women with the most severe phenotype of polycystic ovary syndrome (PCOS). diagnostic usage 3 3.4.22.B28 Polycystic Ovary Syndrome https://pubmed.ncbi.nlm.nih.gov/26376770/ Association of Calpain (CAPN) 10 (UCSNP-43, rs3792267) gene polymorphism with elevated serum androgens in young women with the most severe phenotype of polycystic ovary syndrome (PCOS). ongoing research 2 3.4.22.B28 Polycystic Ovary Syndrome https://pubmed.ncbi.nlm.nih.gov/26376770/ Association of Calpain (CAPN) 10 (UCSNP-43, rs3792267) gene polymorphism with elevated serum androgens in young women with the most severe phenotype of polycystic ovary syndrome (PCOS). unassigned - 3.4.22.B28 Polyneuropathies https://pubmed.ncbi.nlm.nih.gov/8887940/ Alterations in the neutral proteinase activities of central and peripheral nervous systems of acrylamide-, carbon disulfide-, or 2,5-hexanedione-treated rats. unassigned - 3.4.22.B28 Precursor Cell Lymphoblastic Leukemia-Lymphoma https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. causal interaction 3 3.4.22.B28 Precursor Cell Lymphoblastic Leukemia-Lymphoma https://pubmed.ncbi.nlm.nih.gov/26358320/ GAS2-Calpain2 axis contributes to the growth of leukemic cells. causal interaction 1 3.4.22.B28 Precursor Cell Lymphoblastic Leukemia-Lymphoma https://pubmed.ncbi.nlm.nih.gov/26317226/ Increased ?-Calpain Activity in Blasts of Common B-Precursor Childhood Acute Lymphoblastic Leukemia Correlates with Their Lower Susceptibility to Apoptosis. diagnostic usage 3 3.4.22.B28 Precursor Cell Lymphoblastic Leukemia-Lymphoma https://pubmed.ncbi.nlm.nih.gov/26358320/ GAS2-Calpain2 axis contributes to the growth of leukemic cells. diagnostic usage 3 3.4.22.B28 Precursor Cell Lymphoblastic Leukemia-Lymphoma https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. therapeutic application 4 3.4.22.B28 Precursor Cell Lymphoblastic Leukemia-Lymphoma https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. ongoing research 4 3.4.22.B28 Precursor Cell Lymphoblastic Leukemia-Lymphoma https://pubmed.ncbi.nlm.nih.gov/26317226/ Increased ?-Calpain Activity in Blasts of Common B-Precursor Childhood Acute Lymphoblastic Leukemia Correlates with Their Lower Susceptibility to Apoptosis. ongoing research 2 3.4.22.B28 Precursor Cell Lymphoblastic Leukemia-Lymphoma https://pubmed.ncbi.nlm.nih.gov/26317226/ Increased ?-Calpain Activity in Blasts of Common B-Precursor Childhood Acute Lymphoblastic Leukemia Correlates with Their Lower Susceptibility to Apoptosis. unassigned - 3.4.22.B28 Precursor Cell Lymphoblastic Leukemia-Lymphoma https://pubmed.ncbi.nlm.nih.gov/10873099/ Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. unassigned - 3.4.22.B28 Precursor Cell Lymphoblastic Leukemia-Lymphoma https://pubmed.ncbi.nlm.nih.gov/26358320/ GAS2-Calpain2 axis contributes to the growth of leukemic cells. unassigned - 3.4.22.B28 Prediabetic State https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. causal interaction 3 3.4.22.B28 Prediabetic State https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. therapeutic application 4 3.4.22.B28 Prediabetic State https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. ongoing research 4 3.4.22.B28 Prediabetic State https://pubmed.ncbi.nlm.nih.gov/30778623/ Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. unassigned - 3.4.22.B28 Premature Birth https://pubmed.ncbi.nlm.nih.gov/26551007/ Erythropoietin Modulates Cerebral and Serum Degradation Products from Excess Calpain Activation following Prenatal Hypoxia-Ischemia. causal interaction 1 3.4.22.B28 Premature Birth https://pubmed.ncbi.nlm.nih.gov/26551007/ Erythropoietin Modulates Cerebral and Serum Degradation Products from Excess Calpain Activation following Prenatal Hypoxia-Ischemia. unassigned - 3.4.22.B28 Prenatal Injuries https://pubmed.ncbi.nlm.nih.gov/24983520/ Erythropoietin attenuates loss of potassium chloride co-transporters following prenatal brain injury. therapeutic application 1 3.4.22.B28 Prenatal Injuries https://pubmed.ncbi.nlm.nih.gov/24983520/ Erythropoietin attenuates loss of potassium chloride co-transporters following prenatal brain injury. unassigned - 3.4.22.B28 Prion Diseases https://pubmed.ncbi.nlm.nih.gov/22272295/ Remarkable reduction of MAP2 in the brains of scrapie-infected rodents and human prion disease possibly correlated with the increase of calpain. causal interaction 1 3.4.22.B28 Prion Diseases https://pubmed.ncbi.nlm.nih.gov/22272295/ Remarkable reduction of MAP2 in the brains of scrapie-infected rodents and human prion disease possibly correlated with the increase of calpain. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/21368866/ Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. causal interaction 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/28498452/ Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells. causal interaction 3 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/7575520/ Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. causal interaction 2 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. causal interaction 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. causal interaction 1 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. causal interaction 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. causal interaction 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. causal interaction 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/18726991/ Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. causal interaction 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/21069721/ Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. causal interaction 3 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. causal interaction 2 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/28498452/ Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells. diagnostic usage 1 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/7575520/ Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. diagnostic usage 3 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. diagnostic usage 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. diagnostic usage 3 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. diagnostic usage 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/21368866/ Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. therapeutic application 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/28498452/ Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells. therapeutic application 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/7575520/ Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. therapeutic application 3 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. therapeutic application 1 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. therapeutic application 2 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. therapeutic application 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. therapeutic application 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/18726991/ Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. therapeutic application 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/21069721/ Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. therapeutic application 3 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/7575520/ Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. ongoing research 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12393869/ The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. ongoing research 1 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. ongoing research 3 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12907643/ Calpain-2 as a target for limiting prostate cancer invasion. ongoing research 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. ongoing research 2 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. ongoing research 4 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/21069721/ Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. ongoing research 2 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/21506119/ Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. ongoing research 1 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. ongoing research 1 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/30378157/ Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells. ongoing research 3 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/21506119/ Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/23801747/ Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/24769209/ Cholesterol-induced activation of TRPM7 regulates cell proliferation, migration, and viability of human prostate cells. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/30378157/ Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/21368866/ Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/12851726/ Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/16865282/ Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/18726991/ Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/21069721/ Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/29599325/ Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/15492240/ Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. unassigned - 3.4.22.B28 Prostatic Neoplasms https://pubmed.ncbi.nlm.nih.gov/28498452/ Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells. unassigned - 3.4.22.B28 Protein Deficiency https://pubmed.ncbi.nlm.nih.gov/17989922/ The interaction of superoxide with nitric oxide destabilizes hypoxia-inducible factor-1alpha. unassigned - 3.4.22.B28 Proteinuria https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. causal interaction 1 3.4.22.B28 Proteinuria https://pubmed.ncbi.nlm.nih.gov/33208557/ Inhibiting calpain 1 and 2 in cyclin G associated kinase-knockout mice mitigates podocyte injury. causal interaction 1 3.4.22.B28 Proteinuria https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. diagnostic usage 2 3.4.22.B28 Proteinuria https://pubmed.ncbi.nlm.nih.gov/29954830/ The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury. therapeutic application 1 3.4.22.B28 Proteinuria https://pubmed.ncbi.nlm.nih.gov/33208557/ Inhibiting calpain 1 and 2 in cyclin G associated kinase-knockout mice mitigates podocyte injury. therapeutic application 2 3.4.22.B28 Proteinuria https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. ongoing research 3 3.4.22.B28 Proteinuria https://pubmed.ncbi.nlm.nih.gov/29954830/ The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury. unassigned - 3.4.22.B28 Proteinuria https://pubmed.ncbi.nlm.nih.gov/33208557/ Inhibiting calpain 1 and 2 in cyclin G associated kinase-knockout mice mitigates podocyte injury. unassigned - 3.4.22.B28 Proteinuria https://pubmed.ncbi.nlm.nih.gov/17082241/ Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. unassigned - 3.4.22.B28 Proteostasis Deficiencies https://pubmed.ncbi.nlm.nih.gov/27812546/ ? Cell-specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity. causal interaction 3 3.4.22.B28 Proteostasis Deficiencies https://pubmed.ncbi.nlm.nih.gov/27812546/ ? Cell-specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity. therapeutic application 2 3.4.22.B28 Proteostasis Deficiencies https://pubmed.ncbi.nlm.nih.gov/27812546/ ? Cell-specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity. ongoing research 2 3.4.22.B28 Proteostasis Deficiencies https://pubmed.ncbi.nlm.nih.gov/27812546/ ? Cell-specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity. unassigned - 3.4.22.B28 Pulmonary Arterial Hypertension https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. causal interaction 4 3.4.22.B28 Pulmonary Arterial Hypertension https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. causal interaction 4 3.4.22.B28 Pulmonary Arterial Hypertension https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. diagnostic usage 3 3.4.22.B28 Pulmonary Arterial Hypertension https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. therapeutic application 3 3.4.22.B28 Pulmonary Arterial Hypertension https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. therapeutic application 2 3.4.22.B28 Pulmonary Arterial Hypertension https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. ongoing research 4 3.4.22.B28 Pulmonary Arterial Hypertension https://pubmed.ncbi.nlm.nih.gov/22005303/ Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. unassigned - 3.4.22.B28 Pulmonary Arterial Hypertension https://pubmed.ncbi.nlm.nih.gov/26248159/ Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. unassigned - 3.4.22.B28 Pulmonary Disease, Chronic Obstructive https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. causal interaction 4 3.4.22.B28 Pulmonary Disease, Chronic Obstructive https://pubmed.ncbi.nlm.nih.gov/31088299/ Reactive Oxygen Species-Dependent Calpain Activation Contributes to Airway and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease. causal interaction 4 3.4.22.B28 Pulmonary Disease, Chronic Obstructive https://pubmed.ncbi.nlm.nih.gov/31088299/ Reactive Oxygen Species-Dependent Calpain Activation Contributes to Airway and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease. diagnostic usage 2 3.4.22.B28 Pulmonary Disease, Chronic Obstructive https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. therapeutic application 4 3.4.22.B28 Pulmonary Disease, Chronic Obstructive https://pubmed.ncbi.nlm.nih.gov/31088299/ Reactive Oxygen Species-Dependent Calpain Activation Contributes to Airway and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease. therapeutic application 4 3.4.22.B28 Pulmonary Disease, Chronic Obstructive https://pubmed.ncbi.nlm.nih.gov/29047085/ Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD. unassigned - 3.4.22.B28 Pulmonary Disease, Chronic Obstructive https://pubmed.ncbi.nlm.nih.gov/31088299/ Reactive Oxygen Species-Dependent Calpain Activation Contributes to Airway and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease. unassigned - 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/20846163/ The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in mice. causal interaction 4 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/26071646/ Crosstalk between calpain activation and TGF-?1 augments collagen-I synthesis in pulmonary fibrosis. causal interaction 4 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/29666896/ Calpain inhibition attenuates bleomycin-induced pulmonary fibrosis via switching the development of epithelial-mesenchymal transition. causal interaction 4 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/27509983/ Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System. causal interaction 4 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/20846163/ The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in mice. therapeutic application 4 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/26071646/ Crosstalk between calpain activation and TGF-?1 augments collagen-I synthesis in pulmonary fibrosis. therapeutic application 1 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/27509983/ Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System. therapeutic application 2 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/34231213/ Pleural mesothelial cell migration into lung parenchyma by calpain contributes to idiopathic pulmonary fibrosis. therapeutic application 1 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/20846163/ The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in mice. ongoing research 4 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/29666896/ Calpain inhibition attenuates bleomycin-induced pulmonary fibrosis via switching the development of epithelial-mesenchymal transition. ongoing research 4 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/27509983/ Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System. ongoing research 4 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/34231213/ Pleural mesothelial cell migration into lung parenchyma by calpain contributes to idiopathic pulmonary fibrosis. ongoing research 3 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/34231213/ Pleural mesothelial cell migration into lung parenchyma by calpain contributes to idiopathic pulmonary fibrosis. unassigned - 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/20846163/ The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in mice. unassigned - 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/26071646/ Crosstalk between calpain activation and TGF-?1 augments collagen-I synthesis in pulmonary fibrosis. unassigned - 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/29666896/ Calpain inhibition attenuates bleomycin-induced pulmonary fibrosis via switching the development of epithelial-mesenchymal transition. unassigned - 3.4.22.B28 Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/27509983/ Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System. unassigned - 3.4.22.B28 Pulmonary Heart Disease https://pubmed.ncbi.nlm.nih.gov/22582173/ Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. causal interaction 4 3.4.22.B28 Pulmonary Heart Disease https://pubmed.ncbi.nlm.nih.gov/22582173/ Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. therapeutic application 4 3.4.22.B28 Pulmonary Heart Disease https://pubmed.ncbi.nlm.nih.gov/22582173/ Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. unassigned - 3.4.22.B28 Purpura, Thrombocytopenic, Idiopathic https://pubmed.ncbi.nlm.nih.gov/7986718/ Evidence implicating calpain (Ca(2+)-dependent neutral protease) in the destructive thrombocytopenia of the Wiskott-Aldrich syndrome. diagnostic usage 4 3.4.22.B28 Purpura, Thrombocytopenic, Idiopathic https://pubmed.ncbi.nlm.nih.gov/7986718/ Evidence implicating calpain (Ca(2+)-dependent neutral protease) in the destructive thrombocytopenia of the Wiskott-Aldrich syndrome. ongoing research 2 3.4.22.B28 Purpura, Thrombocytopenic, Idiopathic https://pubmed.ncbi.nlm.nih.gov/7986718/ Evidence implicating calpain (Ca(2+)-dependent neutral protease) in the destructive thrombocytopenia of the Wiskott-Aldrich syndrome. unassigned - 3.4.22.B28 Purpura, Thrombotic Thrombocytopenic https://pubmed.ncbi.nlm.nih.gov/2346725/ Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. causal interaction 1 3.4.22.B28 Purpura, Thrombotic Thrombocytopenic https://pubmed.ncbi.nlm.nih.gov/21731431/ Calpain activator dibucaine induces platelet apoptosis. causal interaction 4 3.4.22.B28 Purpura, Thrombotic Thrombocytopenic https://pubmed.ncbi.nlm.nih.gov/1421394/ Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles. diagnostic usage 4 3.4.22.B28 Purpura, Thrombotic Thrombocytopenic https://pubmed.ncbi.nlm.nih.gov/2346725/ Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. diagnostic usage 3 3.4.22.B28 Purpura, Thrombotic Thrombocytopenic https://pubmed.ncbi.nlm.nih.gov/10490730/ Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. diagnostic usage 3 3.4.22.B28 Purpura, Thrombotic Thrombocytopenic https://pubmed.ncbi.nlm.nih.gov/10490730/ Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. therapeutic application 1 3.4.22.B28 Purpura, Thrombotic Thrombocytopenic https://pubmed.ncbi.nlm.nih.gov/2346725/ Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. ongoing research 3 3.4.22.B28 Purpura, Thrombotic Thrombocytopenic https://pubmed.ncbi.nlm.nih.gov/1421394/ Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles. unassigned - 3.4.22.B28 Purpura, Thrombotic Thrombocytopenic https://pubmed.ncbi.nlm.nih.gov/10490730/ Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. unassigned - 3.4.22.B28 Purpura, Thrombotic Thrombocytopenic https://pubmed.ncbi.nlm.nih.gov/21731431/ Calpain activator dibucaine induces platelet apoptosis. unassigned - 3.4.22.B28 Purpura, Thrombotic Thrombocytopenic https://pubmed.ncbi.nlm.nih.gov/2346725/ Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. unassigned - 3.4.22.B28 Renal Insufficiency https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. causal interaction 4 3.4.22.B28 Renal Insufficiency https://pubmed.ncbi.nlm.nih.gov/17567592/ Calpain inhibition but not reticulum endoplasmic stress preconditioning protects rat kidneys from p-aminophenol toxicity. causal interaction 4 3.4.22.B28 Renal Insufficiency https://pubmed.ncbi.nlm.nih.gov/17567592/ Calpain inhibition but not reticulum endoplasmic stress preconditioning protects rat kidneys from p-aminophenol toxicity. diagnostic usage 3 3.4.22.B28 Renal Insufficiency https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. therapeutic application 4 3.4.22.B28 Renal Insufficiency https://pubmed.ncbi.nlm.nih.gov/17567592/ Calpain inhibition but not reticulum endoplasmic stress preconditioning protects rat kidneys from p-aminophenol toxicity. ongoing research 3 3.4.22.B28 Renal Insufficiency https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. unassigned - 3.4.22.B28 Renal Insufficiency https://pubmed.ncbi.nlm.nih.gov/17567592/ Calpain inhibition but not reticulum endoplasmic stress preconditioning protects rat kidneys from p-aminophenol toxicity. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/9441801/ Prostacyclin analog-suppressed ischemia-reperfusion injury of the rat liver: evaluation by calpain mu activation. causal interaction 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/11035539/ Involvement of calpain isoforms in ischemia-reperfusion injury in rat retina. causal interaction 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/14676682/ Calpain inhibitor I reduces intestinal ischemia-reperfusion injury in the rat. causal interaction 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/15528229/ Calpain inhibitor-1 protects the rat heart from ischemia-reperfusion injury: analysis by mechanical work and energetics. causal interaction 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/19966051/ Cardioprotective effects of a novel calpain inhibitor SNJ-1945 for reperfusion injury after cardioplegic cardiac arrest. causal interaction 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/20473717/ The protective effects and potential mechanism of Calpain inhibitor Calpeptin against focal cerebral ischemia-reperfusion injury in rats. causal interaction 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/20883775/ Disruption of Rac1 signaling reduces ischemia-reperfusion injury in the diabetic heart by inhibiting calpain. causal interaction 2 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. causal interaction 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/28284837/ CaSR and calpain contribute to the ischemia reperfusion injury of spinal cord. causal interaction 3 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/9869615/ Calpain mediates ischemic injury of the liver through modulation of apoptosis and necrosis. causal interaction 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/10989732/ [Demonstration of secondary free radicals and the role of calpain in functional changes associated with the myocardial ischemia-reperfusion sequence] causal interaction 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/12646718/ Glucocorticoids preserve calpastatin and troponin I during cardiopulmonary bypass in immature pigs. causal interaction 3 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/22575511/ Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. causal interaction 2 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/30659884/ Structure and proteolytic susceptibility of the inhibitory C-terminal tail of cardiac troponin I. causal interaction 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/11035539/ Involvement of calpain isoforms in ischemia-reperfusion injury in rat retina. diagnostic usage 2 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. diagnostic usage 3 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/18666321/ Protective effect of prednisolone on ischemia-induced liver injury in rats. diagnostic usage 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/9441801/ Prostacyclin analog-suppressed ischemia-reperfusion injury of the rat liver: evaluation by calpain mu activation. therapeutic application 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/10818771/ Calpain methods in hepatic ischemia-reperfusion injury. therapeutic application 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/11035539/ Involvement of calpain isoforms in ischemia-reperfusion injury in rat retina. therapeutic application 3 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/11893579/ Attenuation of neutrophil-mediated myocardial ischemia-reperfusion injury by a calpain inhibitor. therapeutic application 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/14676682/ Calpain inhibitor I reduces intestinal ischemia-reperfusion injury in the rat. therapeutic application 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/15528229/ Calpain inhibitor-1 protects the rat heart from ischemia-reperfusion injury: analysis by mechanical work and energetics. therapeutic application 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/15763548/ Inhibitors of calpain activation (PD150606 and E-64) and renal ischemia-reperfusion injury. therapeutic application 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/19966051/ Cardioprotective effects of a novel calpain inhibitor SNJ-1945 for reperfusion injury after cardioplegic cardiac arrest. therapeutic application 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/20473717/ The protective effects and potential mechanism of Calpain inhibitor Calpeptin against focal cerebral ischemia-reperfusion injury in rats. therapeutic application 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/20883775/ Disruption of Rac1 signaling reduces ischemia-reperfusion injury in the diabetic heart by inhibiting calpain. therapeutic application 2 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/22819130/ Protective effects of adenosine on the diabetic myocardium against ischemia-reperfusion injury: Role of calpain. therapeutic application 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. therapeutic application 3 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/28284837/ CaSR and calpain contribute to the ischemia reperfusion injury of spinal cord. therapeutic application 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/31278945/ Calpain silencing alleviates myocardial ischemia-reperfusion injury through the NLRP3/ASC/Caspase-1 axis in mice. therapeutic application 2 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/9869615/ Calpain mediates ischemic injury of the liver through modulation of apoptosis and necrosis. therapeutic application 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/22575511/ Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. therapeutic application 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/23435869/ Neuroprotective Effect of Resveratrol on Ischemia/Reperfusion Injury in Rats Through TRPC6/CREB Pathways. therapeutic application 2 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/9441801/ Prostacyclin analog-suppressed ischemia-reperfusion injury of the rat liver: evaluation by calpain mu activation. ongoing research 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/10818771/ Calpain methods in hepatic ischemia-reperfusion injury. ongoing research 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/11035539/ Involvement of calpain isoforms in ischemia-reperfusion injury in rat retina. ongoing research 3 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/14676682/ Calpain inhibitor I reduces intestinal ischemia-reperfusion injury in the rat. ongoing research 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/15528229/ Calpain inhibitor-1 protects the rat heart from ischemia-reperfusion injury: analysis by mechanical work and energetics. ongoing research 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/19966051/ Cardioprotective effects of a novel calpain inhibitor SNJ-1945 for reperfusion injury after cardioplegic cardiac arrest. ongoing research 1 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/20473717/ The protective effects and potential mechanism of Calpain inhibitor Calpeptin against focal cerebral ischemia-reperfusion injury in rats. ongoing research 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/22819130/ Protective effects of adenosine on the diabetic myocardium against ischemia-reperfusion injury: Role of calpain. ongoing research 3 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/8357852/ Calpain activity alters in rat myocardial subfractions after ischemia or reperfusion. ongoing research 2 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/10989732/ [Demonstration of secondary free radicals and the role of calpain in functional changes associated with the myocardial ischemia-reperfusion sequence] ongoing research 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/18666321/ Protective effect of prednisolone on ischemia-induced liver injury in rats. ongoing research 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/23435869/ Neuroprotective Effect of Resveratrol on Ischemia/Reperfusion Injury in Rats Through TRPC6/CREB Pathways. ongoing research 4 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/10818771/ Calpain methods in hepatic ischemia-reperfusion injury. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/11281557/ Prednisolone suppresses ischemia-reperfusion injury of the rat liver by reducing cytokine production and calpain mu activation. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/11893579/ Attenuation of neutrophil-mediated myocardial ischemia-reperfusion injury by a calpain inhibitor. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/15763548/ Inhibitors of calpain activation (PD150606 and E-64) and renal ischemia-reperfusion injury. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/22819130/ Protective effects of adenosine on the diabetic myocardium against ischemia-reperfusion injury: Role of calpain. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/27077802/ Calpain 2-mediated autophagy defect increases susceptibility of fatty livers to ischemia-reperfusion injury. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/31278945/ Calpain silencing alleviates myocardial ischemia-reperfusion injury through the NLRP3/ASC/Caspase-1 axis in mice. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/8357852/ Calpain activity alters in rat myocardial subfractions after ischemia or reperfusion. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/18666321/ Protective effect of prednisolone on ischemia-induced liver injury in rats. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/23435869/ Neuroprotective Effect of Resveratrol on Ischemia/Reperfusion Injury in Rats Through TRPC6/CREB Pathways. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/25297462/ cGMP/PKG Pathway as a common mediator of cardioprotection. Translatability and mechanism. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/9441801/ Prostacyclin analog-suppressed ischemia-reperfusion injury of the rat liver: evaluation by calpain mu activation. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/14676682/ Calpain inhibitor I reduces intestinal ischemia-reperfusion injury in the rat. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/15528229/ Calpain inhibitor-1 protects the rat heart from ischemia-reperfusion injury: analysis by mechanical work and energetics. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/19966051/ Cardioprotective effects of a novel calpain inhibitor SNJ-1945 for reperfusion injury after cardioplegic cardiac arrest. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/20473717/ The protective effects and potential mechanism of Calpain inhibitor Calpeptin against focal cerebral ischemia-reperfusion injury in rats. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/20883775/ Disruption of Rac1 signaling reduces ischemia-reperfusion injury in the diabetic heart by inhibiting calpain. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/28284837/ CaSR and calpain contribute to the ischemia reperfusion injury of spinal cord. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/9869615/ Calpain mediates ischemic injury of the liver through modulation of apoptosis and necrosis. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/10989732/ [Demonstration of secondary free radicals and the role of calpain in functional changes associated with the myocardial ischemia-reperfusion sequence] unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/12646718/ Glucocorticoids preserve calpastatin and troponin I during cardiopulmonary bypass in immature pigs. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/22575511/ Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/30659884/ Structure and proteolytic susceptibility of the inhibitory C-terminal tail of cardiac troponin I. unassigned - 3.4.22.B28 Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/25068024/ Calpain system and its involvement in myocardial ischemia and reperfusion injury. unassigned - 3.4.22.B28 Respiratory Distress Syndrome https://pubmed.ncbi.nlm.nih.gov/16391721/ Chronicles in drug discovery. causal interaction 3 3.4.22.B28 Respiratory Distress Syndrome https://pubmed.ncbi.nlm.nih.gov/16391721/ Chronicles in drug discovery. therapeutic application 4 3.4.22.B28 Respiratory Distress Syndrome https://pubmed.ncbi.nlm.nih.gov/16391721/ Chronicles in drug discovery. unassigned - 3.4.22.B28 Respiratory Insufficiency https://pubmed.ncbi.nlm.nih.gov/19661453/ Caspase and Calpain Activation Both Contribute to Sepsis Induced Diaphragmatic Weakness. causal interaction 2 3.4.22.B28 Respiratory Insufficiency https://pubmed.ncbi.nlm.nih.gov/19661453/ Caspase and Calpain Activation Both Contribute to Sepsis Induced Diaphragmatic Weakness. therapeutic application 1 3.4.22.B28 Respiratory Insufficiency https://pubmed.ncbi.nlm.nih.gov/19661453/ Caspase and Calpain Activation Both Contribute to Sepsis Induced Diaphragmatic Weakness. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/16843603/ Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester. causal interaction 4 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/17088543/ Apoptosis in retinal degeneration involves cross-talk between apoptosis-inducing factor (AIF) and caspase-12 and is blocked by calpain inhibitors. causal interaction 1 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/16528750/ Presence of calpain-induced proteolysis in retinal degeneration and dysfunction in a rat model of acute ocular hypertension. causal interaction 4 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/17069801/ Contribution of calpains to photoreceptor cell death in N-methyl-N-nitrosourea-treated rats. causal interaction 3 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/17171699/ Calpain activity in retinal degeneration. diagnostic usage 3 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/20547152/ Activation of mitochondrial calpain and release of apoptosis-inducing factor from mitochondria in RCS rat retinal degeneration. diagnostic usage 3 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/18982459/ Photoreceptor cell death mechanisms in inherited retinal degeneration. diagnostic usage 3 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/16843603/ Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester. therapeutic application 4 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/17088543/ Apoptosis in retinal degeneration involves cross-talk between apoptosis-inducing factor (AIF) and caspase-12 and is blocked by calpain inhibitors. therapeutic application 1 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/17171699/ Calpain activity in retinal degeneration. therapeutic application 3 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/20547152/ Activation of mitochondrial calpain and release of apoptosis-inducing factor from mitochondria in RCS rat retinal degeneration. therapeutic application 1 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/20823194/ Calpain inhibitor protects cells against light-induced retinal degeneration. therapeutic application 4 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/8529410/ Calpain activity in the retinas of normal and RCS rats. therapeutic application 1 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/16528750/ Presence of calpain-induced proteolysis in retinal degeneration and dysfunction in a rat model of acute ocular hypertension. therapeutic application 4 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/17069801/ Contribution of calpains to photoreceptor cell death in N-methyl-N-nitrosourea-treated rats. therapeutic application 4 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/19729009/ Calpains are activated by light but their inhibition has no neuroprotective effect against light-damage. therapeutic application 1 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/20807308/ Photoreceptor rescue and toxicity induced by different calpain inhibitors. therapeutic application 3 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/26844699/ Unfolded protein response-induced dysregulation of calcium homeostasis promotes retinal degeneration in rat models of autosomal dominant retinitis pigmentosa. therapeutic application 1 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/15575367/ Involvement of calpain isoforms in retinal degeneration in WBN/Kob rats. ongoing research 4 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/16843603/ Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester. ongoing research 3 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/17171699/ Calpain activity in retinal degeneration. ongoing research 2 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/20547152/ Activation of mitochondrial calpain and release of apoptosis-inducing factor from mitochondria in RCS rat retinal degeneration. ongoing research 3 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/20823194/ Calpain inhibitor protects cells against light-induced retinal degeneration. ongoing research 4 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/20807308/ Photoreceptor rescue and toxicity induced by different calpain inhibitors. ongoing research 4 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/26844699/ Unfolded protein response-induced dysregulation of calcium homeostasis promotes retinal degeneration in rat models of autosomal dominant retinitis pigmentosa. ongoing research 2 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/15575367/ Involvement of calpain isoforms in retinal degeneration in WBN/Kob rats. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/17171699/ Calpain activity in retinal degeneration. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/20547152/ Activation of mitochondrial calpain and release of apoptosis-inducing factor from mitochondria in RCS rat retinal degeneration. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/20823194/ Calpain inhibitor protects cells against light-induced retinal degeneration. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/8529410/ Calpain activity in the retinas of normal and RCS rats. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/16405498/ Calpain is activated in degenerating photoreceptors in the rd1 mouse. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/18982459/ Photoreceptor cell death mechanisms in inherited retinal degeneration. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/19729009/ Calpains are activated by light but their inhibition has no neuroprotective effect against light-damage. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/20807308/ Photoreceptor rescue and toxicity induced by different calpain inhibitors. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/26844699/ Unfolded protein response-induced dysregulation of calcium homeostasis promotes retinal degeneration in rat models of autosomal dominant retinitis pigmentosa. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/16843603/ Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/17088543/ Apoptosis in retinal degeneration involves cross-talk between apoptosis-inducing factor (AIF) and caspase-12 and is blocked by calpain inhibitors. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/16528750/ Presence of calpain-induced proteolysis in retinal degeneration and dysfunction in a rat model of acute ocular hypertension. unassigned - 3.4.22.B28 Retinal Degeneration https://pubmed.ncbi.nlm.nih.gov/17069801/ Contribution of calpains to photoreceptor cell death in N-methyl-N-nitrosourea-treated rats. unassigned - 3.4.22.B28 Retinal Detachment https://pubmed.ncbi.nlm.nih.gov/24408986/ Control of photoreceptor autophagy after retinal detachment: the switch from survival to death. therapeutic application 1 3.4.22.B28 Retinal Detachment https://pubmed.ncbi.nlm.nih.gov/24408986/ Control of photoreceptor autophagy after retinal detachment: the switch from survival to death. unassigned - 3.4.22.B28 Retinal Diseases https://pubmed.ncbi.nlm.nih.gov/31968260/ Structural Insights into the Unique Activation Mechanisms of a Non-classical Calpain and Its Disease-Causing Variants. causal interaction 1 3.4.22.B28 Retinal Diseases https://pubmed.ncbi.nlm.nih.gov/32840357/ Companion Diagnosis for Retinal Neuroprotective Treatment by Real-Time Imaging of Calpain Activation Using a Novel Fluorescent Probe. ongoing research 3 3.4.22.B28 Retinal Diseases https://pubmed.ncbi.nlm.nih.gov/32840357/ Companion Diagnosis for Retinal Neuroprotective Treatment by Real-Time Imaging of Calpain Activation Using a Novel Fluorescent Probe. unassigned - 3.4.22.B28 Retinal Diseases https://pubmed.ncbi.nlm.nih.gov/31968260/ Structural Insights into the Unique Activation Mechanisms of a Non-classical Calpain and Its Disease-Causing Variants. unassigned - 3.4.22.B28 Retinitis Pigmentosa https://pubmed.ncbi.nlm.nih.gov/17069801/ Contribution of calpains to photoreceptor cell death in N-methyl-N-nitrosourea-treated rats. causal interaction 3 3.4.22.B28 Retinitis Pigmentosa https://pubmed.ncbi.nlm.nih.gov/17069801/ Contribution of calpains to photoreceptor cell death in N-methyl-N-nitrosourea-treated rats. therapeutic application 4 3.4.22.B28 Retinitis Pigmentosa https://pubmed.ncbi.nlm.nih.gov/17069801/ Contribution of calpains to photoreceptor cell death in N-methyl-N-nitrosourea-treated rats. unassigned - 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/10749891/ Mitotic clonal expansion during preadipocyte differentiation: calpain-mediated turnover of p27. causal interaction 1 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/15634230/ Expression of late myogenic differentiation markers in sarcoplasmic masses of patients with myotonic dystrophy. diagnostic usage 3 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/10075737/ Caspase-dependent activation of calpain during drug-induced apoptosis. therapeutic application 1 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/10749891/ Mitotic clonal expansion during preadipocyte differentiation: calpain-mediated turnover of p27. therapeutic application 1 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/10534570/ Proteolytic degradation of the retinoblastoma family protein p107: A putative cooperative role of calpain and proteasome. ongoing research 1 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/17977825/ Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. ongoing research 2 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/18632617/ SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival. ongoing research 2 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/15634230/ Expression of late myogenic differentiation markers in sarcoplasmic masses of patients with myotonic dystrophy. ongoing research 4 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/10086333/ Posttranslational regulation of the retinoblastoma gene family member p107 by calpain protease. unassigned - 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/10534570/ Proteolytic degradation of the retinoblastoma family protein p107: A putative cooperative role of calpain and proteasome. unassigned - 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/17977825/ Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. unassigned - 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/18632617/ SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival. unassigned - 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/10075737/ Caspase-dependent activation of calpain during drug-induced apoptosis. unassigned - 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/15634230/ Expression of late myogenic differentiation markers in sarcoplasmic masses of patients with myotonic dystrophy. unassigned - 3.4.22.B28 Retinoblastoma https://pubmed.ncbi.nlm.nih.gov/10749891/ Mitotic clonal expansion during preadipocyte differentiation: calpain-mediated turnover of p27. unassigned - 3.4.22.B28 Sarcoglycanopathies https://pubmed.ncbi.nlm.nih.gov/11731278/ Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. causal interaction 3 3.4.22.B28 Sarcoglycanopathies https://pubmed.ncbi.nlm.nih.gov/11731278/ Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. diagnostic usage 2 3.4.22.B28 Sarcoglycanopathies https://pubmed.ncbi.nlm.nih.gov/11731278/ Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. unassigned - 3.4.22.B28 Sarcoma, Synovial https://pubmed.ncbi.nlm.nih.gov/32204400/ Calcium-Dependent Calpain Activation-Mediated Mitochondrial Dysfunction and Oxidative Stress Are Required for Cytotoxicity of Epinecidin-1 in Human Synovial Sarcoma SW982 Cells. ongoing research 2 3.4.22.B28 Sarcoma, Synovial https://pubmed.ncbi.nlm.nih.gov/32204400/ Calcium-Dependent Calpain Activation-Mediated Mitochondrial Dysfunction and Oxidative Stress Are Required for Cytotoxicity of Epinecidin-1 in Human Synovial Sarcoma SW982 Cells. unassigned - 3.4.22.B28 Sarcopenia https://pubmed.ncbi.nlm.nih.gov/22950758/ Age-related loss of nitric oxide synthase in skeletal muscle causes reductions in calpain S-nitrosylation that increase myofibril degradation and sarcopenia. causal interaction 3 3.4.22.B28 Sarcopenia https://pubmed.ncbi.nlm.nih.gov/22950758/ Age-related loss of nitric oxide synthase in skeletal muscle causes reductions in calpain S-nitrosylation that increase myofibril degradation and sarcopenia. therapeutic application 1 3.4.22.B28 Sarcopenia https://pubmed.ncbi.nlm.nih.gov/22950758/ Age-related loss of nitric oxide synthase in skeletal muscle causes reductions in calpain S-nitrosylation that increase myofibril degradation and sarcopenia. unassigned - 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/15780729/ Establishment of Schistosoma japonicum calpain-specific mouse T cell hybridomas and identification of a T cell epitope that stimulates IFNgamma production. causal interaction 2 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/11227763/ Cloning and molecular characterization of calpain, a calcium-activated neutral proteinase, from different strains of Schistosoma japonicum. diagnostic usage 3 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/11227763/ Cloning and molecular characterization of calpain, a calcium-activated neutral proteinase, from different strains of Schistosoma japonicum. therapeutic application 3 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/15780729/ Establishment of Schistosoma japonicum calpain-specific mouse T cell hybridomas and identification of a T cell epitope that stimulates IFNgamma production. therapeutic application 1 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/29739616/ Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons. therapeutic application 1 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/11227763/ Cloning and molecular characterization of calpain, a calcium-activated neutral proteinase, from different strains of Schistosoma japonicum. ongoing research 1 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/29739616/ Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons. ongoing research 2 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/11227763/ Cloning and molecular characterization of calpain, a calcium-activated neutral proteinase, from different strains of Schistosoma japonicum. unassigned - 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/24436452/ Use of an Sm-p80-Based Therapeutic Vaccine to Kill Established Adult Schistosome Parasites in Chronically Infected Baboons. unassigned - 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/29739616/ Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons. unassigned - 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/29997146/ Schistosoma mansoni antigen Sm-p80: prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models. unassigned - 3.4.22.B28 Schistosomiasis https://pubmed.ncbi.nlm.nih.gov/15780729/ Establishment of Schistosoma japonicum calpain-specific mouse T cell hybridomas and identification of a T cell epitope that stimulates IFNgamma production. unassigned - 3.4.22.B28 Schistosomiasis mansoni https://pubmed.ncbi.nlm.nih.gov/9364694/ Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. therapeutic application 3 3.4.22.B28 Schistosomiasis mansoni https://pubmed.ncbi.nlm.nih.gov/9364694/ Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. ongoing research 1 3.4.22.B28 Schistosomiasis mansoni https://pubmed.ncbi.nlm.nih.gov/9364694/ Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. unassigned - 3.4.22.B28 Scleroderma, Systemic https://pubmed.ncbi.nlm.nih.gov/32393322/ Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis. causal interaction 3 3.4.22.B28 Scleroderma, Systemic https://pubmed.ncbi.nlm.nih.gov/32393322/ Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis. diagnostic usage 4 3.4.22.B28 Scleroderma, Systemic https://pubmed.ncbi.nlm.nih.gov/32393322/ Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/8836550/ Regional distribution and time-course of calpain activation following kainate-induced seizure activity in adult rat brain. causal interaction 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. causal interaction 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/33802221/ Asiatic Acid Prevents Cognitive Deficits by Inhibiting Calpain Activation and Preserving Synaptic and Mitochondrial Function in Rats with Kainic Acid-Induced Seizure. causal interaction 4 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/11012026/ Synthesis and biological evaluation of novel piperidine carboxamide derived calpain inhibitors. causal interaction 1 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/25229715/ BDNF is required for seizure-induced but not developmental up-regulation of KCC2 in the neonatal hippocampus. causal interaction 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. causal interaction 4 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/30186110/ M-Calpain Activation Facilitates Seizure Induced KCC2 Down Regulation. causal interaction 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/30423475/ Calpain activation and neuronal death during early epileptogenesis. causal interaction 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/31495081/ Calpain-2 as a Treatment Target in Prenatal Stress-induced Epileptic Spasms in Infant Rats. causal interaction 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/33132163/ Calpain-2 activation in mouse hippocampus plays a critical role in seizure-induced neuropathology. causal interaction 4 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/8836550/ Regional distribution and time-course of calpain activation following kainate-induced seizure activity in adult rat brain. diagnostic usage 1 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/10213161/ Calpain inhibitor I retards seizure offset in the hippocampus of freely moving rats. diagnostic usage 1 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. diagnostic usage 1 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/9330373/ Developmental changes in calpain activity, GluR1 receptors and in the effect of kainic acid treatment in rat brain. diagnostic usage 2 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/30423475/ Calpain activation and neuronal death during early epileptogenesis. diagnostic usage 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/31585309/ Calpain-dependent cleavage of GABAergic proteins during epileptogenesis. diagnostic usage 1 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/8836550/ Regional distribution and time-course of calpain activation following kainate-induced seizure activity in adult rat brain. therapeutic application 2 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/10213161/ Calpain inhibitor I retards seizure offset in the hippocampus of freely moving rats. therapeutic application 1 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. therapeutic application 4 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/11012026/ Synthesis and biological evaluation of novel piperidine carboxamide derived calpain inhibitors. therapeutic application 4 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/18721885/ Calpain activity contributes to the control of SNAP-25 levels in neurons. therapeutic application 2 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. therapeutic application 4 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/31495081/ Calpain-2 as a Treatment Target in Prenatal Stress-induced Epileptic Spasms in Infant Rats. therapeutic application 4 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/31585309/ Calpain-dependent cleavage of GABAergic proteins during epileptogenesis. therapeutic application 2 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/33132163/ Calpain-2 activation in mouse hippocampus plays a critical role in seizure-induced neuropathology. therapeutic application 4 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/1384274/ Effect of seizure activity and calpain inhibitor I on LTP in juvenile hippocampal slices. ongoing research 2 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/8836550/ Regional distribution and time-course of calpain activation following kainate-induced seizure activity in adult rat brain. ongoing research 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/10213161/ Calpain inhibitor I retards seizure offset in the hippocampus of freely moving rats. ongoing research 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. ongoing research 4 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/29209207/ Antiepileptic and Neuroprotective Effects of Oleamide in Rat Striatum on Kainate-Induced Behavioral Seizure and Excitotoxic Damage via Calpain Inhibition. ongoing research 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/9330373/ Developmental changes in calpain activity, GluR1 receptors and in the effect of kainic acid treatment in rat brain. ongoing research 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. ongoing research 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/30186110/ M-Calpain Activation Facilitates Seizure Induced KCC2 Down Regulation. ongoing research 2 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/30423475/ Calpain activation and neuronal death during early epileptogenesis. ongoing research 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/31495081/ Calpain-2 as a Treatment Target in Prenatal Stress-induced Epileptic Spasms in Infant Rats. ongoing research 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/33132163/ Calpain-2 activation in mouse hippocampus plays a critical role in seizure-induced neuropathology. ongoing research 3 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/1384274/ Effect of seizure activity and calpain inhibitor I on LTP in juvenile hippocampal slices. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/10213161/ Calpain inhibitor I retards seizure offset in the hippocampus of freely moving rats. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/29209207/ Antiepileptic and Neuroprotective Effects of Oleamide in Rat Striatum on Kainate-Induced Behavioral Seizure and Excitotoxic Damage via Calpain Inhibition. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/9330373/ Developmental changes in calpain activity, GluR1 receptors and in the effect of kainic acid treatment in rat brain. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/18721885/ Calpain activity contributes to the control of SNAP-25 levels in neurons. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/31585309/ Calpain-dependent cleavage of GABAergic proteins during epileptogenesis. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/33802221/ Asiatic Acid Prevents Cognitive Deficits by Inhibiting Calpain Activation and Preserving Synaptic and Mitochondrial Function in Rats with Kainic Acid-Induced Seizure. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/11012026/ Synthesis and biological evaluation of novel piperidine carboxamide derived calpain inhibitors. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/25229715/ BDNF is required for seizure-induced but not developmental up-regulation of KCC2 in the neonatal hippocampus. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/27345730/ Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/30186110/ M-Calpain Activation Facilitates Seizure Induced KCC2 Down Regulation. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/31495081/ Calpain-2 as a Treatment Target in Prenatal Stress-induced Epileptic Spasms in Infant Rats. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/33132163/ Calpain-2 activation in mouse hippocampus plays a critical role in seizure-induced neuropathology. unassigned - 3.4.22.B28 Seizures https://pubmed.ncbi.nlm.nih.gov/30423475/ Calpain activation and neuronal death during early epileptogenesis. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/15563579/ Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3. causal interaction 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. causal interaction 3 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/19661453/ Caspase and Calpain Activation Both Contribute to Sepsis Induced Diaphragmatic Weakness. causal interaction 2 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/33038189/ Calpain Activation and Organ Failure in Sepsis: Molecular Insights and Therapeutic Perspectives. causal interaction 3 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/8721383/ Ca2(+)-dependent and Ca2(+)-independent proteinase contents in the skeletal muscle in septic rats. causal interaction 1 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/19329553/ Calpain Activation Contributes to Endotoxin Induced Diaphragmatic Dysfunction. causal interaction 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/22268136/ Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release. causal interaction 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/23425388/ The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis. causal interaction 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/24441549/ Cleavage of I?B? by calpain induces myocardial NF-?B activation, TNF-? expression, and cardiac dysfunction in septic mice. causal interaction 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/25170071/ Muscle-specific calpastatin overexpression prevents diaphragm weakness in cecal ligation puncture-induced sepsis. causal interaction 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/26246018/ Deletion of capn4 Protects the Heart Against Endotoxemic Injury by Preventing ATP Synthase Disruption and Inhibiting Mitochondrial Superoxide Generation. causal interaction 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/27880847/ Activation of Both the Calpain and Ubiquitin-Proteasome Systems Contributes to Septic Cardiomyopathy through Dystrophin Loss/Disruption and mTOR Inhibition. causal interaction 2 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/31944887/ SS31, a mitochondrially targeted antioxidant, prevents sepsis-induced reductions in diaphragm strength and endurance. causal interaction 1 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/32968209/ Targeted inhibition of calpain in mitochondria alleviates oxidative stress-induced myocardial injury. causal interaction 3 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/11236903/ Dantrolene reduces serum TNFalpha and corticosterone levels and muscle calcium, calpain gene expression, and protein breakdown in septic rats. diagnostic usage 3 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/26246018/ Deletion of capn4 Protects the Heart Against Endotoxemic Injury by Preventing ATP Synthase Disruption and Inhibiting Mitochondrial Superoxide Generation. diagnostic usage 3 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/27880847/ Activation of Both the Calpain and Ubiquitin-Proteasome Systems Contributes to Septic Cardiomyopathy through Dystrophin Loss/Disruption and mTOR Inhibition. diagnostic usage 3 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/15563579/ Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3. therapeutic application 1 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. therapeutic application 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/19661453/ Caspase and Calpain Activation Both Contribute to Sepsis Induced Diaphragmatic Weakness. therapeutic application 1 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/33038189/ Calpain Activation and Organ Failure in Sepsis: Molecular Insights and Therapeutic Perspectives. therapeutic application 3 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/11236903/ Dantrolene reduces serum TNFalpha and corticosterone levels and muscle calcium, calpain gene expression, and protein breakdown in septic rats. therapeutic application 1 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/19329553/ Calpain Activation Contributes to Endotoxin Induced Diaphragmatic Dysfunction. therapeutic application 2 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/22268136/ Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release. therapeutic application 2 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/23425388/ The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis. therapeutic application 3 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/24441549/ Cleavage of I?B? by calpain induces myocardial NF-?B activation, TNF-? expression, and cardiac dysfunction in septic mice. therapeutic application 2 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/25170071/ Muscle-specific calpastatin overexpression prevents diaphragm weakness in cecal ligation puncture-induced sepsis. therapeutic application 3 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/26246018/ Deletion of capn4 Protects the Heart Against Endotoxemic Injury by Preventing ATP Synthase Disruption and Inhibiting Mitochondrial Superoxide Generation. therapeutic application 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/27880847/ Activation of Both the Calpain and Ubiquitin-Proteasome Systems Contributes to Septic Cardiomyopathy through Dystrophin Loss/Disruption and mTOR Inhibition. therapeutic application 1 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/15563579/ Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3. ongoing research 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. ongoing research 1 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/11236903/ Dantrolene reduces serum TNFalpha and corticosterone levels and muscle calcium, calpain gene expression, and protein breakdown in septic rats. ongoing research 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/15179136/ Calpain inhibitors improve myocardial dysfunction and inflammation induced by endotoxin in rats. ongoing research 1 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/22268136/ Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release. ongoing research 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/26246018/ Deletion of capn4 Protects the Heart Against Endotoxemic Injury by Preventing ATP Synthase Disruption and Inhibiting Mitochondrial Superoxide Generation. ongoing research 4 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/11236903/ Dantrolene reduces serum TNFalpha and corticosterone levels and muscle calcium, calpain gene expression, and protein breakdown in septic rats. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/15179136/ Calpain inhibitors improve myocardial dysfunction and inflammation induced by endotoxin in rats. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/15563579/ Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/18492780/ Calpain activity and muscle wasting in sepsis. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/19661453/ Caspase and Calpain Activation Both Contribute to Sepsis Induced Diaphragmatic Weakness. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/33038189/ Calpain Activation and Organ Failure in Sepsis: Molecular Insights and Therapeutic Perspectives. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/8721383/ Ca2(+)-dependent and Ca2(+)-independent proteinase contents in the skeletal muscle in septic rats. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/19329553/ Calpain Activation Contributes to Endotoxin Induced Diaphragmatic Dysfunction. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/22268136/ Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/23425388/ The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/24441549/ Cleavage of I?B? by calpain induces myocardial NF-?B activation, TNF-? expression, and cardiac dysfunction in septic mice. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/25170071/ Muscle-specific calpastatin overexpression prevents diaphragm weakness in cecal ligation puncture-induced sepsis. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/31944887/ SS31, a mitochondrially targeted antioxidant, prevents sepsis-induced reductions in diaphragm strength and endurance. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/32968209/ Targeted inhibition of calpain in mitochondria alleviates oxidative stress-induced myocardial injury. unassigned - 3.4.22.B28 Sepsis https://pubmed.ncbi.nlm.nih.gov/27880847/ Activation of Both the Calpain and Ubiquitin-Proteasome Systems Contributes to Septic Cardiomyopathy through Dystrophin Loss/Disruption and mTOR Inhibition. unassigned - 3.4.22.B28 Sinusitis https://pubmed.ncbi.nlm.nih.gov/32832531/ Elevated levels of calpain 14 in nasal tissue in chronic rhinosinusitis. unassigned - 3.4.22.B28 Skin Diseases https://pubmed.ncbi.nlm.nih.gov/10606846/ The calcium-activated neutral protease calpain I is present in normal foetal skin and is decreased in neonatal harlequin ichthyosis. diagnostic usage 1 3.4.22.B28 Skin Diseases https://pubmed.ncbi.nlm.nih.gov/10606846/ The calcium-activated neutral protease calpain I is present in normal foetal skin and is decreased in neonatal harlequin ichthyosis. ongoing research 4 3.4.22.B28 Skin Diseases https://pubmed.ncbi.nlm.nih.gov/10606846/ The calcium-activated neutral protease calpain I is present in normal foetal skin and is decreased in neonatal harlequin ichthyosis. unassigned - 3.4.22.B28 Small Cell Lung Carcinoma https://pubmed.ncbi.nlm.nih.gov/15471877/ Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. causal interaction 4 3.4.22.B28 Small Cell Lung Carcinoma https://pubmed.ncbi.nlm.nih.gov/24878626/ Capsaicin induces apoptosis in human small cell lung cancer via the TRPV6 receptor and the calpain pathway. ongoing research 2 3.4.22.B28 Small Cell Lung Carcinoma https://pubmed.ncbi.nlm.nih.gov/15471877/ Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. ongoing research 1 3.4.22.B28 Small Cell Lung Carcinoma https://pubmed.ncbi.nlm.nih.gov/17630920/ Nicotine, lung and cancer. ongoing research 2 3.4.22.B28 Small Cell Lung Carcinoma https://pubmed.ncbi.nlm.nih.gov/24878626/ Capsaicin induces apoptosis in human small cell lung cancer via the TRPV6 receptor and the calpain pathway. unassigned - 3.4.22.B28 Small Cell Lung Carcinoma https://pubmed.ncbi.nlm.nih.gov/17630920/ Nicotine, lung and cancer. unassigned - 3.4.22.B28 Small Cell Lung Carcinoma https://pubmed.ncbi.nlm.nih.gov/15471877/ Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. unassigned - 3.4.22.B28 Spasm https://pubmed.ncbi.nlm.nih.gov/33257295/ Vitamin E reduces spasms caused by prenatal stress by lowering calpain expression. causal interaction 4 3.4.22.B28 Spasm https://pubmed.ncbi.nlm.nih.gov/33257295/ Vitamin E reduces spasms caused by prenatal stress by lowering calpain expression. unassigned - 3.4.22.B28 Spermatic Cord Torsion https://pubmed.ncbi.nlm.nih.gov/11058563/ Inhibition of calpain but not caspase protects the testis against injury after experimental testicular torsion of rat. causal interaction 3 3.4.22.B28 Spermatic Cord Torsion https://pubmed.ncbi.nlm.nih.gov/11327551/ Involvement of calpain for apoptosis in dysfunction of the unaffected testis in rats with experimental testicular torsion. causal interaction 4 3.4.22.B28 Spermatic Cord Torsion https://pubmed.ncbi.nlm.nih.gov/11058563/ Inhibition of calpain but not caspase protects the testis against injury after experimental testicular torsion of rat. therapeutic application 4 3.4.22.B28 Spermatic Cord Torsion https://pubmed.ncbi.nlm.nih.gov/11327551/ Involvement of calpain for apoptosis in dysfunction of the unaffected testis in rats with experimental testicular torsion. therapeutic application 2 3.4.22.B28 Spermatic Cord Torsion https://pubmed.ncbi.nlm.nih.gov/11466220/ Nitric oxide promotes germ cell necrosis in the delayed phase after experimental testicular torsion of rat. therapeutic application 2 3.4.22.B28 Spermatic Cord Torsion https://pubmed.ncbi.nlm.nih.gov/11327551/ Involvement of calpain for apoptosis in dysfunction of the unaffected testis in rats with experimental testicular torsion. ongoing research 2 3.4.22.B28 Spermatic Cord Torsion https://pubmed.ncbi.nlm.nih.gov/11466220/ Nitric oxide promotes germ cell necrosis in the delayed phase after experimental testicular torsion of rat. unassigned - 3.4.22.B28 Spermatic Cord Torsion https://pubmed.ncbi.nlm.nih.gov/11058563/ Inhibition of calpain but not caspase protects the testis against injury after experimental testicular torsion of rat. unassigned - 3.4.22.B28 Spermatic Cord Torsion https://pubmed.ncbi.nlm.nih.gov/11327551/ Involvement of calpain for apoptosis in dysfunction of the unaffected testis in rats with experimental testicular torsion. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/8734437/ Role of calpain in spinal cord injury: increased calpain immunoreactivity in rat spinal cord after impact trauma. causal interaction 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/8845743/ Role of calpain in spinal cord injury: increased mcalpain immunoreactivity in spinal cord after compression injury in the rat. causal interaction 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9106471/ Increased calpain content and progressive degradation of neurofilament protein in spinal cord injury. causal interaction 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9369980/ Role of calpain and its inhibitors in tissue degeneration and neuroprotection in spinal cord injury. causal interaction 3 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9668671/ Role of calpain in spinal cord injury: effects of calpain and free radical inhibitors. causal interaction 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9878837/ Calpain activity and translational expression increased in spinal cord injury. causal interaction 3 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10737623/ Pretreatment with calpain inhibitor CEP-4143 inhibits calpain I activation and cytoskeletal degradation, improves neurological function, and enhances axonal survival after traumatic spinal cord injury. causal interaction 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10837800/ E-64-d prevents both calpain upregulation and apoptosis in the lesion and penumbra following spinal cord injury in rats. causal interaction 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/11059793/ Increased calpain expression is associated with apoptosis in rat spinal cord injury: calpain inhibitor provides neuroprotection. causal interaction 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/11462799/ Cell death in spinal cord injury (SCI) requires de novo protein synthesis. Calpain inhibitor E-64-d provides neuroprotection in SCI lesion and penumbra. causal interaction 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/12738057/ Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. causal interaction 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/12815713/ Early induction of secondary injury factors causing activation of calpain and mitochondria-mediated neuronal apoptosis following spinal cord injury in rats. causal interaction 3 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15144879/ Relatively low levels of calpain expression in juvenile rat correlate with less neuronal apoptosis after spinal cord injury. causal interaction 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/16902996/ Estrogen treatment of spinal cord injury attenuates calpain activation and apoptosis. causal interaction 3 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/17476592/ Sustained Calpain Inhibition Improves Locomotor Function and Tissue Sparing Following Contusive Spinal Cord Injury. causal interaction 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/17676387/ Direct Evidence for Calpain Involvement in Apoptotic Death of Neurons in Spinal Cord Injury in Rats and Neuroprotection with Calpain Inhibitor. causal interaction 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/18086148/ Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in rats. causal interaction 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/29090802/ Role of Calpain in Spinal Cord Injury: Effects of Calpain and Free Radical Inhibitors causal interaction 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. causal interaction 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15453993/ Higher calpastatin levels correlate with resistance to calpain-mediated proteolysis and neuronal apoptosis in juvenile rats after spinal cord injury. causal interaction 3 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. causal interaction 3 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15715081/ Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats. causal interaction 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. causal interaction 3 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/18627259/ Intraspinal MDL28170 microinjection improves functional and pathological outcome following spinal cord injury. causal interaction 3 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/21540996/ Role of plasma membrane calcium ATPase 2 in spinal cord pathology. causal interaction 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/23507938/ Role of calpain in apoptosis. causal interaction 3 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/33415854/ [Effects of electroacupuncture on motor function and calpain expression in rats with acute spinal cord injury]. causal interaction 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9878837/ Calpain activity and translational expression increased in spinal cord injury. diagnostic usage 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10878587/ Calpain activity and expression increased in activated glial and inflammatory cells in penumbra of spinal cord injury lesion. diagnostic usage 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15144879/ Relatively low levels of calpain expression in juvenile rat correlate with less neuronal apoptosis after spinal cord injury. diagnostic usage 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. diagnostic usage 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9369980/ Role of calpain and its inhibitors in tissue degeneration and neuroprotection in spinal cord injury. therapeutic application 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9668671/ Role of calpain in spinal cord injury: effects of calpain and free radical inhibitors. therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10366029/ Increased calpain I-mediated proteolysis, and preferential loss of dephosphorylated NF200, following traumatic spinal cord injury. therapeutic application 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10737623/ Pretreatment with calpain inhibitor CEP-4143 inhibits calpain I activation and cytoskeletal degradation, improves neurological function, and enhances axonal survival after traumatic spinal cord injury. therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10837800/ E-64-d prevents both calpain upregulation and apoptosis in the lesion and penumbra following spinal cord injury in rats. therapeutic application 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/11059793/ Increased calpain expression is associated with apoptosis in rat spinal cord injury: calpain inhibitor provides neuroprotection. therapeutic application 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/11462799/ Cell death in spinal cord injury (SCI) requires de novo protein synthesis. Calpain inhibitor E-64-d provides neuroprotection in SCI lesion and penumbra. therapeutic application 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/12738057/ Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/14599661/ Calpain inhibitor prevented apoptosis and maintained transcription of proteolipid protein and myelin basic protein genes in rat spinal cord injury. therapeutic application 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15785234/ Calpain inhibitors prevent neuronal cell death and ameliorate motor disturbances after compression-induced spinal cord injury in rats. therapeutic application 3 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/16902996/ Estrogen treatment of spinal cord injury attenuates calpain activation and apoptosis. therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/17476592/ Sustained Calpain Inhibition Improves Locomotor Function and Tissue Sparing Following Contusive Spinal Cord Injury. therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/17676387/ Direct Evidence for Calpain Involvement in Apoptotic Death of Neurons in Spinal Cord Injury in Rats and Neuroprotection with Calpain Inhibitor. therapeutic application 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/18656362/ Therapeutic efficacy of SJA6017, a calpain inhibitor, in rat spinal cord injury. therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/19575128/ Calpain inhibitor AK 295 inhibits calpain-induced apoptosis and improves neurologic function after traumatic spinal cord injury in rats. therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/21303658/ 2-BFI attenuates experimental autoimmune encephalomyelitis-induced spinal cord injury with enhanced B-CK, CaATPase, but reduced calpain activity. therapeutic application 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/26240815/ Therapeutic Efficacy of E-64-d, a Selective Calpain Inhibitor, in Experimental Acute Spinal Cord Injury. therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/29090802/ Role of Calpain in Spinal Cord Injury: Effects of Calpain and Free Radical Inhibitors therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/12614588/ Evaluation of conditions for calpain inhibition in the rat spinal cord: effective postinjury inhibition with intraspinal MDL28170 microinjection. therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15453993/ Higher calpastatin levels correlate with resistance to calpain-mediated proteolysis and neuronal apoptosis in juvenile rats after spinal cord injury. therapeutic application 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. therapeutic application 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15715081/ Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats. therapeutic application 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/18627259/ Intraspinal MDL28170 microinjection improves functional and pathological outcome following spinal cord injury. therapeutic application 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/23507938/ Role of calpain in apoptosis. therapeutic application 3 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/8845743/ Role of calpain in spinal cord injury: increased mcalpain immunoreactivity in spinal cord after compression injury in the rat. ongoing research 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9668671/ Role of calpain in spinal cord injury: effects of calpain and free radical inhibitors. ongoing research 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9878837/ Calpain activity and translational expression increased in spinal cord injury. ongoing research 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10878587/ Calpain activity and expression increased in activated glial and inflammatory cells in penumbra of spinal cord injury lesion. ongoing research 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/11462799/ Cell death in spinal cord injury (SCI) requires de novo protein synthesis. Calpain inhibitor E-64-d provides neuroprotection in SCI lesion and penumbra. ongoing research 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/14599661/ Calpain inhibitor prevented apoptosis and maintained transcription of proteolipid protein and myelin basic protein genes in rat spinal cord injury. ongoing research 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/17476592/ Sustained Calpain Inhibition Improves Locomotor Function and Tissue Sparing Following Contusive Spinal Cord Injury. ongoing research 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/18656362/ Therapeutic efficacy of SJA6017, a calpain inhibitor, in rat spinal cord injury. ongoing research 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/19575128/ Calpain inhibitor AK 295 inhibits calpain-induced apoptosis and improves neurologic function after traumatic spinal cord injury in rats. ongoing research 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/29090802/ Role of Calpain in Spinal Cord Injury: Effects of Calpain and Free Radical Inhibitors ongoing research 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15715081/ Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats. ongoing research 1 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/27137651/ Calpain inhibitor attenuates ER stress-induced apoptosis in injured spinal cord after bone mesenchymal stem cells transplantation. ongoing research 4 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/33415854/ [Effects of electroacupuncture on motor function and calpain expression in rats with acute spinal cord injury]. ongoing research 2 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10366029/ Increased calpain I-mediated proteolysis, and preferential loss of dephosphorylated NF200, following traumatic spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10818764/ The role of calpain in neurofilament protein degradation associated with spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10878587/ Calpain activity and expression increased in activated glial and inflammatory cells in penumbra of spinal cord injury lesion. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/14599661/ Calpain inhibitor prevented apoptosis and maintained transcription of proteolipid protein and myelin basic protein genes in rat spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15785234/ Calpain inhibitors prevent neuronal cell death and ameliorate motor disturbances after compression-induced spinal cord injury in rats. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/18656362/ Therapeutic efficacy of SJA6017, a calpain inhibitor, in rat spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/19575128/ Calpain inhibitor AK 295 inhibits calpain-induced apoptosis and improves neurologic function after traumatic spinal cord injury in rats. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/21303658/ 2-BFI attenuates experimental autoimmune encephalomyelitis-induced spinal cord injury with enhanced B-CK, CaATPase, but reduced calpain activity. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/26240815/ Therapeutic Efficacy of E-64-d, a Selective Calpain Inhibitor, in Experimental Acute Spinal Cord Injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/26974309/ Cleavage of Na(+) channels by calpain increases persistent Na(+) current and promotes spasticity after spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/31815668/ Calpain fosters the hyperexcitability of motoneurons after spinal cord injury and leads to spasticity. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/12614588/ Evaluation of conditions for calpain inhibition in the rat spinal cord: effective postinjury inhibition with intraspinal MDL28170 microinjection. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/20499928/ Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/27137651/ Calpain inhibitor attenuates ER stress-induced apoptosis in injured spinal cord after bone mesenchymal stem cells transplantation. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/8734437/ Role of calpain in spinal cord injury: increased calpain immunoreactivity in rat spinal cord after impact trauma. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/8845743/ Role of calpain in spinal cord injury: increased mcalpain immunoreactivity in spinal cord after compression injury in the rat. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9106471/ Increased calpain content and progressive degradation of neurofilament protein in spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9369980/ Role of calpain and its inhibitors in tissue degeneration and neuroprotection in spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9668671/ Role of calpain in spinal cord injury: effects of calpain and free radical inhibitors. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10737623/ Pretreatment with calpain inhibitor CEP-4143 inhibits calpain I activation and cytoskeletal degradation, improves neurological function, and enhances axonal survival after traumatic spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10837800/ E-64-d prevents both calpain upregulation and apoptosis in the lesion and penumbra following spinal cord injury in rats. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/11059793/ Increased calpain expression is associated with apoptosis in rat spinal cord injury: calpain inhibitor provides neuroprotection. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/11462799/ Cell death in spinal cord injury (SCI) requires de novo protein synthesis. Calpain inhibitor E-64-d provides neuroprotection in SCI lesion and penumbra. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/12738057/ Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/12815713/ Early induction of secondary injury factors causing activation of calpain and mitochondria-mediated neuronal apoptosis following spinal cord injury in rats. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/16902996/ Estrogen treatment of spinal cord injury attenuates calpain activation and apoptosis. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/17476592/ Sustained Calpain Inhibition Improves Locomotor Function and Tissue Sparing Following Contusive Spinal Cord Injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/17676387/ Direct Evidence for Calpain Involvement in Apoptotic Death of Neurons in Spinal Cord Injury in Rats and Neuroprotection with Calpain Inhibitor. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/18086148/ Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in rats. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/29090802/ Role of Calpain in Spinal Cord Injury: Effects of Calpain and Free Radical Inhibitors unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15453993/ Higher calpastatin levels correlate with resistance to calpain-mediated proteolysis and neuronal apoptosis in juvenile rats after spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15616663/ Potential contribution of proteases to neuronal damage. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15715081/ Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15860369/ Calpain: a death protein that mediates progression of liver injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/18627259/ Intraspinal MDL28170 microinjection improves functional and pathological outcome following spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/21540996/ Role of plasma membrane calcium ATPase 2 in spinal cord pathology. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/23507938/ Role of calpain in apoptosis. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/33415854/ [Effects of electroacupuncture on motor function and calpain expression in rats with acute spinal cord injury]. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/9878837/ Calpain activity and translational expression increased in spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Injuries https://pubmed.ncbi.nlm.nih.gov/15144879/ Relatively low levels of calpain expression in juvenile rat correlate with less neuronal apoptosis after spinal cord injury. unassigned - 3.4.22.B28 Spinal Cord Ischemia https://pubmed.ncbi.nlm.nih.gov/16847592/ Degradation of spectrin via calpains in the ventral horn after transient spinal cord ischemia in rabbits. causal interaction 4 3.4.22.B28 Spinal Cord Ischemia https://pubmed.ncbi.nlm.nih.gov/16847592/ Degradation of spectrin via calpains in the ventral horn after transient spinal cord ischemia in rabbits. therapeutic application 1 3.4.22.B28 Spinal Cord Ischemia https://pubmed.ncbi.nlm.nih.gov/16847592/ Degradation of spectrin via calpains in the ventral horn after transient spinal cord ischemia in rabbits. ongoing research 4 3.4.22.B28 Spinal Cord Ischemia https://pubmed.ncbi.nlm.nih.gov/16847592/ Degradation of spectrin via calpains in the ventral horn after transient spinal cord ischemia in rabbits. unassigned - 3.4.22.B28 Spinocerebellar Ataxias https://pubmed.ncbi.nlm.nih.gov/34191270/ Variants in Genes of Calpain System as Modifiers of Spinocerebellar Ataxia Type 3 Phenotype. unassigned - 3.4.22.B28 Spinocerebellar Ataxias https://pubmed.ncbi.nlm.nih.gov/21653538/ N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. unassigned - 3.4.22.B28 Staphylococcal Infections https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. causal interaction 1 3.4.22.B28 Staphylococcal Infections https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. therapeutic application 1 3.4.22.B28 Staphylococcal Infections https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. ongoing research 2 3.4.22.B28 Staphylococcal Infections https://pubmed.ncbi.nlm.nih.gov/19185618/ Improvement of deficient natural killer activity and delayed bactericidal activity by a thiol proteinase inhibitor, E-64-d, in leukocytes from Chediak-Higashi syndrome patients in vitro. unassigned - 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/9353308/ Regulation of cyclin D1 by calpain protease. causal interaction 1 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/16632474/ Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli. causal interaction 4 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/17880706/ Effect of starvation on global gene expression and proteolysis in rainbow trout (Oncorhynchus mykiss). causal interaction 4 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/18055788/ A key role for calpains in retinal ganglion cell death. causal interaction 1 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/23527186/ Effect of Nutrient Restriction and Re-Feeding on Calpain Family Genes in Skeletal Muscle of Channel Catfish (Ictalurus punctatus). causal interaction 4 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/12381384/ The effect of early posthatch starvation on calpain mRNA levels. diagnostic usage 1 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/16632474/ Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli. diagnostic usage 2 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/17880706/ Effect of starvation on global gene expression and proteolysis in rainbow trout (Oncorhynchus mykiss). diagnostic usage 1 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/9353308/ Regulation of cyclin D1 by calpain protease. therapeutic application 4 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/15621511/ Identification and molecular characterization of the rainbow trout calpains (Capn1 and Capn2): their expression in muscle wasting during starvation. therapeutic application 2 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/16632474/ Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli. therapeutic application 1 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/17880706/ Effect of starvation on global gene expression and proteolysis in rainbow trout (Oncorhynchus mykiss). therapeutic application 1 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/18055788/ A key role for calpains in retinal ganglion cell death. therapeutic application 1 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/23527186/ Effect of Nutrient Restriction and Re-Feeding on Calpain Family Genes in Skeletal Muscle of Channel Catfish (Ictalurus punctatus). therapeutic application 1 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/15621511/ Identification and molecular characterization of the rainbow trout calpains (Capn1 and Capn2): their expression in muscle wasting during starvation. ongoing research 1 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/12381384/ The effect of early posthatch starvation on calpain mRNA levels. unassigned - 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/15178460/ Pak regulates calpain-dependent degradation of E3b1. unassigned - 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/15621511/ Identification and molecular characterization of the rainbow trout calpains (Capn1 and Capn2): their expression in muscle wasting during starvation. unassigned - 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/28219118/ BmCalpains are involved in autophagy and apoptosis during metamorphosis and after starvation in Bombyx mori. unassigned - 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/9353308/ Regulation of cyclin D1 by calpain protease. unassigned - 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/18055788/ A key role for calpains in retinal ganglion cell death. unassigned - 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/23527186/ Effect of Nutrient Restriction and Re-Feeding on Calpain Family Genes in Skeletal Muscle of Channel Catfish (Ictalurus punctatus). unassigned - 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/16632474/ Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli. unassigned - 3.4.22.B28 Starvation https://pubmed.ncbi.nlm.nih.gov/17880706/ Effect of starvation on global gene expression and proteolysis in rainbow trout (Oncorhynchus mykiss). unassigned - 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/18088374/ Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus. causal interaction 4 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. causal interaction 3 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. diagnostic usage 1 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/31585309/ Calpain-dependent cleavage of GABAergic proteins during epileptogenesis. diagnostic usage 1 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/18088374/ Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus. therapeutic application 1 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. therapeutic application 4 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/31585309/ Calpain-dependent cleavage of GABAergic proteins during epileptogenesis. therapeutic application 2 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/27449758/ Calpain-dependent truncated form of TrkB-FL increases in neurodegenerative processes. ongoing research 4 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/28237317/ A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy. ongoing research 4 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/15729144/ Proteolysis of NR2B by calpain in the hippocampus of epileptic rats. unassigned - 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/27449758/ Calpain-dependent truncated form of TrkB-FL increases in neurodegenerative processes. unassigned - 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/31585309/ Calpain-dependent cleavage of GABAergic proteins during epileptogenesis. unassigned - 3.4.22.B28 Status Epilepticus https://pubmed.ncbi.nlm.nih.gov/18088374/ Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus. unassigned - 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/21305563/ CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. causal interaction 4 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/21561529/ Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells. causal interaction 3 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/21305563/ CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. diagnostic usage 3 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/25342484/ Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. diagnostic usage 4 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/21561529/ Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells. therapeutic application 4 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/17971859/ Honokiol induces calpain-mediated glucose-regulated protein-94 cleavage and apoptosis in human gastric cancer cells and reduces tumor growth. therapeutic application 4 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/21305563/ CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. ongoing research 2 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/25342484/ Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. ongoing research 3 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/17971859/ Honokiol induces calpain-mediated glucose-regulated protein-94 cleavage and apoptosis in human gastric cancer cells and reduces tumor growth. unassigned - 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/25342484/ Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. unassigned - 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/21561529/ Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells. unassigned - 3.4.22.B28 Stomach Neoplasms https://pubmed.ncbi.nlm.nih.gov/21305563/ CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. causal interaction 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/20116408/ Neuroprotective actions of aminoguanidine involve reduced the activation of calpain and caspase-3 in a rat model of stroke. causal interaction 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/8014200/ Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. causal interaction 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/8548709/ Inhibiting calpain, rescuing cells. causal interaction 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. causal interaction 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. causal interaction 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/12843408/ The calpain system. causal interaction 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/14630341/ beta2-Adrenergic receptor responsiveness of the calpain-calpastatin system and attenuation of neuronal death in rat hippocampus after transient global ischemia. causal interaction 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. causal interaction 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/15790561/ Regulation of N-methyl-D-aspartate receptors by calpain in cortical neurons. causal interaction 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/16956607/ Inhibition of calpain-mediated cell death by a novel peptide inhibitor. causal interaction 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/17168715/ Currently evaluated calpain and caspase inhibitors for neuroprotection in experimental brain ischemia. causal interaction 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/18207136/ Contribution of calpain activation to early stages of hippocampal damage during oxygen-glucose deprivation. causal interaction 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/18396356/ Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. causal interaction 2 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/19041242/ Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. causal interaction 2 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/19422795/ A novel calpastatin-based inhibitor improves postischemic neurological recovery. causal interaction 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/21504847/ Synthesis of cinnamoyl ketoamides as hybrid structures of antioxidants and calpain inhibitors. causal interaction 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/22514792/ The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. causal interaction 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/23295187/ Calpain cleaves methionine aminopeptidase-2 in a rat model of ischemia/reperfusion. causal interaction 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/25698931/ Involvement of calpains in adult neurogenesis: implications for stroke. causal interaction 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/25851230/ Towards Understanding the Role of the Na²?-Ca²? Exchanger Isoform 3. causal interaction 2 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/27306474/ Can 'calpain-cathepsin hypothesis' explain Alzheimer neuronal death? causal interaction 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/30145792/ Melatonin, a calpain inhibitor in the central nervous system: Current status and future perspectives. causal interaction 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. diagnostic usage 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. therapeutic application 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/20116408/ Neuroprotective actions of aminoguanidine involve reduced the activation of calpain and caspase-3 in a rat model of stroke. therapeutic application 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. therapeutic application 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/8014200/ Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. therapeutic application 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/8548709/ Inhibiting calpain, rescuing cells. therapeutic application 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. therapeutic application 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/12843408/ The calpain system. therapeutic application 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. therapeutic application 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/15790561/ Regulation of N-methyl-D-aspartate receptors by calpain in cortical neurons. therapeutic application 2 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/16954597/ Calpain and synaptic function. therapeutic application 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/16956607/ Inhibition of calpain-mediated cell death by a novel peptide inhibitor. therapeutic application 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/17168715/ Currently evaluated calpain and caspase inhibitors for neuroprotection in experimental brain ischemia. therapeutic application 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/18396356/ Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. therapeutic application 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/19041242/ Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. therapeutic application 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/19422795/ A novel calpastatin-based inhibitor improves postischemic neurological recovery. therapeutic application 2 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/21504847/ Synthesis of cinnamoyl ketoamides as hybrid structures of antioxidants and calpain inhibitors. therapeutic application 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/22514792/ The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. therapeutic application 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/25698931/ Involvement of calpains in adult neurogenesis: implications for stroke. therapeutic application 2 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/27306474/ Can 'calpain-cathepsin hypothesis' explain Alzheimer neuronal death? therapeutic application 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. ongoing research 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/20116408/ Neuroprotective actions of aminoguanidine involve reduced the activation of calpain and caspase-3 in a rat model of stroke. ongoing research 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. ongoing research 4 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/18207136/ Contribution of calpain activation to early stages of hippocampal damage during oxygen-glucose deprivation. ongoing research 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/19422795/ A novel calpastatin-based inhibitor improves postischemic neurological recovery. ongoing research 1 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/22514792/ The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. ongoing research 3 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/23295187/ Calpain cleaves methionine aminopeptidase-2 in a rat model of ischemia/reperfusion. ongoing research 2 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/24259890/ Beneficial effects of antecedent exercise training on limb motor function and calpain expression in a rat model of stroke. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/16954597/ Calpain and synaptic function. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/19162106/ Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/20116408/ Neuroprotective actions of aminoguanidine involve reduced the activation of calpain and caspase-3 in a rat model of stroke. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/8014200/ Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/8548709/ Inhibiting calpain, rescuing cells. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/10842583/ Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/12843408/ The calpain system. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/14630341/ beta2-Adrenergic receptor responsiveness of the calpain-calpastatin system and attenuation of neuronal death in rat hippocampus after transient global ischemia. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/14688621/ Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/15790561/ Regulation of N-methyl-D-aspartate receptors by calpain in cortical neurons. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/16956607/ Inhibition of calpain-mediated cell death by a novel peptide inhibitor. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/17168715/ Currently evaluated calpain and caspase inhibitors for neuroprotection in experimental brain ischemia. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/18207136/ Contribution of calpain activation to early stages of hippocampal damage during oxygen-glucose deprivation. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/18396356/ Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/19041242/ Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/19422795/ A novel calpastatin-based inhibitor improves postischemic neurological recovery. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/21504847/ Synthesis of cinnamoyl ketoamides as hybrid structures of antioxidants and calpain inhibitors. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/22514792/ The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/23295187/ Calpain cleaves methionine aminopeptidase-2 in a rat model of ischemia/reperfusion. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/25698931/ Involvement of calpains in adult neurogenesis: implications for stroke. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/25851230/ Towards Understanding the Role of the Na²?-Ca²? Exchanger Isoform 3. unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/27306474/ Can 'calpain-cathepsin hypothesis' explain Alzheimer neuronal death? unassigned - 3.4.22.B28 Stroke https://pubmed.ncbi.nlm.nih.gov/30145792/ Melatonin, a calpain inhibitor in the central nervous system: Current status and future perspectives. unassigned - 3.4.22.B28 Subarachnoid Hemorrhage https://pubmed.ncbi.nlm.nih.gov/12184858/ Systemic administration of a calpain inhibitor reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat. causal interaction 3 3.4.22.B28 Subarachnoid Hemorrhage https://pubmed.ncbi.nlm.nih.gov/30337208/ Calpeptin Reduces Neurobehavioral Deficits and Neuronal Apoptosis Following Subarachnoid Hemorrhage in Rats. causal interaction 1 3.4.22.B28 Subarachnoid Hemorrhage https://pubmed.ncbi.nlm.nih.gov/32226486/ Calpastatin peptide attenuates early brain injury following experimental subarachnoid hemorrhage. causal interaction 4 3.4.22.B28 Subarachnoid Hemorrhage https://pubmed.ncbi.nlm.nih.gov/12184858/ Systemic administration of a calpain inhibitor reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat. therapeutic application 4 3.4.22.B28 Subarachnoid Hemorrhage https://pubmed.ncbi.nlm.nih.gov/32226486/ Calpastatin peptide attenuates early brain injury following experimental subarachnoid hemorrhage. therapeutic application 1 3.4.22.B28 Subarachnoid Hemorrhage https://pubmed.ncbi.nlm.nih.gov/12184858/ Systemic administration of a calpain inhibitor reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat. ongoing research 2 3.4.22.B28 Subarachnoid Hemorrhage https://pubmed.ncbi.nlm.nih.gov/12184858/ Systemic administration of a calpain inhibitor reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat. unassigned - 3.4.22.B28 Subarachnoid Hemorrhage https://pubmed.ncbi.nlm.nih.gov/30337208/ Calpeptin Reduces Neurobehavioral Deficits and Neuronal Apoptosis Following Subarachnoid Hemorrhage in Rats. unassigned - 3.4.22.B28 Subarachnoid Hemorrhage https://pubmed.ncbi.nlm.nih.gov/32226486/ Calpastatin peptide attenuates early brain injury following experimental subarachnoid hemorrhage. unassigned - 3.4.22.B28 Synucleinopathies https://pubmed.ncbi.nlm.nih.gov/30591714/ Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson's disease/dementia with Lewy bodies. causal interaction 3 3.4.22.B28 Synucleinopathies https://pubmed.ncbi.nlm.nih.gov/30591714/ Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson's disease/dementia with Lewy bodies. therapeutic application 4 3.4.22.B28 Synucleinopathies https://pubmed.ncbi.nlm.nih.gov/30591714/ Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson's disease/dementia with Lewy bodies. unassigned - 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/25009256/ Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. causal interaction 4 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/31156179/ Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice. causal interaction 3 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/21442128/ Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. causal interaction 1 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/23508964/ Negative regulation of 26S proteasome stability via calpain-mediated cleavage of Rpn10 upon mitochondrial dysfunction in neurons. causal interaction 1 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/31640160/ Novel Peptidomic Approach for Identification of Low and High Molecular Weight Tauopathy Peptides Following Calpain Digestion, and Primary Culture Neurotoxic Challenges. diagnostic usage 4 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/21442128/ Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. diagnostic usage 4 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/25009256/ Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. therapeutic application 4 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/31156179/ Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice. therapeutic application 4 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/25009256/ Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. ongoing research 2 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/31156179/ Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice. ongoing research 2 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/31640160/ Novel Peptidomic Approach for Identification of Low and High Molecular Weight Tauopathy Peptides Following Calpain Digestion, and Primary Culture Neurotoxic Challenges. unassigned - 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/25009256/ Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. unassigned - 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/31156179/ Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice. unassigned - 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/23508964/ Negative regulation of 26S proteasome stability via calpain-mediated cleavage of Rpn10 upon mitochondrial dysfunction in neurons. unassigned - 3.4.22.B28 Tauopathies https://pubmed.ncbi.nlm.nih.gov/21442128/ Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. unassigned - 3.4.22.B28 Thrombocytopenia https://pubmed.ncbi.nlm.nih.gov/7986718/ Evidence implicating calpain (Ca(2+)-dependent neutral protease) in the destructive thrombocytopenia of the Wiskott-Aldrich syndrome. diagnostic usage 4 3.4.22.B28 Thrombocytopenia https://pubmed.ncbi.nlm.nih.gov/7986718/ Evidence implicating calpain (Ca(2+)-dependent neutral protease) in the destructive thrombocytopenia of the Wiskott-Aldrich syndrome. ongoing research 2 3.4.22.B28 Thrombocytopenia https://pubmed.ncbi.nlm.nih.gov/28746873/ Deletion of GLUT1 and GLUT3 Reveals Multiple Roles for Glucose Metabolism in Platelet and Megakaryocyte Function. ongoing research 2 3.4.22.B28 Thrombocytopenia https://pubmed.ncbi.nlm.nih.gov/7986718/ Evidence implicating calpain (Ca(2+)-dependent neutral protease) in the destructive thrombocytopenia of the Wiskott-Aldrich syndrome. unassigned - 3.4.22.B28 Thrombocytopenia https://pubmed.ncbi.nlm.nih.gov/28746873/ Deletion of GLUT1 and GLUT3 Reveals Multiple Roles for Glucose Metabolism in Platelet and Megakaryocyte Function. unassigned - 3.4.22.B28 Thrombosis https://pubmed.ncbi.nlm.nih.gov/15131115/ Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth. causal interaction 2 3.4.22.B28 Thrombosis https://pubmed.ncbi.nlm.nih.gov/12494459/ SNARE protein degradation upon platelet activation: calpain cleaves SNAP-23. causal interaction 1 3.4.22.B28 Thrombosis https://pubmed.ncbi.nlm.nih.gov/19820200/ Shear-induced interaction of platelets with von Willebrand factor results in glycoprotein Ib{alpha} shedding. causal interaction 2 3.4.22.B28 Thrombosis https://pubmed.ncbi.nlm.nih.gov/24297866/ Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype. causal interaction 4 3.4.22.B28 Thrombosis https://pubmed.ncbi.nlm.nih.gov/24297866/ Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype. diagnostic usage 3 3.4.22.B28 Thrombosis https://pubmed.ncbi.nlm.nih.gov/15131115/ Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth. therapeutic application 1 3.4.22.B28 Thrombosis https://pubmed.ncbi.nlm.nih.gov/24297866/ Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype. therapeutic application 1 3.4.22.B28 Thrombosis https://pubmed.ncbi.nlm.nih.gov/15131115/ Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth. unassigned - 3.4.22.B28 Thrombosis https://pubmed.ncbi.nlm.nih.gov/12494459/ SNARE protein degradation upon platelet activation: calpain cleaves SNAP-23. unassigned - 3.4.22.B28 Thrombosis https://pubmed.ncbi.nlm.nih.gov/19820200/ Shear-induced interaction of platelets with von Willebrand factor results in glycoprotein Ib{alpha} shedding. unassigned - 3.4.22.B28 Thrombosis https://pubmed.ncbi.nlm.nih.gov/24297866/ Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype. unassigned - 3.4.22.B28 Tinnitus https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. causal interaction 3 3.4.22.B28 Tinnitus https://pubmed.ncbi.nlm.nih.gov/34282564/ Neuroinflammation and Tinnitus. causal interaction 3 3.4.22.B28 Tinnitus https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. therapeutic application 4 3.4.22.B28 Tinnitus https://pubmed.ncbi.nlm.nih.gov/34282564/ Neuroinflammation and Tinnitus. therapeutic application 2 3.4.22.B28 Tinnitus https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. unassigned - 3.4.22.B28 Tinnitus https://pubmed.ncbi.nlm.nih.gov/34282564/ Neuroinflammation and Tinnitus. unassigned - 3.4.22.B28 Tongue Neoplasms https://pubmed.ncbi.nlm.nih.gov/34122116/ Asiatic Acid Induces Endoplasmic Reticulum Stress and Activates the Grp78/IRE1?/JNK and Calpain Pathways to Inhibit Tongue Cancer Growth. unassigned - 3.4.22.B28 Trauma, Nervous System https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. causal interaction 4 3.4.22.B28 Trauma, Nervous System https://pubmed.ncbi.nlm.nih.gov/9469575/ New inhibitors of calpain prevent degradation of cytoskeletal and myelin proteins in spinal cord in vitro. causal interaction 3 3.4.22.B28 Trauma, Nervous System https://pubmed.ncbi.nlm.nih.gov/30337208/ Calpeptin Reduces Neurobehavioral Deficits and Neuronal Apoptosis Following Subarachnoid Hemorrhage in Rats. causal interaction 1 3.4.22.B28 Trauma, Nervous System https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. therapeutic application 4 3.4.22.B28 Trauma, Nervous System https://pubmed.ncbi.nlm.nih.gov/9469575/ New inhibitors of calpain prevent degradation of cytoskeletal and myelin proteins in spinal cord in vitro. therapeutic application 4 3.4.22.B28 Trauma, Nervous System https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. ongoing research 4 3.4.22.B28 Trauma, Nervous System https://pubmed.ncbi.nlm.nih.gov/8622952/ Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. unassigned - 3.4.22.B28 Trauma, Nervous System https://pubmed.ncbi.nlm.nih.gov/9469575/ New inhibitors of calpain prevent degradation of cytoskeletal and myelin proteins in spinal cord in vitro. unassigned - 3.4.22.B28 Trauma, Nervous System https://pubmed.ncbi.nlm.nih.gov/30337208/ Calpeptin Reduces Neurobehavioral Deficits and Neuronal Apoptosis Following Subarachnoid Hemorrhage in Rats. unassigned - 3.4.22.B28 Tremor https://pubmed.ncbi.nlm.nih.gov/25257175/ Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity. causal interaction 3 3.4.22.B28 Tremor https://pubmed.ncbi.nlm.nih.gov/25257175/ Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity. therapeutic application 4 3.4.22.B28 Tremor https://pubmed.ncbi.nlm.nih.gov/25257175/ Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity. unassigned - 3.4.22.B28 Triple Negative Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/28536704/ Calpain-1 Expression in Triple-Negative Breast Cancer: A Potential Prognostic Factor Independent of the Proliferative/Apoptotic Index. causal interaction 4 3.4.22.B28 Triple Negative Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/28536704/ Calpain-1 Expression in Triple-Negative Breast Cancer: A Potential Prognostic Factor Independent of the Proliferative/Apoptotic Index. diagnostic usage 4 3.4.22.B28 Triple Negative Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27894956/ Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. therapeutic application 1 3.4.22.B28 Triple Negative Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27894956/ Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. ongoing research 1 3.4.22.B28 Triple Negative Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/27894956/ Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. unassigned - 3.4.22.B28 Triple Negative Breast Neoplasms https://pubmed.ncbi.nlm.nih.gov/28536704/ Calpain-1 Expression in Triple-Negative Breast Cancer: A Potential Prognostic Factor Independent of the Proliferative/Apoptotic Index. unassigned - 3.4.22.B28 Tuberculosis https://pubmed.ncbi.nlm.nih.gov/23913588/ The RD1 locus in the Mycobacterium tuberculosis genome contributes to the maturation and secretion of IL-1? from infected macrophages through the elevation of cytoplasmic calcium levels and calpain activation. causal interaction 2 3.4.22.B28 Tuberculosis https://pubmed.ncbi.nlm.nih.gov/23913588/ The RD1 locus in the Mycobacterium tuberculosis genome contributes to the maturation and secretion of IL-1? from infected macrophages through the elevation of cytoplasmic calcium levels and calpain activation. ongoing research 2 3.4.22.B28 Tuberculosis https://pubmed.ncbi.nlm.nih.gov/23913588/ The RD1 locus in the Mycobacterium tuberculosis genome contributes to the maturation and secretion of IL-1? from infected macrophages through the elevation of cytoplasmic calcium levels and calpain activation. unassigned - 3.4.22.B28 Tuberculosis, Pleural https://pubmed.ncbi.nlm.nih.gov/27261452/ Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis. causal interaction 3 3.4.22.B28 Tuberculosis, Pleural https://pubmed.ncbi.nlm.nih.gov/27261452/ Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis. diagnostic usage 1 3.4.22.B28 Tuberculosis, Pleural https://pubmed.ncbi.nlm.nih.gov/27261452/ Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis. unassigned - 3.4.22.B28 Uremia https://pubmed.ncbi.nlm.nih.gov/12631067/ Calpain is activated in experimental uremia: is calpain a mediator of uremia-induced myocardial injury? causal interaction 4 3.4.22.B28 Uremia https://pubmed.ncbi.nlm.nih.gov/12631067/ Calpain is activated in experimental uremia: is calpain a mediator of uremia-induced myocardial injury? therapeutic application 1 3.4.22.B28 Uremia https://pubmed.ncbi.nlm.nih.gov/12694339/ Calpain is a mediator of myocardial injury in experimental uremia: is it activated by endogenous ouabain? unassigned - 3.4.22.B28 Uremia https://pubmed.ncbi.nlm.nih.gov/12631067/ Calpain is activated in experimental uremia: is calpain a mediator of uremia-induced myocardial injury? unassigned - 3.4.22.B28 Urinary Bladder Neck Obstruction https://pubmed.ncbi.nlm.nih.gov/18979176/ Expression of parathyroid hormone-related protein in the partially obstructed and reversed rabbit bladder. unassigned - 3.4.22.B28 Urinary Incontinence https://pubmed.ncbi.nlm.nih.gov/19756344/ The role of calpain-calpastatin system in the development of stress urinary incontinence. diagnostic usage 1 3.4.22.B28 Urinary Incontinence https://pubmed.ncbi.nlm.nih.gov/19756344/ The role of calpain-calpastatin system in the development of stress urinary incontinence. therapeutic application 1 3.4.22.B28 Urinary Incontinence https://pubmed.ncbi.nlm.nih.gov/19756344/ The role of calpain-calpastatin system in the development of stress urinary incontinence. ongoing research 3 3.4.22.B28 Urinary Incontinence https://pubmed.ncbi.nlm.nih.gov/19756344/ The role of calpain-calpastatin system in the development of stress urinary incontinence. unassigned - 3.4.22.B28 Uterine Cervical Neoplasms https://pubmed.ncbi.nlm.nih.gov/19266085/ Aspirin Has Antitumor Effects via Expression of Calpain Gene in Cervical Cancer Cells. causal interaction 1 3.4.22.B28 Uterine Cervical Neoplasms https://pubmed.ncbi.nlm.nih.gov/19266085/ Aspirin Has Antitumor Effects via Expression of Calpain Gene in Cervical Cancer Cells. therapeutic application 3 3.4.22.B28 Uterine Cervical Neoplasms https://pubmed.ncbi.nlm.nih.gov/21876174/ Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. therapeutic application 1 3.4.22.B28 Uterine Cervical Neoplasms https://pubmed.ncbi.nlm.nih.gov/19266085/ Aspirin Has Antitumor Effects via Expression of Calpain Gene in Cervical Cancer Cells. ongoing research 4 3.4.22.B28 Uterine Cervical Neoplasms https://pubmed.ncbi.nlm.nih.gov/21876174/ Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. unassigned - 3.4.22.B28 Uterine Cervical Neoplasms https://pubmed.ncbi.nlm.nih.gov/19266085/ Aspirin Has Antitumor Effects via Expression of Calpain Gene in Cervical Cancer Cells. unassigned - 3.4.22.B28 Uveitis https://pubmed.ncbi.nlm.nih.gov/25994508/ CAPN5 mutation in hereditary uveitis: the R243L mutation increases calpain catalytic activity and triggers intraocular inflammation in a mouse model. causal interaction 1 3.4.22.B28 Uveitis https://pubmed.ncbi.nlm.nih.gov/25994508/ CAPN5 mutation in hereditary uveitis: the R243L mutation increases calpain catalytic activity and triggers intraocular inflammation in a mouse model. ongoing research 1 3.4.22.B28 Uveitis https://pubmed.ncbi.nlm.nih.gov/25994508/ CAPN5 mutation in hereditary uveitis: the R243L mutation increases calpain catalytic activity and triggers intraocular inflammation in a mouse model. unassigned - 3.4.22.B28 Vaccinia https://pubmed.ncbi.nlm.nih.gov/10195769/ Recombinant vaccinia viruses and gene gun vectors expressing the large subunit of Schistosoma mansoni calpain used in a murine immunization-challenge model. ongoing research 4 3.4.22.B28 Vaccinia https://pubmed.ncbi.nlm.nih.gov/10195769/ Recombinant vaccinia viruses and gene gun vectors expressing the large subunit of Schistosoma mansoni calpain used in a murine immunization-challenge model. unassigned - 3.4.22.B28 Vascular Calcification https://pubmed.ncbi.nlm.nih.gov/26047104/ Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL. causal interaction 4 3.4.22.B28 Vascular Calcification https://pubmed.ncbi.nlm.nih.gov/26047104/ Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL. therapeutic application 1 3.4.22.B28 Vascular Calcification https://pubmed.ncbi.nlm.nih.gov/26047104/ Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL. ongoing research 3 3.4.22.B28 Vascular Calcification https://pubmed.ncbi.nlm.nih.gov/26047104/ Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL. unassigned - 3.4.22.B28 Vasospasm, Intracranial https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. causal interaction 4 3.4.22.B28 Vasospasm, Intracranial https://pubmed.ncbi.nlm.nih.gov/15104408/ Attenuation of vasospasm and hemoglobin-induced constriction in the rabbit basilar artery by a novel protease inhibitor. causal interaction 3 3.4.22.B28 Vasospasm, Intracranial https://pubmed.ncbi.nlm.nih.gov/15320829/ Continuous elevation of intracellular Ca2+ is essential for the development of cerebral vasospasm. causal interaction 4 3.4.22.B28 Vasospasm, Intracranial https://pubmed.ncbi.nlm.nih.gov/1370069/ Effects of inhibitors of protein kinase C and calpain in experimental delayed cerebral vasospasm. therapeutic application 4 3.4.22.B28 Vasospasm, Intracranial https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. therapeutic application 4 3.4.22.B28 Vasospasm, Intracranial https://pubmed.ncbi.nlm.nih.gov/1370069/ Effects of inhibitors of protein kinase C and calpain in experimental delayed cerebral vasospasm. ongoing research 1 3.4.22.B28 Vasospasm, Intracranial https://pubmed.ncbi.nlm.nih.gov/1370069/ Effects of inhibitors of protein kinase C and calpain in experimental delayed cerebral vasospasm. unassigned - 3.4.22.B28 Vasospasm, Intracranial https://pubmed.ncbi.nlm.nih.gov/11168679/ The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. unassigned - 3.4.22.B28 Vasospasm, Intracranial https://pubmed.ncbi.nlm.nih.gov/15104408/ Attenuation of vasospasm and hemoglobin-induced constriction in the rabbit basilar artery by a novel protease inhibitor. unassigned - 3.4.22.B28 Vasospasm, Intracranial https://pubmed.ncbi.nlm.nih.gov/15320829/ Continuous elevation of intracellular Ca2+ is essential for the development of cerebral vasospasm. unassigned - 3.4.22.B28 Venous Thrombosis https://pubmed.ncbi.nlm.nih.gov/14987918/ Increased calpain expression following experimental cerebral venous thrombosis in rats. causal interaction 4 3.4.22.B28 Venous Thrombosis https://pubmed.ncbi.nlm.nih.gov/14987918/ Increased calpain expression following experimental cerebral venous thrombosis in rats. unassigned - 3.4.22.B28 Ventilator-Induced Lung Injury https://pubmed.ncbi.nlm.nih.gov/22140070/ Activation of calpains mediates early lung neutrophilic inflammation in ventilator-induced lung injury. causal interaction 4 3.4.22.B28 Ventilator-Induced Lung Injury https://pubmed.ncbi.nlm.nih.gov/22140070/ Activation of calpains mediates early lung neutrophilic inflammation in ventilator-induced lung injury. therapeutic application 4 3.4.22.B28 Ventilator-Induced Lung Injury https://pubmed.ncbi.nlm.nih.gov/22140070/ Activation of calpains mediates early lung neutrophilic inflammation in ventilator-induced lung injury. ongoing research 3 3.4.22.B28 Ventilator-Induced Lung Injury https://pubmed.ncbi.nlm.nih.gov/22140070/ Activation of calpains mediates early lung neutrophilic inflammation in ventilator-induced lung injury. unassigned - 3.4.22.B28 Ventricular Dysfunction, Left https://pubmed.ncbi.nlm.nih.gov/23242912/ A new calpain inhibitor protects left ventricular dysfunction induced by mild ischemia-reperfusion in in situ rat hearts. therapeutic application 3 3.4.22.B28 Ventricular Dysfunction, Left https://pubmed.ncbi.nlm.nih.gov/23242912/ A new calpain inhibitor protects left ventricular dysfunction induced by mild ischemia-reperfusion in in situ rat hearts. unassigned - 3.4.22.B28 Vertigo https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. causal interaction 3 3.4.22.B28 Vertigo https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. therapeutic application 4 3.4.22.B28 Vertigo https://pubmed.ncbi.nlm.nih.gov/10753402/ Noise, Calpain, Calpain Inhibitors, and Neuroprotection: A Preliminary Report of Tinnitus Control. unassigned - 3.4.22.B28 Virus Diseases https://pubmed.ncbi.nlm.nih.gov/26747784/ Targeting host calpain proteases decreases influenza A virus infection. therapeutic application 2 3.4.22.B28 Virus Diseases https://pubmed.ncbi.nlm.nih.gov/34198327/ Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease. ongoing research 2 3.4.22.B28 Virus Diseases https://pubmed.ncbi.nlm.nih.gov/26747784/ Targeting host calpain proteases decreases influenza A virus infection. unassigned - 3.4.22.B28 Virus Diseases https://pubmed.ncbi.nlm.nih.gov/34198327/ Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease. unassigned - 3.4.22.B28 Walker-Warburg Syndrome https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. causal interaction 3 3.4.22.B28 Walker-Warburg Syndrome https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. ongoing research 2 3.4.22.B28 Walker-Warburg Syndrome https://pubmed.ncbi.nlm.nih.gov/16566880/ Coexisting muscular dystrophies and epilepsy in children. unassigned - 3.4.22.B28 Whooping Cough https://pubmed.ncbi.nlm.nih.gov/19191907/ Calpain inhibition induces activation of the distinct signalling pathways and cell migration in human monocytes. causal interaction 1 3.4.22.B28 Whooping Cough https://pubmed.ncbi.nlm.nih.gov/21723247/ Calpain inhibitors stimulate phagocyte functions via activation of human formyl peptide receptors. causal interaction 1 3.4.22.B28 Whooping Cough https://pubmed.ncbi.nlm.nih.gov/12649322/ Calpain regulates neutrophil chemotaxis. therapeutic application 1 3.4.22.B28 Whooping Cough https://pubmed.ncbi.nlm.nih.gov/18443189/ Calpain-mediated regulation of the distinct signaling pathways and cell migration in human neutrophils. therapeutic application 1 3.4.22.B28 Whooping Cough https://pubmed.ncbi.nlm.nih.gov/19191907/ Calpain inhibition induces activation of the distinct signalling pathways and cell migration in human monocytes. therapeutic application 1 3.4.22.B28 Whooping Cough https://pubmed.ncbi.nlm.nih.gov/21723247/ Calpain inhibitors stimulate phagocyte functions via activation of human formyl peptide receptors. therapeutic application 2 3.4.22.B28 Whooping Cough https://pubmed.ncbi.nlm.nih.gov/12649322/ Calpain regulates neutrophil chemotaxis. unassigned - 3.4.22.B28 Whooping Cough https://pubmed.ncbi.nlm.nih.gov/18443189/ Calpain-mediated regulation of the distinct signaling pathways and cell migration in human neutrophils. unassigned - 3.4.22.B28 Whooping Cough https://pubmed.ncbi.nlm.nih.gov/19191907/ Calpain inhibition induces activation of the distinct signalling pathways and cell migration in human monocytes. unassigned - 3.4.22.B28 Whooping Cough https://pubmed.ncbi.nlm.nih.gov/21723247/ Calpain inhibitors stimulate phagocyte functions via activation of human formyl peptide receptors. unassigned - 3.4.22.B28 Wiskott-Aldrich Syndrome https://pubmed.ncbi.nlm.nih.gov/7986718/ Evidence implicating calpain (Ca(2+)-dependent neutral protease) in the destructive thrombocytopenia of the Wiskott-Aldrich syndrome. diagnostic usage 4 3.4.22.B28 Wiskott-Aldrich Syndrome https://pubmed.ncbi.nlm.nih.gov/1558970/ Effect of platelet calpain on normal T-lymphocyte CD43: hypothesis of events in the Wiskott-Aldrich syndrome. ongoing research 2 3.4.22.B28 Wiskott-Aldrich Syndrome https://pubmed.ncbi.nlm.nih.gov/7986718/ Evidence implicating calpain (Ca(2+)-dependent neutral protease) in the destructive thrombocytopenia of the Wiskott-Aldrich syndrome. ongoing research 2 3.4.22.B28 Wiskott-Aldrich Syndrome https://pubmed.ncbi.nlm.nih.gov/16723743/ Inhibition of calpain stabilises podosomes and impairs dendritic cell motility. ongoing research 3 3.4.22.B28 Wiskott-Aldrich Syndrome https://pubmed.ncbi.nlm.nih.gov/1558970/ Effect of platelet calpain on normal T-lymphocyte CD43: hypothesis of events in the Wiskott-Aldrich syndrome. unassigned - 3.4.22.B28 Wiskott-Aldrich Syndrome https://pubmed.ncbi.nlm.nih.gov/7986718/ Evidence implicating calpain (Ca(2+)-dependent neutral protease) in the destructive thrombocytopenia of the Wiskott-Aldrich syndrome. unassigned - 3.4.22.B28 Wiskott-Aldrich Syndrome https://pubmed.ncbi.nlm.nih.gov/11557038/ Bruton's tyrosine kinase is a substrate of calpain in human platelets. unassigned - 3.4.22.B28 Wiskott-Aldrich Syndrome https://pubmed.ncbi.nlm.nih.gov/16723743/ Inhibition of calpain stabilises podosomes and impairs dendritic cell motility. unassigned - 3.4.22.B28 Wiskott-Aldrich Syndrome https://pubmed.ncbi.nlm.nih.gov/22133775/ Tyrosine phosphorylation of WASP promotes calpain-mediated podosome disassembly. unassigned - 3.4.22.B28 Wolfram Syndrome https://pubmed.ncbi.nlm.nih.gov/25422446/ A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome. causal interaction 4 3.4.22.B28 Wolfram Syndrome https://pubmed.ncbi.nlm.nih.gov/32632005/ Calpain inhibitor and ibudilast rescue ? cell functions in a cellular model of Wolfram syndrome. therapeutic application 3 3.4.22.B28 Wolfram Syndrome https://pubmed.ncbi.nlm.nih.gov/25422446/ A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome. therapeutic application 4 3.4.22.B28 Wolfram Syndrome https://pubmed.ncbi.nlm.nih.gov/32632005/ Calpain inhibitor and ibudilast rescue ? cell functions in a cellular model of Wolfram syndrome. ongoing research 4 3.4.22.B28 Wolfram Syndrome https://pubmed.ncbi.nlm.nih.gov/25422446/ A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome. ongoing research 3 3.4.22.B28 Wolfram Syndrome https://pubmed.ncbi.nlm.nih.gov/32632005/ Calpain inhibitor and ibudilast rescue ? cell functions in a cellular model of Wolfram syndrome. unassigned - 3.4.22.B28 Wolfram Syndrome https://pubmed.ncbi.nlm.nih.gov/25422446/ A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome. unassigned -